Novo Nordisk's dosing in CagriSema obesity drug trial puzzles investors
- Novo Nordisk shareholders were seeking on Friday to find out why such a high number of patients in the late-stage trial of its next-generation obesity drug candidate CagriSema did not reach the highest dose strength of the medicine.
- 12/20/2024
|
Novo Nordisk stock just tanked 25%: here's what happened
- Novo Nordisk A/S (CPH: NOVO-B) is being punished this morning after posting a disappointing update related to CagriSema. The pharmaceutical behemoth said its experimental weight-loss treatment helped patients lower their weight by 22.7% in a late-stage trial – lower than 25% it had originally expected.
- 12/20/2024
|
Why Novo Nordisk Stock Got Destroyed Today, but Eli Lilly and Viking Stocks Are Up
- Bad news for Novo Nordisk (NVO -17.77%) Friday was good news for Eli Lilly (LLY 4.88%) and Viking Therapeutics (VKTX 5.86%), its two main rivals in the field of weight loss drugs. This morning, Novo reported headline results from its phase 3 trial of a new weight loss drug, CagriSema, and while objectively not bad, the results were less great than Novo was shooting for.
- 12/20/2024
|
Novo Nordisk shares plummet after weight-loss drug's disappointing trial results
- Investors and analysts had eagerly awaited this data as a test of Novo's case that it has a strong pipeline of drugs to follow Wegovy in the fiercely competitive anti-obesity market.
- 12/20/2024
|
Novo Nordisk Selloff Is an Overreaction, Barclays' Field Says
- Emily Field, Barclays' head of European pharmaceutical research, reacts to the selloff in Novo Nordisk's shares after its experimental obesity shot CagriSema failed to meet expectations. She speaks on "Bloomberg Open Interest.
- 12/20/2024
|
Earnings Growth & Price Strength Make Novo Nordisk (NVO) a Stock to Watch
- The Zacks Focus List offers investors a way to easily find top-rated stocks and build a winning investment portfolio. Here's why you should take advantage.
- 12/20/2024
|
Novo Nordisk stock plunges on obesity shot trial results
- Novo Nordisk (NVO) is falling by over 20% in Friday's pre-market trading after its experimental weight-loss shot CagriSema was found to help recipients lose less weight than previously forecasted in its clinical trial. Yahoo Finance senior health reporter Anjalee Khemlani expands upon this story and compares Novo Nordisk's stock performance with that of GLP-1 drug competitor Eli Lilly (LLY).
- 12/20/2024
|
Novo Nordisk Stock Eyes Worst Day, Week on Record
- Novo Nordisk A/S (NYSE:NVO) stock is down 18.9% to trade at $82.25 at last check, after the pharmaceutical company's weight loss drug CagriSema missed expectations of a late-stage study.
- 12/20/2024
|
Novo Nordisk: CagriSema Underwhelms In REDEFINE-1 Trial
- Shares of Novo Nordisk A/S are down after underwhelming REDEFINE-1 trial results. The results were positive, but underperformed company and market expectations (including my own). The trial's flexible dosing protocol led to fewer patients reaching the highest dose, impacting the overall efficacy results.
- 12/20/2024
|
PCE Data Lower Than Expected, NVO Falls on New Obesity Drug, AFRM Upgraded
- Jenny Horne joins the Futures show with live reaction to the latest PCE inflation data. November rate rose just 0.1% from October, but on an annual basis checked in at 2.4% On the stock front, Novo Nordisk (NVO) slid sharply after disappointing clinical data for its new obesity drug CagriSema.
- 12/20/2024
|
Novo Nordisk Stock: A Rare Buying Opportunity
- As I'm writing these lines, Novo Nordisk A/S stock is down about 16% on the pre-market session after the news came out that CagriSema delivered disappointing trial results. I think this selloff is a rare buying opportunity to buy NVO stock at about fair stock price, judging by the long-term average valuation ratios. The business experienced 22.7% YoY revenue growth in US dollars during Q3 FY2024 and managed to expand its EBIT margin to over 47% (+95 bps QoQ and +161 bps YoY).
- 12/20/2024
|
Novo Nordisk shares drop after weight loss drug trial disappoints
- Novo Nordisk (NYSE:NVO) shares plunged more than 20% before Friday's opening bell after the drugmaker reported results from a late-stage trial of its weight loss drug CagriSema that fell short of expectations. The company reported that patients in the trial achieved weight loss of 22.7% after 68 weeks, below the 25% it had previously guided.
- 12/20/2024
|
Novo Nordisk Sinks on Disappointing Trial Results for Next Gen Weight Loss Drug
- Novo Nordisk's (NVO) U.S.-listed shares sank over 19% in premarket trading Friday after releasing trial results for its next generation of weight loss drug, meant to add to its current lineup of Ozempic and Wegovy.
- 12/20/2024
|
Novo Nordisk Is Ready to Ramp Up GLP-1 Manufacturing Following $11B Factory Deal
- Novo has handed Wolff one of the most complex jobs in all of pharmaceuticals.
- 12/19/2024
|
Got $250? 2 Healthcare Stocks to Buy and Hold Forever
- One of the great things about the stock market is that one doesn't have to be a genius or a multimillionaire to take advantage of its wealth-building power. A person who starts out even with a relatively modest sum, like $250, then progressively (and consistently) invests more over time, and stays invested for the long term, will typically see their efforts yield significant returns -- provided they choose the right companies to buy.
- 12/19/2024
|
Novo Nordisk: A New Boost for GLP-1 Sales on the Horizon
- Recent sales of a little-known stock, Madrigal Pharmaceuticals NASDAQ: MDGL, could bode well for Novo Nordisk A/S NYSE: NVO. The pharma industry giant has seen explosive sales growth for its GLP-1 agonist drug, semaglutide.
- 12/18/2024
|
Novo Holdings completes $16.5 bln takeover of Catalent
- Novo Holdings has completed its $16.5 billion takeover of Catalent , the contract drug manufacturer announced on Wednesday, days after the companies said all regulatory closing conditions were fulfilled.
- 12/18/2024
|
Photys Therapeutics Announces Research Collaboration with Novo Nordisk to Develop Induced Proximity PHICS Technology for Cardiometabolic Diseases
- Partnership leverages proprietary PHICS™ technology to bring together a kinase and target of interest to modulate protein function, in this case an undisclosed cardiometabolic target Total potential deal value up to $186M in upfront, development and commercial milestone payments, in addition to R&D funding and tiered royalty payments on commercial sales WALTHAM, Mass., Dec. 18, 2024 (GLOBE NEWSWIRE) -- Photys Therapeutics, Inc., a proximity-based therapeutics company, today announced a multi-year collaboration and license agreement with Novo Nordisk to develop novel proximity-based therapeutics for a cardiometabolic disease target.
- 12/18/2024
|
Ozempic Dethroned? A Head-to-Head Study Confirms This Company Has the Best Weight Loss Drug
- When you think of a top weight loss drug, chances are that Ozempic is the name that first comes to mind. Although it is approved for diabetes (Wegovy is the equivalent version, which is approved for weight loss), many people have been using it for years to lose weight, and it has been highly effective in doing that.
- 12/18/2024
|
Novo Nordisk's Ozempic faces EU review for potential eye disease connection
- The European Union's drug regulator said it would assess two new Danish studies that link Novo Nordisk's popular diabetes drug Ozempic to a rare eye disease.
- 12/18/2024
|
Healthy Returns: Novo Nordisk's Ozempic faces scrutiny over potential link to rare eye condition
- A vision-threatening eye condition may be linked to Ozempic. Meanwhile, Nearly 80% of doctors are using telemedicine weekly, a new Doximity report finds.
- 12/17/2024
|
NVO to Invest $1.2B in New Rare Disease Drugs Facility in Denmark
- Novo Nordisk is set to invest $1.2 billion for a new facility in Odense, Denmark, to produce various product types for rare diseases, including haemophilia.
- 12/17/2024
|
Novo Nordisk A/S (NVO) is Attracting Investor Attention: Here is What You Should Know
- Recently, Zacks.com users have been paying close attention to Novo Nordisk (NVO). This makes it worthwhile to examine what the stock has in store.
- 12/17/2024
|
Novo's Ozempic faces scrutiny over potential link to rare eye disease
- Danish health authorities said on Monday they would ask the European Union's drug regulator to review the findings of two Danish studies linking Novo Nordisk's popular diabetes drug Ozempic to a rare sight-threatening eye condition.
- 12/16/2024
|
Novo Nordisk A/S - share repurchase programme
- Bagsværd, Denmark, 16 December 2024 – On 11 November 2024, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules"). This programme is part of the overall share repurchase programme of up to DKK 20 billion to be executed during a 12-month period beginning 6 February 2024.
- 12/16/2024
|
Novo Nordisk plans $1.2bn Danish factory investment
- Novo Nordisk (NYSE:NVO), the Danish pharmaceutical company, plans to invest $1.2 billion in a new production facility in Odense, Denmark, focused on treatments for rare diseases. In an announcement, the company said the site will feature both a factory and a warehouse, designed to be modular and adaptable to support various rare disease products, including treatments for haemophilia.
- 12/16/2024
|
Novo Nordisk to invest $1.2 bln in new plant in Denmark
- Danish drugmaker Novo Nordisk will invest 8.5 billion crowns ($1.20 billion) in a new facility in Odense, Denmark, for the production of rare disease drugs, it said on Monday.
- 12/16/2024
|
Novo Nordisk invests DKK 8.5 billion in new production facility in Odense, Denmark
- Bagsværd, Denmark, 16 December 2024 – Today, Novo Nordisk announced plans to invest 8.5 billion Danish kroner to establish a completely new production facility in Odense, Denmark. The investment marks the first time in this century that Novo Nordisk breaks ground in Denmark by establishing a new production site.
- 12/16/2024
|
Regulatory conditions on Novo Holdings' $16.5 bln Catalent deal fulfilled, companies say
- All regulatory closing conditions related to Novo Holdings' $16.5 billion acquisition of U.S. contract drug maker Catalent had been fulfilled, the companies said on Saturday, adding that the transaction is expected to be completed in the coming days.
- 12/14/2024
|
Novo Nordisk A/S: The acquisition of Catalent by Novo Holdings, and the related acquisition by Novo Nordisk of three manufacturing sites from Novo Holdings, is cleared to close
- Bagsværd, Denmark, 14 December 2024 — As of today, all regulatory closing conditions relating to the review of Novo Holdings A/S's pending acquisition of Catalent, Inc. (Catalent), including expiry of the timing agreement in the US, have been fulfilled. Catalent is a global contract development and manufacturing organisation headquartered in New Jersey (US). The parties are now free to close the transaction, as well as Novo Nordisk's subsequent acquisition of three Catalent manufacturing sites from Novo Holdings A/S.
- 12/14/2024
|
Novo Nordisk's CagriSema May Trump Lilly's Zepbound - Buy This Dip
- NVO's reiterated FY2024 guidance and underwhelming FY2025 guidance in "the high teens" imply growth headwinds after the high-double digit growth observed in FY2023. This may be worsened by the uncertain regulation surrounding "drug compounders and companies that sell their products," pending further clarity in 2025. Even so, we believe that FY2025 is likely to be trough year, with FY2026 bringing forth robust numbers, assuming regulatory approvals for CagriSema.
- 12/13/2024
|
Novo Nordisk's Ozempic Potentially Linked To Rare Vision Loss Risk, But Absolute Risk Is Low: Study
- A recent cohort study conducted in Denmark and Norway reveals a potential link between the use of semaglutide for type 2 diabetes and an increased risk of non-arteritic anterior ischemic optic neuropathy (NAION).
- 12/13/2024
|
NVO Gets Positive CHMP Opinion in EU for Ozempic Expanded Use in CKD
- Novo Nordisk's diabetes drug, Ozempic, receives positive CHMP opinion in the EU for expanded use in T2D and CKD patients.
- 12/13/2024
|
Ozempic Works on Kidney Disease, Regulator Says. Why Novo Nordisk Stock Is Falling.
- Novo Nordisk's Ozempic will become the first and only GLP-1 drug to be shown to reduce progression of kidney disease in adults with Type 2 diabetes.
- 12/13/2024
|
3 Growth Stocks That Can Be No-Brainer Buys in 2025
- Finding a good growth stock to buy these days isn't easy. Many that have been doing well are at sky-high valuations.
- 12/13/2024
|
European drug regulator allows Novo to include reduction of kidney disease in Ozempic label
- The European Medicines Agency (EMA) will allow Novo Nordisk to add risk reduction for events related to kidney disease to the label of its diabetes drug Ozempic, the Danish drugmaker said in a statement on Thursday.
- 12/12/2024
|
Novo Nordisk A/S: European regulatory authority adopts positive opinion for an update of the Ozempic® label to reflect risk reduction of kidney disease-related events
- Bagsværd, Denmark, 12 December 2024 – Novo Nordisk today announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for an update of the Ozempic® (once-weekly subcutaneous semaglutide) label to reflect data from the FLOW kidney outcomes trial. The FLOW trial assessed the risk reduction from Ozempic® therapy in chronic kidney disease-related events, including persistent ≥50% decline in estimated glomerular filtration rate (eGFR), onset of persistent eGFR
- 12/12/2024
|
Novo Nordisk: Just The Right Price (Rating Upgrade)
- For the first time since I initiated coverage on the Danish weight loss treatments company Novo Nordisk earlier this year, it's now attractive enough to be upgraded to a Buy. Fears of a slump in its blockbuster weight loss treatment, Wegovy's sales in late September were assuaged with the company's Q3 2024 results. Market multiples for Novo Nordisk are also attractive now, especially with a forward P/E for 2025 at 28.3x.
- 12/11/2024
|
Healthy Returns: A huge deal to boost Novo Nordisk's manufacturing is one step closer to closing
- Novo Nordisk parent's huge manufacturing deal is one step closer to closing. Meanwhile, Nobel Prize winners urge senators to oppose confirmation of RFK Jr.
- 12/11/2024
|
Novo Nordisk A/S (NVO) Price Prediction and Forecast 2025-2030
- When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no signs of slowing down, much to the delight of its Danish manufacturer, Novo Nordisk A/S (NYSE: NVO). A Scandinavian economic behemoth, Novo Nordisk is the highest-valued company in Europe at over $500 billion, which exceeds Denmark’s entire GDP. Ironically, Ozempic and Wegovy, as with many of Novo Nordisk’s other products, were created primarily for treating diabetes. The weight-loss factor has become a very profitable and unintended side-effect. Founded a century ago, Copenhagen-based Nordisk originally made insulin. After coming to the US in 1982, it underwent several corporate changes until becoming Novo Nordisk in 1989. In addition to diabetes drugs, the company also makes drug treatments for wound healing, menopausal hormone replacement, and human growth hormone. Headwinds While Novo Nordisk has built itself into a pharmaceutical giant, it has seriously run afoul of regulatory laws on several occasions. Novo Nordisk’s practices have raised red flags in Denmark as well as in the US and UK for years, with the more recent ones being: A 2017 $59 million fine from the DOJ due to lack of FDA disclosures concerning cancer risks from diabetes drug Victoza; Membership suspension from the UK’s Association of British Pharmacy Industry over ethics violations tantamount to bribing of health professionals; 235 active Ozempic related product liability lawsuits as of August, 2024; A 2024 investigation led by the US Senate confirmed predatory pricing of Ozempic by almost 1500% vs. its price in Europe, and 1000% for Wegovy. Regardless, investors are much more concerned with future stock performance over the next 1, 5, to 10 years. While most Wall Street analysts will calculate 12-month forward projections, it’s clear that nobody has a consistent crystal ball, and plenty of unforeseen circumstances can render even near-term projections irrelevant. 24/7 Wall Street aims to present some farther-looking insights based on Novo Nordisk’s own numbers, along with business and market development information that may be of help to our readers’ own research. Key Points In This Article Novo Nordisk’s R&D is heavily invested in improved obesity treatments Novo Nordisk sees the obesity drug market expanding to $100 billion by 2030. To that end, it has Amycretin in FDA phase-1 and CagriSegma in phase-2 trials, which both show greater efficacy potential than Wegovy and Ozempic. Although the number of Ozempic-related lawsuits are piling up, Novo Nordisk’s stance is that the complaints are unwarranted, and will either be dismissed or settled. Novo Nordisk’s past acquisitions for both greater production capacity and logistical flexibility will reap benefits through geopolitical risk mitigation and broader product menu options. Entering untapped markets, such as China, will be key to Novo Nordisk’s future growth. If you’re looking for some stocks with huge potential, make sure to grab a free copy of our brand-new “The Next NVIDIA” report. It features a software stock we’re confident has 10X potential. Novo Nordisk News and Updates 12/9/2024 Novo Nordisk has received European approval to acquire Catalent, a U.S. drug manufacturer responsible for producing a large portion of Novo Nordisk’s popular obesity drug, Wegovy. However, the deal still needs to be cleared by the U.S. Federal Trade Commission before it can be finalized. 12/6/2024 Novo Nordisk announced a major price reduction for two of its insulin products. Starting in January 2026, the list price of Fiasp will drop by 75%, while Tresiba will see a 72.2% reduction. Novo Nordisk will also discontinue unbranded versions of Tresiba by the end of 2025. 12/5/2024 Novo Nordisk announced a large investment of DKK 2.9 billion ($411 million) to construct a new quality control laboratory in Hillerød, Denmark. The new 53,000-square-meter facility is expected to be operational by 2027 and will be Novo Nordisk’s largest quality control investment to date. 12/3/2024 Novo Nordisk’s India team wants to launch the weight-loss drug Wegovy sooner than planned. They’re concerned about falling behind the company’s rival, Eli Lilly, whose similar drug Mounjaro is expected to launch next year. 11/27/2024 Health Canada has granted approval for Novo Nordisk’s weight-loss drug, Wegovy. Wegovy now becomes the first treatment in Canada to address both obesity and the risk of heart-related issues in adults with pre-existing cardiovascular disease. 11/26/2024 A new proposal from President Joe Biden suggests that Medicaid and Medicare should cover the cost of weight-loss drugs for patients, which could lead to increased demand for drugs like Ozempic. Currently, these insurance programs cover the medication for diabetes, but not those for obesity. 11/25/2024 Each month over 200,000 U.S. patients rely on compounded copies of Novo Nordisk’s weightloss drug, Wegovy. An industry group has urged the FDA to consider the role of these copies in easing the obesity drug shortage before officially banning them. 11/22/2024 BMO Capital remains optimistic about Novo Nordisk, reaffirming its “Outperform” rating and setting a $156 price target. The firm anticipates positive impacts on Novo Nordisk’s stock due to potential EU approval of Novo Holdings’ acquisition of Catalent. 11/21/2024 Novo Nordisk’s stock price declined 3.01% today, dipping as low as $101.51. 11/20/2024 Novo Nordisk and Eli Lilly are reaching out to labor unions and HR to advocate for anti-obesity drugs like Ozempic, Mounjaro, Wegovy, and Zepbound. 5-10 Year Review Novo Nordisk bread and butter diabetes and obesity drugs obscure its other remedies for estrogen replacement, wound treatment, and HGH, among others. Novo Nordisk has spared no expense in expanding its pharmaceutical reach and scope. In addition to adding new factories to ramp up production to meet demand for Ozempic and Wegovy, the company’s expansion towards treating other afflictions saw billions spent in acquisitions. The past decade has seen the following events: In 2015, Novo Nordisk announced a $400 million collaboration with Sanofi subsidiary Ablynx, to use its nanobody technology to develop a new drug. After an unsuccessful bid to acquire Ablynx in 2018, Novo Nordisk bought diabetes drug company Ziylo. 2020 saw Novo Nordisk buying Corvidia Therapeutics from AstraZeneca for its heart disease treatments. Novo Nordisk announced it would acquire Emisphere Technologies for $1.35 billion in December 2020, adding another diabetes pill to its catalog. In November 2021, Novo Nordisk acquired Dicerna Pharmaceuticals and its RNAi therapeutics, for $3.3 billion. Intending to expand its sickle cell disease and rare blood disorders portfolio, 2022 saw Novo Nordisk buying Forma Therapeutics for $1.1 billion. Flush with Ozempic and Wegovy cash, Novo Nordisk bought Inversago Pharma for $1 billion, Embark Biotech for up to $500 million, ocedurenone—an experimental drug for uncontrolled hypertension and potentially beneficial in treating cardiovascular and kidney diseases—from KBP Biosciences for $1.3 billion during 2023. To address expanding Ozempic and Wegovy demand, Novo Nordisk’s parent, Novo Holdings, bought NJ-based Catalent, a global provider of drug delivery systems, gene therapies, manufacturing, biologics, and other operations, in 2024. 2024 also saw the acquisitions of Cardior Pharmaceuticals for its cardiovascular treatment portfolio, and Austria’s Single use Support, a fluid management company. Fiscal Year (DEC) Price Revenues Net Income DKK (=US$0.15) DKK (=US$0.15) 2015 $29.04 107.927B/$16.19B 34.860B/$5.23B 2016 $17.93 111.780B/$16.76B 37.925B/$5.69B 2017 $26.83 111.696B/$16.75B 38.130B/$5.72B 2018 $23.03 111.831B/$16.77B 38.628B/$5.79B 2019 $28.94 122.021B/$18.30B 38.951B/$5.84B 2020 $34.92 126.946B/$19.04B 42.138B/$6.32B 2021 $56.00 140.800B/$21.12B 47.757B/$7.16B 2022 $67.67 176.954B/$26.54B 55.525B/$8.33B 2023 $103.45 232.261B/$34.84B 83.683B/$12.55B 2024 LTM (as of June) $142.74 258.003B/$38.70B 89.898B/$13.48B Key Drivers for Novo Nordisk’s Stock in the Future The obesity and weight-loss drug market is expected to his $100 billion by 2030. A more potent obesity treatment called CagriSema combines semaglutide, the active ingredient in Ozempic, with amylin and calcitonin receptor agonists. Amylin helps regulate blood sugar levels, similar to GLP-1, while calcitonin controls calcium levels in the blood. Results for two late-stage FDA trials of the drug are expected by the end of 2024. Wegovy’s June 2024 approval for sales in China opens the door to a new market, which has hundreds of million prospective new customers from China’s burgeoning middle and upper class. New experimental obesity drug Amycretin, a single molecule that operates as a GLP-1 receptor agonist that reduces one’s appetite, is in phase-1 FDA trials. The new pill achieved a 13.1% average weight loss after 12 weeks, more than doubling the efficacy of Wegovy for the same time span. With the obesity drug market expected to reach $100 billion by 2030, genetic-based treatments currently in the R&D stage could become the next pharma golden ring. While some legal experts believe that the number of Ozempic lawsuits over gastroparesis and other afflictions, such as pancreatitis, kidney, and gallbladder issues, can reach as high as 20,000, Novo Nordisk is apparently confident it can reach a settlement that will allow it to continue its growth trajectory without impediment. Stock Price Prediction for 2025 Out of 11 Wall Street analysts, their consensus recommendation is “outperform/hold”, based on 5 buy, 2 outperform, 2 hold, and 2 sell. Their consensus 12-month target price for Novo Nordisk is $140.07, which is a 26.10% gain over today’s stock price. The 24/7 Wall Street 12-month projected target is a more conservative $124.20. This would be 12.12% above today’s price. Novo Nordisk’s Next 5 Years’ Outlook Novo Nordisk’s median P/E ratio has been 26.40 from 2010 to the present. The following price predictions are based on a 25 P/E. In the subsequent 5 years to follow, Novo Nordisk’s newest products, presently in FDA trials, are targeting the obesity market. It is anticipated to reach $100 billion by 2030. Obesity drugs competing against offerings from Eli Lilly and other rivals require drugs that meet the following criteria: Sufficient efficacy to fulfill the medical needs of a large population of patients; Tolerable enough for prolonged patient treatment to obtain a significant and consistent therapeutic effect; Flexible enough to be prescribed to patients without an abundance of diagnostic testing or monitoring; Formulaically efficient enough to manufacture and distribute at scale. With Wegovy gaining acceptance for China in Q2 2024, this opens the door for Novo Nordisk to gain a foothold in a potentially larger market than the entirety of its European share. China’s middle and wealthy classes have multiplied exponentially as China’s GDP has grown. Obesity, heart diseases, and other ailments common in the West have escalated in China as diets and lifestyles adapted to mimic Western tastes and trends. Our price target for 2026 is $136.62. The new obesity drug CagriSema is presently near completion of FDA phase-2 trials. Assuming there are no negative results to bar initiating clinical phase-3 trials, these would presumably occur throughout 2025 and 2026. Therefore, CagriSema is likely to be cleared for public dissemination and ready for market by 2027. Although it is administered via injection, rather than in pill form, early results show a 200% higher weight loss reduction in 32 weeks, over Wegovy. Our price target for 2027 is $153.01. Although Novo Nordisk’s pipeline of new drugs under FDA review targets obesity, its revamped product menu has expanded via acquisitions. Revenues from its HGH, estrogen replacement, and wound treatment products, as well as other diabetes variants, should all contribute to the bottom line with full production, marketing, and sales integration by 2028. We predict a price of $165.26. Obesity pill Amecrytin, which acts as an appetite suppressant without the effects of amphetamines, is presently in FDA phase-1 trials, but should be cleared for market and ready for distribution in 2029. Its weight-loss efficacy doubles that of Wegovy in shorter 3-month periods, and its pill configuration convenience should make it a hit prescription for doctors. Our price target is $186.74. Novo Nordisk Stock in 2030 Ozempic is an injection administered drug. R&D for a genetic based obesity drug is currently in the works by Novo Nordisk, Eli Lilly, and several other rivals. With the obesity treatment market expected to hit $100 billion in 2030, even the announcement of a genetic-based drug ready to start FDA trials would generate significant buzz. With Novo Nordisk the current market leader, such an announcement in 2030 is not a stretch. Our target price is $192.34. Cumulatively, 24/7 Wall Street anticipates Novo Nordisk to appreciate 79% over the next 5 years. Year EPS P/E multiple Price 2025 $4.97 25 $124.20 2026 $5.46 25 $136.62 2027 $6.12 25 $153.01 2028 $6.61 25 $165.26 2029 $7.47 25 $186.74 2030 $7.69 25 $192.34 100 Million Americans Are Missing This Crucial Retirement Tool The thought of burdening your family with a financial disaster is most Americans’ nightmare. However, recent studies show that over 100 million Americans still don’t have proper life insurance in the event they pass away. Life insurance can bring peace of mind – ensuring your loved ones are safeguarded against unforeseen expenses and debts. With premiums often lower than expected and a variety of plans tailored to different life stages and health conditions, securing a policy is more accessible than ever. A quick, no-obligation quote can provide valuable insight into what’s available and what might best suit your family’s needs. Life insurance is a simple step you can take today to help secure peace of mind for your loved ones tomorrow. Click here to learn how to get a quote in just a few minutes. The post Novo Nordisk A/S (NVO) Price Prediction and Forecast 2025-2030 appeared first on 24/7 Wall St..
- 12/11/2024
|
PFE or NVO: Which Is the Better Value Stock Right Now?
- Investors interested in stocks from the Large Cap Pharmaceuticals sector have probably already heard of Pfizer (PFE) and Novo Nordisk (NVO). But which of these two stocks offers value investors a better bang for their buck right now?
- 12/09/2024
|
Novo Nordisk Just Got One Step Closer to Resolving Wegovy Supply Issue
- The proposed buyout of contract drug manufacturer Catalent won't raise competition concerns, the European Commission said.
- 12/09/2024
|
Novo Nordisk A/S - share repurchase programme
- Bagsværd, Denmark, 9 December 2024 – On 11 November 2024, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules"). This programme is part of the overall share repurchase programme of up to DKK 20 billion to be executed during a 12-month period beginning 6 February 2024.
- 12/09/2024
|
The Zacks Analyst Blog Berkshire Hathaway, Exxon Mobil, Novo Nordisk and Universal Health Realty Income Trust
- Berkshire Hathaway, Exxon Mobil, Novo Nordisk and Universal Health Realty Income Trust are included in this Analyst Blog.
- 12/09/2024
|
Eli Lilly Stock Just Got Even Sweeter. Here's Why It's Worth Buying Now
- According to a sneak peek of the data from one of Eli Lilly's (LLY 0.13%) late-stage clinical trials, the cardiometabolic medicine juggernaut now looks even stronger in comparison to its similarly powerful arch-rival, Novo Nordisk, (NVO 1.79%) and it isn't the first time.
- 12/09/2024
|
3 No-Brainer Growth Stocks to Buy in December
- Growth. It's what most investors want more than anything else from their stocks. Some stocks can deliver more of it than others.
- 12/07/2024
|
The European Commission approves the acquisition of Catalent by Novo Holdings and the related acquisition by Novo Nordisk of three manufacturing sites from Novo Holdings
- Bagsværd, Denmark, 6 December 2024 — Today, the European Commission approved Novo Holdings A/S' acquisition of Catalent, Inc. (Catalent), a global contract development and manufacturing organisation headquartered in New Jersey (US), as well as Novo Nordisk's subsequent acquisition of three manufacturing sites from Novo Holdings A/S.
- 12/06/2024
|
Novo Holdings' $16.5 bln Catalent buy wins EU antitrust approval
- Novo Holdings on Friday gained unconditional EU antitrust approval for its $16.5 bln acquisition of U.S. contract drug maker Catalent after EU regulators said they did not see any competition issues.
- 12/06/2024
|
Structure CEO on the competitive landscape for oral GLP-1 drugs
- Raymond Stevens, Structure Therapeutics CEO, joins 'Fast Money' to talk its oral GLP-1 offerings.
- 12/05/2024
|
Novavax to Sell Czech Manufacturing Plant to Novo Nordisk for $200M
- NVAX intends to use the payment from Novo to advance the development of its vaccine pipeline. The deal is expected to be closed by the end of this year.
- 12/05/2024
|
Novo Nordisk A/S (NVO) Is a Trending Stock: Facts to Know Before Betting on It
- Zacks.com users have recently been watching Novo Nordisk (NVO) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
- 12/05/2024
|
Novo Nordisk to cut US list prices of two insulin products by more than 70%
- Danish drug maker Novo Nordisk said on Thursday it will reduce the U.S. list prices of two insulin products by more than 70% from January of 2026.
- 12/05/2024
|
Eli Lilly's Zepbound Tops Novo Nordisk's Wegovy in Weight-Loss Trial
- Eli Lilly's (LLY) popular weight-loss drug Zepbound outperformed Wegovy, a competitor drug from Danish drugmaker Novo Nordisk (NVO), according to the results of a new clinical study released Wednesday.
- 12/04/2024
|
Stock Of The Day: Where Will The Eli Lilly Rally End?
- Shares of Eli Lilly and Company LLY are trading higher on Wednesday. The company said that its Zepbound drug was more effective in helping adults with obesity lose weight than Novo Nordisk A/S's NVO Wegovy.
- 12/04/2024
|
Lilly's Zepbound Beats Novo's Wegovy in Weight-Loss Drug Trial
- Eli Lilly & Co. said its weight-loss drug Zepbound outperformed rival Novo Nordisk A/S's Wegovy in the first head-to-head trial of the two blockbusters. In the study sponsored by Lilly, those on Zepbound lost an average of about 50 pounds over 72 weeks.
- 12/04/2024
|
Eli Lilly's Weight-Loss Drug Zepbound Is Better than Novo's Wegovy, Study Finds
- On average, Zepbound led to a superior weight loss of 20.2% compared to 13.7% with Wegovy, Lilly said.
- 12/04/2024
|
Eli Lilly's Zepbound causes greater weight loss than Novo Nordisk's Wegovy in head-to-head trial
- Eli Lilly said its obesity drug Zepbound led to more weight loss than its main rival, Novo Nordisk's Wegovy, in the first head-to-head clinical trial on the two weekly injections. The findings suggest Zepbound may be a superior treatment for weight loss, helping patients with obesity or who are overweight lose 20.2% of their body weight on average after 72 weeks.
- 12/04/2024
|
Novavax to sell Czech manufacturing unit to Novo Nordisk for $200 mln
- COVID-19 vaccine maker Novavax said on Wednesday it will sell its manufacturing facility in Czech Republic to Wegovy-maker Novo Nordisk for $200 million and use the proceeds for its vaccine pipeline.
- 12/04/2024
|
Want To Bet On Ozempic, Wegovy Success? Defiance Introduces Leveraged ETF To Capture Novo Nordisk Momentum
- On Tuesday, Defiance ETFs introduced NVOX, the first single-stock leveraged ETF focused on Danish pharmaceutical giant Novo Nordisk A/S NVO.
- 12/03/2024
|
Novo Nordisk to present new data from sickle cell disease and haemophilia trials at the 66th American Society of Hematology (ASH) annual meeting
- Bagsværd, Denmark, 3 December 2024 – Novo Nordisk today announced the presentation of 13 abstracts, three of which will be presented in oral sessions, at the upcoming 66th Annual Meeting and Exposition of the American Society of Hematology (ASH), which will take place from 7 to 10 December 2024 in San Diego, California.
- 12/03/2024
|
Novo Nordisk and AstraZeneca top of the 2025 drug picks for US investment bank - read why
- Success in 2025 for the pharma sector will hinge on the success of key drug pipeline developments, according to JPMorgan's latest research. With concerns over US drug pricing policies easing and significant patent expirations on the horizon, the focus shifts to pipeline progress to drive growth, the American investment bank reckons, And it says Novo Nordisk (NYSE:NVO) and AstraZeneca PLC (LSE:AZN) are set to lead the way, bolstered by strong mid-term growth and promising news flow.
- 12/03/2024
|
Defiance Launches NVOX, the First 2X Leveraged Single-Stock ETF on Novo Nordisk
- MIAMI, Dec. 03, 2024 (GLOBE NEWSWIRE) -- Defiance ETFs today launched NVOX, the world's first single-stock leveraged ETF for the pharmaceutical stock Novo Nordisk (NYSE: NVO). As the weight loss market continues to expand and Novo Nordisk is a key provider in that space, NVOX offers retail investors 2X daily long leveraged exposure to the change in the daily share price of Novo Nordisk without the need for a margin account.
- 12/03/2024
|
Exclusive: Novo Nordisk India execs urge early Wegovy launch as weight-loss rival looms
- Novo Nordisk's team in India has been pushing the Danish drugmaker's global leadership for an earlier launch of its popular weight-loss drug Wegovy over fears of falling behind rival Eli Lilly in the potentially huge market, two sources familiar with the plans told Reuters.
- 12/03/2024
|
Fmr. FDA Commissioner on how Trump could impact GLP-1 industry
- Dr. Scott Gottlieb joins 'Fast Money' to talk how a Trump administration could impact the GLP-1 drug industry.
- 12/02/2024
|
Novo Nordisk A/S - share repurchase programme
- Bagsværd, Denmark, 2 December 2024 – On 11 November 2024, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules"). This programme is part of the overall share repurchase programme of up to DKK 20 billion to be executed during a 12-month period beginning 6 February 2024.
- 12/02/2024
|
Eli Lilly and Novo Nordisk's Obesity Moat Just Got Stronger
- Data from their most serious competitor, Amgen, suggests the biotech won't upstage the market leaders.
- 11/30/2024
|
The Score: GM, Macy's, Novo Nordisk and More Stocks That Defined the Week
- Here are some of the major companies whose stocks moved on the week's news.
- 11/29/2024
|
Is Novo Nordisk Stock a Buy?
- Few companies garner as much reliable attention as Novo Nordisk (NVO) does these days. With a bull market coinciding with a historic run of growth for the Danish pharmaceutical giant related to its GLP-1 drugs, it's no surprise that its share prices have nearly doubled over the last three years.
- 11/29/2024
|
Biotech funding has been an issue in the pharmaceutical industry, says Novo Holdings partner
- Johan Hueffer, senior partner, principal investments at Novo Holdings, discusses investment in life sciences and his macro perspective.
- 11/29/2024
|
LLY, NVO Stock Up as Biden Proposes Medicare Cover for Obesity Drugs
- The Biden administration believes that including obesity drugs in Medicare coverage will reduce out-of-pocket costs for the drugs and make them affordable.
- 11/27/2024
|
Canada approves Novo Nordisk's obesity drug to reduce risk of non-fatal heart attack
- Canada's health regulator has approved Novo Nordisk's weight loss drug Wegovy to reduce the risk of nonfatal heart attack or myocardial infarction in some adults, the Danish drugmaker said on Wednesday.
- 11/27/2024
|
Millions more Americans might get access to GLP-1 drugs
- A new proposal by the Biden administration would see obesity drugs covered under Medicare and Medicaid. Transcript: Conway Gittens: The Dow and the S&P 500 closed at fresh record highs on Tuesday as investors tried to pick winners and losers in Donald Trump's tariff plans.
- 11/26/2024
|
Eli Lilly, Novo Nordisk Stocks Gain as Biden Moves to Expand Coverage of Weight-Loss Drugs
- Eli Lilly (LLY) and Novo Nordisk (NVO) shares rose Tuesday after the Biden administration proposed expanding coverage of the companies' popular weight-loss drugs in government-backed healthcare plans including Medicare and Medicaid.
- 11/26/2024
|
Obesity drugmaker stocks gain as Biden proposal expands coverage for anti-obesity medications
- Shares of obesity drugmakers moved higher on Tuesday after the Biden administration proposed expanded coverage of anti-obesity medications under Medicare and Medicaid. Currently, these programs cover the use of anti-obesity medications for certain conditions like diabetes, but under the proposal, this would be expanded to include obesity.
- 11/26/2024
|
Biden administration plans to expand coverage of GLP-1 drugs for Americans with Medicare & Medicaid
- CNBC's Bertha Coombs joins 'Squawk on the Street' to report on Biden's administration plan to expand coverage of GLP-1 drugs for Americans with Medicare and Medicaid.
- 11/26/2024
|
Novo Nordisk shares rise as Biden proposes obesity care coverage
- Shares of Danish weight-loss drug maker Novo Nordisk rose 1.3% on Tuesday as U.S. President Jo Biden proposed expanding coverage of anti-obesity drugs for millions on Medicare and Medicaid.
- 11/26/2024
|
Novo Nordisk: Supply Strains, Competition, And RFK Concerns Mask Solid Fundamentals
- Novo Nordisk's stock declined 22% over the past six months, influenced by competitive pressures and supply constraints. Eli Lilly's Zepbound is rapidly gaining market share, challenging Novo's dominance in the weight-loss drug sector. Novo's $16.5 billion acquisition of Catalent aims to alleviate supply issues, with EU antitrust approval likely, enhancing Wegovy's production capacity.
- 11/26/2024
|
Mizuho's Jared Holz on what Trump's FDA pick means for biotech innovation
- Mizuho's Jared Holz joins 'Fast Money' to talk what's next for biopharma space after president-elect Trump names his pick for FDA head.
- 11/25/2024
|
Novo Nordisk A/S - share repurchase programme
- Bagsværd, Denmark, 25 November 2024 – On 11 November 2024, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules"). This programme is part of the overall share repurchase programme of up to DKK 20 billion to be executed during a 12-month period beginning 6 February 2024.
- 11/25/2024
|
Novo Nordisk: Can CagriSema Show 25% Weight Loss In REDEFINE-1 Trial?
- Novo Nordisk will report the topline results from the REDEFINE-1 trial of CagriSema in obese patients before the end of the year. Management expects CagriSema to generate 25% weight loss after 68 weeks of treatment. Based on the mechanism of action and phase 2 results in obese patients and type 2 diabetes patients, I agree and expect CagriSema to generate 24-27% weight loss.
- 11/24/2024
|
EU antitrust regulators set to okay $16.5 bln Novo Holdings, Catalent deal, source says
- EU antitrust regulators are set to clear without conditions Novo Holdings' planned $16.5 billion takeover of Catalent , a person with direct knowledge of the matter said on Friday.
- 11/22/2024
|
Novo Nordisk Plunges 25% in 3 Months: How to Play the Stock
- Despite the current downward trend of NVO, it is a good stock to retain in one's portfolio for long-term gains due to strong demand for its GLP-1 drugs.
- 11/22/2024
|
Franklin International Equity Fund Q3 2024 Commentary
- Jinda Noipho Performance Data Average Annual Total Returns 4(%) 1 Mth 3 Mths 1 Year 3 Year 5 Year 10 Year Since Inception Inception Date Class C (MUTF:LMGEX) - With Sales Charges a -1.46 4.15 21.61 5.98 7.49 4.70 4.22 02/17/1995 Class C - Without Sales Charges a -0.47 5.15 22.61 5.98 7.49 4.70 4.22 02/17/1995 Class A - With Sales Charges a -5.86 -0.42 16.85 4.77 7.09 4.90 6.80 02/03/2009 Class A - Without Sales Charges a -0.37 5.38 23.66 6.86 8.37 5.52 7.20 02/03/2009 MSCI EAFE Index-NR 0.92 7.26 24.77 5.48 8.20 5.71 - - Click to enlarge Share Class Details Sales Charges Expenses CUSIP Ticker Max CDSC Gross Net Class A 524686292 LMEAX 5.50% - 1.32% 1.28% Class C 524686284 LMGEX - 1.00% 2.17% 2.05% Click to enlarge Performance data quoted represents past performance, which does not guarantee future results. Current performance may be lower or higher than the figures shown. Principal value and investment returns will fluctuate, and investors' shares, when redeemed, may be worth more or less than the original cost. Performance would have been lower if fees had not been waived in various periods. Total returns assume the reinvestment of all distributions and the deduction of all fund expenses. Returns with sales charge reflect a deduction of the stated maximum sales charge. Returns for periods of less than one year are not annualized. All classes of shares may not be available to all investors or through all distribution channels. For current month-end performance, please call Franklin Templeton at (800) DIAL BEN/(800) 342-5236 or visit www.franklintempleton.com. An investor cannot invest directly in an index, and unmanaged index returns do not reflect any fees, expenses or sales charges. Net Returns ('NR') include income net of tax withholding when dividends are paid. The MSCI EAFE Index is a free float-adjusted market capitalization-weighted index designed to measure developed market equity performance, excluding the U.S. and Canada. Source: MSCI makes no warranties and shall have no liability with respect to any MSCI data reproduced herein. No further redistribution or use is permitted. This report is not prepared or endorsed by MSCI. Click to enlarge Performance Review Global equities ended the third quarter of 2024 collectively higher as they recovered from bouts of heightened volatility, including a market selloff in early August following an interest-rate hike by the Bank of Japan, as well as the release of a weaker-than-expected employment report in the United States, which led to recession fears. However, stock markets rebounded as resilient economic reports and a continued disinflation trend reignited hopes for an economic soft landing. Interest-rate cuts by the European Central Bank (ECB), the People's Bank of China (PBoC) and other central banks further bolstered equities worldwide. On the economic front, global manufacturing activity contracted for the third consecutive month in September, while flash reports for the same month indicated services activity continued to expand across regions. In this environment, the MSCI EAFE Index of stocks returned 7.26% in US-dollar terms. Quarterly Key Performance Drivers Regions Sectors HELPED KONAMI Group Corporation (OTCPK:KNAMF) Japan Industrials (Stock Selection) Chugai Pharmaceutical Co., Ltd. (chcgf) European Banks (Stock Selection and Overweight) Shell Plc (SHEL) Japan Communication Services (Stock Selection) HURT Novo Nordisk A/S Class B (NVO) European Health Care (Stock Selection) Mazda Motor Corp. (OTCPK:MZDAY) Developed Asia ex Japan (Underweight) ASML Holding NV (ASML) Japan Consumer Discretionary (Stock Selection) Click to enlarge The fund underperformed the benchmark for the third quarter of 2024. Stock selection results were mixed across regions and was negative overall, especially in continental Europe where the health care sector was notably weak. Stock selection was more moderately negative in the smaller markets of Australia, New Zealand & Canada, and Developed Asia ex Japan. Selection added meaningful value in Japan, led by industrials and communication services, and in the United Kingdom. Allocation decisions detracted, due primarily to an underweight in Developed Asia ex Japan, which outperformed within the benchmark for the quarter. An allocation to emerging markets, which is not in the benchmark, also detracted. Our diversified 1, multifactor stock selection model results were negative for the quarter, led down by the sentiment and alternative dimensions. The quality and value dimensions had little impact. At quarter-end, the portfolio was attractively valued with a lower 12-month forward price-to-earnings ratio 2 than the benchmark. The portfolio was well diversified across regions and sectors when compared to the benchmark. At the region level, the largest overweight was to the United Kingdom, and the largest underweight was to the developed Asia ex Japan. Sector allocations were close to the benchmark, with a modest overweight to information technology and underweight to financials. Outlook & Strategy The outlook for global equities continues to improve, helped by a continued disinflation trend in major developed markets. We believe the probability of a recession in the United States is remote amid ongoing economic resilience, although we continue to be wary of elevated equity valuations. Interest-rate cuts by the Fed 3, ECB, PBoC and other central banks have bolstered equities worldwide. Summer market volatility tested investor conviction, but fundamentals prevailed and stocks quickly rebounded. In the near term we may see continued volatility in reaction to Central bank actions, as well as the impact of the US election. While we expect to see further interest-rate cuts, the expectation of these cuts may be fully reflected in current prices. Against this background, we are confident that investors will continue to reward stocks that are attractively valued and invest in companies that have solid growth prospects and the ability to generate cash for their shareholders. We believe that our well-diversified, disciplined strategy will serve investors well in this environment. Portfolio Diversification Top Holdings % Novo Nordisk A/S (NVO) 2.71 ASML Holding NV (ASML) 2.16 Novartis AG (NVS) 1.88 SAP SE (SAP) 1.56 Roche Holding AG (OTCQX:RHHBY) 1.47 Allianz SE (OTCPK:ALIZF) 1.18 Hitachi Ltd (OTCPK:HTHIY) 1.14 UniCredit SpA (OTCPK:UNCFF) 1.11 Nestle SA (OTCPK:NSRGY) 1.06 Deutsche Telekom AG (OTCQX:DTEGY) 1.05 Click to enlarge Footnotes 1 Diversification does not assure a profit or protect against loss. It is possible to lose money in a diversified portfolio. 2 Forward price to earnings (forward P/E) is a measure of the price-to-earnings (P/E) ratio using forecasted earnings for the P/E calculation. 3 The Federal Reserve ("Fed") is responsible for the formulation of policies designed to promote economic growth, full employment, stable prices, and a sustainable pattern of international trade and payments. 4 Periods shorter than one year are shown as cumulative total returns. Not FDIC Insured | No Bank Guarantee | May Lose Value Inception Date 12/31/1992 Benchmark MSCI EAFE Index-NR Click to enlarge Fund Details Fund Description Seeks maximum long-term total return by investing primarily in non-U.S. stocks. Uses a quantitative process that assesses stocks by relative attractiveness based on a variety of measures including value, cash flow, earnings growth and sentiment. Region, country and sector allocations are based on rankings generated by the subadviser's proprietary models. May invest up to 35% of its total assets in emerging markets. Investment Team Chris Floyd, CFA Years with Firm 24 Years Experience 25 Sundaram Chettiappan, CFA Years with Firm 5 Years Experience 18 Chandra Seethamraju, Ph.D. Years with Firm 11 Years Experience 24 Click to enlarge What Are The Risks? All investments involve risks, including possible loss of principal. Equity securities are subject to price fluctuation and possible loss of principal. International investments are subject to special risks, including currency fluctuations and social, economic and political uncertainties, which could increase volatility. These risks are magnified in emerging markets. Active and frequent trading may increase a shareholder's tax liability and transaction costs. To the extent the portfolio invests in a concentration of certain securities, regions or industries, it is subject to increased volatility. Derivative instruments can be illiquid, may disproportionately increase losses, and have a potentially large impact on performance. These and other risks are discussed in the fund's prospectus. Important Information The information provided is not a complete analysis of every material fact regarding any country, market, industry, security or fund. Because market and economic conditions are subject to change, comments, opinions and analyses are rendered as of the date of this material and may change without notice. A portfolio manager's assessment of a particular security, investment or strategy is not intended as individual investment advice or a recommendation or solicitation to buy, sell or hold any security or to adopt any investment strategy; it is intended only to provide insight into the fund's portfolio selection process. Holdings are subject to change. Before investing, carefully consider a fund's investment objectives, risks, charges and expenses. You can find this and other information in each prospectus, or summary prospectus, if available, at www.franklintempleton.com. Please read it carefully. Franklin Distributors, LLC. Member FINRA/SIPC. Franklin Distributors, LLC and Franklin Templeton Investment Solutions are Franklin Templeton companies. CFA® and Chartered Financial Analyst® are trademarks owned by CFA Institute. Source: FactSet. Important data provider notices and terms available at www.franklintempletondatasources.com. a. Gross expenses are the fund's total annual operating expenses as of the fund's prospectus available at the time of publication. Actual expenses may be higher and may impact portfolio returns. Net expenses reflect contractual fee waivers, expense caps and/or reimbursements, which cannot be terminated prior to 12/31/2025 without Board consent. Additional amounts may be voluntarily waived and/or reimbursed and may be modified or discontinued at any time without notice. © 2024 Franklin Templeton. All rights reserved. Click to enlarge Original Post Editor's Note: The summary bullets for this article were chosen by Seeking Alpha editors.Editor's Note: This article discusses one or more securities that do not trade on a major U.S. exchange. Please be aware of the risks associated with these stocks.
- 11/22/2024
|
Ypsomed will make injection pens for Novo Nordisk's CagriSema, says source
- Swiss medical technology company Ypsomed's contract with Novo Nordisk includes the supply of injection pens for the Danish drugmaker's next-generation experimental obesity drug CagriSema, a source familiar with the matter has told Reuters.
- 11/22/2024
|
PFE vs. NVO: Which Stock Is the Better Value Option?
- Investors interested in stocks from the Large Cap Pharmaceuticals sector have probably already heard of Pfizer (PFE) and Novo Nordisk (NVO). But which of these two stocks offers value investors a better bang for their buck right now?
- 11/21/2024
|
Are Dietary Drug Stocks Eli Lilly and Novo Nordisk Ready To Rise Again?
- In today's article I will try to answer the question on whether the two premier diet drug companies stocks have finally stopped going down? I will look at two stocks (dietary drug is in parenthesis): Novo Nordisk NYSE:NVO (Wegovy) and Eli Lilly NYSE:LLY (Zepbound) Today I read this: WEIGHT-LOSS DRUG COVERAGE RISES AMONG LARGE US
- 11/20/2024
|
Is Novo Nordisk Stock a Buy Right Now?
- Novo Nordisk stock has been pretty volatile lately, making it hard to judge whether now is a good opportunity to buy shares.
- 11/20/2024
|
Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons
- Bagsværd, Denmark, 19 November 2024 — This company announcement discloses the data of the transaction(s) made in Novo Nordisk shares by the company's board members, executives and their associated persons in accordance with Article 19 of Regulation No. 596/2014 on market abuse.
- 11/19/2024
|
Novo Nordisk A/S (NVO) Price Prediction and Forecast 2025-2030
- When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion sales in 2023, it shows no signs of slowing down, much to the delight of its Danish manufacturer, Novo Nordisk A/S (NYSE: NVO). A Scandinavian economic behemoth, Novo Nordisk is the highest valued company in Europe at over $500 billion, which exceeds Denmark’s entire GDP. Ironically, Ozempic and Wegovy, as with many of Novo Nordisk’s other products, were created primarily for treating diabetes. The weight-loss factor has become a very profitable and unintended side-effect. Founded a century ago, Copenhagen-based Nordisk originally made insulin. After coming to the US in 1982, it underwent several corporate changes until becoming Novo Nordisk in 1989. In addition to diabetes drugs, the company also makes drug treatments for wound healing, menopausal hormone replacement, and human growth hormone. Headwinds While Novo Nordisk has built itself into a pharmaceutical giant, it has seriously run afoul of regulatory laws on several occasions. Novo Nordisk’s practices have raised red flags in Denmark as well as in the US and UK for years, with the more recent ones being: A 2017 $59 million fine from the DOJ due to lack of FDA disclosures concerning cancer risks from diabetes drug Victoza; Membership suspension from the UK’s Association of British Pharmacy Industry over ethics violations tantamount to bribing of health professionals; 235 active Ozempic related product liability lawsuits as of August, 2024; A 2024 investigation led by the US Senate confirmed predatory pricing of Ozempic by almost 1500% vs. its price in Europe, and 1000% for Wegovy. Regardless, investors are much more concerned with future stock performance over the next 1, 5, to 10 years. While most Wall Street analysts will calculate 12-month forward projections, it’s clear that nobody has a consistent crystal ball, and plenty of unforeseen circumstances can render even near term projections irrelevant. 24/7 Wall Street aims to present some farther looking insights based on Novo Nordisk’s own numbers, along with business and market development information that may be of help to our readers’ own research. Key Points In This Article Novo Nordisk’s R&D is heavily invested in improved obesity treatments Novo Nordisk sees the obesity drug market expanding to $100 billion by 2030. To that end, it has Amycretin in FDA phase-1 and CagriSegma in phase-2 trials, which both show greater efficacy potential than Wegovy and Ozempic. Although the number of Ozempic-related lawsuits are piling up, Novo Nordisk’s stance is that the complaints are unwarranted, and will either be dismissed or settled. Novo Nordisk’s past acquisitions for both greater production capacity and logistical flexibility will reap benefits through geopolitical risk mitigation and broader product menu options. Entering untapped markets, such as China, will be key to Novo Nordisk’s future growth. If you’re looking for some stocks with huge potential, make sure to grab a free copy of our brand-new “The Next NVIDIA” report. It features a software stock we’re confident has 10X potential. Novo Nordisk News and Updates 11/18/2024 Novo Nordisk is launching a share repurchase program. The company plans to buy back up to DKK 20 billion worth of B shares over the next 12 months, starting in February 2024. To date, Novo Nordisk has already purchased B shares valued at over DKK 17 billion. The latest phase of the repurchase program will see Novo Nordisk buy back up to DKK 3.1 billion worth of B shares between November 11, 2024, and February 3, 2025. 5-10 Year Review Novo Nordisk bread and butter diabetes and obesity drugs obscure its other remedies for estrogen replacement, wound treatment, and HGH, among others. Novo Nordisk has spared no expense in expanding its pharmaceutical reach and scope. In addition to adding new factories to ramp up production to meet demand for Ozempic and Wegovy, the company’s expansion towards treating other afflictions saw billions spent in acquisitions. The past decade has seen the following events: In 2015, Novo Nordisk announced a $400 million collaboration with Sanofi subsidiary Ablynx, to use its nanobody technology to develop a new drug. After an unsuccessful bid to acquire Ablynx in 2018, Novo Nordisk bought diabetes drug company Ziylo. 2020 saw Novo Nordisk buying Corvidia Therapeutics from AstraZeneca for its heart disease treatments. Novo Nordisk announced it would acquire Emisphere Technologies for $1.35 billion in December 2020, adding another diabetes pill to its catalog. In November 2021, Novo Nordisk acquired Dicerna Pharmaceuticals and its RNAi therapeutics, for $3.3 billion. Intending to expand its sickle cell disease and rare blood disorders portfolio, 2022 saw Novo Nordisk buying Forma Therapeutics for $1.1 billion. Flush with Ozempic and Wegovy cash, Novo Nordisk bought Inversago Pharma for $1 billion, Embark Biotech for up to $500 million, ocedurenone—an experimental drug for uncontrolled hypertension and potentially beneficial in treating cardiovascular and kidney diseases—from KBP Biosciences for $1.3 billion during 2023. To address expanding Ozempic and Wegovy demand, Novo Nordisk’s parent, Novo Holdings, bought NJ-based Catalent, a global provider of drug delivery systems, gene therapies, manufacturing, biologics, and other operations, in 2024. 2024 also saw the acquisitions of Cardior Pharmaceuticals for its cardiovascular treatment portfolio, and Austria’s Single use Support, a fluid management company. Fiscal Year (DEC) Price Revenues Net Income DKK (=US$0.15) DKK (=US$0.15) 2015 $29.04 107.927B/$16.19B 34.860B/$5.23B 2016 $17.93 111.780B/$16.76B 37.925B/$5.69B 2017 $26.83 111.696B/$16.75B 38.130B/$5.72B 2018 $23.03 111.831B/$16.77B 38.628B/$5.79B 2019 $28.94 122.021B/$18.30B 38.951B/$5.84B 2020 $34.92 126.946B/$19.04B 42.138B/$6.32B 2021 $56.00 140.800B/$21.12B 47.757B/$7.16B 2022 $67.67 176.954B/$26.54B 55.525B/$8.33B 2023 $103.45 232.261B/$34.84B 83.683B/$12.55B 2024 LTM (as of June) $142.74 258.003B/$38.70B 89.898B/$13.48B Key Drivers for Novo Nordisk’s Stock in the Future The obesity and weight-loss drug market is expected to his $100 billion by 2030. A more potent obesity treatment called CagriSema combines semaglutide, the active ingredient in Ozempic, with amylin and calcitonin receptor agonists. Amylin helps regulate blood sugar levels, similar to GLP-1, while calcitonin controls calcium levels in the blood. Results for two late-stage FDA trials of the drug are expected by the end of 2024. Wegovy’s June 2024 approval for sales in China opens the door to a new market, which has hundreds of million prospective new customers from China’s burgeoning middle and upper class. New experimental obesity drug Amycretin, a single molecule that operates as a GLP-1 receptor agonist that reduces one’s appetite, is in phase-1 FDA trials. The new pill achieved a 13.1% average weight loss after 12 weeks, more than doubling the efficacy of Wegovy for the same time span. With the obesity drug market expected to reach $100 billion by 2030, genetic-based treatments currently in the R&D stage could become the next pharma golden ring. While some legal experts believe that the number of Ozempic lawsuits over gastroparesis and other afflictions, such as pancreatitis, kidney, and gallbladder issues, can reach as high as 20,000, Novo Nordisk is apparently confident it can reach a settlement that will allow it to continue its growth trajectory without impediment. Stock Price Prediction for 2025 Out of 11 Wall Street analysts, their consensus recommendation is “outperform/hold”, based on 5 buy, 2 outperform, 2 hold, and 2 sell. Their consensus 12-month target price for Novo Nordisk is $140.07, which is a 37.67% gain over today’s stock price. The 24/7 Wall Street 12-month projected target is a more conservative $124.20. This would be a 22.08% gain from today’s price. Novo Nordisk’s Next 5 Years’ Outlook Novo Nordisk’s median P/E ratio has been 26.40 from 2010 to the present. The following price predictions are based on a 25 P/E. In the subsequent 5 years to follow, Novo Nordisk’s newest products, presently in FDA trials, are targeting the obesity market. It is anticipated to reach $100 billion by 2030. Obesity drugs competing against offerings from Eli Lilly and other rivals require drugs that meet the following criteria: Sufficient efficacy to fulfill the medical needs of a large population of patients; Tolerable enough for prolonged patient treatment to obtain a significant and consistent therapeutic effect; Flexible enough to be prescribed to patients without an abundance of diagnostic testing or monitoring; Formulaically efficient enough to manufacture and distribute at scale. With Wegovy gaining acceptance for China in Q2 2024, this opens the door for Novo Nordisk to gain a foothold in a potentially larger market than the entirety of its European share. China’s middle and wealthy classes have multiplied exponentially as China’s GDP has grown. Obesity, heart diseases, and other ailments common in the West have escalated in China as diets and lifestyles adapted to mimic Western tastes and trends. Our price target for 2026 is $136.62. The new obesity drug CagriSema is presently near completion of FDA phase-2 trials. Assuming there are no negative results to bar initiating clinical phase-3 trials, these would presumably occur throughout 2025 and 2026. Therefore, CagriSema is likely to be cleared for public dissemination and ready for market by 2027. Although it is administered via injection, rather than in pill form, early results show a 200% higher weight loss reduction in 32 weeks, over Wegovy. Our price target for 2027 is $153.01. Although Novo Nordisk’s pipeline of new drugs under FDA review targets obesity, its revamped product menu has expanded via acquisitions. Revenues from its HGH, estrogen replacement, and wound treatment products, as well as other diabetes variants, should all contribute to the bottom line with full production, marketing, and sales integration by 2028. We predict a price of $165.26. Obesity pill Amecrytin, which acts as an appetite suppressant without the effects of amphetamines, is presently in FDA phase-1 trials, but should be cleared for market and ready for distribution in 2029. Its weight-loss efficacy doubles that of Wegovy in shorter 3-month periods, and its pill configuration convenience should make it a hit prescription for doctors. Our price target is $186.74. Novo Nordisk Stock in 2030 Ozempic is an injection administered drug. R&D for a genetic based obesity drug is currently in the works by Novo Nordisk, Eli Lilly, and several other rivals. With the obesity treatment market expected to hit $100 billion in 2030, even the announcement of a genetic-based drug ready to start FDA trials would generate significant buzz. With Novo Nordisk the current market leader, such an announcement in 2030 is not a stretch. Our target price is $192.34. Cumulatively, 24/7 Wall Street anticipates Novo Nordisk to appreciate 79% over the next 5 years. Year EPS P/E multiple Price 2025 $4.97 25 $124.20 2026 $5.46 25 $136.62 2027 $6.12 25 $153.01 2028 $6.61 25 $165.26 2029 $7.47 25 $186.74 2030 $7.69 25 $192.34 The #1 Thing to Do Before You Claim Social Security (Sponsor) Choosing the right (or wrong) time to claim Social Security can dramatically change your retirement. So, before making one of the biggest decisions of your financial life, it’s a smart idea to get an extra set of eyes on your complete financial situation. A financial advisor can help you decide the right Social Security option for you and your family. Finding a qualified financial advisor doesn’t have to be hard. SmartAsset’s free tool matches you with up to three financial advisors who serve your area, and you can interview your advisor matches at no cost to decide which one is right for you. Click here to match with up to 3 financial pros who would be excited to help you optimize your Social Security outcomes. Have questions about retirement or personal finance? Email us at Retire@247wallst.com! By emailing your questions to 24/7 Wall St., you agree to have them published anonymously on 247wallst.com. By submitting your story, you understand and agree that we may use your story, or versions of it, in all media and platforms, including via third parties. The post Novo Nordisk A/S (NVO) Price Prediction and Forecast 2025-2030 appeared first on 24/7 Wall St..
- 11/19/2024
|
Medicaid dominates coverage of Novo, Lilly weight-loss drugs
- U.S. government health plans account for the lion's share of coverage for popular new weight-loss drugs, far beyond the reimbursement available from private employers and insurers, according to an analysis shared with Reuters.
- 11/18/2024
|
Novo Nordisk launches Wegovy weight drug in China at fraction of price
- Novo Nordisk (NYSE:NVO) has begun rolling out its Wegovy weight loss drug in China at well below the price of the product in the US. A month's supply of the starter dose of Wegovy in China has been priced at 1,400 yuan ($193.27), according to Chinese financial media outlet Yicai.
- 11/18/2024
|
Novo Nordisk A/S - share repurchase programme
- Bagsværd, Denmark, 18 November 2024 – On 11 November 2024, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules"). This programme is part of the overall share repurchase programme of up to DKK 20 billion to be executed during a 12-month period beginning 6 February 2024.
- 11/18/2024
|
Novo Nordisk has launched obesity drug Wegovy in China
- Novo Nordisk said on Monday it has launched its popular obesity drug Wegovy in China, the world's second-largest pharmaceuticals market.
- 11/18/2024
|
3 Growth Stocks You Can Buy Right Now Without Any Hesitation
- 3 Growth Stocks You Can Buy Right Now Without Any Hesitation
- 11/18/2024
|
Eli Lilly and Novo Want to Shake off Ozempic Copycats. Are They Ready To Meet Demand?
- The makers of Ozempic and Zepbound are fighting to stop compounded copies of their drugs. But it's unclear whether they can ramp up production enough.
- 11/17/2024
|
Vaccine Maker Stocks Slump After RFK Jr. Nominated as HHS Head
- In the 2024 presidential election's latest impact on the stock markets, shares of several vaccine makers were down Friday morning following the nomination of Robert F. Kennedy Jr. to head the Department of Health and Human Services.
- 11/15/2024
|
Novo Nordisk A/S (NVO) Price Prediction and Forecast 2025-2030
- When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion sales in 2023, it shows no signs of slowing down, much to the delight of its Danish manufacturer, Novo Nordisk A/S (NYSE: NVO). A Scandinavian economic behemoth, Novo Nordisk is the highest valued company in Europe at over $500 billion, which exceeds Denmark’s entire GDP. Ironically, Ozempic and Wegovy, as with many of Novo Nordisk’s other products, were created primarily for treating diabetes. The weight-loss factor has become a very profitable and unintended side-effect. Founded a century ago, Copenhagen-based Nordisk originally made insulin. After coming to the US in 1982, it underwent several corporate changes until becoming Novo Nordisk in 1989. In addition to diabetes drugs, the company also makes drug treatments for wound healing, menopausal hormone replacement, and human growth hormone. Headwinds While Novo Nordisk has built itself into a pharmaceutical giant, it has seriously run afoul of regulatory laws on several occasions. Novo Nordisk’s practices have raised red flags in Denmark as well as in the US and UK for years, with the more recent ones being: A 2017 $59 million fine from the DOJ due to lack of FDA disclosures concerning cancer risks from diabetes drug Victoza; Membership suspension from the UK’s Association of British Pharmacy Industry over ethics violations tantamount to bribing of health professionals; 235 active Ozempic related product liability lawsuits as of August, 2024; A 2024 investigation led by the US Senate confirmed predatory pricing of Ozempic by almost 1500% vs. its price in Europe, and 1000% for Wegovy. Regardless, investors are much more concerned with future stock performance over the next 1, 5, to 10 years. While most Wall Street analysts will calculate 12-month forward projections, it’s clear that nobody has a consistent crystal ball, and plenty of unforeseen circumstances can render even near term projections irrelevant. 24/7 Wall Street aims to present some farther looking insights based on Novo Nordisk’s own numbers, along with business and market development information that may be of help to our readers’ own research. Key Points In This Article Novo Nordisk’s R&D is heavily invested in improved obesity treatments Novo Nordisk sees the obesity drug market expanding to $100 billion by 2030. To that end, it has Amycretin in FDA phase-1 and CagriSegma in phase-2 trials, which both show greater efficacy potential than Wegovy and Ozempic. Although the number of Ozempic-related lawsuits are piling up, Novo Nordisk’s stance is that the complaints are unwarranted, and will either be dismissed or settled. Novo Nordisk’s past acquisitions for both greater production capacity and logistical flexibility will reap benefits through geopolitical risk mitigation and broader product menu options. Entering untapped markets, such as China, will be key to Novo Nordisk’s future growth. If you’re looking for some stocks with huge potential, make sure to grab a free copy of our brand-new “The Next NVIDIA” report. It features a software stock we’re confident has 10X potential. 5-10 Year Review Novo Nordisk bread and butter diabetes and obesity drugs obscure its other remedies for estrogen replacement, wound treatment, and HGH, among others. Novo Nordisk has spared no expense in expanding its pharmaceutical reach and scope. In addition to adding new factories to ramp up production to meet demand for Ozempic and Wegovy, the company’s expansion towards treating other afflictions saw billions spent in acquisitions. The past decade has seen the following events: In 2015, Novo Nordisk announced a $400 million collaboration with Sanofi subsidiary Ablynx, to use its nanobody technology to develop a new drug. After an unsuccessful bid to acquire Ablynx in 2018, Novo Nordisk bought diabetes drug company Ziylo. 2020 saw Novo Nordisk buying Corvidia Therapeutics from AstraZeneca for its heart disease treatments. Novo Nordisk announced it would acquire Emisphere Technologies for $1.35 billion in December 2020, adding another diabetes pill to its catalog. In November 2021, Novo Nordisk acquired Dicerna Pharmaceuticals and its RNAi therapeutics, for $3.3 billion. Intending to expand its sickle cell disease and rare blood disorders portfolio, 2022 saw Novo Nordisk buying Forma Therapeutics for $1.1 billion. Flush with Ozempic and Wegovy cash, Novo Nordisk bought Inversago Pharma for $1 billion, Embark Biotech for up to $500 million, ocedurenone—an experimental drug for uncontrolled hypertension and potentially beneficial in treating cardiovascular and kidney diseases—from KBP Biosciences for $1.3 billion during 2023. To address expanding Ozempic and Wegovy demand, Novo Nordisk’s parent, Novo Holdings, bought NJ-based Catalent, a global provider of drug delivery systems, gene therapies, manufacturing, biologics, and other operations, in 2024. 2024 also saw the acquisitions of Cardior Pharmaceuticals for its cardiovascular treatment portfolio, and Austria’s Single use Support, a fluid management company. Fiscal Year (DEC) Price Revenues Net Income DKK (=US$0.15) DKK (=US$0.15) 2015 $29.04 107.927B/$16.19B 34.860B/$5.23B 2016 $17.93 111.780B/$16.76B 37.925B/$5.69B 2017 $26.83 111.696B/$16.75B 38.130B/$5.72B 2018 $23.03 111.831B/$16.77B 38.628B/$5.79B 2019 $28.94 122.021B/$18.30B 38.951B/$5.84B 2020 $34.92 126.946B/$19.04B 42.138B/$6.32B 2021 $56.00 140.800B/$21.12B 47.757B/$7.16B 2022 $67.67 176.954B/$26.54B 55.525B/$8.33B 2023 $103.45 232.261B/$34.84B 83.683B/$12.55B 2024 LTM (as of June) $142.74 258.003B/$38.70B 89.898B/$13.48B Key Drivers for Novo Nordisk’s Stock in the Future The obesity and weight-loss drug market is expected to his $100 billion by 2030. A more potent obesity treatment called CagriSema combines semaglutide, the active ingredient in Ozempic, with amylin and calcitonin receptor agonists. Amylin helps regulate blood sugar levels, similar to GLP-1, while calcitonin controls calcium levels in the blood. Results for two late-stage FDA trials of the drug are expected by the end of 2024. Wegovy’s June 2024 approval for sales in China opens the door to a new market, which has hundreds of million prospective new customers from China’s burgeoning middle and upper class. New experimental obesity drug Amycretin, a single molecule that operates as a GLP-1 receptor agonist that reduces one’s appetite, is in phase-1 FDA trials. The new pill achieved a 13.1% average weight loss after 12 weeks, more than doubling the efficacy of Wegovy for the same time span. With the obesity drug market expected to reach $100 billion by 2030, genetic-based treatments currently in the R&D stage could become the next pharma golden ring. While some legal experts believe that the number of Ozempic lawsuits over gastroparesis and other afflictions, such as pancreatitis, kidney, and gallbladder issues, can reach as high as 20,000, Novo Nordisk is apparently confident it can reach a settlement that will allow it to continue its growth trajectory without impediment. Stock Price Prediction for 2025 Out of 11 Wall Street analysts, their consensus recommendation is “outperform/hold”, based on 5 buy, 2 outperform, 2 hold, and 2 sell. Their consensus 12-month target price for Novo Nordisk is $140.07, which is a 31.02% gain over today’s stock price. The 24/7 Wall Street 12-month projected target is a more conservative $124.20. This would be a 16.17% gain from today’s price. Novo Nordisk’s Next 5 Years’ Outlook Novo Nordisk’s median P/E ratio has been 26.40 from 2010 to the present. The following price predictions are based on a 25 P/E. In the subsequent 5 years to follow, Novo Nordisk’s newest products, presently in FDA trials, are targeting the obesity market. It is anticipated to reach $100 billion by 2030. Obesity drugs competing against offerings from Eli Lilly and other rivals requires drugs that meet the following criteria: Sufficient efficacy to fulfill the medical needs of a large population of patients; Tolerable enough for prolonged patient treatment to obtain a significant and consistent therapeutic effect; Flexible enough to be prescribed to patients without an abundance of diagnostic testing or monitoring; Formulaically efficient enough to manufacture and distribute at scale. With Wegovy gaining acceptance for China in Q2 2024, this opens the door for Novo Nordisk to gain a foothold in a potentially larger market than the entirety of its European share. China’s middle and wealthy classes have multiplied exponentially as China’s GDP has grown. Obesity, heart diseases, and other ailments common in the West have escalated in China as diets and lifestyles adapted to mimic Western tastes and trends. Our price target for 2026 is $136.62. The new obesity drug CagriSema is presently near completion of FDA phase-2 trials. Assuming there are no negative results to bar initiating clinical phase-3 trials, these would presumably occur throughout 2025 and 2026. Therefore, CagriSema is likely to be cleared for public dissemination and ready for market by 2027. Although it is administered via injection, rather than in pill form, early results show a 200% higher weight loss reduction in 32 weeks, over Wegovy. Our price target for 2027 is $153.01. Although Novo Nordisk’s pipeline of new drugs under FDA review targets obesity, its revamped product menu has expanded via acquisitions. Revenues from its HGH, estrogen replacement, and wound treatment products, as well as other diabetes variants, should all contribute to the bottom line with full production, marketing, and sales integration by 2028. We predict a price of $165.26. Obesity pill Amecrytin, which acts as an appetite suppressant without the effects of amphetamines, is presently in FDA phase-1 trials, but should be cleared for market and ready for distribution in 2029. Its weight-loss efficacy doubles that of Wegovy in shorter 3-month periods, and its pill configuration convenience should make it a hit prescription for doctors. Our price target is $186.74. Novo Nordisk Stock in 2030 Ozempic is an injection administered drug. R&D for a genetic based obesity drug is currently in the works by Novo Nordisk, Eli Lilly, and several other rivals. With the obesity treatment market expected to hit $100 billion in 2030, even the announcement of a genetic-based drug ready to start FDA trials would generate significant buzz. With Novo Nordisk the current market leader, such an announcement in 2030 is not a stretch. Our target price is $192.34. Cumulatively, 24/7 Wall Street anticipates Novo Nordisk to appreciate 79% over the next 5 years. Year EPS P/E multiple Price 2025 $4.97 25 $124.20 2026 $5.46 25 $136.62 2027 $6.12 25 $153.01 2028 $6.61 25 $165.26 2029 $7.47 25 $186.74 2030 $7.69 25 $192.34 The #1 Thing to Do Before You Claim Social Security (Sponsor) Choosing the right (or wrong) time to claim Social Security can dramatically change your retirement. So, before making one of the biggest decisions of your financial life, it’s a smart idea to get an extra set of eyes on your complete financial situation. A financial advisor can help you decide the right Social Security option for you and your family. Finding a qualified financial advisor doesn’t have to be hard. SmartAsset’s free tool matches you with up to three financial advisors who serve your area, and you can interview your advisor matches at no cost to decide which one is right for you. Click here to match with up to 3 financial pros who would be excited to help you optimize your Social Security outcomes. Have questions about retirement or personal finance? Email us at Retire@247wallst.com! By emailing your questions to 24/7 Wall St., you agree to have them published anonymously on 247wallst.com. By submitting your story, you understand and agree that we may use your story, or versions of it, in all media and platforms, including via third parties. The post Novo Nordisk A/S (NVO) Price Prediction and Forecast 2025-2030 appeared first on 24/7 Wall St..
- 11/14/2024
|
Novo Nordisk says it is gradually phasing out human insulin pens globally
- Novo Nordisk is gradually ending production of human insulin pens, the drugmaker told Reuters, as it spends billions to ramp up manufacturing of its popular obesity and diabetes injections.
- 11/14/2024
|
EU regulators quiz Novo Nordisk, Catalent rivals on $16.5 bln deal
- EU antitrust regulators have asked pharma rivals and customers for feedback in four business areas in light of Novo Holdings' planned $16.5 billion takeover of Catalent , people familiar with the matter said.
- 11/13/2024
|
Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons
- Bagsværd, Denmark, 13 November 2024 — This company announcement discloses the data of the transaction(s) made in Novo Nordisk shares by the company's board members, executives and their associated persons in accordance with Article 19 of Regulation No. 596/2014 on market abuse.
- 11/13/2024
|
Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons
- Bagsværd, Denmark, 12 November 2024 — This company announcement discloses the data of the transaction(s) made in Novo Nordisk shares by the company's board members, executives and their associated persons in accordance with Article 19 of Regulation No. 596/2014 on market abuse.
- 11/12/2024
|
Here's Why Novo Nordisk (NVO) is a Strong Growth Stock
- The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
- 11/12/2024
|
Novo Stock Has Been Slammed. How a New Weight-Loss Drug Could Boost Shares by 10%.
- Novo drug CagriSema, which combines semaglutide with cagrilintide, could help patients lose 25% of their body weight.
- 11/11/2024
|
Novo Nordisk A/S (NVO) Price Prediction and Forecast 2025-2030
- When it comes to weight loss drugs, Ozempic has become a phenomenon.
- 11/11/2024
|
Novo Nordisk: Be Greedy When Others Are Fearful
- Novo Nordisk's stock has dropped to $110 per share, but operational performance remains strong, with no signs of business deterioration. Despite Eli Lilly's underperformance in GLP-1 sales, Novo Nordisk's diabetes and obesity treatments, especially Ozempic and Wegovy, continue to show robust growth. Legal concerns over compounded versions of Ozempic and Wegovy exist, but I believe Novo Nordisk's brand trust and regulatory backing will mitigate long-term impact.
- 11/11/2024
|
Does This New Issue Threaten Eli Lilly and Novo Nordisk Shares?
- The good times aren't over, but the peak of the party might be passing.
- 11/10/2024
|
Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons
- Bagsværd, Denmark, 8 November 2024 – This company announcement discloses the data of the transaction(s) made in Novo Nordisk shares by the company's board members, executives and their associated persons in accordance with Article 19 of Regulation No. 596/2014 on market abuse.
- 11/08/2024
|
Novo Nordisk A/S - share repurchase programme
- Bagsværd, Denmark, 8 November 2024 – The execution of Novo Nordisk A/S' overall share repurchase programme for 2024 of DKK 20 billion continues. As part of this, Novo Nordisk A/S has now initiated a new share repurchase programme of up to DKK 3,136,206,122.30 in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules”).
- 11/08/2024
|
Novo Nordisk A/S purchases B shares worth DKK 4,736 million from Novo Holdings A/S under the 2024 share repurchase programme
- Bagsværd, Denmark, 8 November 2024 – Today, Novo Nordisk A/S has entered into an agreement to purchase 6,311,250 B shares of DKK 0.10 at a value of DKK 4,736,088,225.00 from Novo Holdings A/S. The transaction is part of Novo Nordisk A/S' 2024 share repurchase programme of up to a total of DKK 20 billion to be executed during a 12-month period beginning 6 February 2024. The transaction price is DKK 750.42 per share and has been calculated as the three-day volume weighted average market price from 6 November 2024 to 8 November 2024 in the open window following the announcement of Novo Nordisk A/S' quarterly financial results.
- 11/08/2024
|
Bristol-Myers Squibb Leads Biopharma Recovery With Almost 25% Growth In Market Cap, But Novo Nordisk And Lilly Suffer Market Setbacks
- The biopharmaceutical sector showed signs of recovery in the third quarter of 2024, fueled by increased investor optimism following the U.S. Federal Reserve's interest rate cuts in September.
- 11/08/2024
|
Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons
- Bagsværd, Denmark, 8 November 2024 — This company announcement discloses the data of the transaction(s) made in Novo Nordisk shares by the company's board members, executives and their associated persons in accordance with Article 19 of Regulation No. 596/2014 on market abuse.
- 11/08/2024
|
Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons
- Bagsværd, Denmark, 7 November 2024 — This company announcement discloses the data of the transaction(s) made in Novo Nordisk shares by the company's board members, executives and their associated persons in accordance with Article 19 of Regulation No. 596/2014 on market abuse.
- 11/07/2024
|
Novo Nordisk CEO on earnings: Very bullish on 2025 despite demand concerns
- Lars Fruergaard Jørgensen, Novo Nordisk CEO, joins 'Money Movers' to discuss Jorgensen's comments on demand in 2025, if demand is waning for GLP-1 drugs, and much more.
- 11/07/2024
|
These 3 Stocks Are Winning Thanks to Baby Boomers
- According to a March 2023 study from the Bank of America Institute about consumer spending, seniors born in 1964 or earlier were the only age cohort in the U.S.
- 11/07/2024
|
Novo Nordisk expects high demand for its obesity drugs in India, says country head
- Popular weight-loss drug Wegovy maker Novo Nordisk expects high demand and acceptance for its anti-obesity drug, when launched in India, a top executive said.
- 11/06/2024
|
NVO Misses Q3 Earnings & Revenue Estimates, Updates 2024 View
- Novo Nordisk reports lower-than-expected Q3 results, missing both earnings and revenue estimates. Management updates 2024 financial guidance.
- 11/06/2024
|
Novo Nordisk A/S (NVO) Q3 2024 Earnings Call Transcript
- Novo Nordisk A/S (NVO) Q3 2024 Earnings Conference Call November 6, 2024 7:00 AM ET Company Participants Jacob Martin Wiborg Rode - Head of Investor Relations Lars Fruergaard Jorgensen - President and Chief Executive Officer Camilla Sylvest - Executive Vice President and Head of Commercial Strategy & Corporate Affairs Doug Langa - Executive Vice President and Head of North America Operations Martin Holst Lange - Executive Vice President and Head of Development Karsten Munk Knudsen - Executive Vice President and Chief Financial Officer Conference Call Participants Richard Parkes - BNP Paribas Exane Sachin Jain - Bank of America Louise Chen - Cantor Fitzgerald Michael Nedelcovych - TD Cowen Jo Walton - UBS Richard Vosser - JPMorgan Florent Cespedes - Bernstein Martin Parkhoi - SEB Kerry Holford - Berenberg Mattias Haggblom - Handelsbanken Operator Good day, and thank you for standing by. Welcome to the Third Quarter 2024 Novo Nordisk A/S Earnings Conference Call.
- 11/06/2024
|
Novo Nordisk Stock Slips as Sales Grow Less Than Expected
- After rising in premarket trading, Novo Nordisk's (NVO) U.S.-listed shares fell after the market opened Wednesday as its third-quarter sales fell short of estimates despite continued growth form weight-loss drugs Ozempic and Wegovy.
- 11/06/2024
|
Novo Nordisk CFO says 2025 sales could see high-teens percentage growth
- Novo Nordisk's sales growth next year could be in the high teens in percentage terms, Chief Financial Officer Karsten Munk Knudsen said on an analyst call following the release of third-quarter earnings on Wednesday.
- 11/06/2024
|
Novo Nordisk Stock Rises on Earnings Beat, Narrowed Outlook
- Novo Nordisk's (NVO) U.S.-listed shares rose Wednesday morning as it reported better third-quarter profits than expected, though sales of its drugs including popular weight-loss treatments Ozempic and Wegovy grew less than expected.
- 11/06/2024
|
Novo Nordisk CEO on Wegovy prices, supplies and compounding
- Novo Nordisk reported forecast-beating quarterly sales of its popular Wegovy weight-loss drug on Wednesday, sending its shares up nearly 9%.
- 11/06/2024
|
Ozempic maker Novo Nordisk nudges higher profit forecast
- Novo Nordisk on Wednesday nudged higher its outlook for the year as the drugmaker registered another quarter of strong sales of its weight-loss drugs.
- 11/06/2024
|
Novo Nordisk says its experimental drug CagriSema has similar side effects to Wegovy
- Novo Nordisk said the side effects in trials so far for its experimental obesity drug CagriSema were similar to its GLP-1 drugs already on the market, and reiterated its expectation the new injection will deliver 25% weight loss.
- 11/06/2024
|
Novo Nordisk lifts curbs on Wegovy prescriptions in the U.S., says CEO
- Novo Nordisk is lifting curbs on prescriptions of its weight-loss drug Wegovy in the United States and is increasing supply in that market, its CEO said on Wednesday.
- 11/06/2024
|
Novo Nordisk says it is aware of 10 deaths from compounded weight-loss drug copies
- Novo Nordisk is aware of 100 hospitalizations and 10 deaths resulting from people taking compounded copies of its popular weight-loss and diabetes drugs, the drugmaker's finance chief said on Wednesday.
- 11/06/2024
|
Novo Nordisk Q3 numbers boosted by Wegovy beat
- Novo Nordisk (NYSE:NVO) reported better-than-expected third-quarter sales of its weight-loss drug Wegovy, reaching $2.49 billion, exceeding analyst expectations of $2.29 billion and increasing 48% from the previous quarter. The strong performance is seen as a positive sign amid competition from Eli Lilly's obesity drug, Zepbound.
- 11/06/2024
|
Novo Nordisk's Wegovy Sales Beat Expectations
- The pharmaceutical giant narrowed its full-year guidance after its blockbuster Wegovy weight-loss drug beat sales expectations in the third quarter.
- 11/06/2024
|
Novo Nordisk quarterly profit meets expectations as Wegovy maker narrows full-year guidance
- Novo Nordisk quarterly profit meets expectations as Wegovy maker narrows full-year guidance
- 11/06/2024
|
Novo Nordisk's sales increased by 23% in Danish kroner and by 24% at constant exchange rates to DKK 204.7 billion in the first nine months of 2024
- Bagsværd, 6 November 2024 - Financial report for the period 1 January 2024 to 30 September 2024
- 11/06/2024
|
Novo Nordisk Q3 in line with expectations, narrows FY guidance range
- Weight-loss and diabetes drugmaker Novo Nordisk on Wednesday posted third-quarter operating profit in line with expectations and narrowed its full-year sales and profit guidance range.
- 11/06/2024
|
Novo Nordisk's sales increased by 23% in Danish kroner and by 24% at constant exchange rates to DKK 204.7 billion in the first nine months of 2024
- Bagsværd, 6 November 2024 - Financial report for the period 1 January 2024 to 30 September 2024
- 11/06/2024
|
Novo Nordisk Earnings Are Soon. It's All About Weight-Loss Drug Sales.
- Investors want assurance the new GLP-1 weight-loss medicines can live up to their blockbuster expectations.
- 11/05/2024
|
What's in Store for These 5 Drug & Biotech Stocks in Q3 Earnings?
- Let us look at five large biotech and generic drug companies, NVO, GILD, MRNA, VTRS and TEVA, which are gearing up for their earnings releases this week.
- 11/05/2024
|
Earnings Exchange: Supermicro, Novo Nordisk, CVS Health
- Steve Grasso, CEO of Grasso Global, joins CNBC's 'The Exchange' to discuss outlooks on three stocks: Supermicro, Novo Nordisk, and CVS Health.
- 11/05/2024
|
PFE or NVO: Which Is the Better Value Stock Right Now?
- Investors looking for stocks in the Large Cap Pharmaceuticals sector might want to consider either Pfizer (PFE) or Novo Nordisk (NVO). But which of these two stocks presents investors with the better value opportunity right now?
- 11/05/2024
|
Novo Nordisk Q3 Preview: Will $285 Million Weight Loss Bet Offset Bearish Charts?
- Novo Nordisk AS NVO will report third-quarter earnings on Wednesday. Wall Street expects 88 cents in EPS and $10.49 billion in revenues when the company reports after market hours.
- 11/05/2024
|
Novo Nordisk A/S - share repurchase programme
- Bagsværd, Denmark, 5 November 2024 – On 7 August 2024, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules"). This programme is part of the overall share repurchase programme of up to DKK 20 billion to be executed during a 12-month period beginning 6 February 2024.
- 11/05/2024
|
Hims & Hers Stock Jumps. A Generic Version of Novo Nordisk Diabetes Drug Is Close.
- The telehealth company will launch a generic version of Novo's type 2 diabetes drug liraglutide in 2025.
- 11/05/2024
|
Catalent misses Q1 revenue estimates ahead of $16.5 bln deal close with Novo Holdings
- Contract drug manufacturer Catalent , which is in the process of being acquired by Novo Holdings, posted a surprise first-quarter loss and revenue below Wall Street estimates on Tuesday.
- 11/05/2024
|
Hims & Hers Health plans to offer generic version of Novo Nordisk's diabetes drug in 2025
- Telehealth firm Hims & Hers Health said on Monday it plans to bring a generic version of Novo Nordisk's diabetes drug, liraglutide, to its platform in 2025.
- 11/04/2024
|
What Wall Street Analysts Think of Novo Nordisk's Stock Ahead of Earnings
- Novo Nordisk (NVO), maker of popular weight-loss drugs Ozempic and Wegovy, is set to report third-quarter earnings Wednesday morning, with Wall Street analysts generally bullish on the Danish drugmaker's stock.
- 11/04/2024
|
Wall Street Bulls Look Optimistic About Novo Nordisk (NVO): Should You Buy?
- When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?
- 11/04/2024
|
Novo Nordisk Before Q3 Earnings: How Should Investors Play the Stock?
- NVO's third-quarter revenues are expected to have been driven by its diabetes and obesity care product sales, especially Wegovy, Ozempic and Rybelsus.
- 11/04/2024
|
Super Micro, Ferrari, Marriott, Airbnb, Novo Nordisk, and More Stocks to Watch This Week
- U.S. Election Day, a Federal Reserve meeting, and earnings reports from around 100 S&P 500 companies.
- 11/03/2024
|
Wegovy effective in MASH fatty liver fibrosis trial says Novo
- Novo Nordisk (NYSE:NVO) has reported another successful trial for its Wegovy or Semaglutide drug, this time in the treatment of fibrosis caused by the fatty liver condition known as MASH. Headline results from part 1 of the ongoing ESSENCE trial, a phase three, 240-week, double-blinded trial in 1,200 adults with metabolic dysfunction-associated steatohepatitis (MASH) and moderate to advanced liver fibrosis, showed it met its primary endpoint, Compared to placebo there was a statistically significant and superior improvement in liver fibrosis with no worsening of steatohepatitis, said the Danish group which is Europe's largest company.
- 11/01/2024
|
Novo's Wegovy helps improve liver fibrosis in late-stage trial
- Novo Nordisk said on Friday its weight-loss drug Wegovy met the main goal of a late-stage trial by showing improvement in liver fibrosis with no worsening of steatohepatitis.
- 11/01/2024
|
Novo Nordisk A/S: Semaglutide 2.4 mg demonstrates superior improvement in both liver fibrosis and MASH resolution in the ESSENCE trial
- Bagsværd, Denmark, 1 November 2024 – Novo Nordisk today announced the headline results from part 1 of the ongoing ESSENCE trial, a pivotal phase 3, 240-week, double-blinded trial in 1,200 adults with metabolic dysfunction-associated steatohepatitis (MASH) and moderate to advanced liver fibrosis (stage 2 or 3)1. Part 1 of the ESSENCE trial evaluated the effect of once-weekly semaglutide 2.4 mg on liver tissue (histology) compared to placebo on top of standard of care for the first 800 randomised people at 72 weeks.
- 11/01/2024
|
Novo Nordisk's Ozempic and Wegovy now available in the U.S. after shortages, FDA says
- All doses of Novo Nordisk's weight loss injection Wegovy and diabetes drug Ozempic are now available in the U.S., according to an update on the FDA's drug shortage database. It is a sign that Novo Nordisk's efforts to ramp up the supply of those drugs are starting to pay off, as demand continues to skyrocket in the U.S.
- 10/30/2024
|
US FDA says lowest dose of Novo Nordisk's weight-loss drug now available
- The lowest dose of Novo Nordisk's weight-loss drug, Wegovy, was listed as available, the U.S. health regulator's website showed on Wednesday.
- 10/30/2024
|
Tiziana Life Sciences reports promising preclinical results for novel combination therapy targeting obesity
- Tiziana Life Sciences Ltd (NASDAQ:TLSA) has reported positive results from a preclinical study evaluating the combination of its lead development candidate intranasal foralumab and semaglutide, which is marketed by Novo Nordisk (NYSE:NVO) under the brand names Ozempic and Wegovy. The study demonstrated that this combination effectively promotes liver homeostasis and reduces inflammation in preclinical models of diet-induced obesity.
- 10/30/2024
|
The Zacks Analyst Blog Apple, Novo Nordisk, RTX and FONAR
- Apple, Novo Nordisk, RTX and FONAR are included in this Analyst Blog.
- 10/30/2024
|
1 Huge New Reason to Buy Eli Lilly or Novo Nordisk Stock Right Now and Hold It Forever
- One key disease-prevention market is drawing closer to being within reach.
- 10/29/2024
|
Novo Nordisk (NVO) Stock Falls Amid Market Uptick: What Investors Need to Know
- In the latest trading session, Novo Nordisk (NVO) closed at $112.46, marking a -0.82% move from the previous day.
- 10/28/2024
|
Novo Nordisk A/S (NVO) is Attracting Investor Attention: Here is What You Should Know
- Zacks.com users have recently been watching Novo Nordisk (NVO) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
- 10/28/2024
|
Novo Nordisk A/S - share repurchase programme
- Bagsværd, Denmark, 28 October 2024 – On 7 August 2024, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules"). This programme is part of the overall share repurchase programme of up to DKK 20 billion to be executed during a 12-month period beginning 6 February 2024.
- 10/28/2024
|
This Is Huge News for Novo Nordisk (Hint: It Doesn't Involve Ozempic)
- Novo Nordisk just released data from a clinical trial featuring its oral semaglutide treatment, Rybelsus.
- 10/26/2024
|
CTLT Stock Falls as Potential Hindrance to NVO Buyout Deal Increases
- Catalent stock faces uncertainty as several pharma companies voice concern about potential limited competition following the acquisition, especially in weight-loss drug manufacturing.
- 10/24/2024
|
Lilly to launch its obesity drug in Denmark, Novo Nordisk's home market
- Lilly will launch its Mounjaro obesity drug in Denmark next week, the U.S. drugmaker said on Thursday, bringing competition to the home country of its biggest weight-loss rival, Danish pharmaceuticals group Novo Nordisk.
- 10/24/2024
|
Novo Nordisk's diabetes drug Ozempic may reduce the risk of Alzheimer's disease, study says
- Novo Nordisk's blockbuster diabetes drug Ozempic may reduce the risk of developing Alzheimer's disease, according to a new analysis of electronic health records. The findings suggest that Ozempic and other GLP-1 treatments could potentially delay or prevent the memory-robbing condition in patients with diabetes.
- 10/24/2024
|
Novo Nordisk asks US to stop compounding pharmacies from making weight-loss drug copies
- Novo Nordisk on Tuesday asked the U.S. Food and Drug Administration to ban compounding pharmacies from making copycat versions of its popular weight-loss and diabetes drugs, which it said were too complex for those manufacturers to produce safely.
- 10/23/2024
|
Novo Nordisk's Death Cross: Is A Turnaround Coming For The Ozempic, Wegovy Maker?
- Novo Nordisk A/S NVO just hit a technical red flag — a Death Cross.
- 10/23/2024
|
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
- Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.
- 10/23/2024
|
Novo Nordisk asks FDA to ban compounding pharmacies from making Ozempic, Wegovy copies
- Novo Nordisk asked the Food and Drug Administration to prevent compounding pharmacies from making cheaper versions of its popular weight loss injection Wegovy and diabetes treatment Ozempic. The Danish drugmaker argues that the medications are too complex for those manufacturers to make safely.
- 10/23/2024
|
Why Novo Nordisk (NVO) Dipped More Than Broader Market Today
- Novo Nordisk (NVO) closed at $116.47 in the latest trading session, marking a -0.73% move from the prior day.
- 10/22/2024
|
NVO's Rybelsus Meets Primary Goal in MACE Study for Diabetes Patients
- A late-stage study shows that Novo Nordisk's oral semaglutide, Rybelsus, cuts the risk of MACE by 14% in T2D patients compared to placebo.
- 10/22/2024
|
5 Large Drug Stocks Likely to Outpace Q3 Earnings Estimates
- Let us look at some big drug/biotech stocks, NVO, NVS, PFE, REGN and BIIB, which are poised to beat on third-quarter earnings.
- 10/22/2024
|
Dr. Scot Gottlieb on Novo Nodrisk's oral diabetes drug, future of weight-loss drugs
- Former FDA Commissioner Dr. Scot Gottlieb joins 'Squawk Box' to discuss news of Novo Nordisk's oral diabetes drug cutting heart-related risks in patients, state of the weight-loss drugs market, and more.
- 10/22/2024
|
NVO Stock Falls 5% in a Month: Should Investors Buy Now or Wait?
- Despite the current downward trend of Novo Nordisk, it is an excellent stock to buy for long-term gains, driven by the stellar performance of its GLP-1 drugs.
- 10/21/2024
|
NVO's Alhemo Gets Positive CHMP Opinion in EU for Haemophilia A or B
- The CHMP of the regulatory body in the EU adopts a positive opinion recommending the approval of Novo Nordisk's Alhemo for haemophilia A or B with inhibitors.
- 10/21/2024
|
Novo Nordisk: Time To Stay Calm Amid The Recent Plunge (Rating Upgrade)
- Novo Nordisk faces growth deceleration concerns, intensified by competitive pressures from Eli Lilly and supply chain issues. NVO can improve buying sentiments by expanding its indications beyond its core weight loss and diabetes categories. NVO's growth-adjusted valuation has improved markedly, while its first-mover advantage should anchor its ability to scale profitably.
- 10/21/2024
|
Novo Nordisk A/S - share repurchase programme
- Bagsværd, Denmark, 21 October 2024 – On 7 August 2024, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules"). This programme is part of the overall share repurchase programme of up to DKK 20 billion to be executed during a 12-month period beginning 6 February 2024.
- 10/21/2024
|
Catalent CEO to remain in charge of contract drugmaker after Novo Holdings' buyout
- Catalent president and CEO Alessandro Maselli said on Monday he will stay on as the contract drugmaker's chief after it is acquired by Novo Holdings, the controlling shareholder of weight-loss drug manufacturer Novo Nordisk.
- 10/21/2024
|
Novo Nordisk's oral diabetes drug cuts heart-related risks by 14% in study
- Novo Nordisk said on Monday an oral version of its drug semaglutide, helped significantly reduce the risk of cardiovascular events in patients in a late-stage study.
- 10/21/2024
|
Novo Nordisk A/S: Oral semaglutide demonstrates a 14% reduction in risk of major adverse cardiovascular events in adults with type 2 diabetes in the SOUL trial
- Bagsværd, Denmark, 21 October 2024 — Novo Nordisk today announced the headline results from the SOUL cardiovascular outcomes trial. The double-blinded, randomised trial compared oral semaglutide to placebo as an adjunct to standard of care for the prevention of major adverse cardiovascular events (MACE). The trial enrolled 9,650 people with type 2 diabetes and established cardiovascular disease (CVD) and/or chronic kidney disease (CKD). As part of standard of care, 49% of patients received SGLT2i at some point during the trial.
- 10/21/2024
|
Novo Nordisk A/S: Alhemo® recommended for European approval as first once-daily subcutaneous prophylactic treatment for people living with haemophilia A or B with inhibitors
- Bagsværd, Denmark, 18 October 2024 – Novo Nordisk today announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion, recommending approval of Alhemo® (concizumab) as the first once-daily subcutaneous prophylactic treatment for people aged 12 years or older living with haemophilia A or B with inhibitors.
- 10/18/2024
|
Consumer groups ask FTC to block Novo Holdings-Catalent deal
- Five U.S. consumer groups and two large labor unions urged the U.S. Federal Trade Commission on Thursday to block Novo Nordisk's controlling shareholder from acquiring contract drug manufacturer Catalent , saying the deal threatens competition in weight loss drugs and cutting-edge gene therapies.
- 10/17/2024
|
Ozempic, weight loss drugs found to cut substance abuse
- Weight loss drugs such as Novo Nordisk (NYSE:NVO) AS' Ozempic have been found to cut alcohol and opioid abuse, according to a new study. Published in the journal Addiction, the study showed the rate of opioid overdoses among people taking GLP-1 drugs was 40% lower than those who were not.
- 10/17/2024
|
Novo Resources Reports 2024 Sustainability Report
- VANCOUVER, British Columbia, Oct. 16, 2024 (GLOBE NEWSWIRE) -- Novo Resources Corp. (Novo or the Company) (ASX: NVO) (TSX: NVO) (OTCQX: NSRPF) is pleased to advise the release of its 2024 Sustainability Report, which outlines progress over the past year.
- 10/16/2024
|
Eli Lilly vs. Novo Nordisk: Which Weight Loss Stock is The Better Opportunity Over The Next 10 Years?
- These are two of healthcare's biggest darlings right now, but one looks better positioned for the long run.
- 10/16/2024
|
Novo Nordisk (NVO) Registers a Bigger Fall Than the Market: Important Facts to Note
- Novo Nordisk (NVO) closed the most recent trading day at $117.81, moving -1.64% from the previous trading session.
- 10/15/2024
|
Novo Nordisk A/S (NVO) Is a Trending Stock: Facts to Know Before Betting on It
- Recently, Zacks.com users have been paying close attention to Novo Nordisk (NVO). This makes it worthwhile to examine what the stock has in store.
- 10/15/2024
|
AZN or NVO: Which Is the Better Value Stock Right Now?
- Investors interested in Large Cap Pharmaceuticals stocks are likely familiar with Astrazeneca (AZN) and Novo Nordisk (NVO). But which of these two stocks offers value investors a better bang for their buck right now?
- 10/14/2024
|
Novo Nordisk A/S - share repurchase programme
- Bagsværd, Denmark, 14 October 2024 – On 7 August 2024, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules"). This programme is part of the overall share repurchase programme of up to DKK 20 billion to be executed during a 12-month period beginning 6 February 2024.
- 10/14/2024
|
Wegovy weight loss drug roll out falling short in the UK
- Plans to roll out weight loss drug Wegovy through the NHS have fallen short of expectations after the treatment's approval late last year. Just 800 patients had received prescriptions of the drug by April, according to Sky News, against Department of Health estimates that 13,500 people would be on Wegovy by then.
- 10/14/2024
|
3 No-Brainer Growth Stocks to Buy in October
- These stocks look like slam-dunk picks for growth investors.
- 10/13/2024
|
Wegovy maker Novo Nordisk bets big on talent, AI partnerships in India
- Novo Nordisk , whose global profile has risen along with demand for its Wegovy weight-loss drug, is bolstering operations in the world's most populous nation by beefing up senior leadership in India and partnering with local AI start-ups, a top executive told Reuters.
- 10/11/2024
|
US Senator Warren calls for scrutiny of Novo Holdings' Catalent deal
- U.S. Senator Elizabeth Warren has asked antitrust regulators to closely scrutinize a $16.5 billion deal in which Novo Nordisk's controlling shareholder would acquire contract drug manufacturer Catalent , saying it may give the pharmaceutical company an unlawful advantage in weight loss and obesity drugs.
- 10/10/2024
|
2 No-Brainer Dividend Growth Stocks to Buy Right Now
- These two pharmaceutical giants are positioned for growth with their innovative diabetes and obesity treatments.
- 10/10/2024
|
Got $5,000? These 3 Growth Stocks Are on Sale Right Now.
- These stocks are all down 14% or more in the past three months.
- 10/09/2024
|
Novo Nordisk (NVO) Stock Declines While Market Improves: Some Information for Investors
- Novo Nordisk (NVO) closed the most recent trading day at $117.20, moving -0.48% from the previous trading session.
- 10/08/2024
|
Prediction: 3 of Wall Street's Most Influential Stocks Can Plunge if Kamala Harris Wins in November
- A victory for the current vice president on Nov. 5 may be bad news for three market-leading businesses.
- 10/08/2024
|
Novo Nordisk launches new initiative to prevent childhood obesity in disadvantaged urban communities
- Bagsværd, Denmark, 8 October 2024 – Novo Nordisk today announced a new global initiative to prevent obesity in children. The Childhood Obesity Prevention Initiative aims to accelerate the prevention of childhood obesity in disadvantaged urban communities globally. Together with a coalition of partners such as city governments, academic institutions and non-profit organisations, the initiative will support six cities in designing, implementing and evaluating tailored solutions focused on physical activity and healthy eating.
- 10/08/2024
|
Novo Nordisk A/S – Share repurchase programme
- Bagsværd, Denmark, 7 October 2024 – On 7 August 2024, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules"). This programme is part of the overall share repurchase programme of up to DKK 20 billion to be executed during a 12-month period beginning 6 February 2024.
- 10/07/2024
|
Novo Nordisk downgraded amid supply bottlenecks
- Jefferies has downgraded its rating on Novo Nordisk (NYSE:NVO) to "underperform" and cut its price target to DKK 575, down from the previous DKK 782.90. The downgrade comes amid concerns over the supply of the Danish drugs giant's weight-loss drug, Wegovy, particularly in the United States, where prescriptions for the 0.25 mg starter dose have dropped significantly.
- 10/07/2024
|
Prediction: These 2 Stocks Will Join Nvidia, Meta, Apple, Amazon, and Microsoft in the Trillion-Dollar Club by 2030
- These companies have been on fire for a while, but they haven't peaked yet.
- 10/06/2024
|
Novo Nordisk to invest $158 million in insulin plant in Brazil
- Danish drugmaker Novo Nordisk will invest 864 million reais ($158.2 million) to revamp a plant in Brazil responsible for pumping out a quarter of its insulin production globally, the firm said on Friday.
- 10/04/2024
|
Investors Heavily Search Novo Nordisk A/S (NVO): Here is What You Need to Know
- Zacks.com users have recently been watching Novo Nordisk (NVO) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
- 10/04/2024
|
Novo Nordisk Is Still a Buy, Analysts Say. Slowing Growth for Ozempic and Wegovy Isn't a Problem.
- The company is expected to present critical results from a trial of its CagriSema weight-loss injection in the fourth quarter.
- 10/02/2024
|
Wegovy and Ozempic drive impressive prescription growth, says Citi
- Analysts from Citi are bullish about the GLP-1 market, particularly within obesity and diabetes treatments, signaling a positive outlook for key players despite facing some supply constraints. According to Citi, there was an impressive 244% increase in total prescriptions for obesity drugs, such as Wegovy, and an 18% rise for diabetes medications, including Ozempic and Rybelsus.
- 09/30/2024
|
Novo Nordisk A/S – Share repurchase programme
- Bagsværd, Denmark, 30 September 2024 – On 7 August 2024, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules"). This programme is part of the overall share repurchase programme of up to DKK 20 billion to be executed during a 12-month period beginning 6 February 2024.
- 09/30/2024
|
Success in This New Battleground Could Make Eli Lilly and Novo Nordisk Stock Absolutely Fly for Years
- Eli Lilly and Novo Nordisk are spending billions to find new cardiometabolic drugs. Both companies are interested in the possibilities of genetic medicines.
- 09/28/2024
|
3 Stocks That Could Rise on European Bank Interest Rate Cuts
- U.S. stocks reacted positively following the Federal Open Market Committee's announcement in mid-September that it would lower interest rates by 50 basis points, wider than many analysts had anticipated. Generally, a lower federal funds rate is often a boon for stocks, as businesses are able to more easily secure loans to facilitate growth and consumers may be more likely to increase spending habits.
- 09/27/2024
|
PFE vs. NVO: Which Stock Is the Better Value Option?
- Investors interested in stocks from the Large Cap Pharmaceuticals sector have probably already heard of Pfizer (PFE) and Novo Nordisk (NVO). But which of these two stocks presents investors with the better value opportunity right now?
- 09/27/2024
|
Novo Nordisk Just Committed More Than $1.1 Billion to Make the Next Ozempic, but Is the Stock a Buy?
- It's in Novo Nordisk's best interest to produce more winning cardiometabolic drugs. To that end, it's inking collaboration deals with multiple early-stage biotechs.
- 09/27/2024
|
Novo Nordisk And Evotec Collaborate On Stem Cell-Based Therapy Development
- On Thursday, Evotec SE EVO entered a technology development partnership with Novo Nordisk A/S NVO in cell therapy.
- 09/26/2024
|
Is It Worth Investing in Novo Nordisk (NVO) Based on Wall Street's Bullish Views?
- When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?
- 09/26/2024
|
Novo Nordisk's $600 Million Gambit Could Be a Game Changer for the Stock. Here's Why.
- Novo Nordisk is cutting a lot of deals with small biotechs. The latest deal seeks to develop gene-editing therapies, perhaps for obesity.
- 09/26/2024
|
Evotec and Novo Nordisk forge technology development partnership
- German drug and development company Evotec has entered into a technology development partnership with Novo Nordisk to support clinical and commercial manufacturing of stem cell-based therapies, the company said on Thursday.
- 09/26/2024
|
Evotec and Novo Nordisk Enter into Technology Development Partnership to Support Next-Generation Cell Therapies
- Novo Nordisk will provide funding for technology development activities at Evotec to support clinical and commercial manufacturing of stem cell-based therapies HAMBURG, GERMANY / ACCESSWIRE / September 26, 2024 / Evotec SE (Frankfurt Stock Exchange:EVT, SDAX/TecDAX, ISIN: DE0005664809; NASDAQ:EVO) announced today that Evotec has entered a technology development partnership with Novo Nordisk in cell therapy. Both Evotec and Novo Nordisk have significant expertise and a strategic focus to support stem cell-based therapies.
- 09/26/2024
|
Lose Weight With Novo Nordisk Drugs, Gain Money With Stock
- Some experts believe Novo Nordisk A/S NVO products not only help people lose weight and control diabetes, they can help treat the country's addiction crisis.
- 09/25/2024
|
LLY, NVO & Mag 7: Stocks to Watch After Fed's Rate Cut
- Steven E. Orr says people are getting healthier, and the accessibility of weight loss drugs from companies like Eli Lilly (LLY) and Novo Nordisk (NVO) make them attractive for investors. However, he warns against Mag 7 stocks, instead pointing to commodities like Gold (/GC) and Silver (/SI).
- 09/25/2024
|
Novo Nordisk's diabetes drug Ozempic may lower the risk of opioid overdoses, study says
- Novo Nordisk's blockbuster diabetes drug Ozempic may decrease the risk of opioid overdoses in certain patients, according to a new study. The results suggest semaglutide, the active ingredient in Ozempic, could potentially become a new alternative treatment for opioid use disorder, which could help address the ongoing opioid epidemic.
- 09/25/2024
|
Belltopper Gold Project Video
- VANCOUVER, British Columbia, Sept. 25, 2024 (GLOBE NEWSWIRE) -- Novo Resources Corp. (Novo or the Company) (ASX: NVO) (TSX: NVO) (OTCQX: NSRPF) is pleased to provide a video update on the Company's highly prospective Belltopper Gold Project (“Belltopper”), following the Company's recent announcement titled “Belltopper Mineralisation Modelling Defines Prospectivity” released to the ASX on 25 September 2024 (“Belltopper Announcement”).
- 09/25/2024
|
Novo Nordisk (NVO) Rises Higher Than Market: Key Facts
- Novo Nordisk (NVO) closed at $125.44 in the latest trading session, marking a +1.41% move from the prior day.
- 09/24/2024
|
GLP-1 demand is going to remain higher than supply for foreseeable future, says BMO's Evan Seigerman
- Evan Seigerman, BMO senior analyst, joins 'Closing Bell Overtime' to talk today's Capitol Hill hearing with Novo Nordisk's CEO and the demand for weight-loss drugs.
- 09/24/2024
|
Healthy Returns: Weight loss drug Wegovy could face Medicare price negotiations next
- Novo Nordisk's weight loss drug Wegovy could face Medicare price negotiations next. Meanwhile, Particle Health files an antitrust suit against Epic Systems.
- 09/24/2024
|
Novo Nordisk CEO testifies before Senate on weight loss drug prices
- CNBC's Angelica Peebles reports on Novo Nordisk's testimony before the Senate Health, Education, Labor, and Pensions Committee.
- 09/24/2024
|
Novo Nordisk's Setback Won't Last: A Game-Changing Drug Emerges
- Novo Nordisk NYSE: NVO took a hit on its stock price last week after it received bad news on one of its in-development treatments. At the same time, shares of big and small competitors rallied as a result.
- 09/24/2024
|
Novo Nordisk CEO set to defend Ozempic, Wegovy prices on Capitol Hill
- The CEO of Novo Nordisk is set to face pointed questions on Capitol Hill Tuesday about the prices of the Danish pharmaceutical giant's blockbuster drugs Ozempic and Wegovy.
- 09/24/2024
|
Novo Nordisk CEO to testify at Senate hearing over high weight loss drug prices
- Novo Nordisk's top executive is slated to face a Senate grilling over the high prices of the company's weight loss drug Wegovy and diabetes treatment Ozempic. The Danish drugmaker's CEO, Lars Fruergaard Jørgensen, will testify at a Senate Health, Education, Labor and Pensions Committee hearing at 10 a.m.
- 09/24/2024
|
Novo Nordisk CEO faces US Congress scrutiny over weight-loss drug pricing
- U.S. Senator Bernie Sanders is set to question Novo Nordisk CEO Lars Jorgensen on Tuesday over the drugmaker's prices for its popular weight-loss and diabetes medicines that can cost Americans more than $1,000 a month.
- 09/24/2024
|
2 Weight-Loss Stocks That Could Rocket Higher This Year
- Injections that help folks manage their appetite already generate over $45 billion in annual revenue. Total sales of weight-management drugs are expected to reach $100 billion annually by 2030.
- 09/24/2024
|
Novo says Ozempic to be eligible for US price negotiations in less than a year
- Novo Nordisk's blockbuster diabetes drug Ozempic will be eligible for U.S. government's price negotiations in less than a year based on current criteria, the Danish drugmaker's CEO Lars Fruergaard Jorgensen said in his written testimony on Monday.
- 09/23/2024
|
Novo Nordisk Stock Slips as CEO Faces Senate Inquiry Into Wegovy, Ozempic Prices
- Novo Nordisk's (NVO) U.S.-listed shares lost ground Monday, a day before a Senate hearing on the costs of the company's popular weight-loss drugs Wegovy and Ozempic.
- 09/23/2024
|
Novo Nordisk CEO To Face Senate Scrutiny Over High Ozempic And Wegovy Prices, Hearing Scheduled On Tuesday
- Lars Fruergaard Jørgensen, President and CEO of Novo Nordisk A/S NVO, is set to face tough questions from the U.S. lawmakers regarding the steep prices of the company's diabetes and weight-loss drugs, including Ozempic and Wegovy.
- 09/23/2024
|
NVO Stock Down on Unsatisfactory Data From Mid-Stage Obesity Study
- Novo Nordisk stock falls 5.5% on unsatisfactory safety and efficacy data from a mid-stage study of investigational obesity candidate, monlunabant.
- 09/23/2024
|
Novo Nordisk A/S (NVO) is Attracting Investor Attention: Here is What You Should Know
- Zacks.com users have recently been watching Novo Nordisk (NVO) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
- 09/23/2024
|
Novo Nordisk A/S - share repurchase programme
- Bagsværd, Denmark, 23 September 2024 – On 7 August 2024, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules"). This programme is part of the overall share repurchase programme of up to DKK 20 billion to be executed during a 12-month period beginning 6 February 2024.
- 09/23/2024
|
Novo Nordisk faces US congressional grilling over price of weight loss drugs, FT reports
- Novo Nordisk's chief executive is preparing for a showdown next week with U.S. Senator Bernie Sanders over the high price of blockbuster diabetes and weight loss drugs, as Ozempic falls into the scope of U.S. government price controls, the Financial Times reported on Monday.
- 09/23/2024
|
Novo Nordisk, Chewy And FedEx Are Among Top 10 Large Cap Losers Last Week (Sept 15-Sept 21): Are The Others In Your Portfolio?
- These ten large-cap stocks were the worst performers in the last week. Are they in your portfolio?
- 09/22/2024
|
3 Stocks That Could Rise on European Bank Interest Rate Cuts
- U.S. stocks reacted positively following the Federal Open Market Committee's announcement in mid-September that it would lower interest rates by 50 basis points, wider than many analysts had anticipated. Generally, a lower federal funds rate is often a boon for stocks, as businesses are able to more easily secure loans to facilitate growth and consumers may be more likely to increase spending habits.
- 09/22/2024
|
Why Novo Nordisk Stock Fell While Eli Lilly and Viking Therapeutics Bumped Higher Today
- The latest news from the Danish drug developer was not encouraging. Its experimental weight loss drug produced results, but also a set of side effects.
- 09/20/2024
|
Novo Nordisk Sinks on Obesity Drug Study's Disappointing Results
- Novo Nordisk's (NVO) U.S.-listed shares lost ground Friday after a study of the pharmaceutical firm's latest obesity treatment showed less effectiveness in higher doses.
- 09/20/2024
|
NVO Gets Positive CHMP Opinion for Wegovy's Label Update in EU
- Novo Nordisk receives a positive opinion from the CHMP for a label update of Wegovy to reflect reduced heart failure symptoms and improved physical function.
- 09/20/2024
|
NVO Stock Loses Around $29B in 3 Months: Buy the Dip or Steer Clear?
- Despite the current downward trend of Novo Nordisk, it is an excellent stock to buy for long-term gains, driven by the stellar performance of its GLP-1 drugs.
- 09/20/2024
|
Novo Nordisk shares drop more than 4% on disappointing obesity pill data
- Novo Nordisk fell more than 4% on Friday to their lowest level since Aug. 10 after the Danish drugmaker reported results from a Phase 2a trial of its experimental obesity pill monlunabant that came in below market expectations.
- 09/20/2024
|
Novo's Wegovy Backed by EU Regulator For Obesity-Related Heart Conditions. FDA Could Be Next.
- The blockbuster drug strengthens its case that obesity drugs have health benefits beyond weight-loss.
- 09/20/2024
|
Novo Nordisk A/S: Monlunabant phase 2a trial in obesity successfully completed
- Bagsværd, Denmark, 20 September 2024 – Novo Nordisk today announced headline results from a phase 2a clinical trial with monlunabant, a small molecule oral cannabinoid receptor 1 (CB1) inverse agonist. Monlunabant, formerly INV-202, was part of the acquisition of Inversago Pharmaceuticals Inc. announced in August 2023 [Link].
- 09/20/2024
|
EU regulator backs use of Novo's Wegovy for obesity-related heart condition
- The European Medicines Agency backed the use of Novo Nordisk's Wegovy in patients with an obesity-related heart condition, the Danish drugmaker said on Thursday.
- 09/19/2024
|
Novo Nordisk A/S: Wegovy® recommended by the European regulatory authorities for label update to reflect reduced heart failure symptoms and improved physical function
- Wegovy ® recommended by the European regulatory authorities for label update to reflect reduced heart failure symptoms and improved physical function
- 09/19/2024
|
Novo Nordisk: The Street Is Not Seeing The Growth Acceleration Potential
- Novo Nordisk A/S's shares have stalled recently, but this looks like a natural digestion of gains from prior years. Supply constraints for the obesity business are easing, and we should see growth pick up in the second half of the year and more so in 2025. Oral amycretin candidate data look good, with no new safety and tolerability signals.
- 09/19/2024
|
Novo Nordisk Just Took a $530 Million Step Onto Moderna's Turf. Here's What It Means for Both Stocks
- Novo Nordisk and Korro Bio just signed a big collaboration deal. The pair aim to develop medicines involving mRNA, which is Moderna's specialty.
- 09/19/2024
|
Multiple Strong Catalysts And Attractive Valuation Make Novo Nordisk A Buy
- Novo Nordisk's weight-loss drugs, Ozempic and Wegovy, have multiple positive catalysts, making NVO stock attractive for medium-to-long term investors. Insurance coverage for Ozempic and Wegovy may be rising significantly. Medicare and Medicaid are covering a significant number of the prescriptions of these drugs, with Medicaid covering Wegovy in 20 states.
- 09/18/2024
|
Novo says Ozempic 'very likely' to be on 2027 Medicare negotiation list, Bloomberg News reports
- Danish drugmaker Novo Nordisk expects its diabetes drug Ozempic will "very likely" be on the U.S. government's 2027 list of price negotiations, Bloomberg News reported on Tuesday citing a company executive.
- 09/17/2024
|
Novo Nordisk shares sink on medicare price negotiation fears
- Jared Holz, Mizuho, joins 'Fast Money' to talk how possible Medicare price negotiations are impacting Novo Nordisk shares.
- 09/17/2024
|
Novo Nordisk A/S - share repurchase programme
- Bagsværd, Denmark, 16 September 2024 – On 7 August 2024, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules"). This programme is part of the overall share repurchase programme of up to DKK 20 billion to be executed during a 12-month period beginning 6 February 2024.
- 09/16/2024
|
2 Unstoppable Healthcare Stocks to Buy Right Now for Less Than $200
- Novo Nordisk is the leader in developing drugs in a fast-growing area. DexCom's recent drop doesn't take away from its long runway for growth.
- 09/14/2024
|
Novo Nordisk (NVO) Outperforms Broader Market: What You Need to Know
- Novo Nordisk (NVO) reachead $136.66 at the closing of the latest trading day, reflecting a +1.06% change compared to its last close.
- 09/12/2024
|
NVO Oral Obesity Pill Tops Wegovy; LLY, VKTX, GPCR Stocks Rise
- Stocks of LLY, VKTX and GPCR, which make oral pills for obesity, rose on Wednesday in response to Novo Nordisk's positive data.
- 09/12/2024
|
Metals, Energy, Crypto: Stocks & ETFs to Watch
- Gold (/GC) reached another new all-time high, Tesla (TSLA) continues to drive forward in the Mag 7, and Bitcoin (/BTC) marches toward the 60k level. Mish Schneider with MarketGauge.com talks about her top stock and ETF picks in several closely watched market sectors.
- 09/12/2024
|
Novo Nordisk Stock Rises as Oral Obesity Pill Outshines Wegovy
- NVO stock gains 4.2% after it presents efficacy data superior to Wegovy for its new oral pill, amycretin, in an early-stage study.
- 09/12/2024
|
Five Top Obesity Stocks to Buy and Hold Long Term
- Karl-Hendrik Tittel / Getty Images There's also Altimmune (NASDAQ:ALT), whose pemvidutide treatment led to weight loss while preserving lean mass.
- 09/12/2024
|
Roche Setback Is Big for Eli Lilly, Novo Nordisk as Obesity Drug Battle Ramps Up
- The company's stock was falling after a report detailing side effects from its once-daily weight-loss pill.
- 09/12/2024
|
2 Weight Loss Drug Stocks Worth Stashing Away for Years
- As the high-growth trade fizzles out in September, even some top-tier secular growth plays will take an outsized hit to the chin.
- 09/11/2024
|
PFE or NVO: Which Is the Better Value Stock Right Now?
- Investors with an interest in Large Cap Pharmaceuticals stocks have likely encountered both Pfizer (PFE) and Novo Nordisk (NVO). But which of these two companies is the best option for those looking for undervalued stocks?
- 09/11/2024
|
Novo Nordisk Jumps After New Weight-Loss Pill Tops Wegovy; Eli Lilly, Viking Shares Rise
- Novo Nordisk stock rose moderately Wednesday after the pharma giant said its new weight-loss drug, amycretin, outperformed Wegovy.
- 09/11/2024
|
Novo Nordisk's New Obesity Pill Beats Wegovy In Early Trial
- Ozempic maker Novo Nordisk on Wednesday said data showed its hotly anticipated weight loss pill prompts greater and more rapid weight loss than its blockbuster treatment Wegovy, amid competition from Mounjaro maker Eli Lilly, pharma titans like Pfizer and biotech upstarts.
- 09/11/2024
|
Novo Nordisk Stock Rises After Study Finds Obesity Drug Safe For Kids
- A late-stage clinical trial showed drug helped children aged 6-11 reduce their BMI.
- 09/11/2024
|
Weight loss jabs of six-year-olds? Here's the latest clinical findings
- A recent study has found that liraglutide, a drug approved for obesity treatment in adults and teens, is safe and effective for children as young as six when combined with diet and exercise. The research, presented at a medical conference and published in the New England Journal of Medicine, showed that liraglutide reduced body mass and slowed weight gain in children aged 6 to 11.
- 09/11/2024
|
2 Biotech Stocks To Watch In September 2024
- Here are biotech stocks to check out this month.
- 09/10/2024
|
Novo Nordisk experimental obesity pill has mild-to-moderate side effects in early trial
- Novo Nordisk's highly anticipated experimental weight-loss pill amycretin was safe and tolerable for patients in an early-stage trial, with mild-to-moderate side effects, the company said on Wednesday.
- 09/10/2024
|
Novo's older obesity drug is safe and effective for children, study finds
- Novo Nordisk's older weight-loss drug Saxenda helped children between the ages of 6 and under 12 reduce their body mass index by 7.4% in a 56-week trial, according to results presented at a medical meeting on Wednesday.
- 09/10/2024
|
Obesity drugs in kindergarten? Novo Nordisk GLP-1 drug works for kids as young as 6, study finds.
- Amid an ongoing debate over what role, if any, GLP-1 medications should play in treating children who are still in elementary school, researchers have concluded that a Novo Nordisk obesity drug may be safe and effective for kids as young as 6 years of age.
- 09/10/2024
|
Is Novo Nordisk (NVO) a Buy as Wall Street Analysts Look Optimistic?
- Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter?
- 09/10/2024
|
Novo Nordisk A/S (NVO) Is a Trending Stock: Facts to Know Before Betting on It
- Novo Nordisk (NVO) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
- 09/10/2024
|
Novo Nordisk A/S - share repurchase programme
- Bagsværd, Denmark, 9 September 2024 – On 7 August 2024, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules"). This programme is part of the overall share repurchase programme of up to DKK 20 billion to be executed during a 12-month period beginning 6 February 2024.
- 09/09/2024
|
Novo Nordisk A/S - share repurchase programme
- Novo Nordisk A/S – Share repurchase programme Bagsværd, Denmark, 9 September 2024 – On 7 August 2024, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules"). This programme is part of the overall share repurchase programme of up to DKK 20 billion to be executed during a 12-month period beginning 6 February 2024.
- 09/09/2024
|
Eli Lilly's weekly insulin intensifies race with Novo Nordisk
- A pair of late-stage trials found that Eli Lilly's experimental once-weekly insulin can lower blood sugar as effectively as widely used daily insulins, the drugmaker said Thursday, intensifying the company's race with Novo Nordisk to develop longer-acting insulins.
- 09/05/2024
|
How Lilly, Novo Could Beat Tesla To The Trillion-Dollar Club; Plus, Nvidia's Battle With Microsoft, Apple
- Weight-loss drug kingpins Eli Lilly and Novo Nordisk could join the trillion-dollar company club before even Tesla, according to a report.
- 09/04/2024
|
Ozempic shortages in EU will not affect all member states - Novo Nordisk
- Intermittent shortages of diabetes drug Ozempic in the European Union that are expected to continue into the final quarter of 2024 because of strong demand will not affect all member states, the Danish drugmaker Novo Nordisk said.
- 09/04/2024
|
Weight-loss drugs could reduce COVID-related deaths: Study
- A new study found that weekly injections of 2.4 mg of semaglutide could lower the risk of deaths related to COVID-19, marking another potential benefit of these blockbuster drugs.
- 09/03/2024
|
Novo Nordisk's Says Ozempic Shortage Deteriorates. Why It's Good News For Eli Lilly.
- While Novo is struggling to keep up with demand for its obesity drugs, U.S. rival Eli Lilly sees supply restraints easing.
- 09/03/2024
|
Novo Nordisk's Ozempic shortage expected to continue into Q4
- Novo Nordisk said the shortage of lower strengths of its diabetes drug Ozempic has deteriorated, with intermittent shortages for all strengths expected into the final quarter of 2024 due to increased demand and along with capacity constraints at some of its manufacturing sites.
- 09/02/2024
|
Novo to present at the Resources Rising Stars Gold Coast Investor Conference
- VANCOUVER, British Columbia, Sept. 02, 2024 (GLOBE NEWSWIRE) -- Novo Resources Corp. (Novo or the Company) (ASX: NVO) (TSX: NVO) (OTCQX: NSRPF) is pleased to advise that the Company's Executive Co-Chairman and Acting Chief Executive Officer Mike Spreadborough will present at the Resources Rising Stars Gold Coast Investor Conference, being held on Tuesday 3rd and Wednesday 4th September 2024.
- 09/02/2024
|
3 GLP-1 Stocks to Buy Now For Big Long-Term Gains
- The surge in interest investors have displayed for companies delivering weight loss drugs has been impressive.
- 09/01/2024
|
3 No-Brainer Stocks to Buy in September
- Eli Lilly is a growth machine that never runs out of opportunities. Novo Nordisk is still gaining momentum.
- 08/31/2024
|
These 3 Factors Could Make Eli Lilly Stock a Better Buy Than Novo Nordisk Right Now
- Eli Lilly and Novo Nordisk compete in a handful of different markets. Novo Nordisk is scaling up its output and upgrading its medicines a bit more slowly.
- 08/31/2024
|
This New Finding About Ozempic and Wegovy Could Hurt Novo Nordisk's Stock
- Wegovy and Ozempic are based on the same molecule called semaglutide. An investigation into the side effects of semaglutide was just published.
- 08/30/2024
|
Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons
- Bagsværd, Denmark, 30 August 2024 — This company announcement discloses the data of the transaction(s) made in Novo Nordisk shares by the company's board members, executives and their associated persons in accordance with Article 19 of Regulation No. 596/2014 on market abuse.
- 08/30/2024
|
Catalent beats revenue estimates ahead of deal close with Novo Nordisk parent
- Contract drug manufacturer Catalent beat analysts' estimates for fourth-quarter revenue on Thursday, helped by its biologics segment that develops and manufactures cell and gene therapies.
- 08/29/2024
|
Investors Heavily Search Novo Nordisk A/S (NVO): Here is What You Need to Know
- Recently, Zacks.com users have been paying close attention to Novo Nordisk (NVO). This makes it worthwhile to examine what the stock has in store.
- 08/28/2024
|
We've had "diabesity"; now here's what "pre-diabesity" means for Novo Nordisk, Eli Lily et al
- The surge in GLP-1 obesity-related research is highlighting a critical shift in medical literature, according to a recent analysis by Deutsche Bank. It notes that managing obesity is becoming increasingly vital, with terms like "diabesity"—the intersection of diabetes and obesity—gaining traction since 2023.
- 08/28/2024
|
Ozempic Could Have a Terrible Side Effect. Is Novo Nordisk in Trouble?
- A recent study claims that Ozempic is linked with a higher risk of suicidal thoughts than other drugs. However, other studies have reached the opposite conclusion.
- 08/27/2024
|
Novo Nordisk A/S - share repurchase programme
- Bagsværd, Denmark, 26 August 2024 – On 7 August 2024, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules"). This programme is part of the overall share repurchase programme of up to DKK 20 billion to be executed during a 12-month period beginning 6 February 2024.
- 08/26/2024
|
2 No-Brainer Healthcare Stocks to Buy With $1,000
- Novo Nordisk's innovative wheel is still spinning and bearing fruit in the form of strong financial results. HCA Healthcare is a leading hospital chain that continues to wrestle market share away from its peers.
- 08/24/2024
|
These Were the Top-Selling GLP-1 Drugs Last Quarter From Eli Lilly and Novo Nordisk
- Eli Lilly and Novo Nordisk's top diabetes drugs each brought in more than $3 billion in sales last quarter. Ozempic has been on the market for longer, but its growth rate isn't as impressive as that of other drugs.
- 08/23/2024
|
Novo Nordisk Vs. Eli Lilly: Beyond The Weight-Loss Drug Battle
- The rivalry between Novo Nordisk A/S NVO and Eli Lilly and Co LLY has heated up as both companies vie for dominance in the booming obesity-drug market. But for investors, the real story may lie beyond just weight-loss treatments.
- 08/21/2024
|
Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons
- Bagsværd, Denmark, 20 August 2024 — This company announcement discloses the data of the transaction(s) made in Novo Nordisk shares by the company's board members, executives and their associated persons in accordance with Article 19 of Regulation No. 596/2014 on market abuse.
- 08/20/2024
|
Ozempic and Wegovy use among patients with depression needs more scrutiny, researchers say
- There's a new twist in the ongoing debate over whether drugs widely used for weight loss are linked with thoughts of self-injury or suicide.
- 08/20/2024
|
Top 10 pharmaceutical companies in 2024: S&P Global's latest ratings and rankings
- In the ever-evolving pharmaceutical landscape, financial stability and business resilience are crucial for long-term success. S&P Global, a leading financial information firm, recently released a comprehensive report evaluating the world's top pharmaceutical companies based on their business and financial risk profiles.
- 08/19/2024
|
Novo Nordisk A/S - share repurchase programme
- Bagsværd, Denmark, 19 August 2024 – On 7 August 2024, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules"). This programme is part of the overall share repurchase programme of up to DKK 20 billion to be executed during a 12-month period beginning 6 February 2024.
- 08/19/2024
|
Prediction: These 2 Unstoppable Pharma Stocks Will Continue to Soar Through 2025 and Beyond
- Novo Nordisk and Eli Lilly won't be constrained by manufacturing too much longer. That means they'll sell more of their in-demand drugs.
- 08/19/2024
|
Novo Nordisk: Great Value Buying Opportunity, Thanks To The Much-Needed Rotation
- The recent market correction and market's overreaction to the supposedly softer Wegovy sales have triggered NVO's discounted entry points. With Ozempic/Wegovy no longer in shortage and manufacturing capacity continuing to ramp up, it is unsurprising that the management has raised their FY2024 guidance. NVO continues to report robust GLP-1, obesity, and diabetic therapy market shares in the North American and International regions as well.
- 08/18/2024
|
Novo Nordisk and Eli Lilly Could Have a Big Rival in the GLP-1 Market in a Few Years
- The anti-obesity market is a huge growth opportunity in healthcare. Novo Nordisk and Eli Lilly dominate it today, but it may not be long before there's more competition.
- 08/18/2024
|
These 3 Healthcare Companies Had the Top-Selling Drugs Last Year
- Keytruda, Humira, and Ozempic generated a combined $53 billion in sales last year. The companies that make these drugs generate a lot of their sales from them.
- 08/18/2024
|
3 Fantastic Growth Stocks to Buy in August
- Eli Lilly is a biopharma giant that could still deliver strong growth. Novo Nordisk's growth story isn't over thanks to Ozempic, Wegovy, and a promising pipeline.
- 08/17/2024
|
Novo Nordisk Pharmatech unit to build $220 mln plant in Denmark
- Novo Nordisk's Pharmatech unit will build a 1.5 billion Danish crowns ($220.83 million) plant in Denmark to meet significantly higher demand for the production of medicines to fight chronic diseases, the company said on Friday.
- 08/16/2024
|
Medicare Slashes Merck, Novo, AstraZeneca Drug Prices Up To 79% In IRA Negotiations
- Diabetes treatments from Merck, Novo Nordisk and AstraZeneca will face the steepest cuts under the IRA, a list showed Thursday.
- 08/15/2024
|
Is Novo Nordisk's Earnings Miss a Cause for Concern for Investors?
- Novo Nordisk's recent earnings numbers came in slightly lower than expectations. The company also reduced its forecast for earnings growth this year.
- 08/15/2024
|
Here is What to Know Beyond Why Novo Nordisk A/S (NVO) is a Trending Stock
- Novo Nordisk (NVO) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
- 08/14/2024
|
Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons
- Bagsværd, Denmark, 14 August 2024 — This company announcement discloses the data of the transaction(s) made in Novo Nordisk shares by the company's board members, executives and their associated persons in accordance with Article 19 of Regulation No. 596/2014 on market abuse.
- 08/14/2024
|
3 Stable Blue-Chip Stocks to Buy for the Market Storm
- The volatility that has rocked markets since the beginning of July might not be over just yet. August has proven to be extremely rocky.
- 08/14/2024
|
Here's How to Play Novo Nordisk (NVO) After Q2 Earnings Miss
- Novo Nordisk (NVO) is an excellent stock to buy for long-term gains, driven by the stellar performance of its GLP-1 drugs. New investors should utilize the existing opportunity to make an entry.
- 08/13/2024
|
Why Novo Nordisk (NVO) is a Top Growth Stock for the Long-Term
- Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
- 08/13/2024
|
3 Biotech Stocks Poised for a Comeback After Last Week's Market Meltdown
- Due to their sometimes speculative nature, biotech stocks are especially sensitive to broader market corrections like the one experienced last week. This can be exceptionally stressful for investors, especially those who bought into biotech stocks at overbought points in the stocks' trading cycle.
- 08/13/2024
|
Novo Nordisk Just Hit 3 Snags in a Row. Is Its Stock Still a Buy?
- Novo Nordisk has had a somewhat rough summer. Two different interactions with regulators didn't go its way.
- 08/13/2024
|
Is Novo Nordisk (NVO) a Solid Growth Stock? 3 Reasons to Think "Yes"
- Novo Nordisk (NVO) could produce exceptional returns because of its solid growth attributes.
- 08/12/2024
|
Is It Worth Investing in Novo Nordisk (NVO) Based on Wall Street's Bullish Views?
- The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings often affect a stock's price.
- 08/12/2024
|
Novo Nordisk A/S – Share repurchase programme
- Bagsværd, Denmark, 12 August 2024 – On 7 August 2024, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules"). This programme is part of the overall share repurchase programme of up to DKK 20 billion to be executed during a 12-month period beginning 6 February 2024.
- 08/12/2024
|
Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons
- Bagsværd, Denmark, 12 August 2024 — This company announcement discloses the data of the transaction(s) made in Novo Nordisk shares by the company's board members, executives and their associated persons in accordance with Article 19 of Regulation No. 596/2014 on market abuse.
- 08/12/2024
|
Weight Loss Stocks Could Become Alzheimer's Drugs Stocks. Here's Why That's Bullish for Novo Nordisk
- One of Novo Nordisk's medicines could be helpful for treating Alzheimer's disease. A lot of questions need answering before it'll make any new revenue.
- 08/12/2024
|
Novo Nordisk: Reality Is Starting To Set In
- Novo Nordisk A/S investors recently endured a rare bear market after the stock topped out in June 2024. Novo Nordisk faces heightened competitive risks from arch-rival Eli Lilly, as seen in Eli Lilly's recent results. Novo Nordisk is expanding its coverage into new channels. However, pricing challenges could affect its revenue outlook.
- 08/10/2024
|
Novo Nordisk: How Concerning Is Wegovy's Growth Come-Off?
- Novo Nordisk's sharp price drop following its Q2 2024 results is attributed particularly to slowing sales growth of Wegovy, calling for a closer look at the hugely popular treatment's numbers. A combination of factors resulted in the relative growth cool-off, including prices in the US market, limited supply and competition needs to be considered too. Overall, though, there's a still a lot to like about the company that leads the obesity market, with its upgraded sales outlook and strong projected operating margin.
- 08/10/2024
|
Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons
- Bagsværd, Denmark, 9 August 2024 — This company announcement discloses the data of the transaction(s) made in Novo Nordisk shares by the company's board members, executives and their associated persons in accordance with Article 19 of Regulation No. 596/2014 on market abuse.
- 08/09/2024
|
What Eli Lilly, Novo Nordisk earnings show about GLP-1 sales
- Recent earnings from Eli Lilly and Company (LLY) and Novo Nordisk (NVO) highlight the demand for GLP-1 drugs and why not all GLP-1 providers may be created equal. Yahoo Finance senior healthcare reporter Anjalee Khemlani discusses both companies' earnings results, with Eli Lilly seeing strong sales of its GLP-1 drugs Mounjaro and Zepbound.
- 08/09/2024
|
Novo Nordisk's Shares Go on a Rollercoaster Ride After Earnings
- Novo Nordisk NYSE: NVO is the world's second-largest pharmaceutical company, with a market capitalization of $538 billion. The Danish firm's shares have performed well so far in 2024, returning 23%, outperforming its sector.
- 08/09/2024
|
It's Too Soon to Buy the Dip in Weight Loss Drugmakers
- Obesity drugmakers like Eli Lilly NYSE: LLY and Novo Nordisk NYSE: NVO were not immune to the broad market sell-off sparked by the June CPI report, but investors looking to get into these names should be cheering. The stocks are down 20% or more from their highs, offering big discounts and the opportunity for fat profits over the long term.
- 08/09/2024
|
Eli Lilly Narrows Gap with Novo Nordisk
- Madison Muller, Bloomberg Health Reporter, discusses Eli Lilly earnings on Bloomberg Intelligence. -------- More on Bloomberg Television and Markets Like this video?
- 08/08/2024
|
Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons
- Bagsværd, Denmark, 8 August 2024 — This company announcement discloses the data of the transaction(s) made in Novo Nordisk shares by the company's board members, executives and their associated persons in accordance with Article 19 of Regulation No. 596/2014 on market abuse.
- 08/08/2024
|
Novo Nordisk's Growth Opportunities Go Far Beyond Just Weight Loss and Diabetes
- GLP-1 drugs have helped people lose weight, but they can have other positive effects. A recent study found that they could help with Alzheimer's disease.
- 08/08/2024
|
Novo Nordisk Withdraws Wegovy FDA Heart Failure Submission, Terminates Development Of Two Early Stage Assets
- Earlier on Wednesday, Denmark's most valuable company, Novo Nordisk A/S NVO, reported second-quarter earnings that missed the analyst consensus.
- 08/07/2024
|
Market Misses: ABNB, NVO, LYFT & RIVN
- Despite a positive first half to Wednesday's trading day, a few notable stocks fell when earnings didn't meet expectations. Caroline Woods joins Oliver Renick to take a closer look at Airbnb (ABNB), Novo Nordisk (NVO), LYFT (LYFT) and Rivian (RIVN).
- 08/07/2024
|
Why Shares of Wegovy Maker Novo Nordisk Are Tumbling Today
- Sales of weight-loss drug Wegovy and type 2 diabetes therapy Ozempic both missed expectations. A combination of supply shortages and competition are proving to be unexpected hurdles.
- 08/07/2024
|
NVO Stock Alert: Why Is Novo Nordisk Down 8% Today?
- Novo Nordisk (NYSE:NVO) stock is falling on Wednesday after the pharmaceutical company announced results for the second quarter of 2024. A major blow to the company comes from its revenue of $3.8 billion.
- 08/07/2024
|
Novo Nordisk A/S (NVO) Q2 2024 Earnings Call Transcript
- Novo Nordisk A/S (NVO) Q2 2024 Earnings Conference Call August 7, 2024 7:00 AM ET Company Participants Jacob Martin Wiborg Rode - Head of Investor Relations Lars Fruergaard Jørgensen - Chief Executive Officer Camilla Sylvest - Executive Vice President, Head of Commercial Strategy & Corporate Affairs Doug Langa - Executive Vice President, Head of North America Operations Martin Holst Lange - Executive Vice President, Head of Development Karsten Munk Knudsen - Chief Financial Officer Conference Call Participants Emily Field - Barclays Evan Seigerman - BMO Capital Markets Sachin Jain - Bank of America Richard Vosser - JPMorgan Peter Verdult - Citigroup James Quigley - Goldman Sachs Emmanuel Papadakis - Deutsche Bank Simon Baker - Redburn Atlantic Mark Purcell - Morgan Stanley Operator Good day, and thank you for standing by. Welcome to the First Six Months of 2024 Novo Nordisk A/S Earnings Conference Call.
- 08/07/2024
|
Novo Nordisk is scaling Wegovy supply 'significantly': CFO
- Novo Nordisk (NVO) shares are falling in Wednesday's pre-market session — and into the regular trading session — after the pharmaceutical giant missed second quarter revenue estimates ($3.8 billion vs. expectations of $4.1 billion) tied to Wegovy sales.
- 08/07/2024
|
Novo Nordisk Dives On Rare Miss As Pricing Pressure Weighs On Ozempic, Wegovy
- Novo Nordisk stock tumbled Wednesday after the drugmaker reported a rare sales miss for its two biggest moneymakers, Ozempic and Wegovy.
- 08/07/2024
|
Novo Nordisk Slides as Weight-Loss Drugs Fuel Less Growth Than Expected
- Novo Nordisk's (NVO) American depositary receipts (ADRs) slipped in pre-market trading Wednesday morning after rising sales of the company's weight-loss drugs failed to boost earnings to the level of growth analysts expected for the quarter.
- 08/07/2024
|
'Attractive' growth ahead for Novo Nordisk, CEO says
- Novo Nordisk CEO Lars Fruergaard Jørgensen discusses the pharmaceutical company's second-quarter earnings.
- 08/07/2024
|
Novo Nordisk: Growth Only Limited By Manufacturing Capacity
- Novo has helped to create a new market that should provide over 20% growth in the medium term. Three additional drivers for Novo include increasing obesity treatment capacity, insurance coverage, and the development of new pill-based obesity treatments. At 1.5x PEG I arrive at a YE25 price target of US$162 +29% upside potential.
- 08/07/2024
|
Novo Nordisk (NVO) Falls as Q2 Earnings and Sales Miss, View Up
- Novo Nordisk (NVO) falls as it reports lower-than-expected Q2 results, missing both earnings and revenue estimates. However, sales of Diabetes and Obesity care products increase year over year.
- 08/07/2024
|
US patients staying on Wegovy obesity drug for 'around six months', Novo Nordisk says
- U.S. patients are staying on Novo Nordisk's Wegovy weight-loss medication for "around six months", an executive said on Wednesday, adding that the company is confident that over time as shortages ease that will increase to 12 months.
- 08/07/2024
|
Novo Nordisk's Wegovy miss 'will likely raise questions', says investment bank
- Ozempic maker Novo Nordisk's (NYSE:NVO) weightloss drug sales were below expectations in the second quarter but this is not a significant concern, analysts said. Sales of Wegovy, the brand for semaglutide approved as a weightloss treatment, came in 14% below consensus, while sales of Ozempic, which is approved in the US for diabetes, were 3% lower than consensus forecasts.
- 08/07/2024
|
Is It Too Late to Buy Novo Nordisk Stock After Its 57% Surge?
- Novo Nordisk is the leader in the glucagon-like peptide 1 (GLP-1) agonists market with 70% share. The company has notched some big wins with Wegovy this year, opening up several new billion-dollar markets.
- 08/07/2024
|
Novo Nordisk CEO on Wegovy, Ozempic, Profit Forecast, US Market
- Novo Nordisk A/S Chief Executive Officer Lars Fruergaard Jorgensen discusses Wegovy and Ozempic sales, the US market and the scaling of manufacturing. He speaks to Francine Lacqua on Bloomberg Television.
- 08/07/2024
|
Ozempic Maker Novo Nordisk Sinks On Disappointing Earnings Amid Booming Demand For Weight Loss And Diabetes Drugs
- Pharma giant Novo Nordisk on Wednesday reported booming demand for its weight loss and diabetes drugs Ozempic and Wegovy, but shares sank after the Danish firm disappointed investors with less-than-expected profits for the second quarter and a slimmed-down profit outlook for the year as it faces growing competition in the lucrative market and pressure to ease persistent supply constraints.
- 08/07/2024
|
Ozempic maker Novo Nordisk falls after cutting profit outlook
- Shares in Novo Nordisk (NYSE:NVO), the maker of weightloss and diabetes drugs Wegovy and Ozempic, fell over 5% after it slightly lowered the profit outlook for this year. Operating profit for Europe's largest company by market valuation increased 18% in the second quarter of 2024 to 57.8 billion Danish krone (DKK), slower than the 27% growth seen in the first quarter.
- 08/07/2024
|
Ozempic maker Novo Nordisk misses profit estimates as it builds out capacity
- Novo Nordisk, Europe's largest company by market cap thanks to its wildly popular weight-loss drugs, managed just a small increase in second-quarter profits as it builds out the capacity to make the products.
- 08/07/2024
|
Wegovy maker Novo Nordisk posts earnings miss, cuts operating profit outlook
- Novo Nordisk on Wednesday announced its second quarter earnings for 2024.
- 08/07/2024
|
Obesity drugmaker Novo Nordisk misses Q2 profit forecast
- Novo Nordisk on Wednesday posted second-quarter operating profit below expectations, raised its 2024 sales forecast but cut profit outlook, as competition from Eli Lilly in the booming weight-loss drug market intensifies.
- 08/07/2024
|
Novo Nordisk's sales increased by 24% in Danish kroner and by 25% at constant exchange rates to DKK 133.4 billion in the first six months of 2024
- Bagsværd, 7 August 2024 - Financial report for the period 1 January 2024 to 30 June 2024 Operating profit increased by 18% in Danish kroner and by 19% at constant exchange rates (CER) to DKK 57.8 billion. Operating profit is impacted by the impairment loss related to ocedurenone of DKK 5.7 billion.
- 08/07/2024
|
Eli Lilly (LLY) & Novo Nordisk (NVO) Earnings: A Closer Look
- Given their underperformance in 2024, a positive set of quarterly results could easily push both stocks higher.
- 08/06/2024
|
US FDA says two more doses of Novo Nordisk's weight-loss drug now available
- Two more doses of Novo Nordisk's weight-loss drug, Wegovy, is now available, the U.S. Food and Drug Administration's updated shortages list showed on Tuesday.
- 08/06/2024
|
Novo Nordisk A/S - share repurchase programme
- Bagsværd, Denmark, 06 August 2024 – On 6 May 2024, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules"). This programme is part of the overall share repurchase programme of up to DKK 20 billion to be executed during a 12-month period beginning 6 February 2024.
- 08/06/2024
|
Will These 5 Medical Stocks Surpass Q2 Earnings Forecasts?
- Let's look at five biotech and drug companies, AMGN, GILD, LLY, VTRS & NVO, due to release their second-quarter 2024 results this week.
- 08/05/2024
|
Lilly, Novo Nordisk battle for weight-loss market lands at the pharmacy shelf
- As Eli Lilly's weight-loss drug Zepbound gains ground in the U.S. against Novo Nordisk's Wegovy, some doctors say their guiding principle for writing prescriptions is simple: which drug can my patients actually get at the pharmacy?
- 08/05/2024
|
Fake weight loss drugs spark warnings on Ozempic supply squeeze
- Pharmacists have warned against buying fake weight loss jabs online as shortages of Ozempic persist in the UK. The National Pharmacy Association (NPA) said patients were risking their health over a possible “explosion in the unlicensed sale of medication online” on Monday.
- 08/05/2024
|
3 Unstoppable Stocks to Buy in August
- Novo Nordisk is big but has plenty of room to grow. Vertex Pharmaceuticals' existing products and pipeline programs give it multiple growth catalysts.
- 08/03/2024
|
Eli Lilly vs Novo Nordisk: A Recent Study Suggests This Company Has the Best Weight Loss Drug
- A recent study compared the effectiveness of tirzepatide against semaglutide. Tirzepatide has been more effective in helping people lose weight in trials, and the study corroborated that.
- 08/03/2024
|
PFE vs. NVO: Which Stock Is the Better Value Option?
- Investors interested in stocks from the Large Cap Pharmaceuticals sector have probably already heard of Pfizer (PFE) and Novo Nordisk (NVO). But which of these two stocks offers value investors a better bang for their buck right now?
- 08/02/2024
|
What You Need To Know Ahead of Novo Nordisk Earnings Wednesday
- Novo Nordisk (NVO) is set to report earnings for the second quarter on Wednesday morning after a first half in which the company's market of potential customers for its Ozempic and Wegovy weight-loss drugs expanded.
- 08/02/2024
|
What Are the Hottest Weight Loss Stocks Right Now? 3 Top Picks.
- Easily one of the biggest trends right now in the field of medicine is the weight loss drug surge. Without attempting to sound cynical, the reality is that the sector enjoys a massive total addressable market.
- 08/01/2024
|
Novo Nordisk to launch weight-loss drug Wegovy in Australia this month
- Danish drugmaker Novo Nordisk will launch its hugely popular weight-loss drug Wegovy in Australia this month, a spokesperson for the company said on Thursday.
- 08/01/2024
|
Oxford Nanopore soars as Novo Nordisk builds stake
- Oxford Nanopore Technologies PLC (LSE:ONT), the London-listed tech group, has rallied close to 12% this morning after it was revealed drug giant Novo Nordisk (NYSE:NVO) had bought a £50 million stake. a UK-listed company specialising in molecular sensing technology based on nanopores.
- 08/01/2024
|
The Top 7 Stocks to Buy Now: Summer 2024
- Catalysts are forming around a lot of the top stocks right now, making this a good time for investors to buy. Many companies are seeing a boost in their share price following strong earnings reports.
- 07/31/2024
|
Novo Nordisk GLP-1 drug shows encouraging signs in early stage Alzheimer's trial
- A small clinical trial revealed that a weight-loss drug from the GLP-1 receptor agonist class slowed brain volume loss in people with mild Alzheimer's disease. The trial results, presented at the Alzheimer's Association International Conference, offered initial insights into how GLP-1 drugs might affect difficult-to-treat brain disorders.
- 07/30/2024
|
Older GLP-1 drug from Novo Nordisk may slow Alzheimer's disease progression by protecting the brain, study says
- An older, once-daily drug for diabetes and obesity from Novo Nordisk called liraglutide may slow the progression of Alzheimer's disease by protecting patients' brains, according to data from a mid-stage trial. Novo Nordisk sells liraglutide under the brand names Saxenda and Victoza, which are seeing sales decline as demand for the company's weekly diabetes injection Ozempic and weight loss shot Wegovy skyrockets.
- 07/30/2024
|
Focus: Patients push back against Novo Nordisk move to scrap an insulin product
- Novo Nordisk's decision to stop selling its long-acting insulin Levemir in the United States has left some diabetes patients struggling to switch treatments, patients and doctors in a dozen U.S. states told Reuters.
- 07/30/2024
|
Novo Nordisk (NVO) Surpasses Market Returns: Some Facts Worth Knowing
- Novo Nordisk (NVO) concluded the recent trading session at $128.05, signifying a +1.04% move from its prior day's close.
- 07/29/2024
|
Is Trending Stock Novo Nordisk A/S (NVO) a Buy Now?
- Zacks.com users have recently been watching Novo Nordisk (NVO) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
- 07/29/2024
|
What Will Be the Best Weight Loss Drug Stock of 2030: Eli Lilly, or Novo Nordisk?
- The market for weight loss therapies is going to get larger and larger. Novo Nordisk and Eli Lilly both have powerful new candidates in the pipeline.
- 07/29/2024
|
Novo Nordisk A/S – Share repurchase programme
- Bagsværd, Denmark, 29 July 2024 – On 6 May 2024, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules"). This programme is part of the overall share repurchase programme of up to DKK 20 billion to be executed during a 12-month period beginning 6 February 2024.
- 07/29/2024
|
This Could Send Ozempic's Sales Potential to a Whole Other Level
- Ozempic's potential usefulness continues to grow as more studies are done on the diabetes drug. There are multiple potential brain benefits related to using the drug, which could unlock more growth opportunities.
- 07/28/2024
|
Novo Nordisk's Next-Gen Diabetes Candidate Could Challenge Ozempic -- Is the Stock a Buy?
- There are dozens of investigational GLP-1 medicines in development. Novo Nordisk, the leader in the field, arguably has the most promising candidates.
- 07/27/2024
|
Europe's Markets Are Cheap. 4 Stocks to Play.
- Nevertheless, its member economies are poised for a rebound.
- 07/26/2024
|
Should You Invest in Novo Nordisk (NVO) Ahead of Q2 Earnings?
- Novo Nordisk's (NVO) second-quarter revenues are expected to have been driven by its diabetes and obesity care product sales, especially Wegovy, Ozempic and Rybelsus.
- 07/26/2024
|
Pharmaceutical stocks to watch for end of 2024
- Pharma stocks can be strong investments regardless of economic conditions, as this stability arises because the demand for medications and healthcare services remains steady, even when prices rise.
- 07/26/2024
|
Novo Nordisk's Wegovy wins EU backing for reducing heart risks
- Novo Nordisk's blockbuster Wegovy weight loss drug has received backing from the European Union's medical regulator to expand its use to include reducing the rise of serious heart events in overweight and obese adults. The Danish pharmaceutical giant said Thursday that the European Medical Agency had adopted a "positive opinion" on the label expansion, after reviewing the outcomes of a closely watched SELECT trial.
- 07/26/2024
|
Why Weight Loss Drug Developer Stocks Tumbled on Thursday
- A clinical-stage biotech is coming for their lunch. It aims to advance its own weight-loss drug to a phase 3 clinical study in the very near future.
- 07/25/2024
|
EU regulator backs use of Novo's Wegovy to lower heart risks
- The European Medicines Agency has backed the use of Novo Nordisk's Wegovy to lower heart risks in overweight or obese adults, the company said on Thursday.
- 07/25/2024
|
Wegovy approved in UK for cardiovascular problems in obese adults
- The Medicines and Healthcare products Regulatory Agency (MHRA) has approved semaglutide, known commercially as Wegovy, to reduce the risk of serious heart problems or strokes in overweight and obese adults. This approval makes semaglutide the first weight loss drug in the UK prescribed to prevent cardiovascular events in individuals with established cardiovascular disease.
- 07/24/2024
|
3 Stocks to Buy if There Is No Interest Rate Cut This Year
- While we're eagerly waiting for an interest rate cut, one must remember that there is no certainty when it comes to government decisions. Several factors come into play, and the policymakers will not announce a rate cut until they are certain about the inflation level.
- 07/24/2024
|
EDEN: Ultimately A Bet On Novo Nordisk
- EDEN has a major skew towards Novo Nordisk. We aren't especially worried about Novo Nordisk's valuation, but it could never be a steal considering its coverage and fame. Crude analysis suggests growth expectations are baked in, and deceleration now as well as competitive and other exogenous risks are possible sources of disappointment.
- 07/23/2024
|
Novo Nordisk (NVO) Advances While Market Declines: Some Information for Investors
- In the most recent trading session, Novo Nordisk (NVO) closed at $133.28, indicating a +0.08% shift from the previous trading day.
- 07/23/2024
|
Novo Nordisk's Wegovy weight loss drug wins UK approval for use as a heart treatment
- The U.K.'s health regulator on Tuesday approved the use of Novo Nordisk's Wegovy weight loss drug to reduce the risk of overweight and obese adults suffering from serious heart problems or strokes. It follows similar label expansion by the U.S. Food and Drug Administration in March.
- 07/23/2024
|
Novo Nordisk's Wegovy gets UK approval for lowering heart risks
- Novo Nordisk's weight-loss drug Wegovy has secured the UK regulator's approval for its use to reduce the risk of overweight and obese adults suffering serious heart problems or strokes, the agency said on Tuesday.
- 07/23/2024
|
Wegovy-maker Novo Nordisk buys land in Denmark for potential new production plant
- Novo Nordisk , the maker of weight-loss drug Wegovy, has bought a site in Denmark's third largest city Odense and begun preparatory excavation works for a potential new production plant, it said on Tuesday,
- 07/23/2024
|
Novo Nordisk A/S - share repurchase programme
- Bagsværd, Denmark, 22 July 2024 – On 6 May 2024, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules"). This programme is part of the overall share repurchase programme of up to DKK 20 billion to be executed during a 12-month period beginning 6 February 2024.
- 07/22/2024
|
Novo Nordisk Faces Setback in Netherlands Over Wegovy Insurance Coverage
- The famed Danish drug maker Novo Nordisk A/S NVO expressed disappointment on Wednesday following a recommendation by the Dutch Health Care Institute advising the Netherlands government against including the company's popular weight-loss drug, Wegovy, in the basic insurance coverage.
- 07/17/2024
|
Zacks Industry Outlook Eli Lilly, Novo Nordisk, Merck and Pfizer
- Eli Lilly, Novo Nordisk, Merck and Pfizer have been highlighted in this Industry Outlook article.
- 07/17/2024
|
Does Roche have weight-loss giants Novo Nordisk and Eli Lilly on the run?
- The potential of a once-a-day pill for obesity unsettled the weight loss stocks. Shares in Novo Nordisk (NYSE:NVO) and Eli Lilly and Co (NYSE:LLY) were off 4% and 2% respectively on news that Roche's new pill had shown promise in early-stage clinical trials.
- 07/17/2024
|
Roche obesity-pill trial results weigh on shares of Eli Lilly, Novo Nordisk
- Shares of weight-loss drug developers including Eli Lilly & Co., Novo Nordisk and Structure Therapeutics fell sharply early Wednesday after Roche Holding AG announced early-stage trial data for its experimental obesity pill.
- 07/17/2024
|
Novo Nordisk and Eli Lilly shares slide on new obesity drug trial from Roche
- Novo Nordisk and Eli Lilly shares slid Wednesday on promising early-stage trial data from Roche's latest obesity drug candidate. Roche said its experimental once-daily pill showed average weight loss of 6.1% in four weeks.
- 07/17/2024
|
Novo Nordisk (NVO) Stock Drops Despite Market Gains: Important Facts to Note
- In the most recent trading session, Novo Nordisk (NVO) closed at $140.87, indicating a -0.37% shift from the previous trading day.
- 07/16/2024
|
3 Hot Growth Stocks That Will Make You Forget About AMD
- Advanced Micro Devices (NASDAQ: AMD ) stock has been heating up for July. The top rival of Nvidia (NASDAQ: NVDA ) recently announced its intent to acquire Silo AI in an all-cash deal worth around $665 million.
- 07/16/2024
|
Novo Nordisk A/S (NVO) is Attracting Investor Attention: Here is What You Should Know
- Novo Nordisk (NVO) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
- 07/16/2024
|
4 Large Drug Stocks to Watch as Innovation, M&A Pick Up
- Drug and biotech companies are seeing significant innovation in 2024. In the Large-Cap Pharmaceuticals industry, Eli Lilly (LLY), Novo Nordisk (NVO), Merck (MRK) and Pfizer (PFE) are worth retaining in one's portfolio.
- 07/16/2024
|
Novo Nordisk investor backs $100m Alzheimer's funding round
- Novo Holdings, the main shareholder of Novo Nordisk (NYSE:NVO), has led a $100 million Series C funding round for Swiss company Asceneuron, which is developing a next-generation treatment for Alzheimer's. ASN51 is an oral small molecule drug targeting intracellular tau, protein tangles inside nerve cells, which could potentially revolutionize Alzheimer's treatment, according to Novo's senior partner Naveed Siddiqi.
- 07/16/2024
|
7 Top-Quality Stocks to Buy Now: July 2024
- Investors should look for top-quality stocks for the remainder of the year. With plenty of uncertainties, a nearing presidential election, geopolitical issues, and a lack of a clear economic trajectory, you want to make sure the stock you're jumping into is top-quality and fundamentally solid.
- 07/15/2024
|
Novo Nordisk (NVO) GLP-1 Drug Regarded Safe for Brain by Oxford
- Oxford study demonstrates that Novo Nordisk's (NVO) semaglutide is not associated with a risk of adverse neuropsychiatric outcomes compared with other antidiabetic medications over one year.
- 07/15/2024
|
Here's 80 Billion More Reasons to Buy Novo Nordisk Stock
- Novo Nordisk is already developing its next set of weight loss therapies. At least one market research firm is incredibly optimistic about its prospects.
- 07/13/2024
|
Novo Nordisk faces scrutiny on Capitol Hill for pulling Levemir insulin from US market
- Democratic U.S. Senate aides will meet with Novo Nordisk executives on Tuesday to discuss fallout from its decision to stop selling one of its long-acting insulins in the country, two sources familiar with the meeting told Reuters.
- 07/12/2024
|
Ozempic linked with lower dementia risk, nicotine use, British study finds
- Novo Nordisk's popular diabetes treatment Ozempic could be tied to a lower risk of cognitive problems, according to an observational study published by researchers at Oxford University.
- 07/12/2024
|
PFE or NVO: Which Is the Better Value Stock Right Now?
- Investors interested in stocks from the Large Cap Pharmaceuticals sector have probably already heard of Pfizer (PFE) and Novo Nordisk (NVO). But which of these two stocks offers value investors a better bang for their buck right now?
- 07/12/2024
|
Novo Nordisk Gains as Ozempic Found To Lower Dementia Rates
- American depositary receipts (ADRs) of Novo Nordisk (NVO) rose in intraday trading Friday after the release of an Oxford study that showed the Danish company's Ozempic diabetes drug was linked to lower rates of dementia and a range of mental problems.
- 07/12/2024
|
Study finds Novo Nordisk's Ozempic may reduce dementia
- The study looked at semaglutide, the scientific name for Novo Nordisk's NVO, -2.07% NOVO.B, +0.52% Ozempic, with the intent of looking at whether it caused neurological problems. Instead, it found a 48% decline in dementia relative to those who took sitagliptin, Merck's diabetes drug that's known as Januvia.
- 07/12/2024
|
3 Global Stocks Worth Buying as America Stumbles
- MoneyWeek columnist Bill Bonner wrote in the June 28 edition of the U.K. financial publication that the two men running for president of the United States are perfect candidates for a nation in decline. That got me thinking about global stocks.
- 07/12/2024
|
The 3 Most Undervalued Pharma Stocks to Buy in July 2024
- Undervalued pharma stocks can make good investments, whether during times of a booming economy or a faltering one. That is because people will still need medications and healthcare services regardless of the ongoing economic conditions.
- 07/12/2024
|
Novo Nordisk (NVO) Soars 38% YTD: How Should You Play the Stock?
- Novo Nordisk (NVO) is an excellent stock to retain as share prices continue to rise, driven by the stellar performance of GLP-1 drugs. New investors should look for stock price dips to make an entry.
- 07/11/2024
|
Novo (NVO) Gets CRL From FDA for Weekly Basal Insulin Icodec
- Novo's (NVO) efforts to get approval for once-weekly basal insulin icodec in the United States suffer a setback as the FDA issues a CRL.
- 07/11/2024
|
US FDA declines to approve Novo Nordisk's weekly insulin
- The U.S. Food and Drug Administration has declined to approve Novo Nordisk's weekly insulin in patients with diabetes, the Danish drugmaker said on Wednesday.
- 07/10/2024
|
Novo Nordisk receives Complete Response Letter in the US for once-weekly basal insulin icodec
- Bagsværd, Denmark, 10 July 2024 – Novo Nordisk today announced that the US Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) covering the Biologics License Application for once-weekly basal insulin icodec for the treatment of diabetes mellitus.
- 07/10/2024
|
US Senator Sanders optimistic Novo Nordisk can be pressured to cut Wegovy, Ozempic prices
- Senator Bernie Sanders on Wednesday expressed confidence that Novo Nordisk can be convinced to cut the U.S. prices of its popular Ozempic and Wegovy used for weight loss by publicly shaming the drugmaker over how much it charges compared to prices in other countries.
- 07/10/2024
|
3 Pharma Stocks That Could Make Your Grandchildren Rich
- Pharmaceutical stocks have not set the world on fire, with a few exceptions. Since the pandemic ended, pharma stocks have largely fallen out of favor with investors amid declining sales and mixed financial results.
- 07/10/2024
|
Weight Loss Drugs: Challenges with Affordability & Supply
- Affordability and supply are key challenges for GLP-1 weight loss drugs but these issues are actively being addressed, notes Maurits Pot. He and Rahul Jasuja assess the market opportunity of this part of the health care space.
- 07/10/2024
|
Novo Nordisk, Indonesia's Bio Farma sign deal to produce insulin
- Danish drugmaker Novo Nordisk has signed a deal with Indonesia's state-owned pharmaceutical company Bio Farma to produce insulin to combat diabetes in the Southeast Asian country, a Bio Farma senior official said on Wednesday.
- 07/10/2024
|
Novo Nordisk shares take a hit after a report revealed Eli Lilly's better weight loss drug
- Shares in Novo Nordisk, maker of the wildly popular obesity drug Wegovy, were down 1.1% on Tuesday after the publication of a data analysis showing rival Eli Lilly's own treatment Mounjaro leads to faster and greater weight loss.
- 07/09/2024
|
Novo Nordisk Falls as Study Says Eli Lilly Weight-Loss Ingredient More Effective
- The stock price of a pair of pharmaceutical companies are moving in opposite directions Tuesday following the publication of a new scientific study, with Eli Lilly (LLY) shares rising and American depositary receipts (ADRs) of Danish drugmaker Novo Nordisk (NVO) slipping.
- 07/09/2024
|
Eli Lilly weight-loss drug found more effective than Novo Nordisk's Ozempic
- Novo Nordisk (NYSE:NVO) shares fell and Eli Lilly and Co (NYSE:LLY) rose after a study found the US company's weight-loss drug may be more effective. Lilly's tirzepatide, branded as Mounjaro, was pitted against semaglutide, which Novo Nordisk (NYSE:NVO) makes under the Wegovy higher-dose brand for weight loss and Ozempic for type-2 diabetes, though the patients in the trial were all taking Ozempic.
- 07/09/2024
|
Novo Nordisk's stock slumps after study finds Wegovy lags Lilly's Mounjaro in speed and scale of weight loss
- The stock of Danish biotech Novo Nordisk was down 1.6% premarket Tuesday, after a study found that the company's obesity drug Wegovy lags its main rival, Eli Lilly & Co. Inc.'s Mounjaro, in speed and magnitude of weight loss.
- 07/09/2024
|
Imperial College spin-out Myricx Bio lands £90m of new investment
- An Imperial College spin-out has landed £90 million in Series-A funding backed by heavyweight investors, including an offshoot of the British Business Bank (BBB). Myricx Bio, the recipient of this funding, is at the forefront of developing innovative cancer treatments.
- 07/09/2024
|
Novo Nordisk shares down after analysis finds Lilly drug leads to better weight loss
- Shares in Novo Nordisk , maker of the wildly popular obesity drug Wegovy were down 1.1% on Tuesday after the publication of a data analysis showing rival Eli Lilly's own treatment Mounjaro leads to faster and greater weight loss.
- 07/09/2024
|
Patients Lost More Weight On Eli Lilly's Mounjaro Than Novo Nordisk's Ozempic
- Patients lost more significantly more weight on Eli Lilly's Mounjaro than Novo Nordisk's Ozempic, according to a new study.
- 07/08/2024
|
Novo Nordisk A/S - share repurchase programme
- Bagsværd, Denmark, 08 July 2024 – On 6 May 2024, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules"). This programme is part of the overall share repurchase programme of up to DKK 20 billion to be executed during a 12-month period beginning 6 February 2024.
- 07/08/2024
|
Copper, Gold Stocks Sparkle, Among 5 Leaders Near Buy Points
- Southern Copper and gold stock Agnico eagle surged above early buy points on hopeful signs for U.S. and China policy.
- 07/06/2024
|
Novo Nordisk reprimanded in UK for failure to disclose payments to healthcare sector
- Danish drugmaker Novo Nordisk has been reprimanded by UK regulators for failing to disclose fees and expenses paid to individuals and organisations in Britain amounting to about 7.8 million pounds ($9.97 million) between 2020 and 2022.
- 07/05/2024
|
Is It Too Late to Buy Novo Nordisk Stock?
- Novo Nordisk's valuation is high, and the U.S. patent for semaglutide expires in early 2026. However, the drugmaker has a promising pipeline that could drive growth for years to come.
- 07/05/2024
|
Novo Nordisk shares drop as study links drugs to vision loss
- Novo Nordisk (NYSE:NVO) shares have dropped by close to 4% this week, shedding more than £350 billion from its market cap, after a study suggested there may be a link between its blockbuster weight loss drugs Wegovy and Ozempic and vision loss. Those who have been prescribed the weight-loss injection are at a higher risk of developing an eye condition linked to blindness, the study said.
- 07/04/2024
|
NVO, LLY Slip After Study Links Obesity Drug Use to Vision Loss
- A new study led by investigators of a Harvard-affiliated teaching hospital found that Novo Nordisk's (NVO) GLP-1 drugs Ozempic and Wegovy could be linked to rare cases of vision loss.
- 07/04/2024
|
Novo Nordisk shares shrug off concerns over study linking weight loss drugs to rare eye condition
- Blockbuster weight loss drugs such as Wegovy and Ozempic may be associated with a rare eye condition, according to a new study released Wednesday. A Novo Nordisk spokesperson said there were "key methodological limitations" to the study.
- 07/04/2024
|
Weight-loss drugs linked to rare vision loss: Harvard study
- Novo Nordisk (NVO) and Eli Lilly (LLY) shares dip in reaction to a Harvard study that found GLP-1 weight-loss drugs Ozempic and Wegovy could be linked to rare cases of vision loss. Yahoo Finance health reporter Anjalee Khemlani explains the study's findings.
- 07/03/2024
|
Using Ozempic Or Wegovy Could Raise Risk For Rare Form Of Blindness, Study Suggests
- People who use Ozempic or Wegovy for treating obesity or Type 2 diabetes may have an increased risk of developing a rare form of blindness, according to a study published Wednesday in the journal JAMA Network, which Novo Nordisk has criticized for being insufficient.
- 07/03/2024
|
Novo Nordisk, Eli Lilly Tumble After Study Suggests Weight-Loss Drugs Can Lead To Blindness
- Novo Nordisk stock skidded Wednesday after a new study suggests its diabetes and weight-loss drug can lead to a blindness-causing disease.
- 07/03/2024
|
The 7 Best Stocks to Buy in July 2024
- The first half of the trading year is in the books, and by all accounts, it was a resounding success. The benchmark S&P 500 index rose 15% from January through the end of June, hitting all-time highs on 31 separate occasions.
- 07/03/2024
|
Wegovy, Ozempic linked with sight-threatening eye disorder in study
- Patients using Novo Nordisk's wildly popular weigh-loss drug Wegovy and its similar medicines for type 2 diabetes may be at increased risk for a sight-threatening eye condition, according to data from a study published on Wednesday.
- 07/03/2024
|
Novo Nordisk and Eli Lilly Slide as Biden Blasts Weight-Loss Drug Prices
- Novo Nordisk (NVO) American depositary receipts (ADRs) and Eli Lilly (LLY) shares lost ground Tuesday after U.S. President Joe Biden and Senator Bernie Sanders called out the companies in an op-ed for the cost of their medicines.
- 07/02/2024
|
Weighing the Future of Weight Loss Drugs
- How are obesity drugs impacting other industries? Julia Angeles discusses the future of weight loss drugs.
- 07/02/2024
|
Why Novo Nordisk Stock Is Slipping Today
- A USA Today op-ed from President Joe Biden and Sen. Bernie Sanders criticized Novo Nordisk.
- 07/02/2024
|
Joe Biden Suggests Novo Nordisk, Eli Lilly To Lower Prices For Its Popular Obesity Drugs
- The President of the United States, Joe Biden, and Sen. Bernie Sanders, the Senate Chairman of the Health, Education, Labor, and Pensions Committee, have long been vocal about the exorbitant prices the pharmaceutical industry charges for prescription drugs in the U.S.
- 07/02/2024
|
How To Pick Top Pharma Stocks: Novo Nordisk And More
- This article will outline nine steps I use to identify the most promising pharmaceutical companies and avoid investment pitfalls. In addition, each of the nine steps will provide examples of various factors and how they influence the assessment of the investment attractiveness of this or that company. The rest of the article will contain an analysis of Novo Nordisk, which is a leader in the fast-growing anti-obesity medicines market.
- 07/02/2024
|
Novo, Lilly Dive After Biden Slams Duo For 'Unconscionably High' Drug Prices
- Novo Nordisk stock fell Tuesday after Joe Biden and Bernie Sanders slammed the drugmaker and Eli Lilly for high prices of weight-loss drugs.
- 07/02/2024
|
Novo Nordisk must cut prices of weight-loss drug, Biden says in USA Today piece
- U.S. President Joe Biden and Senator Bernie Sanders called on Novo Nordisk to cut prices of its Ozempic and Wegovy drugs for weight loss and diabetes, in an opinion piece by them published in USA Today on Tuesday.
- 07/02/2024
|
Novo Nordisk steps up ad spend to keep the weight-loss crown
- Novo Nordisk (NYSE:NVO) appears to be taking a no-holds-barred approach to becoming the number one weight-loss drug in the US after it emerged that an ad for one of its key products was viewed nearly 2 billion times between June 3 and June 25, making it the third most-watched commercial during that period. The Wall Street Journal, citing iSpot.tv, reported the Wegovy ad, titled "Discover the Power", was shown 6,271 times and cost an estimated $42 million in national airtime.
- 07/02/2024
|
3 Breakout Biotech Stocks on Track to Double by 2032
- With the technology sector taking over in 2024, now is a great time to consider the best breakout biotech stocks to buy. Investing in these companies can be risky yet extremely rewarding, with careful selection of industry leaders.
- 07/01/2024
|
Novo Nordisk A/S - share repurchase programme
- Bagsværd, Denmark, 01 July 2024 – On 6 May 2024, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules"). This programme is part of the overall share repurchase programme of up to DKK 20 billion to be executed during a 12-month period beginning 6 February 2024.
- 07/01/2024
|
Surprise! Novo Nordisk's Wegovy Just Achieved Another Milestone. Here's What You Need to Know.
- Novo Nordisk's flagship obesity care treatment, Wegovy, recently received approval in China. Obesity is a big medical issue in China, estimated to affect hundreds of millions of people.
- 06/30/2024
|
The Top 3 Weight Loss Drug Stocks to Buy for Huge Gains
- Weight loss drugs have taken the pharmaceutical and medical communities by storm. Not only are the companies behind the medications struggling to keep up with global demand, but reports are emerging that the drugs could alleviate health problems beyond obesity.
- 06/28/2024
|
Novo Nordisk (NVO) Rises Higher Than Market: Key Facts
- In the closing of the recent trading day, Novo Nordisk (NVO) stood at $144.49, denoting a +0.57% change from the preceding trading day.
- 06/27/2024
|
3 Biotech Stocks For The Second Half Of 2024
- 3 Biotech Stocks For The Second Half Of 2024
- 06/27/2024
|
Novo Nordisk's (NVO) Hypertension Drug Study Fails to Meet Goal
- Novo Nordisk (NVO) declines as a late-stage study of its uncontrolled hypertension and advanced chronic kidney disease candidate, ocedurenone, fails to achieve the primary goal.
- 06/27/2024
|
Eli Lilly and Novo Nordisk are ahead in manufacturing but need time to meet demand, says Louise Chen
- Louise Chen, Cantor Fitzgerald analyst, joins CNBC's 'Squawk Box' to discuss Eli Lilly's surge over the past year, manufacturing, and more.
- 06/27/2024
|
Healthcare: Best strategies to invest in pharma stocks
- Novo Nordisk (NVO) and Eli Lilly (LLY) both made headlines recently with positive drug trial results for their respective GLP-1 weight-loss drugs, as well as their approval in China. While these names have been often cited as top picks in the pharmaceutical industry, are there hidden gems to look out for or do Eli Lilly and Novo Nordisk remain at the top of the class?
- 06/26/2024
|
Novo Nordisk makes impairment loss of $816 mln in Q2
- Novo Nordisk said on Wednesday it would recognise an impairment loss of about 5.7 billion Danish crowns ($816.72 million) in the second quarter of 2024, after its CLARION-CKD phase 3 trial failed to meet its primary endpoint.
- 06/26/2024
|
Novo Nordisk stops the ocedurenone CLARION-CKD trial and recognises impairment loss
- Bagsværd, Denmark, 26 June 2024 – Novo Nordisk today announced that the CLARION-CKD phase 3 trial failed to meet its primary endpoint and that it will recognise an impairment loss of around DKK 5.7 billion related to the intangible asset ocedurenone in the second quarter of 2024.
- 06/26/2024
|
Ozempic craze: Novo Nordisk invests $4.1B in US to expand manufacturing
- Novo Nordisk is ramping up the manufacturing capacity of its obesity-related drugs as demand for Wegovy and Ozempic continues to surge. It's pouring $4.1 billion to expand its facility.
- 06/26/2024
|
The Next 7 Trillion-Dollar Stocks to Buy: June 2024 Edition
- At the time of writing, there are precisely seven trillion dollar stocks overall. One of them, Saudi Aramco, doesn't trade in US markets.
- 06/26/2024
|
Novo Nordisk Breaks Out To An All-Time High On China Approval Of Wegovy
- Novo Nordisk gains approval in China for blockbuster drug Wegovy. More than 11% of all adults in China live with diabetes - more than any other country in the world. Both Eli Lilly and Novo Nordisk are disrupting the diet industry with their GLP-1 drugs, offering the potential for significant growth in the future.
- 06/26/2024
|
Novo Nordisk (NVO) to Invest $4.1B in Clayton Facility Expansion
- Novo Nordisk (NVO) plans to invest $4.1 billion in order to expand its Clayton facility with a second manufacturing plant, boosting capacity for injectable treatments and creating 1,000 new jobs.
- 06/25/2024
|
Novo Nordisk Rises as Wegovy Is Approved in China
- American depositary receipts (ADRs) of Danish drugmaker Novo Nordisk (NVO) rose Tuesday on the New York Stock Exchange (NYSE) after the company announced that its popular weight-loss drug Wegovy has been approved to start being sold in China.
- 06/25/2024
|
Why Novo Nordisk (NVO) is a Top Stock for the Long-Term
- Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Focus List.
- 06/25/2024
|
Pfizer's Working on the Next Wegovy, but Can It Beat Novo Nordisk?
- Novo Nordisk is raking in billions from Ozempic and Wegovy. Pfizer wants in on the action, so it's teaming up with a biotech.
- 06/25/2024
|
Novo Nordisk gains approval to sell weight-loss drug Wegovy in China
- Novo Nordisk has gained approval to start marketing its blockbuster weight-loss drug Wegovy in China, opening the door for the Danish pharmaceutical giant to further boost sales of the medicine that has transformed it into Europe's most valuable company.
- 06/25/2024
|
NVO Stock: Novo Nordisk Pops as China Approves Wegovy Weight Loss Drug
- Novo Nordisk (NYSE: NVO ) stock rose on news that China has approved its weight loss drug Wegovy and that the drugmaker will invest $4.1 billion into expanding its U.S. production capacity. The expansion will be built in North Carolina and is part of a $11 billion global production push.
- 06/25/2024
|
Whole Foods is promoting ‘little luxuries' as the next big food trend
- The supermarket chain, acquired by Amazon AMZN, -1.86% in 2017, sees “little luxuries” — meaning treat-style foods packaged in treat-size portions — as a key emerging trend. Or so said Whole Foods Chief Executive Jason Buechel during a Monday keynote talk at the Specialty Food Association's annual Summer Fancy Food Show, held at New York City's Javits Center.
- 06/25/2024
|
Novo Nordisk wins approval for its weight-loss drug from China
- Novo Nordisk A/S (CPH: NOVO-B) climbed 3.0% to an all-time high on Tuesday after China approved the sale of its weight-loss treatment Wegovy. Year-to-date, shares of the pharmaceutical giant are now up a whopping 45%.
- 06/25/2024
|
Wegovy Approved In China—But Novo Nordisk Promises Existing Patients Priority Amid Shortages
- Ozempic maker Novo Nordisk confirmed Tuesday its popular weight loss drug Wegovy had been approved for sale in China, a key victory for the Danish firm that opens the door to an enormous market, but the company told Forbes it will only launch there once it could guarantee supplies for those already taking it as shortages plague the U.S. market and elsewhere.
- 06/25/2024
|
Novo Nordisk's Wegovy weight loss drug approved in China
- Novo Nordisk said Tuesday that its Wegovy weight loss treatment has been approved in China for long-term weight management. The approval opens up the blockbuster drug for sale for those with obesity and at least one weight-related comorbidity.
- 06/25/2024
|
Ozempic maker Novo Nordisk to spend $4.1bn on North Carolina facility
- Novo Nordisk (NYSE:NVO) is investing $4.1 billion to expand its US manufacturing, focusing on its high-demand weight-loss drugs, Ozempic and Wygovy. The investment will fund a new 1.4 million square foot plant near Raleigh, North Carolina, doubling the site's size.
- 06/25/2024
|
Novo Nordisk says Semaglutide approved for long-term weight management in China
- Novo Nordisk's drug Semaglutide has been approved in China for long-term weight management, the company said in a post on an official WeChat account on Tuesday.
- 06/25/2024
|
Novo Nordisk Invests $4.1 Billion For New US Facility—Boosting Ozempic Production
- Novo Nordisk will invest $4.1 billion to develop a new manufacturing facility in the U.S., which will be used to boost production for the company's weight loss and diabetes drugs Wegovy and Ozempic, the Danish firm said Monday.
- 06/24/2024
|
Wegovy-maker Novo Nordisk to spend $4.1 bln to boost US manufacturing
- Obesity drug-maker Novo Nordisk will spend $4.1 billion to build a U.S. facility to fill injection pens for its hugely popular weight-loss treatment Wegovy and diabetes drug Ozempic, it said on Monday.
- 06/24/2024
|
Novo Nordisk announces 4.1 billion USD investment to expand US manufacturing capacity adline
- In 2024, Novo Nordisk plans to boost its current investments, aiming to allocate USD 6.8 billion towards production, a significant increase from the previous year's investment of USD 3.9 billion*.
- 06/24/2024
|
Novo Nordisk to build $4.1 billion North Carolina facility to boost output of Wegovy, Ozempic
- Novo Nordisk said it will spend $4.1 billion to boost the supply of its blockbuster weight loss drug Wegovy, diabetes treatment Ozempic and other injectable therapies. The investment will fund a new manufacturing plant in Clayton, North Carolina, responsible for filling and packaging syringes and injection pens for the drugs.
- 06/24/2024
|
Teva launches generic version of Novo Nordisk's diabetes drug Victoza
- Teva Pharmaceuticals said on Monday it has launched the generic version of Danish drugmaker Novo Nordisk's drug Victoza to treat patients with type 2 diabetes.
- 06/24/2024
|
Nestle launches 'Ozempic face' range as sales of weight-loss drugs soar
- Swiss consumer products giant Nestle S.A. (OTC:NSRGF, VTX:NESN)is introducing to help disguise the effect of rapid weight loss brought by the use of drugs such as Novo Nordisk (NYSE:NVO)'s Ozempic and Wegovy and Eli Lily's Mounjaro Nestle is bracing itself for a slump in sales of staples such as KitKat and Smarties due to the demand for weight-loss products, but is not sitting still with the new product lines to counteract the effect known as ‘Ozepmic face”.
- 06/24/2024
|
Investors Heavily Search Novo Nordisk A/S (NVO): Here is What You Need to Know
- Zacks.com users have recently been watching Novo Nordisk (NVO) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
- 06/24/2024
|
Novo Nordisk A/S - share repurchase programme
- Bagsværd, Denmark, 24 June 2024 – On 6 May 2024, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules"). This programme is part of the overall share repurchase programme of up to DKK 20 billion to be executed during a 12-month period beginning 6 February 2024.
- 06/24/2024
|
7 Strong Buy Blue-Chip Stocks to Keep You in the Green
- If you are tired of waiting for a rate cut, for the economy to improve and for consumer sentiment to soar so your portfolio turns green, it is best to consider rebalancing it. Several blue-chip stocks in the industry are unaffected by the market's ups and downs and have a steady history of outperforming the market.
- 06/24/2024
|
Novo's Wegovy induces higher weight loss in women than men with same heart condition, study shows
- Novo Nordisk's popular obesity drug Wegovy helped women with a common heart disease lose more weight than men who had the same condition, an analysis of study data published in a medical journal has shown.
- 06/23/2024
|
Novo Nordisk A/S: Mim8 demonstrated superior reductions in annualised bleeding rate (ABR) compared to on-demand and prior prophylaxis treatment in people with haemophilia A
- FRONTIER2 data presented at ISTH 2024 showed that up to 95% of people, who had no prior prophylaxis treatment, experienced zero treated bleeds while on Mim8
- 06/23/2024
|
3 Biotech Stocks to Buy Now: June 2024
- Recently, the biotech industry has taken a bit of a slower stance toward growth. With the Covid-19 pandemic in the rearview mirror, the focus of major pharmaceutical developers and biotech companies shifted back toward chronic diseases like diabetes, cancer, and heart disease.
- 06/21/2024
|
Sarepta's Expanded Approval Unlikely To Influence Novo Holdings' Acquisition of Catalent, But Provides Investor Protection Amid Uncertainty
- Shares of Catalent Inc CTLT, which manufactures Elevidys, are trading higher with a strong session volume of 3.6 million compared to an average volume of 1.6 million.
- 06/21/2024
|
The Best Could Be Yet to Come for Novo Nordisk and Ozempic
- Novo Nordisk's top-two blockbuster drugs include the same active ingredient -- semaglutide. The company is testing an even higher-dose version of semaglutide, which may yield even better results.
- 06/21/2024
|
7 Stocks With Impressive Earnings Growth: Real or Engineered?
- Earnings are exactly what they sound like. They're everything that's left over after everything else has been paid.
- 06/19/2024
|
3 Mega Cap Stock Bargains As Markets Hit All-Time Highs
- As markets continue to reach new all-time highs, investors are constantly seeking opportunities that offer both stability and growth potential. With the S&P 500 and Nasdaq recently hitting new all-time highs, investors are out bargain hunting.
- 06/18/2024
|
Brokers Suggest Investing in Novo Nordisk (NVO): Read This Before Placing a Bet
- Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter?
- 06/18/2024
|
Novo Nordisk announces presentation of data from key semaglutide clinical trials in diabetes, obesity and chronic kidney disease at the 84th Scientific Sessions of the American Diabetes Association
- Bagsværd, Denmark, 18 June 2024 – Novo Nordisk today announced the presentation of 34 abstracts highlighting the breadth of its portfolio at the upcoming 84th Scientific Sessions of the American Diabetes Association (ADA). The conference will be held in-person and virtually from 21–24 June 2024 in Orlando, US.
- 06/18/2024
|
Novo Nordisk A/S - share repurchase programme
- Bagsværd, Denmark, 17 June 2024 – On 6 May 2024, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules"). This programme is part of the overall share repurchase programme of up to DKK 20 billion to be executed during a 12-month period beginning 6 February 2024.
- 06/17/2024
|
3 Best Stocks to Buy From the Fantastic 5
- Wall Street loves coming up with cute little phrases, whether that be “FANG” or the more recent Magnificent 7. However, Thornburg portfolio manager Nicholas Anderson would like investors to be familiar with a new concept: targeting the best Fantastic 5 stocks for potentially blistering upside.
- 06/17/2024
|
3 Growth Stocks You Can Buy Right Now Without Any Hesitation
- Eli Lilly appears to be on course to become the first trillion-dollar healthcare stock. Novo Nordisk is one of the best ways to profit from the fast-growing obesity drug market.
- 06/15/2024
|
Novo Nordisk (NVO) Advances While Market Declines: Some Information for Investors
- Novo Nordisk (NVO) closed the most recent trading day at $142.50, moving +0.01% from the previous trading session.
- 06/14/2024
|
Novo Nordisk CEO to testify in US Senate hearing on high cost of Ozempic, Wegovy
- The Senate Committee on Health, Education, Labor, and Pensions said on Friday that Novo Nordisk CEO Lars Jorgensen has agreed to testify voluntarily in a hearing focusing on U.S. prices for weight loss drugs Ozempic and Wegovy.
- 06/14/2024
|
GLP-1 weight-loss drugs: Analyst discusses what investors should know
- GLP-1 weight-loss drugs have been major revenue generators for pharmaceutical companies such as Eli Lilly (LLY) and Novo Nordisk (NVO). Goldman Sachs US Lead Biotechnology Analyst Salveen Richter joins Catalysts to discuss the state of the weight-loss market and the potential headwinds for these pharmaceutical companies.
- 06/14/2024
|
Earnings Growth & Price Strength Make Novo Nordisk (NVO) a Stock to Watch
- Finding strong, market-beating stocks with a positive earnings outlook becomes easier with the Focus List, a top feature of the Zacks Premium portfolio service.
- 06/14/2024
|
3 Stocks to Sell as Ozempic Surges in Popularity
- Novo Nordisk's (NYSE: NVO ) Ozempic diabetes treatment, marketed as a weight loss treatment under the Wegovy brand name, has become the latest mega-blockbuster drug. Yet, while you may be thinking about ways to capitalize on its popularity and the rise of other glucagon-like peptide-1 (GLP-1) weight loss treatments, you should also consider the stocks to sell because of this trend.
- 06/14/2024
|
Got $200? 2 Healthcare Stocks to Buy and Hold Forever.
- Novo Nordisk and Medtronic are longtime leaders in the healthcare industry. Both are proven innovators with attractive prospects in the years ahead.
- 06/14/2024
|
Wegovy's Precarious Position: 3 Drugs Most Likely to Dethrone Novo Nordisk's Blockbuster Obesity Drug
- Eli Lilly has one obesity drug that's already competing against Wegovy, with more drugs potentially on the way. Novo Nordisk could have a more powerful obesity drug than Wegovy waiting in the wings.
- 06/14/2024
|
3 Stocks to Buy as Ozempic Surges in Popularity
- Ozempic and Wegovy (semaglutide for diabetes and weight loss, respectively) are popular weight-loss drugs that have taken the world by storm. Indeed, the craze is showing no signs of slowing down as more supply of GLP-1 receptor agonists comes online to meet blistering demand.
- 06/13/2024
|
Biosplice Announces Collaboration with Novo Nordisk in Diabetes
- SAN DIEGO, June 13, 2024 (GLOBE NEWSWIRE) -- Biosplice Therapeutics, Inc. (“Biosplice”), a clinical-stage biotechnology company pioneering first-in-class therapeutics based on small-molecule inhibition of DYRK/CLK kinases, has entered a collaboration with Novo Nordisk to develop drug candidates for the treatment of diabetes. This agreement builds upon Biosplice's innovative research, supported by robust external scientific literature, demonstrating the potential of DYRK inhibition to stimulate β-cell proliferation in animal models and human islet cells, thus offering a promising avenue for diabetes treatment.
- 06/13/2024
|
ASML, Novo Nordisk, Spotify Boast This Sign Of Stock Market Leadership
- Spotify stock, ASML and Novo Nordisk, are in or near buy zones and boast this key signal of stock market leadership.
- 06/12/2024
|
US Senate panel to weigh Novo Nordisk subpoena over Ozempic, Wegovy prices
- The U.S. Senate health panel said on Tuesday it would vote later this month on whether to subpoena Novo Nordisk over the high U.S. prices for weight loss drugs Ozempic and Wegovy compared to those offered in other countries.
- 06/11/2024
|
Here is What to Know Beyond Why Novo Nordisk A/S (NVO) is a Trending Stock
- Recently, Zacks.com users have been paying close attention to Novo Nordisk (NVO). This makes it worthwhile to examine what the stock has in store.
- 06/10/2024
|
Novo Nordisk A/S - share repurchase programme
- Bagsværd, Denmark, 10 June 2024 – On 6 May 2024, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules"). This programme is part of the overall share repurchase programme of up to DKK 20 billion to be executed during a 12-month period beginning 6 February 2024.
- 06/10/2024
|
The Safety Net Seven: 7 Stocks to Own for Unshakeable Returns
- With so many moving parts in the market, investors shouldn't just focus on explosive growth ideas. Instead, they should turn to the safety of, well, safe stocks to buy.
- 06/10/2024
|
Novo Nordisk Boss on Ozempic and Eating Disorder Criticism, Social Media Pressure
- #Ozempic #Wegovy #obesity #diabetes #weightloss #healthcare #pharmaceuticals #novonordisk #drugs #leadership #CEO Novo Nordisk has revolutionized the weight loss market with its blockbuster diabetes and obesity drugs, Ozempic and Wegovy. Celebrities have helped their popularity soar.
- 06/09/2024
|
Here's Why Demand for Ozempic and Wegovy Could Soar Even Higher
- Novo Nordisk has two hugely successful assets in Ozempic and Wegovy. A recent trial also found semaglutide effective for treating chronic kidney disease.
- 06/08/2024
|
ECB Rate Cut Propels European Markets: 3 Must-Watch Stocks
- Historic ECB rate cut bolstered European stocks, which calls for keeping a tab on Siemens (SIEGY), ASML Holding (ASML) and Novo Nordisk (NVO) for solid growth.
- 06/07/2024
|
Ozempic, Wegovy Really Good Value: Novo Nordisk CEO
- #Ozempic #Wegovy #obesity #diabetes #weightloss #healthcare #pharmaceuticals #novonordisk #drugs #leadership #CEO Novo Nordisk is Europe's most valuable company with booming demand for its blockbuster diabetes and obesity drugs, Ozempic and Wegovy. They're revolutionizing the weight loss drug industry, with some analysts predicting it could be worth up to $150 billion a year.
- 06/07/2024
|
The 3 Most Undervalued Pharma Stocks to Buy in June 2024
- Pharma stocks have two unique characteristics that can make them great investments for many individuals. First, unlike the vast majority of equities, undervalued pharma stocks can rally even when the economy is performing miserably.
- 06/06/2024
|
Novo Nordisk's Ozempic sales double to $700 M in China, driven by weight-loss demand
- Last year, Novo Nordisk, the Danish pharmaceutical giant, witnessed a significant surge in the sales of its diabetes drug Ozempic in China, doubling its revenue to almost $700 million. This remarkable growth accounts for 5 percent of Ozempic's global sales, underscoring China's pivotal role in the drug's international market.
- 06/06/2024
|
Ozempic Just Got Even More Bullish For Novo Nordisk Stock, Yet Again
- Novo Nordisk is working hard to expand Ozempic's addressable market. The drug is helpful in treating chronic kidney disease, per a new trial.
- 06/06/2024
|
Ozempic, Wegovy Weight-Loss Revolution: Novo Nordisk CEO Interview
- #Ozempic #Wegovy #obesity #diabetes #weightloss #healthcare #pharmaceuticals #novonordisk #drugs #leadership #CEO Novo Nordisk is Europe's most valuable company with booming demand for its blockbuster diabetes and obesity drugs, Ozempic and Wegovy. They're revolutionizing the weight loss drug industry, with some analysts predicting it could be worth up to $150 billion a year.
- 06/06/2024
|
European stocks open higher as markets anticipate first ECB rate cut since 2019; Novo Nordisk up 3.5%
- European stocks opened higher Thursday, with markets anticipating the ECB will cut borrowing costs for the first time since September 2019.
- 06/06/2024
|
Chinese drugmakers developing generic drugs of Novo Nordisk's Ozempic
- At least 11 generic versions of Novo Nordisk's popular diabetes drug Ozempic are in the final stages of clinical trials in China, as developers seek to profit from an early patent expiry of the therapy's active ingredient semaglutide in China.
- 06/05/2024
|
Focus: Novo Nordisk braces for generic challenge to Ozempic, Wegovy in China
- Novo Nordisk is facing the prospect of intensifying competition in the promising Chinese market where drugmakers are developing at least 15 generic versions of its diabetes drug Ozempic and weight loss treatment Wegovy, clinical trial records showed.
- 06/05/2024
|
Biotech Blockbusters: 3 Pharma Stocks to Buy in June for Breakthrough Potential
- The biotech sector has been through a lot in the past five years and it is finally rebounding. One of the most important sectors globally, it is hard to imagine life without biotech companies that provide life-changing drugs.
- 06/05/2024
|
Novo Resources Corp. Announces Resignation of Ross Hamilton as Director
- VANCOUVER, British Columbia, June 04, 2024 (GLOBE NEWSWIRE) -- Novo Resources Corp. (Novo or the Company) (ASX: NVO) (TSX: NVO) (OTCQX: NSRPF) advises that Mr Ross Hamilton has resigned as a director of the Company.
- 06/04/2024
|
Here Are 3 More Reasons to Be Bullish on Ozempic and Novo Nordisk Stock
- A couple of new scientific studies on Ozempic were just published. Both indicate that the medicine could be useful in treating addiction.
- 06/04/2024
|
Beyond The Nvidia Juggernaut: 2 Chip Giants, 2 Drugmakers In Spotlight
- As Nvidia stock takes aim at another record high and market-cap dominance, AMD and TSM set up alongside two top drugmakers.
- 06/03/2024
|
Novo Nordisk A/S - share repurchase programme
- Bagsværd, Denmark, 3 June 2024 – On 6 May 2024, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules"). This programme is part of the overall share repurchase programme of up to DKK 20 billion to be executed during a 12-month period beginning 6 February 2024.
- 06/03/2024
|
Novo Nordisk launches national Wegovy® campaign, Power of Wegovy®
- Designed to celebrate diverse, unique portrayals of individuals who partner with their healthcare professional to change the course of their weight-management journey, while educating on the clinical data of Wegovy® Reflects the power of personal journeys to address stigma, and the importance of us all working together to address excess weight and treat obesity PLAINSBORO, N.J. , June 3, 2024 /PRNewswire/ -- Novo Nordisk today launched The Power of Wegovy®, a new national campaign.
- 06/03/2024
|
Earn An 'Embarrassing' Amount Of Cash Flow From These Contrarian Picks
- Amazon CEO Andy Jassy highlights key traits for success in a career professional, including working hard, being can-do, and following through on commitments. There are different paths to success, and income investors can potentially achieve a high level of success by buying quality undervalued companies that pay dividends. In this article, I highlight high-yielding names in REITs, Energy, and Healthcare that I find attractive at present.
- 06/03/2024
|
Prediction: These Could Be the Best-Performing Pharmaceutical Stocks Through 2030
- Eli Lilly and Novo Nordisk are leaders in fast-growing therapeutic areas. Both companies have excellent track records of innovations and solid results.
- 06/02/2024
|
Ozempic and Wegovy Are Fueling Novo Nordisk's Business, but Something Else May Be an Even Bigger Growth Driver in the Long Run
- The vast majority of patients using GLP-1 agonists such as Ozempic and Wegovy are being treated for diabetes or chronic weight management. GLP-1 medications are believed to have further applications, and Wegovy just gained FDA approval to treat people with heart disease.
- 06/02/2024
|
This Is the Biggest Risk for Eli Lilly and Novo Nordisk Investors
- Eli Lilly and Novo Nordisk have generated incredible returns for investors in the past few years. The surging popularity of their weight loss treatments has produced a lot of bullishness.
- 06/01/2024
|
S&P 500 Giants Lead Five Healthy Stocks Near Buy Points
- Eli Lilly is in a buy zone, while weight-loss drug rival Novo Nordisk just forged a lower entry.
- 06/01/2024
|
Ozempic Maker Novo Nordisk Stock Up More Than 31% In 2024, But Is It Too Late To Buy Shares?
- Novo Nordisk stock traded close to a buy point Friday afternoon as shares bounced from their 21-day line this week.
- 05/31/2024
|
Fat profits from obesity? Goldman Sachs forecasts weight loss market will hit $130bn by 2030
- Goldman Sachs predicts that the global market for obesity treatments will surge to $130 billion by 2030, up from an earlier estimate of $100 billion. This revised forecast reflects the growing demand for anti-obesity medications, particularly those based on GLP-1 receptor agonists, which mimic a hormone that helps regulate appetite and blood sugar levels.
- 05/31/2024
|
Wegovy maker Novo Nordisk sues nine spas, clinics and pharmacies over copycat drugs
- Novo Nordisk said on Thursday it had sued nine more medical spas, wellness clinics and pharmacies in the U.S. for selling products claiming to contain semaglutide, the key ingredient in its popular weight-loss drug Wegovy.
- 05/30/2024
|
Catalent stockholders approve deal with Novo Holdings
- Catalent said on Wednesday its stockholders have voted to approve its deal with Novo Holdings, the parent company of Novo Nordisk.
- 05/29/2024
|
Novo Nordisk blames middlemen in U.S. healthcare system for high prices of weight loss drugs Wegovy and Ozempic
- Novo Nordisk has blamed middlemen in the U.S. healthcare system for the high prices of its top-selling weight-loss drugs Wegovy and Ozempic, following the launch of an investigation into the drugs led by U.S. Senator Bernie Sanders.
- 05/28/2024
|
Is Trending Stock Novo Nordisk A/S (NVO) a Buy Now?
- Zacks.com users have recently been watching Novo Nordisk (NVO) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
- 05/28/2024
|
Novo blames US health system after criticism over Wegovy price, Bloomberg reports
- Novo Nordisk said it retains about 60% of the list price of its popular diabetes and obesity drugs - Ozempic and Wegovy - after rebates and fees paid to middlemen in the United States, according to a Bloomberg report on Tuesday.
- 05/28/2024
|
7 Biotech Stocks to Put on Your Breakthrough Radar
- For those seeking to decipher best speculative opportunities in the market, biotech stocks with breakthrough potential may offer plenty of firepower. Let's get some of the bad stuff out of the way first.
- 05/27/2024
|
Novo Nordisk A/S - share repurchase programme
- Bagsværd, Denmark, 27 May 2024 – On 6 May 2024, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules"). This programme is part of the overall share repurchase programme of up to DKK 20 billion to be executed during a 12-month period beginning 6 February 2024.
- 05/27/2024
|
Novo Nordisk: Considerable Growth Beyond Ozempic
- Novo Nordisk is a Danish pharmaceutical company specializing in treatments for diabetes, obesity, and rare diseases. The company's main source of income comes from diabetes treatments, including insulin products and GLP-1 receptor agonists. Novo Nordisk has a long-term growth strategy, focusing on the development of new treatments for cardiovascular diseases, Alzheimer's, Parkinson's, and other emerging markets.
- 05/26/2024
|
Where Will Novo Nordisk Be in 10 Years?
- Novo Nordisk has been a dominant stock lately thanks to Ozempic, and to a lesser extent, Wegovy. The weight-loss market will, however, get a lot more crowded over the next 10 years.
- 05/25/2024
|
Wegovy users have less kidney-related health problems, analysis of Novo study finds
- Novo Nordisk's Wegovy obesity drug reduced adverse kidney-related events by 22% in overweight and obese people in a large study, according to a new analysis the Danish drugmaker published on Saturday.
- 05/25/2024
|
5 Dividend Aristocrats To Sell Before It's Too Late
- Buying stocks at record highs doesn't necessarily mean lower returns, and can actually lead to higher returns in the short term. Valuations matter, but the metric used to evaluate them is important. Cash-adjusted valuations provide a more accurate picture of a company's value. Dividend aristocrats are modestly undervalued, but these five are 50% historically overvalued, a challenging level that has led to long bear markets and poor returns for many years.
- 05/25/2024
|
3 High-Flying Stocks That Could Soar Even More
- Eli Lilly is just getting started with its powerful obesity drug and a loaded pipeline. It's not too late to invest in scorching-hot Novo Nordisk.
- 05/25/2024
|
US FDA panel votes against use of Novo Nordisk's weekly insulin in type 1 diabetes patients
- A panel of independent experts to the U.S. health regulator on Friday voted against the use of Novo Nordisk's weekly insulin in patients with type 1 diabetes due to risks of low blood sugar.
- 05/24/2024
|
Ozempic cuts kidney-disease risks, research finds
- Novo Nordisk's diabetes drug Ozempic reduces the risk of kidney failure and death in patients who have both Type 2 diabetes and chronic kidney disease, according to new research published Friday in the New England Journal of Medicine.
- 05/24/2024
|
Novo Nordisk's Ozempic slows diabetic kidney disease progression in trial
- Novo Nordisk's Ozempic slowed the worsening of kidney dysfunction in patients with type 2 diabetes and lowered the risk of kidney failure, heart problems, stroke and death, according to detailed results from a late-stage trial presented on Friday.
- 05/24/2024
|
Amid ‘Ozempic babies' questions, women account for more than 75% of young adults taking GLP-1 drugs, study finds
- More than three out of four young adults prescribed GLP-1 drugs last year were women, new research shows, raising questions about how societal views of women's weight may influence use of these medications and underscoring the need to better understand how the drugs may affect fertility, pregnancy, and longer-term health outcomes, researchers say.
- 05/22/2024
|
US FDA staff flags risk of low blood sugar for Novo Nordisk's weekly insulin
- The U.S. Food and Drug Administration's (FDA) staff on Wednesday pointed to "notable imbalance" in incidence of low blood sugar in patients with type 1 diabetes treated with Danish drugmaker Novo Nordisk's long-acting weekly insulin.
- 05/22/2024
|
Healthy Returns: Eli Lilly, Novo Nordisk are competing to develop more convenient weekly insulins
- The rivalry between Eli Lilly and Novo Nordisk extends beyond weight loss and diabetes drugs. Meanwhile, Uber has announced new features for caregivers.
- 05/21/2024
|
7 Biotech Stocks That Could Breathe New Life Into Your Portfolio
- Fundamentally, one of the biggest advantages of biotech stocks to buy centers on the underlying prioritization. While the media focuses on attaining wealth, that doesn't mean much if you don't have health.
- 05/20/2024
|
Novo Nordisk weight loss drugs still showing upside risk - analyst
- Novo Nordisk (NYSE:NVO) A/S' weight loss drug rollout continues to offer scope for upside surprises, Citi analysts have said. Despite ongoing supply constraints, four-week rolling prescription growth for the company's GLP-1-based drugs has soared, analysts said on Monday.
- 05/20/2024
|
Is Novo Nordisk Stock a Millionaire Maker?
- Novo Nordisk's already strong financials could look even better in the future as the company's drugs have loads of potential. The company's high-profit margins make it likely that earnings will soar right along with sales.
- 05/18/2024
|
Pharma Stocks Outlook: Where Are 2024's Top Performers Headed Next?
- The three top performing stocks discussed below have appreciated in value by an average of 129.7% in 2024. Such torrid growth logically raises the question of what is possible moving forward.
- 05/17/2024
|
Novo Nordisk A/S - share repurchase programme
- Bagsværd, Denmark, 17 May 2024 – On 6 May 2024, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules"). This programme is part of the overall share repurchase programme of up to DKK 20 billion to be executed during a 12-month period beginning 6 February 2024.
- 05/17/2024
|
Novo Nordisk A/S (NVO) is Attracting Investor Attention: Here is What You Should Know
- Recently, Zacks.com users have been paying close attention to Novo Nordisk (NVO). This makes it worthwhile to examine what the stock has in store.
- 05/17/2024
|
3 Drug Stocks to Watch on Raised 2024 Earnings & Sales Guidance
- Here we discuss three drugmakers, Eli Lilly and Company (LLY), Novo Nordisk (NVO) and Merck (MRK), that have raised their earnings as well as sales guidance for 2024.
- 05/16/2024
|
Novo Resources Announces Change of Auditor
- VANCOUVER, British Columbia, May 16, 2024 (GLOBE NEWSWIRE) -- Novo Resources Corp. (Novo or the Company) (ASX: NVO) (TSX: NVO & NVO.WT.A) (OTCQX: NSRPF) announces that it has changed its auditors from Ernst & Young (the “Former Auditor”) to Deloitte Touche and Tohmatsu (the “Successor Auditor”) effective 6 May 2024.
- 05/16/2024
|
7 Pharma Stocks Harnessing AI Brainpower for Big Breakthroughs
- It's no secret that artificial intelligence ( AI ) promises to transform every industry and sector, pharma included. But how do those companies plan to leverage AI, and what will it do for their stocks?
- 05/16/2024
|
Patent Peril: 3 Stocks at Risk From the FTC's Drug Crusade
- Several drug stocks are at risk as the Federal Trade Commission is going after pharmaceutical companies that it alleges are trying to keep generic drugs at bay from their branded products. The Biden administration is attacking businesses across the board, such as its recent assault on the oil industry.
- 05/16/2024
|
Here's Why Novo Nordisk (NVO) is a Strong Momentum Stock
- Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
- 05/15/2024
|
UK weight-loss drug price rivalry intensifies with Pharmacy2U mark-down
- Britain's Pharmacy2U said on Wednesday it had cut the prices of weight-loss medication Wegovy and Mounjaro, becoming the latest in a slew of online pharmacies and slimming clinics to do so as initial supply shortages of the drugs ease in the country.
- 05/15/2024
|
If You'd Invested $1,000 in Novo Nordisk Stock 5 Years Ago, Here's How Much You'd Have Today
- No prizes for guessing which hugely popular weight loss drug has driven its growth. Determined competition is on the way, but the Danish pharmaceutical star will have defensive advantages.
- 05/15/2024
|
Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons
- Bagsværd, Denmark, 15 May 2024 — This company announcement discloses the data of the transaction(s) made in Novo Nordisk shares by the company's board members, executives and their associated persons in accordance with Article 19 of Regulation No. 596/2014 on market abuse.
- 05/15/2024
|
Novo Nordisk Bets Up to $600 Million on Ozempic 2.0. Here's Why the Stock Is a Buy.
- Novo Nordisk just made a big collaboration commitment with a biotech. This partner is using advanced techniques to develop new medicines.
- 05/15/2024
|
Novo Nordisk owner buys majority stake in Austrian life science tools company
- Novo Holdings, the controlling shareholder of Danish obesity drugmaker Novo Nordisk , said on Wednesday it would buy a controlling stake of about 60% in Single Use Support, an Austria-based life science tools company.
- 05/15/2024
|
No shortage of Wegovy weight-loss drug in Denmark, Novo Nordisk says
- Novo Nordisk does not expect a shortage of its Wegovy weight-loss drug in Denmark despite an earlier warning by the Danish Medicines Agency of strained supply of two separate doses in the coming weeks, the company said.
- 05/15/2024
|
Healthy Returns: One in eight adults have taken Ozempic or other GLP-1s, survey says
- A wide swath of Americans are using GLP-1s despite shortages, a survey says. Meanwhile, Google DeepMind's new AI model can predict the structure of molecules.
- 05/14/2024
|
Novo Nordisk (NVO) Up 3% as Haemophilia Drug Meets Study Goals
- Novo Nordisk's (NVO) shares rise 3.1% as the company meets co-primary endpoints in a late-stage study evaluating its investigational candidate, Mim8, for the treatment of haemophilia A.
- 05/14/2024
|
Here's Why Novo Nordisk (NVO) is a Strong Growth Stock
- Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
- 05/14/2024
|
People on Novo Nordisk's Wegovy maintain weight loss for up to four years, study says
- The results shed light on the long-term effects of Wegovy, and could boost Novo Nordisk's case to insurers and governments to cover the costly drug.
- 05/14/2024
|
Cramer's Stop Trading: Novo Nordisk
- CNBC's Jim Cramer explains why he is keeping an eye on shares of Novo Nordisk.
- 05/14/2024
|
2 Top Pharma Stocks That Just Keep Getting Better and Better
- Eli Lilly and Novo Nordisk are competing in treating diabetes and obesity. Both have launched successful products in these two markets.
- 05/14/2024
|
Biotech Behemoths: 3 Giants Set to Dominate the Health Scene
- Biotechnology is an interesting place to look if you're looking for growth and are not put off by severe levels of volatility. Undoubtedly, there's a bit of speculative zest regarding some of the smaller biotech stocks out there, many of whom depend on just a handful of pipeline candidates.
- 05/14/2024
|
Weight loss wonder drug reduces chance of heart attack and stroke by a fifth
- Weight loss jabs Wegovy, Ozempic, and Rybelsus could lower the risk of heart attacks, strokes, or heart failure in obese individuals, irrespective of their weight loss, according to a recent study. Led by Professor John Deanfield from University College London, the research utilised data from the Select trial funded by Novo Nordisk (NYSE:NVO).
- 05/14/2024
|
Wegovy weight loss sustained for four years in trial, Novo Nordisk says
- Patients taking Novo Nordisk's popular Wegovy obesity treatment maintained an average of 10% weight loss after four years on the treatment, the company said on Tuesday.
- 05/13/2024
|
Novo Nordisk A/S: Once-weekly and once-monthly Mim8 demonstrate superior reduction of treated bleeding episodes compared to on-demand and prior prophylaxis treatment in people with haemophilia A in the Frontier 2 trial
- Bagsværd, Denmark, 13 May 2024 – Novo Nordisk today announced the headline results from the FRONTIER 2 trial, a pivotal phase 3a, 26-week open-label, randomised, controlled, multi-arm trial in 254 people. The trial investigated the efficacy and safety of once-weekly and once-monthly subcutaneous Mim8 versus no prophylaxis and versus prior coagulation factor prophylaxis treatment in people aged 12 years or older with haemophilia A with or without inhibitors.
- 05/13/2024
|
Denmark faces Wegovy shortage due to rising demand, medicines agency says
- The Danish medicines agency on Monday warned of a supply shortage for two separate doses of Novo Nordisk's hugely popular weight loss drug Wegovy due to increasing demand.
- 05/13/2024
|
Bernie Sanders Urges Ozempic Maker Novo Nordisk To Be Fair Over ‘Outrageously Expensive' U.S. Drug Prices
- Bernie Sanders has urged Denmark to rein in its most valuable company, Novo Nordisk, and force it to slash prices on popular weight loss and diabetes treatments Ozempic and Wegovy, taking his fight to lower “outrageously high” drug prices in the United States to the company's doorstep as its profits soar amid ongoing struggles to meet booming appetite for the revolutionary drugs.
- 05/13/2024
|
Novo Nordisk weight loss rollout to prompt ‘dramatic upgrades' - analysts
- Novo Nordisk (NYSE:NVO) could be in line for ‘dramatic earnings upgrades' as pace builds on the rollout of its weight loss drugs, analysts say. Wegovy sales could hit 76 billion Danish Krone (US$11 billion) this year, Morgan Stanley (NYSE:MS) said in a note, after starter doses increased six-fold up to early May.
- 05/13/2024
|
Billionaire Jim Simons Owns These 2 Healthcare Stocks: Should You?
- Novo Nordisk and Exelixis are favorites of billionaire Jim Simons' hedge fund. Novo Nordisk has a deep lineup and pipeline and expertise in diabetes and obesity.
- 05/12/2024
|
Want Decades of Passive Income? 3 Stocks to Buy Now and Hold Forever.
- Novo Nordisk's Ozempic has changed the business entirely. Eli Lilly is a diversified giant with GLP-1 tailwinds.
- 05/11/2024
|
3 Million Reasons Novo Nordisk Still Looks Like a Phenomenal Buy
- Wegovy is a weight-loss drug that's proving it can do more than help people lose weight. Regulators recently approved it as a treatment for reducing cardiovascular risk.
- 05/09/2024
|
Metaphore Biotechnologies to partner with Novo Nordisk on obesity therapies
- Metaphore Biotechnologies said on Thursday it would collaborate with Novo Nordisk to develop up to two therapies for obesity management.
- 05/09/2024
|
Wall Street Bulls Look Optimistic About Novo Nordisk (NVO): Should You Buy?
- The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings often affect a stock's price.
- 05/08/2024
|
Novo Nordisk eyeing upside on US weight loss drug rollout - analysts
- Novo Nordisk (NYSE:NVO) could see consensus estimates boosted over the coming years as sales of its weight loss drugs pick up in the US, analysts say. Novo has 12 million patients on its GLP-1-based drugs, Citi analysts highlighted in a note, while the addressable population for the weight loss treatment approaches one billion.
- 05/08/2024
|
Healthy Returns: Eli Lilly, Novo Nordisk make progress toward boosting weight loss drug supply
- Eli Lilly and Novo Nordisk are boosting supply of their weight loss drugs, while Apple Watch's heart monitoring tech was approved for use in clinical studies.
- 05/07/2024
|
Biotech Breakthroughs: 7 Stocks Driving the Next Wave in Healthcare
- Amid a challenging market environment, one of your best bets could be to target biotech stocks to buy. Yes, the sector can be volatile because much hinges on underlying breakthroughs.
- 05/07/2024
|
Amgen, newer rivals could threaten Novo Nordisk and Eli Lilly's weight loss drug dominance
- Amgen, Viking Therapeutics, Altimmune, AstraZeneca, Boehringer Ingelheim and Zealand Pharma are making encouraging progress on their own treatments.
- 05/07/2024
|
Can Pfizer Challenge Lilly and Novo Nordisk in the Obesity Market?
- The outlook for Pfizer's experimental obesity drug danuglipron is murky at best. Pfizer could pick up another obesity drug via an acquisition, but management says a near-term deal is unlikely.
- 05/04/2024
|
Apple, Glencore, Sony, Novo Nordisk, Shell, Goldman Sach, GSK, Qualcomm, AMD, Starbucks, Amazon – Markets Defused
- Markets Defused aims to present an easy-to-understand and straightforward recap of the week's most engaging stock market news Apple impressed Wall Street, Cook promises AI growth Sony stepped in with $26bn bid to buy Paramount Ozempic and Wegovy gave more record results at Novo Nordisk Goldman Sachs ready to boost banker bonuses in London Qualcomm optimistic about future smartphone sales AMD fell short of high expectations Starbucks revenues disappointed Amazon's beat expectations Apple financials impressed Wall Street, Cook promises AI growth Apple Inc (NASDAQ:AAPL, ETR:APC) investors welcomed the iPhone maker's latest earnings report on Thursday, buying up the shares following Thursday's report. Revenues came in ahead of Wall Street expectations for Apple's first quarter driven by demand in its services businesses – iCloud, Apple TV+, and Apple Music – whilst iPhone sales declined.
- 05/04/2024
|
3 Under-The-Radar Stocks That Could Be Worth Over $1 Trillion by 2030
- There are no true “under-the-radar stocks” in the traditional sense regarding companies with a market capitalization large enough to be viable candidates for a $1 trillion valuation in just six years. However, there are many overlooked gems whose immense potential fails to garner the attention it deserves from investors.
- 05/03/2024
|
Novo Nordisk continues to impress, says buyer Citi
- Novo Nordisk (NYSE:NVO)'s latest results have impressed analysts at Citi, who see little to stop the pharma's value increasing even further as weight control drug Wegovy grows in the US. “While periodic supply constraints continue to impact the business, scaling supply remains management's number one priority.
- 05/03/2024
|
Wegovy maker Novo Nordisk down 4%, heads for worst day since October
- Analysts pored over the details in its first-quarter results and monitored a potential rival weight loss treatment.
- 05/03/2024
|
Novo Nordisk drops 5% after rival Amgen teases weight-loss drug data
- Shares in Danish drugmaker Novo Nordisk dropped as much as 5.3% on Friday, set for their biggest one-day fall since August 2022, after rival Amgen said it was encouraged by interim trial data on its experimental obesity drug.
- 05/03/2024
|
Novo Nordisk falls after strong Q1 results, Mizuho's Jared Holz talks what's next for the company
- Jared Holz, Mizuho, joins 'Fast Money' to talk Novo Nordisk pulling back despite strong quarter.
- 05/02/2024
|
25,000 people begin taking Wegovy each week, but Novo Nordisk stock is sinking anyway
- Danish drugmaker Novo Nordisk, the creator of Ozempic and Wegovy, announced a shocking statistic Thursday: Over 25,000 people begin Wegovy each week. The number is five times larger than the numbers from December—about 5,000 new users a week.
- 05/02/2024
|
Novo Nordisk A/S (NVO) Q1 2024 Earnings Call Transcript
- Novo Nordisk A/S (NVO) Q1 2024 Earnings Conference Call May 2, 2024 7:00 AM ET Company Participants Lars Fruergaard Jørgensen - Chief Executive Officer Camilla Sylvest - Executive Vice President, Head of Commercial Strategy & Corporate Affairs Doug Langa - Executive Vice President, Head of North America Operations Martin Holst Lange - Executive Vice President, Head of Development Karsten Munk Knudsen - Chief Financial Officer Daniel Bohsen - Head of Investor Relations Conference Call Participants Michael Nedelcovych - TD Cowen Richard Vosser - JPMorgan Louise Chen - Cantor Fitzgerald Evan Seigerman - BMO Capital Markets Sachin Jain - Bank of America Peter Verdult - Citi Simon Baker - Redburn Atlantic Florent Cespedes - Bernstein Mark Purcell - Morgan Stanley Harry Sephton - UBS Richard Parkes - BNP Paribas Exxon Michael Novod - Nordea Operator Good day! And thank you for standing by.
- 05/02/2024
|
Novo Nordisk faces competitive market: Novasecta
- Subscribe to CNBC International TV: http://cnb.cx/2wAkfMv Subscribe to CNBC International: http://cnb.cx/2gft82z LinkedIn: https://www.linkedin.com/showcase/cnbc-international/ TikTok: https://www.tiktok.com/@cnbci Facebook: https://www.facebook.com/cnbcinternational Instagram: https://www.instagram.com/cnbcinternational/ Threads: https://www.threads.net/@cnbcinternational X: https://twitter.com/CNBCi Telegram: https://t.me/cnbci
- 05/02/2024
|
Novo Nordisk (NVO) Q1 Earnings Beat, GLP-1 Drugs Boost Sales
- Novo Nordisk (NVO) reports better-than-expected first-quarter results, beating both earnings and revenues, driven by strong sales of Diabetes and Obesity care products.
- 05/02/2024
|
2 Biotech Stocks To Watch Today Amid Earnings
- Here are two biotech stocks to watch after their recent earnings report.
- 05/02/2024
|
Novo Nordisk's Earnings Beat Estimates on Surging Demand for Its Weight-Loss Drugs
- Novo Nordisk (NVO) reported first-quarter earnings Thursday that beat analysts' estimates as demand surged for its weight loss drugs, Ozempic and Wegovy.
- 05/02/2024
|
Novo Nordisk: Wegovy, Ozempic prices in US fell in Q1
- Novo Nordisk has seen the price of its hugely popular weight-loss drug Wegovy and diabetes drug Ozempic fall in the United States as volumes and competition have increased, a senior executive said on Thursday.
- 05/02/2024
|
Novo Nordisk ups guidance after earnings beat expectations
- Novo Nordisk (NYSE:NVO), Europe's biggest company, said it is ramping up production of its diabtes/weightloss drugs Wegovy and Ozempic, after patient numbers quadrupled in the US. First-quarter sales came in at 65.35 billion Danish krone, beating forecasts of DKK 63.75 billion, including almost DKK 35 billion from the drug.
- 05/02/2024
|
Novo Nordisk Hikes Guidance as Weight-Loss Drug Sales Surge. Why the Stock's Falling.
- The Danish pharmaceutical giant, which became Europe's most valuable company last year, said Wegovy sales jumped 106% in the first quarter.
- 05/02/2024
|
Ozempic Maker Novo Nordisk Beats Profit Forecasts Amid Weight Loss Drug Frenzy
- Danish pharma giant Novo Nordisk raised its 2024 outlook and beat first-quarter profit expectations in its first-quarter earnings report Thursday morning, amid a frenzied rush to match booming consumer demand for its popular weight loss and diabetes drugs Ozempic and Wegovy.
- 05/02/2024
|
Novo Nordisk now has more than 130,000 weight-loss prescriptions as it hikes financial outlook
- Novo Nordisk said its Wegovy injectable drug for weight loss now has more than 130,000 weekly prescriptions in North America alone after boosting supplies to meet insatiable demand.
- 05/02/2024
|
Earnings report: Novo Nordisk cashes in on weight loss drug fever with better-than-expected results
- This morning, pharmaceuticals reported triumphant Q1 2024 financial results before markets opened. One of the more memorable highlights was certainly the fact that Novo Nordisk's sales increased by 22% in Danish kroner (by 24% at constant exchange rates) to DKK 65.3 billion for the period.
- 05/02/2024
|
Novo Nordisk beats profit estimates as sales of weight loss drug Wegovy more than double
- Sales of popular weight loss drug Wegovy more than doubled to 9.38 billion kroner.
- 05/02/2024
|
Obesity drugmaker Novo Nordisk's Q1 profit beats forecast
- Novo Nordisk posted on Thursday first-quarter operating profit above analyst forecasts, as the Danish drugmaker races to boost output of its hugely popular weight-loss drug Wegovy and fend off competition from Eli Lilly.
- 05/02/2024
|
Profit from the Panic: 3 Stocks to Pounce on When They Become Steals
- To paraphrase Rudyard Kipling, the secret to success in the stock market is to “keep your head when all about you are losing theirs.” When everyone is panicking and sending the market lower, that's the time for you to be cool as a cucumber and look for stocks to buy on dips.
- 05/01/2024
|
Novo Nordisk owner to invest $200 million in quantum computing startups
- Novo Holdings, the controlling shareholder of Danish obesity drugmaker Novo Nordisk , said on Wednesday it plans to invest around $200 million in quantum computing startups.
- 05/01/2024
|
What Novo Nordisk's Ozempic Success Means for Denmark
- Diabetes and obesity drugs Ozempic and Wegovy have become world famous, generating billions in sales and opening a new market for weight loss drugs. The development of semaglutide, the key ingredient in the medicines, has also transformed their maker, Novo Nordisk, into Europe's most valuable company, with profound implications for its home country of Denmark.
- 05/01/2024
|
FTC Warns ‘Junk Patents' Could Make Drugs Like Ozempic Pricier—Here's How
- The Federal Trade Commission is challenging hundreds of alleged “junk” patent listings filed by several pharmaceutical companies, which regulators claim could increase prices for medications like Novo Nordisk's diabetes drug Ozempic by making it harder to produce generic drugs.
- 04/30/2024
|
FTC challenges 'junk' patents held by 10 drugmakers, including for Novo Nordisk's Ozempic
- The agency sent letters to Novo Nordisk, AstraZeneca, Boehringer Ingelheim, Covis Pharma, GlaxoSmithKline, Novartis, Teva Pharmaceuticals, among others.
- 04/30/2024
|
FTC challenges ‘bogus' patents on Ozempic, other drugs that ‘block competition'
- WASHINGTON — Federal regulators are challenging patents on 20 brand-name drugs, including the blockbuster weight-loss injection Ozempic, in the latest action by the Biden administration targeting industry practices that drive up pharmaceutical prices.
- 04/30/2024
|
Will These 5 Drug/Biotech Stocks Beat Q1 Earnings Forecast?
- Let's look at five large-cap pharma/biotech companies slated to release quarterly results this week.
- 04/30/2024
|
Should You Invest in Novo Nordisk (NVO) Ahead of Q1 Earnings?
- Novo Nordisk's (NVO) revenues in the first quarter of 2024 are expected to have been driven by its diabetes and obesity care product sales, especially Ozempic, Rybelsus and Wegovy.
- 04/29/2024
|
One dose of Novo Nordisk's Wegovy back in supply, FDA website shows
- The U.S. Food and Drug Administration website showed on Monday one dose of Novo Nordisk's weight-loss drug Wegovy is available after being in short supply, while three other doses remained in limited availability due to increased demand.
- 04/29/2024
|
Forget Nvidia, These Unstoppable Stocks Are Better Buys
- Healthcare stocks can offer investors more predictable growth opportunities than artificial intelligence, where there's much more uncertainty in the long run. Eli Lilly and Novo Nordisk have top drugs that can help diabetes and obesity, two significant health concerns around the world.
- 04/27/2024
|
1 Unstoppable Pharmaceutical Stock Investors Shouldn't Sleep On
- Eli Lilly is the developer of GLP-1 treatments Mounjaro and Zepbound. Currently used to treat diabetes and obesity, they could have far more reach.
- 04/27/2024
|
Novo Nordisk: Medicare Coverage To Unlock Another Big Market For Wegovy
- Novo Nordisk's weight loss drug, Wegovy, has received FDA approval for reducing the risk of major cardiovascular adverse events. Wegovy demonstrated a 20% reduction in the risk of major cardiovascular adverse events and a 19% reduction in the risk of all-cause death in the SELECT trial. The approval extends Novo Nordisk's leadership position in the obesity market and makes Wegovy eligible for Medicare coverage.
- 04/26/2024
|
Novo Nordisk hopes to prove Wegovy naysayers wrong
- Europe's biggest company, the Danish weight loss drug kingpin Novo Nordisk (NYSE:NVO)'s upcoming results will be squarely focused on the uptake of the flagship Wegovy drug in the US. Analysts have warned that the company risks undershooting forecasts due to Wegovy's slow uptake.
- 04/26/2024
|
Novo Nordisk (NVO) Stock Sinks As Market Gains: Here's Why
- In the latest trading session, Novo Nordisk (NVO) closed at $126.16, marking a -1.93% move from the previous day.
- 04/24/2024
|
Senate launches investigation into high prices of Ozempic and Wegovy in the U.S.
- Before insurance, Novo Nordisk charges about $1,000 per month for Ozempic in the United States. In Germany, the company charges $59 a month for the same drug.
- 04/24/2024
|
US Senate committee investigates pricing of Novo's Ozempic and Wegovy
- A U.S. Senate committee said on Wednesday it had launched an investigation into the prices of Novo Nordisk's diabetes and weight loss drugs Ozempic and Wegovy in the United States.
- 04/24/2024
|
3 Biotech Stocks With Skyrocketing Potential: April 2024
- Investing in biotech stocks is not for the faint of heart. The sector is prone to wild swings in stock prices, offering a distinctive blend of high risk and high reward.
- 04/24/2024
|
4 Large Drug Stocks to Hold on to Amid Industry Challenges
- Drug and biotech companies are likely to see significant innovation. In the Large-Cap Pharmaceuticals industry, Eli Lilly (LLY), Novo Nordisk (NVO), Merck (MRK) and AbbVie (ABBV) are worth retaining in one's portfolio.
- 04/24/2024
|
Missed Out on Novo Nordisk? 2 Healthcare Stocks With Big Catalysts on the Horizon.
- Novo Nordisk has achieved tremendous success thanks largely to Ozempic and Wegovy. Vertex Pharmaceuticals is another drugmaker that could soon have two new big winners on the market.
- 04/24/2024
|
Novo Nordisk (NVO) Boasts Earnings & Price Momentum: Should You Buy?
- Finding strong, market-beating stocks with a positive earnings outlook becomes easier with the Focus List, a top feature of the Zacks Premium portfolio service.
- 04/23/2024
|
Why Novo Nordisk Topped the Market Today
- The Wegovy and Ozempic maker continues to buy its own shares. It purchased more than 200,000 of them last week.
- 04/22/2024
|
Wegovy vs. Zepbound: Who Wins the Battle of the GLP-1 Drugs?
- The GLP-1 weight loss trend continues to flourish, and the ante keeps rising. The reigning champions in the battle of the bulge are Novo Nordisk A/V NYSE: NVO with its Semaglutide medications Ozempic and Wegovy, and Eli Lilly & Co. NYSE: LLY with its Tirzepatide medications Mounjaro and Zepbound.
- 04/22/2024
|
2 Everlasting Big Pharma Stocks to Buy Today and Hold Forever
- Great pharma companies tend to be entrenched in lucrative markets. Vertex Pharmaceuticals is managing to diversify off a strong base.
- 04/20/2024
|
Missed Out on Eli Lilly and Novo Nordisk? This Small Biotech Has a Promising GLP-1 Drug With Significant Potential
- Eli Lilly and Novo Nordisk are two of the big names in healthcare focused on a hot GLP-1 drug market. But there's a drug from a smaller biotech which could also prove to be a big player in this area.
- 04/20/2024
|
3 Relatively Safe Growth Stocks You Can Buy and Hold
- Eli Lilly has crushed the S&P 500 over the last 12 months and could continue delivering outsized returns. Novo Nordisk's strong fundamentals and solid growth opportunities make it a no-brainer buy.
- 04/20/2024
|
3 Biotech Stocks Set to Double by 2028
- Biotech stocks offer the possibility of groundbreaking medical advancements alongside the potential for explosive growth. While the sector carries inherent risks, a select group of biotech companies possesses the potential to deliver substantial returns in the coming years.
- 04/20/2024
|
Got $500? 3 Healthcare Stocks to Buy and Hold Forever
- Healthcare stocks can be excellent choices for investors, offering a balance of safety and growth. Intuitive Surgical, Bristol Myers Squibb, and Novo Nordisk all have strong growth potential.
- 04/19/2024
|
NVO, ELF, TAN: Stocks & ETFs to Watch
- Mish Schneider discusses her stock and ETF picks as stocks continue to tick lower today. She highlights Novo Nordisk (NVO), E.L.F. Beauty (ELF), and Invesco Solar ETF (TAN). Tune in to find out more about the stock market today.
- 04/17/2024
|
Big pharma is looking to fatten profits with buyouts of weight-loss drug companies. Here are 4 candidates.
- A couple of big-picture trends in biotech could add up to a nice investment opportunity. First, corporate buyouts are back in style.
- 04/16/2024
|
Novo Nordisk (NVO) Stock Falls Amid Market Uptick: What Investors Need to Know
- In the latest trading session, Novo Nordisk (NVO) closed at $123.46, marking a -0.36% move from the previous day.
- 04/16/2024
|
3 Pharma Stocks That Are Money-Printing Machines in 2024
- The future of the U.S. economy appears promising, with robust growth and strong corporate performance. This economic strength has propelled the stock market to record highs, signaling confidence in the economy's resilience.
- 04/15/2024
|
Novo Nordisk and Eli Lilly weight loss drugs may not be a silver bullet, but they have huge potential, says leading US bank
- A staggering $1 trillion could be the annual cost to the US healthcare system if 40% of Americans with obesity begin treatment with GLP-1 drugs at current prices, according to Dr Jonathan Gruber, the Ford Professor of Economics at the Massachusetts Institute of Technology (MIT). This figure, which rivals the entire budget of the Medicare programme, highlights the potential fiscal challenges posed by these promising yet costly treatments for obesity.
- 04/15/2024
|
Novo Nordisk Arms Wegovy to Be a Triple Threat
- Ozempic usage for weight loss has gone viral, making it the highest revenue-generating drug for Novo Nordisk AV/S NYSE: NVO. Originally purposed for Type 2 diabetes, the skyrocketing off-label use for weight loss led Novo to create Wegovy, a stronger version of Ozempic (generic name: semaglutide) for obesity.
- 04/15/2024
|
Nvidia Leads 5 Stocks Near Buy Points As S&P 500 Tests Key Level
- Nvidia, which bucked the S&P 500 downdraft last week, leads this weekend's watch list of five stocks near buy points.
- 04/13/2024
|
Novo Nordisk's Dominance In Obesity & Diabetes Drug Market Backed by Strong Pipeline: Analyst Gives Outperform Rating - Novo Nordisk (NYSE:NVO)
- BMO Capital Markets initiated coverage on Danish drug maker Novo Nordisk A/S NVO after the company garnered interest as it hit the holy grail with the next generation of famed weight loss and diabetes drugs.
- 04/12/2024
|
EU probe of weight loss and diabetes drugs like Wegovy, Ozempic finds no link to suicidal thoughts
- The review examined several drugs from Novo Nordisk, including Wegovy, Ozempic, Rybelsus, and Saxenda, but did not include Eli Lilly's Zepbound and Mounjaro.
- 04/12/2024
|
Obesity-drug power couple Novo Nordisk and Eli Lilly still have room to run, analysts say
- Novo Nordisk and Eli Lilly & Co., the dynamic duo of the weight-loss drug world, still have plenty of upside even after their shares have surged over the past 12 months, BMO Capital Markets analysts said Friday.
- 04/12/2024
|
Popular weight-loss drug doesn't increase suicide risk, EU regulator says
- A committee of the European Medicines Agency said Friday that a popular weight-loss drug doesn't increase the risk of suicide.
- 04/12/2024
|
Shed the Fat, Gain the Profits: 3 Weight-Loss Stocks to Own Until 2027
- Weight-loss stocks remain the focus of many investors. The GLP-1 drugs that many companies have put forward address key health concerns like obesity and diabetes, which have become epidemics in many Western countries.
- 04/12/2024
|
All-Time High Flyers: 7 Stocks to Buy as the Market Peaks
- If you're wondering which stocks to buy in April, here's a good place to start. The stock market is off to a difficult start in the second quarter.
- 04/11/2024
|
This weight-loss ETF has performed well in its first five months. How does it compare with cheaper alternatives?
- A new exchange-traded fund needs an edge to attract investors. This might be its industry focus — a tall order in a crowded market with ETFs covering just about any industry you can imagine.
- 04/10/2024
|
Novo Nordisk's Stock Could Get Another Boost, Thanks to This Huge Development
- Health insurers are going to offer coverage for Wegovy to Medicare patients. Beyond weight loss, Wegovy has shown it can reduce the risk of heart attacks and strokes.
- 04/10/2024
|
Meet Europe's Mag 18. Novo Nordisk Stock, ASML, and Others Can Rival the Mag Seven.
- The Mag Seven stocks have powered gains in the U.S. market. Now, the hunt is on for an equivalent group of outperformers elsewhere.
- 04/09/2024
|
Novo Nordisk parent refiles US application on Catalent deal
- The parent of Wegovy producer Novo Nordisk has refiled an application to the U.S. Federal Trade Commission (FTC) for approval of a $16.5 billion deal to buy manufacturing subcontractor Catalent , a spokesperson said on Monday.
- 04/08/2024
|
Could This New Development Soon Buoy Eli Lilly and Novo Nordisk Stock?
- Novo Nordisk and Eli Lilly make medicines that target GLP-1, which figures in a number of ailments. A new study found that a similar drug could help treat Parkinson's.
- 04/07/2024
|
Wegovy's heart benefits are not just linked with weight loss, new study suggests
- People with obesity-related heart failure and diabetes can get substantial heart-health benefits from the popular obesity drug Wegovy, even if they don't shed a lot of weight on the medication, according to new research.
- 04/06/2024
|
Diabetes medication appears to slow progress of Parkinson's disease in French-backed trial
- A Type 2 diabetes medication called lixisenatide appeared to slow the progression of Parkinson's disease symptoms in a small, mid-stage trial funded by the French Ministry of Health and others, the New England Journal of Medicine reported on Thursday.
- 04/04/2024
|
Could This 1 Detail Help Viking Therapeutics Top Eli Lilly and Novo Nordisk in the Weight Loss Drug Market?
- Eli Lilly and Novo Nordisk have seen demand surpass supply of their weight loss drugs. Their revenues have soared thanks to these popular products.
- 04/04/2024
|
3 Underappreciated Healthcare Stocks to Buy Now: April 2024
- The healthcare sector is a constant source of innovation and growth. Yet, even amidst the spotlight on industry giants, a realm of underappreciated gems still exists.
- 04/03/2024
|
Healthy Returns: Weight loss, diabetes drug ad spending tops $1 billion
- Drugmakers spent big on ads for weight loss and diabetes drugs such as Wegovy and Ozempic. Meanwhile, the FDA approved the first AI diagnostic tool for sepsis.
- 04/03/2024
|
Costco begins offering Novo Nordisk's Ozempic to members
- Costco and its healthcare partner Sesame have started offering weight-loss drugs including Ozempic to Costco members. Under a $179 three-month prescription plan, members will have access to video consultations with a weight-loss doctor and an individualized, clinically-appropriate treatment program.
- 04/03/2024
|
Biotech's Next Gold Rush: Weight-Loss Drugs
- Biotech's next gold rush is weight-loss drugs. There is a dominance of NVO and LLY in this space for now, notes Rahul Jasuja.
- 04/02/2024
|
Wall Street Analysts Think Novo Nordisk (NVO) Is a Good Investment: Is It?
- The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings often affect a stock's price.
- 04/02/2024
|
Healthcare stocks fade as obesity-drug optimism fades
- Healthcare companies fell sharply Monday as ebullience about a new class of weight control drugs subsided.
- 04/01/2024
|
Here's Why Novo Nordisk (NVO) Fell More Than Broader Market
- Novo Nordisk (NVO) closed at $127.55 in the latest trading session, marking a -0.66% move from the prior day.
- 04/01/2024
|
Is Novo Nordisk the Best Healthcare Stock for You?
- Novo Nordisk's business is not only growing at a fast rate; it also generates impressive margins. Demand for its products is strong and could increase in the years ahead.
- 03/31/2024
|
How Novo Nordisk built an empire selling diabetes and weight-loss drugs
- The popularity of Novo Nordisk's (NVO) blockbuster obesity drug Wegovy, and diabetes drug Ozempic, for weight loss, was so great in 2023 that it has been credited with propping up the entire economy of Denmark. It is that impact and buzz that led Yahoo Finance to name Novo Nordisk its 2023 Company of the Year.
- 03/31/2024
|
Diversifying Into This Key Market Is 1 More Reason to Buy Novo Nordisk Stock
- Novo Nordisk is buying Cardior, a clinical-stage biotech that is developing heart disease drugs. Its cardiovascular disease pipeline will get a lot stronger as a result of the acquisition.
- 03/31/2024
|
Omega Therapeutics And Novo Nordisk Collaboration: A Cautious 'Buy'
- Omega Therapeutics is a biotech company focused on developing programmable epigenomic mRNA medicines to control gene manifestation. The company's platform has applications in various diseases, including hepatocellular carcinoma, non-small cell lung cancer, and obesity. Omega Therapeutics has signed a collaboration with Novo Nordisk to develop a drug for obesity management, validating the potential of its platform.
- 03/31/2024
|
Why Eli Lilly And Rival Novo Nordisk Won't Be Troubled By Viking's Latest Weight Loss Data
- Eli Lilly and Novo Nordisk have created what Wall Street believes will be the biggest ever pharmaceutical market with its miraculous weight loss drugs. Novo Nordisk's Ozempic and Wegovy, as well as Eli Lilly's Mounjaro and Zepbound, have already generated billions of dollars in revenue but this may be the tip of the iceberg. Viking Therapeutics' VK2735 has emerged as a strong contender in the GLP-1 drug market, with promising weight loss results in clinical studies.
- 03/31/2024
|
Why Novo Nordisk (NVO) is a Top Stock for the Long-Term
- Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Focus List.
- 03/29/2024
|
International Companies Drive Diabesity Innovation
- International Companies Drive Diabesity Innovation
- 03/29/2024
|
This small-cap stock is expected to take off — if its weight-loss pill trial succeeds
- The stock of small-cap Terns Pharmaceuticals Inc. rose 6% on Thursday, amid bullish analyst comment on the company's pipeline, which includes an oral treatment for obesity that one bank believes could send the stock sharply higher.
- 03/28/2024
|
2 Top Biotech Buyout Candidates
- After a strong resurgence in the back half of 2023 and continued momentum into the first quarter of 2024, biotech stocks are back in vogue. “Hawkish” Federal Reserve Policy, a brutal bear market in 2022, and investor preference for big tech stocks have meant underperformance for biotech stocks.
- 03/28/2024
|
Knocking on the Trillion-Dollar Door: 3 Stocks Ready to Shatter the Market Cap Milestone
- As the stock market rally continues, the trillion-dollar market cap club stands to get just a bit more crowded. Undoubtedly, more than a handful of mega-cap titans could pass the $1 trillion milestone as soon as 2024.
- 03/28/2024
|
Wegovy will be covered by some insurers, but not for weight loss: report
- Some large health insurers in the U.S. will start covering Wegovy, which has become a popular anti-obesity drug — but not for those using it to lose weight, according to a report by The Wall Street Journal.
- 03/28/2024
|
Bernie Sanders Calls On Novo Nordisk To Lower Cost Of Ozempic And Wegovy
- Sen. Bernie Sanders, I-Vt., demanded Novo Nordisk, the Danish drug company that manufactures the wildly popular Ozempic and Wegovy weight loss drugs, lower the list price of the drugs, warning the “outrageously high price has the potential to bankrupt Medicare, the American people and our entire health care system.
- 03/27/2024
|
Novo Nordisk's $1,000 diabetes drug Ozempic can be made for less than $5 a month, study suggests
- Researchers found Novo Nordisk's Ozempic could be manufactured for an estimated 89 cents to $4.73 for a month's supply, figures that include a profit margin.
- 03/27/2024
|
Missed out on Eli Lilly and Novo Nordisk? This pharma stock could be the next ‘big thing'
- Given the pharmaceutical industry's assured success driven by innovation and the development of medications targeting diverse healthcare issues, Eli Lilly (NYSE: LLY) and Novo Nordisk (NYSE: NVO) have emerged as dominant players, capturing significant market demand.
- 03/27/2024
|
Here's Why Ozempic And Mounjaro Rivals Won't Topple Weight Loss Drugmakers Novo Nordisk And Eli Lilly Anytime Soon
- The world is hooked on weight loss drugs and so is the pharmaceutical industry, but as Big Pharma's biggest players and upstart biotechs rush to join the booming market, experts tell Forbes the dominance of Novo Nordisk and Eli Lilly is unlikely to be toppled anytime soon.
- 03/27/2024
|
3 Stocks to Buy for the Next Bull Run: March 2024
- As we approach the end of the year's first quarter, the stock market has enjoyed a strong run. Three months into 2024 and the benchmark S&P 500 index is already up 10%.
- 03/26/2024
|
Novo Nordisk (NVO) to Buy Cardior to Boost Heart Disease Pipeline
- Novo Nordisk (NVO) is set to acquire Cardior Pharmaceuticals for 1.025 billion euros to establish a presence in cardiovascular disease.
- 03/26/2024
|
Wall Street Awaits Consumer Confidence Data
- U.S. stock markets saw a pullback on Monday to start a holiday-shortened week. However, Wall Street is likely to record the fifth consecutive winning month despite volatility.
- 03/26/2024
|
Best Obesity Drug Stock: Eli Lilly, Novo Nordisk, or Viking Therapeutics?
- Eli Lilly has a big winner with Zepbound plus other growth drivers and a promising late-stage pipeline. Novo Nordisk's Ozempic and Wegovy are huge successes with more great drugs potentially on the way.
- 03/26/2024
|
Wall Street Set to Post Fifth Winning Month Amid Volatility
- Wall Street is likely to record the fifth consecutive winning month despite volatility.
- 03/26/2024
|
Why the Market Dipped But Novo Nordisk (NVO) Gained Today
- Novo Nordisk (NVO) closed the most recent trading day at $129.05, moving +0.23% from the previous trading session.
- 03/25/2024
|
Novo Nordisk Buys Heart Disease Drug Maker Cardior in $1.11 Billion Deal
- Novo Nordisk AS (NVO), maker of the weight-loss drug Wegovy, is set to acquire Cardior Pharmaceuticals, a German drug company, in a deal for up to 1.025 billion euros ($1.11 billion).
- 03/25/2024
|
Uncovering Hidden Gems: 1 AI-Powered Healthcare Stock Set to Dominate the Market
- Novo Nordisk is one of the leading drugmakers in the world, developing hit medications such as Ozempic. The company is using artificial intelligence (AI) to process larger volumes of data from clinical trials.
- 03/25/2024
|
Terry Smith's Fundsmith downgraded over recent mis-steps
- Terry Smith's Fundsmith Equity, the UK's most popular fund, has been downgraded by Morningstar due to questions over the manager's recent portfolio moves. Fresh from the fund having underperformed its benchmark for a third successive year, Morningstar reduced its rating to Silver from Gold, although analysts said the portfolio remains "very high quality and different from the benchmark".
- 03/25/2024
|
Novo Nordisk targets heart disease in $1.1 billion deal
- Novo Nordisk, the Danish pharmaceutical whose market cap has swelled due to popular weight loss drugs, on Monday announced it was making an acquisition targeting cardiovascular disease.
- 03/25/2024
|
Novo Nordisk and Eli Lilly May Finally Have Some Real Competition
- Demand for obesity and diabetes treatments such as Ozempic, Mounjaro, and Wegovy is off the charts. Novo Nordisk and Eli Lilly manufacture the primary medications used to treat obesity care and diabetes.
- 03/25/2024
|
Novo Nordisk to buy Cardior Pharmaceuticals for up to $1.1 bln
- Denmark's Novo Nordisk on Monday said it has agreed to buy Cardior Pharmaceuticals for up to 1.03 billion euros ($1.11 billion) to strengthen its cardiovascular pipeline.
- 03/25/2024
|
Nvidia's AI Tech Part of Novo Nordisk's New Supercomputer
- Two of the year's biggest investment themes, artificial intelligence and anti-obesity drugs, are finally meeting up, as Novo Nordisk A/S NYSE: NVO and Nvidia Corp. NASDAQ: NVDA announced a partnership to develop supercomputers.
- 03/24/2024
|
Novo Nordisk (NVO) Gets Positive CHMP Opinion for Insulin Icodec
- Novo Nordisk (NVO) receives a positive opinion from the CHMP for once-weekly basal insulin icodec for the treatment of diabetes in adults.
- 03/22/2024
|
With Shares Trading Near All-Time Highs, Is Now the Time to Take Profits in Novo Nordisk?
- Novo Nordisk dominates the obesity and diabetes markets thanks to its long list of hit medications. Wegovy was just approved for an expanded indication, and Novo Nordisk's Amycretin could be its next blockbuster drug.
- 03/22/2024
|
Did Eli Lilly Just One-Up Novo Nordisk?
- Eli Lilly and Novo Nordisk are fierce competitors in the diabetes and obesity markets. Each company is investing heavily to scale up production to meet demand.
- 03/22/2024
|
Hot Stocks: The 3 Best Opportunities for Investing in Biotech
- When it comes to risk vs. reward in the stock market, the biotech sector has one of the highest potential payoffs.
- 03/21/2024
|
Medicare allows coverage of Wegovy for heart patients
- Older adults may now get Medicare coverage for the popular obesity drug Wegovy, so long as they're using it to cut their risk of serious heart problems and not for weight loss alone, according to new guidance from the Centers for Medicare and Medicaid Services.
- 03/21/2024
|
Novo Nordisk sales face hit on slow US uptake of weight loss drug - analysts
- Novo Nordisk (NYSE:NVO) is at risk of missing first-quarter consensus estimates, due in part to the slow uptake of its flagship Wegovy drug in the US, Jefferies analysts have warned. As per the bank, sales over the first quarter will likely sit at 59.1 billion Danish Krone, 9% lower than consensus estimates of 64.7 billion.
- 03/21/2024
|
Novo Nordisk's once-weekly basal insulin icodec recommended for marketing approval in Europe
- Danish drugmaker Novo Nordisk on Thursday said its once-weekly basal insulin icodec for treatment of diabetes in adults had received a recommendation for marketing authorisation from the European Medicines Agency's human medicines committee.
- 03/21/2024
|
7 Stocks That Are Creating a Buzz on Wall Street
- What a difference a Fed meeting can make. Stocks are again ripping higher after the U.S. Federal Reserve signalled that it still expects to deliver three interest rate cuts this year.
- 03/21/2024
|
Novo Nordisk's New Weight Loss Drug Could Be Better Than Ozempic and Wegovy
- Novo Nordisk recently released trial results for its weight loss pill amycretin. In an early-stage trial, the drug performed better than Wegovy.
- 03/21/2024
|
German health ministry says Ozempic exports are not a concern
- Germany's health ministry said that no large volumes of diabetes drug Ozempic are being exported out of the country, quashing a suggestion by the nation's drugs regulator that outbound trade in the drug, coveted for its weight-loss effect, may have to be banned.
- 03/21/2024
|
3 Biopharma Stocks Predicted to Soar in Q2 2024
- Biopharma stocks have been among the most popular and well-performing stocks this year. With recent trends in weight loss drugs and clinical advancements in treating illnesses, this market is set for significant advances this year.
- 03/20/2024
|
Will Novo Nordisk Overtake Eli Lilly as the Most Valuable Healthcare Stock?
- Novo Nordisk's shares have benefited from some recent positive developments. The delay in the approval of donanemab has held back Eli Lilly's valuation.
- 03/20/2024
|
A new study cites the health risks of intermittent fasting. Could it lift Ozempic sales?
- A new medical study is raising concerns over whether intermittent fasting, a weight-loss method that's gained attention in recent years, could pose heart-health risks.
- 03/19/2024
|
Time to be "Overweight" Viking Therapeutics
- A rising obesity rate and the desire for a quick fix are driving the burgeoning weight loss industry. Stock Strategist Andrew Rocco explains why VKTX stands to benefit the most.
- 03/19/2024
|
3 Top Stocks to Watch From the Best International Money Managers
- #Morningstar #NovoNordisk #StockInvesting Managers of highly rated funds own these foreign stocks. Should you?
- 03/19/2024
|
Is Madrigal Pharmaceuticals Stock a Better Buy Than Eli Lilly and Novo Nordisk After Its Huge FDA Win?
- Last week's FDA approval of Rezdiffra in treating NASH is a huge milestone for Madrigal. Lilly and Novo Nordisk look much more impressive than Madrigal in most ways.
- 03/19/2024
|
Novo Nordisk (NVO) Rises Yet Lags Behind Market: Some Facts Worth Knowing
- Novo Nordisk (NVO) concluded the recent trading session at $132.89, signifying a +0.39% move from its prior day's close.
- 03/18/2024
|
Earnings Growth & Price Strength Make Novo Nordisk (NVO) a Stock to Watch
- Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Focus List.
- 03/18/2024
|
Weight loss drug Wegovy is now approved for heart health — but that won't mean broad insurance coverage just yet
- Some health plans and employers are still reluctant to cover Wegovy due to its hefty price tag, which they say could significantly strain their budgets.
- 03/18/2024
|
Novo Nordisk Isn't in The "Magnificent Seven," but Here's Why I Think It Should Be
- Novo Nordisk is a leader and innovator in the diabetes drug market. The pharmaceutical company is making strides in obesity care, too.
- 03/17/2024
|
Novo Nordisk Is Already Working on Wegovy's Successor -- Time to Buy?
- Novo Nordisk recently presented encouraging phase 1 results for an oral obesity treatment candidate. The company has many more promising programs in its early-stage pipeline.
- 03/17/2024
|
3 Unstoppable Stocks You Can Buy Now Without Any Hesitation
- Investors need not be concerned about the FDA's approval delay for Eli Lilly's Alzheimer's drug. Novo Nordisk recently picked up a regulatory win that makes the stock even more attractive.
- 03/17/2024
|
Weight loss drug Wegovy is now approved for heart health — but that won't mean broad insurance coverage just yet
- Some health plans and employers are still reluctant to cover Wegovy due to its hefty price tag, which they say could significantly strain their budgets.
- 03/16/2024
|
7 Mega-Cap Stocks That Can Turn $10,000 Into $1 Million
- By definition, mega-cap stocks are those which possess a market capitalization above $200 billion. So, investors seeking to turn $10,000 into $1 million through Mega cap companies will be choosing from the top 60 companies on this list.
- 03/15/2024
|
Why Novo Nordisk (NVO) is a Top Momentum Stock for the Long-Term
- Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
- 03/15/2024
|
Novo Nordisk Just Scored a Huge Win. And It's Not Related to Ozempic
- Novo Nordisk primarily focuses on the diabetes and obesity markets with medications like Ozempic and Wegovy. Wegovy was recently granted an extended indication from the FDA to treat cardiovascular disease.
- 03/15/2024
|
3 Weight-Loss Stocks to Buy as GLP-1 Mania Takes Hold
- When many investors hear the word mania, they may think of artificial intelligence (AI) stocks or Bitcoin. Both investments have yielded market-beating returns and have room to run higher.
- 03/15/2024
|
Should Pfizer Acquire Viking Therapeutics to Take on Eli Lilly and Novo Nordisk in the Obesity Drug Market?
- Pfizer's pipeline already includes two obesity drugs. However, doubts about Pfizer's lead obesity program could make buying Viking a smart move.
- 03/15/2024
|
Missed Out on Novo Nordisk? This Much Smaller Danish Biotech Could Be the Next Hot Weight-Loss Stock.
- Novo Nordisk's $600 billion valuation makes it one of the top healthcare companies in the world. For investors looking for stocks with more upside, upstart Zealand Pharma may fit the bill.
- 03/14/2024
|
UPS, IBM, NVO: Expect Less Volatility Than Last Year
- We're bullish on the market this year, notes Andrew Arons. He discusses the long-term market outlook.
- 03/13/2024
|
America versus Europe: The big-cap stocks face off
- Who is better, the United States of America or the European Union? On the one hand, European citizens are by and large privy to free access to healthcare, though the land of the free is considerably less stingy with its food portion sizes.
- 03/13/2024
|
Can WeightWatchers Regain Its Mojo after Oprah Steps Down?
- WW International Inc. NASDAQ: WW (WeightWatchers) has had a disastrous 2024, with its shares collapsing 66.7% year-to-date (YTD). The company made a praiseworthy strategic pivot in 2023, acquiring Sequence Inc. to enter into the GLP-1 clinical weight loss space, gaining the ability to prescribe medications like Novo Nordisk A/V NYSE: NVO owned Ozempic and Wegovy and Eli Lilly& Co. NYSE: LLY GLP-1 agonists like Mounjaro and Zepbound.
- 03/13/2024
|
Why Novo Nordisk Stock Was a Winner Today
- A research firm added the European pharmaceutical sector star to its focus list. It was among four stocks earning this status.
- 03/12/2024
|
What Makes Novo Nordisk (NVO) a Strong Momentum Stock: Buy Now?
- Does Novo Nordisk (NVO) have what it takes to be a top stock pick for momentum investors? Let's find out.
- 03/12/2024
|
All You Need to Know About Novo Nordisk (NVO) Rating Upgrade to Buy
- Novo Nordisk (NVO) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
- 03/12/2024
|
Novo Nordisk-owner to expand in India this year
- Novo Holdings, the controlling shareholder of Danish obesity drugmaker Novo Nordisk , plans to open an office in India this year to tap innovation and a growing healthcare market, its CEO Kasim Kutay said on Tuesday.
- 03/12/2024
|
Novo Nordisk (NVO) Is Considered a Good Investment by Brokers: Is That True?
- The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings often affect a stock's price.
- 03/12/2024
|
1 Big New Reason to Buy Novo Nordisk Stock Hand Over Fist Right This Instant
- Novo Nordisk is one of the leading developers of weight-loss drugs. It just shared some great early-stage clinical trial data from one of its programs.
- 03/12/2024
|
Why Novo Nordisk (NVO) Dipped More Than Broader Market Today
- Novo Nordisk (NVO) concluded the recent trading session at $131.24, signifying a -1.38% move from its prior day's close.
- 03/11/2024
|
Next thing: weight loss funds in the works
- Next thing: weight loss funds in the works.
- 03/11/2024
|
On the Dip: 3 Stocks to Snatch Up Whenever the Market Stumbles
- Building a stock investment portfolio isn't easy. One moment, you are tempted to wait for a dip, and another, you want to give in to the temptation of buying a stock at a premium with the hopes that it will generate strong returns.
- 03/11/2024
|
Novo Nordisk's (NVO) Wegovy Gets FDA Nod to Reduce Heart Risk
- Novo Nordisk (NVO) announces FDA approval of its application seeking label expansion for Wegovy to reduce the risks of major adverse cardiovascular events.
- 03/11/2024
|
Obesity Drugs 2024: The Skinny on the Top 3 Weight-Loss Stocks
- The catalyst for top weight-loss stocks comes down to one sweeping attribute: a burgeoning total addressable market. According to a Goldman Sachs analysis, earlier last year, the global industry for anti-obesity medications (AOMs) reached $6 billion on an annualized basis.
- 03/10/2024
|
Is Novo Nordisk a Buy After Its New Obesity Candidate's Success in a Clinical Trial?
- Shares of Novo Nordisk recently rose to a new all-time high in response to clinical trial results for an experimental new weight-management drug named amycretin. Amycretin is a potential first-in-class dual GLP-1 and amylin agonist that shrank patients' body weight by a placebo-adjusted 12% after 12 weeks of treatment.
- 03/10/2024
|
Missed Out on Eli Lilly and Novo Nordisk? This Could Be the Next Big Weight Loss Stock.
- Viking Therapeutics recently unveiled positive clinical trial results for its anti-obesity medication. The treatment is in phase 2 trials, but its results suggest it could rival other weight loss drugs.
- 03/09/2024
|
The Top 3 Pharma Stocks to Buy in March2024
- Investors' eyes are closely following the massive rally in pharmaceutical stocks amid the red-hot anti-obesity market. In 2024, the projected revenue for the pharma market is estimated to reach $1.15 trillion.
- 03/09/2024
|
Wegovy and Zepbound Are King. Who's Coming for Their Crowns.
- Contenders are beginning to emerge from the lab, some with the potential to unseat Lilly's Zepbound and Novo's Wegovy.
- 03/09/2024
|
Jim Cramer looks at Europe's 'Super 7'
- 'Mad Money' host Jim Cramer looks at Europe's top performing stocks, deemed the 'Super 7'.
- 03/08/2024
|
The European 'Super 7' is a great slate of companies, says Jim Cramer
- 'Mad Money' host Jim Cramer looks at Europe's top performing stocks, deemed the 'Super 7'.
- 03/08/2024
|
Weight-loss drug Wegovy approved by FDA to cut heart attack, stroke risk
- The move confirms that the new class of obesity medications are useful for improving health, not just losing weight.
- 03/08/2024
|
FDA approves Novo Nordisk's Wegovy for use in reducing heart attack risks
- The U.S. FDA has approved Novo Nordisk's Wegovy for use in lowering the risk of stroke and heart attack in overweight or obese adults who are not diabetic, the Danish drugmaker said on Friday.
- 03/08/2024
|
Novo Nordisk's Wegovy wins FDA approval for heart health benefits, in move that could expand insurance coverage
- Novo Nordisk's Wegovy wins FDA approval for heart health benefits, in move that could expand insurance coverage
- 03/08/2024
|
Novo Nordisk CEO says experimental weight loss pill could become a best in class drug
- Lars Fruergaard Jørgensen's remarks came one day after Novo Nordisk impressed investors with early-stage trial data on amycretin.
- 03/08/2024
|
Novo Nordisk (NVO) Up on Upbeat Data From New Obesity Pill Study
- Novo Nordisk (NVO) stock rises as it presents encouraging efficacy data on a new investigational oral obesity pill, amycretin, at its Capital Markets Day.
- 03/08/2024
|
Novo Nordisk hopes to launch experimental obesity drug this decade
- Novo Nordisk's head of development on Friday told Reuters he was very comfortable the drugmaker would be able to launch the pill version of its experimental weight loss drug amycretin this decade.
- 03/08/2024
|
Novo Nordisk CEO says innovation in obesity may justify higher price in some segments
- Novo Nordisk's CEO expects more people to take obesity drugs as prices fall over time, he told Reuters on Friday, adding that new generations of the medicine will justify higher prices in some segments.
- 03/08/2024
|
Tesla Stock Is Rising. Novo Nordisk Overtakes the EV Maker's Valuation.
- The stock move comes as Novo Nordisk, maker of obesity drug Wegovy, overtook Tesla's market value Thursday.
- 03/08/2024
|
Compounded semaglutide poses serious U.S. health issue, Novo Nordisk CEO says
- Novo Nordisk's CEO on Friday said compounded semaglutide in the United States is a serious health issue.
- 03/08/2024
|
Novo Nordisk market cap surpasses Tesla on new obesity pill trial data
- Wegovy obesity drug maker Novo Nordisk surpassed Tesla in market value Thursday after fresh early trial data showed positive results for its new experimental weight loss pill.
- 03/08/2024
|
Novo Nordisk seeks acquisitions to boost obesity, diabetes pipeline
- Novo Nordisk will prioritise acquisitions that can complement its pipeline of obesity and diabetes drugs rather than buying supply chain companies, the Danish group's head of business development told Reuters on Friday.
- 03/08/2024
|
Novo Nordisk hopes to launch experimental obesity drug "within this decade"
- Novo Nordisk's head of development on Friday told Reuters he was very comfortable the drugmaker would be able to launch the pill version of its experimental weight loss drug amycretin this decade.
- 03/08/2024
|
Novo Nordisk shares overhyped? One investment bank certainly thinks they are overvalued
- Novo Nordisk (NYSE:NVO)'s shares are significantly overvalued, based on analysis shared by the American bank Jefferies in a note to clients. It said that, as ever, Novo delivered its 'usual polished performance' at its capital markets day earlier this week, but added "we struggle to justify the stock uptick".
- 03/08/2024
|
Novo Nordisk (NVO) Hits High After Weight Loss Trial
- Novo Nordisk (NVO) shares opened at an all-time high after a promising weight loss trial. Jeff Pierce discusses this as Eli Lilly (LLY) shares fall after Novo Nordisk's weight loss trial shows positive results.
- 03/07/2024
|
Ozempic maker Novo Nordisk surges past Tesla with market value of $566B
- Novo's shares have risen more than three-fold since June 2021 when it launched Wegovy in the US, last year becoming Europe's most valuable listed company, ahead of LVMH.
- 03/07/2024
|
Why Novo Nordisk Stock Is Jumping Today (Hint: It's Not Because of Ozempic or Wegovy)
- Novo Nordisk revealed results from a phase 1 study of amycretin at an investor event on Thursday. Patients taking the experimental drug achieved an average weight loss of 13.1% after 12 weeks.
- 03/07/2024
|
Weight loss drugs: Novo Nordisk stock hits record high on new data
- Shares of Novo Nordisk (NVO) have hit a record high on phase 1 trial data from Amycretin, its latest weight loss product. The new drug shows over 13% weight loss in users after 12 weeks of use, more than double Wegovy's efficacy over the same time period.
- 03/07/2024
|
Novo Nordisk expects China to approve Wegovy this year
- Novo Nordisk said on Thursday it expects Wegovy to be approved for sale in China this year and plans to soon launch the popular weight-loss drug in the largest Asian market with capped volumes.
- 03/07/2024
|
Novo's global obesity drug rollout to be dominated by injectable medicines, CEO says
- Novo Nordisk's global obesity drug rollout will be dominated by its injectable medicines, while its oral version will be introduced later in higher priced markets, the company's Chief Executive Lars Fruergaard Jorgensen said on Thursday.
- 03/07/2024
|
Pharma Stock Hits Record High on Newest Weight-Loss Drug
- Novo Nordisk A/S (NYSE:NVO) stock is gapping to record highs today, after the pharmaceutical company reported positive phase 1 trial results for its experimental weight-loss drug, amycretin.
- 03/07/2024
|
Novo Nordisk Surges. It's on Track to Overtake Tesla's Market Cap.
- The company said its new treatment for weight loss, called Amycretin, appeared even more effective than its popular Wegovy drug in trials.
- 03/07/2024
|
Wegovy Maker Novo Nordisk Stock Surges on Promising Trial of Obesity Pill Amycretin
- The American depositary receipts (ADRs) of Novo Nordisk A/S (NVO) gained more than 8% in early trading Thursday after the Danish maker of Ozempic and Wegovy released promising data on an experimental daily pill aimed at treating obesity.
- 03/07/2024
|
Novo Nordisk expects Catalent deal to close later this year
- Novo Nordisk expects to close its acquisition of Catalent later this year, its chief financial officer said during the company's capital markets day on Thursday, adding that Novo's gross margin is seen falling in the coming years.
- 03/07/2024
|
Ozempic Maker Novo Nordisk More Valuable Than Tesla
- Novo Nordisk is now worth more than Elon Musk's electric vehicle giant Tesla, after shares of the Danish maker of Ozempic surged following the release of promising results for an oral weight loss treatment.
- 03/07/2024
|
NVO Stock Alert: Novo Nordisk Pops on New Weight-Loss Drug
- Novo Nordisk (NYSE: NVO ) stock is soaring higher on Thursday after the pharmaceutical company announced results from a weight loss drug clinical trial. The big news here is the company's oral weight loss drug amycretin producing 13.1% weight loss in patients after 12 weeks.
- 03/07/2024
|
Novo Nordisk obesity pill results send shares to record high
- Novo Nordisk (NYSE:NVO) unveiled a potential game changer during its Capital Markets Day with data on experimental obesity pill amycredtin potentially outperforming blockbuster drug Wegovy. An early-stage test conducted over 12 weeks showed patients taking the pill lost 13% of their weight.
- 03/07/2024
|
Novo Nordisk's New Obesity Pill Beats Wegovy In Early Trial
- Shares of Danish pharma giant Novo Nordisk soared to a record high on Thursday after it reported promising data on a new weight loss pill, a sign of the company's plans to cement its prime position in the burgeoning obesity drug market in the face of stiff competition from industry titans like Eli Lilly and an array of smaller biotech startups.
- 03/07/2024
|
Novo Nordisk shares jump 5% on promising weight loss trial results; Eli Lilly dips
- Novo Nordisk shares climbed 5% on Thursday morning after the Danish pharmaceutical giant reported positive early trial data for a new weight loss drug.
- 03/07/2024
|
Novo Nordisk to present early-stage trial data for new diabetes drug at investor meeting
- Novo Nordisk , maker of obesity drug Wegovy, on Thursday said it would present early-stage trial data for its highly anticipated pipeline drug, amycretin, for treatment of Type 2 diabetes.
- 03/07/2024
|
Novo Nordisk (NVO) Down Despite Kidney Outcomes Study Success
- Novo Nordisk (NVO) declines 3% despite achieving the primary endpoint with statistical significance in the FLOW outcomes study evaluating the efficacy of Ozempic 1 mg to treat CKD indication.
- 03/06/2024
|
Is Viking Therapeutics Stock a Better Buy Than Eli Lilly and Novo Nordisk After the Latest Weight-Loss Drug News?
- Investors are excited about the opportunity for Viking's experimental weight-loss drug VK2735. Viking doesn't compare favorably against Lilly and Novo Nordisk in most categories.
- 03/06/2024
|
Why Novo Nordisk Stock Tumbled by Nearly 3% on Tuesday
- A clinical trial of semaglutide studying its ability to prevent kidney disease-related events was published. The study met its primary endpoint, but many observers were expecting better results.
- 03/05/2024
|
A New Competitor to Wegovy Could Be on the Way. Should Novo Nordisk Be Worried?
- Viking Therapeutics' weight loss candidate produced positive phase 2 results. The drug could eventually be a challenger to Novo Nordisk's Wegovy.
- 03/05/2024
|
Novo Nordisk reveals positive Ozempic kidney results
- Novo Nordisk (NYSE:NVO) said diabetes patients have been able to prevent the onset of chronic kidney disease in trials of semaglutide, which it sells under the Ozempic and Wegovy brands. The Danish drug giant hailed the headline results from its FLOW trial which reduced kidney disease progression, major adverse cardiovascular events and death by 24% compared to placebo.
- 03/05/2024
|
Prediction: Eli Lilly and Novo Nordisk Stock Could Just be Getting Started. Here's Why
- Eli Lilly and Novo Nordisk stock each rose over 50% in 2023 thanks to their diabetes treatments. Industry research suggests the diabetes market will continue to grow for decades to come.
- 03/05/2024
|
Novo Nordisk's diabetes drug Ozempic slashed the risk of kidney disease progression in trial
- The results add to the growing evidence that the highly popular injection has broader health benefits for patients beyond treating Type 2 diabetes.
- 03/05/2024
|
Novo Nordisk shares falls after diabetic kidney results reported
- Novo Nordisk (NYSE:NVO) said diabetes patients have been able to prevent the onset of chronic kidney disease in trials of semaglutide, which it sells under the Ozempic and Wegovy brands. The Danish drug giant hailed the headline results from its FLOW trial which reduced kidney disease progression, major adverse cardiovascular events and death by 24% compared to placebo.
- 03/05/2024
|
Game Changers: 3 Biotech Stocks That Could Be Multibaggers in the Making
- The world of biotech stocks offers a unique blend of high risk and potentially high reward. Companies operating in this space are constantly pushing the boundaries, making them primed investment opportunities in 2024.
- 03/05/2024
|
Novo Nordisk Ozempic trial delays progression of chronic kidney disease
- Novo Nordisk's widely used diabetes drug Ozempic delayed progression of chronic kidney disease in diabetes patients, according to a large late-stage study.
- 03/05/2024
|
The Ozempic Diet Trend is Lifting These 2 Carnivore Stocks
- At $1,300 a month, with limited supply, and side effects including nausea, vomiting and gastrointestinal maladies, there are plenty of reasons to find more cost-effective and appetizing ways to lose weight other than turning to the medical sector and resorting to GLP-1 weight loss drugs like Ozempic and Wegovy from Novo Nordisk A/S NYSE: NVO. And those underlying reasons are putting the carnivore diet back in the spotlight for people seeking GLP-1 alternatives.
- 03/04/2024
|
Better Blockbuster-Drug Stock: Novo Nordisk vs. Eli Lilly
- Blockbuster drugs can be disproportionately beneficial for biopharmas. Novo Nordisk is already squeezing a lot of cash out of semaglutide.
- 03/03/2024
|
Missed Out on Novo Nordisk Stock? Buy This 1 Biotech Stock Right Now.
- Viking Therapeutics wowed the market with its latest phase 2 data. Its weight loss drug candidate might be better than the competition.
- 03/03/2024
|
Can we cut Oprah Winfrey some slack? The struggle to lose weight is real — and drugs can be a lifesaver.
- Yes, Oprah Winfrey is in the news again — in this case, for her decision to sell her stake in WW International WW, +8.33% (formerly known as WeightWatchers) and leave the company's board. The decision came after Winfrey announced, to considerable backlash, that she was taking a weight-loss drug to help her in her longtime battle to lose some pounds and keep them off, in addition to hiking, drinking plenty of water and other methods.
- 03/02/2024
|
Why Novo Nordisk Stock Topped the Market Today
- An analyst cranked his price target higher on the Danish pharmaceutical company. He increased it by 16%.
- 03/01/2024
|
These 4 Stocks Are the "Magnificent Seven" of Healthcare
- The Magnificent Seven are stealing the show this year on the market. They're all technology companies -- but there are opportunities elsewhere, too.
- 03/01/2024
|
Eli Lilly and Novo Nordisk will remain leaders in the weight-loss drug market: Mizuho's Jared Holz
- CNBC's Melissa Lee and Jared Holz, Mizuho Securities America healthcare sector strategist, join 'Squawk on Street' to discuss the weight-loss drug market, why he believes Eli Lilly and Novo Nordisk will remain the frontrunners for the next 2-3 years, and more.
- 02/29/2024
|
What Would George Soros Do? 7 Stocks the Billionaire's Fund Bought & Sold in Q4
- George Soros stocks will always remain relevant for savvy investors. As one of the most successful financiers in history, George Soros's investment strategies attract a massive audience worldwide.
- 02/28/2024
|
Here's Why Novo Nordisk (NVO) is a Strong Momentum Stock
- Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
- 02/28/2024
|
Why Novo Nordisk and Eli Lilly Stocks Slipped Today
- A rival's weight-loss drug candidate did well in a mid-stage clinical trial. The treatment met all of its endpoints in the study.
- 02/27/2024
|
Stock Splits: Should You Buy?
- Many stock splits have occurred in recent years, with companies aiming to increase liquidity within shares and erase barriers to entry for potential investors. Lower share prices are more affordable for a greater portion of investors, although it's worth noting that the rise of fractional share investing has alleviated this issue for some.
- 02/27/2024
|
Zealand's obesity drug shouldn't disrupt Novo Nordisk-Eli Lilly leadership: Mizuho's Jared Holz
- Jared Holz, Mizuho, joins 'Fast Money' to talk obesity drugmakers after a new study out of Zealand Pharma analyzed the impact of GLP-1s on liver disease.
- 02/26/2024
|
Future Juggernauts: The Next 7 Trillion Dollar Companies to Buy Now
- Investors learned an important lesson in 2023: investing in the biggest companies and their stocks is a surefire way to capture strong gains. The Magnificent 7 – all of which are trillion dollar stocks – produced strong returns for investors.
- 02/26/2024
|
These 2 carnivore dining stocks gaining on the Ozempic craze
- The Ozempic and GLP-1 weight loss trend parallels the artificial intelligence (AI) mania that's gone mainstream viral, sending stocks like Novo Nordisk A/S NYSE: NVO and Nvidia Corp. NASDAQ: NVDA through the roof. While GLP-1 users report amazing weight loss results, like Oprah Winfrey losing 60 pounds, users continue to report the side effects of nausea, vomiting, gastrointestinal maladies and the return of weight once getting off the treatment.
- 02/26/2024
|
Novo Nordisk and Eli Lilly rival soars 26% after promising weight-loss drug results
- Zealand Pharma's Phase 2 trial was an "uniquivocal win" for a drug that can treat both liver disease and obesity, analysts said.
- 02/26/2024
|
Novo Nordisk: SOTP After Impressive FY23 And Weight Loss Going Mainstream, Maintain Buy
- Novo Nordisk had a near perfect FY23. Fundamentally, FY24 should look quite similar.
- 02/22/2024
|
Why Novo Nordisk (NVO) is a Top Growth Stock for the Long-Term
- Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
- 02/21/2024
|
3 Top Sectors Investment Dollars Are Pouring Into Now: February 2024
- Top sectors are tough to pin down in advance. Far more often, we look backward at market performance to identify trends and top sectors.
- 02/20/2024
|
Insider Buying: Taking a Controlling Stake in a Struggling Retailer?
- The biggest insider trading news of the week may have been Amazon.com Inc. (NASDAQ: AMZN) founder Jeff Bezos shedding over $4 billion worth of the company's shares as he reportedly prepares to move to Florida to take advantage of the better income tax environment.
- 02/18/2024
|
Novo Nordisk Has More Than Ozempic. One of Its Other Treatments Grew 393% Last Year.
- While Ozempic is often affiliated with weight loss, the drug is not approved by the FDA for such a use. But its sibling treatment, Wegovy, is approved for chronic weight management in obesity patients.
- 02/18/2024
|
Novo Nordisk CEO says food execs are ‘scared' of weight loss drug threat
- The feverish craze for Wegovy, Ozempic and other GLP-1 drugs is not over. It is prompting food executives to call the top boss at Novo Nordisk to ask for advice.
- 02/15/2024
|
S&P 500's surge to new highs: Bull trap hiding in plain sight?
- The SPDR S&P 500 ETF Trust NYSEARCA: SPY is trading at new highs, but as the sharp pullback on February 13 showed, the rally may be showing signs of cracking.
- 02/15/2024
|
Novo Nordisk: These Bold Moves Point Toward Upside
- Novo Nordisk's weight loss drug, Wegovy, shows potential for reducing cardiovascular risks by 20% in overweight or obese individuals. The company is actively working to scale up production of Wegovy to meet increasing demand and decrease cost per unit. Novo Nordisk's partnerships with Regeneron Pharmaceuticals, Omega Therapeutics, and Cellarity demonstrate their commitment to innovative treatments for cardiometabolic diseases.
- 02/15/2024
|
7 Must-Buy Pharma Stocks Amid the Weight Loss Drug Revolution
- It is entirely fair to state that weight loss treatments have massive transformational power. US FDA approval of weight loss medicines could help shrink millions of waistlines.
- 02/14/2024
|
1 Potential Catalyst That Could Light a Fire Under Novo Nordisk's Stock This Year
- Top weight-loss treatment Wegovy generated 400% revenue growth for Novo Nordisk in 2023. The drug can, however, cost patients without insurance coverage more than $16,000 per year.
- 02/14/2024
|
Amgen Takes Aim at Novo Nordisk and Eli Lilly, but Is the Stock a Buy?
- Amgen is the latest big pharma to join the gold rush to treat obesity. Its candidate is distinct from the medicines by Eli Lilly and Novo Nordisk.
- 02/14/2024
|
EDEN: Denmark Exposure With A Lot Of Novo Nordisk
- iShares MSCI Denmark ETF has benefited from weight loss drugs and has a weighting of 23% in the ETF. The EDEN ETF provides exposure to a wide range of Danish companies and is ideal for those looking for single country exposure. The ETF has a diverse sector composition and competitive expense ratio, but there are risks associated with investing in it.
- 02/13/2024
|
Move Aside, Eli Lilly and Novo Nordisk. Wall Street Thinks This Stock Will Be a Bigger Winner Over the Next 12 Months.
- Eli Lilly and Novo Nordisk stocks have soared, thanks largely to their weight-loss drugs. However, analysts think that another big pharma stock will perform much better over the near term.
- 02/13/2024
|
Why Novo Nordisk (NVO) is a Top Stock for the Long-Term
- The Zacks Focus List offers investors a way to easily find top-rated stocks and build a winning investment portfolio. Here's why you should take advantage.
- 02/12/2024
|
Novo Nordisk's Magic Run Continues Even With Increasing Competition
- Novo Nordisk is the developer of blockbuster drugs Ozempic, Rybelsus, and Wegovy. The popularity of these treatments is fueling impressive growth and a bright outlook.
- 02/12/2024
|
Novo Nordisk's controlling shareholder plans to invest up to $7 bln a year by 2030 - FT
- Novo Holdings, the controlling shareholder of Danish obesity drugmaker Novo Nordisk , plans to invest up to $7 billion annually by 2030, the Financial Times reported on Monday.
- 02/12/2024
|
Novo Nordisk Is Scaling a Barrier to Growth. Should You Buy Its Stock Now?
- Novo Nordisk is selling Wegovy faster than it can be made. It's scaling up production as well as acquiring more capacity.
- 02/11/2024
|
Don't Worry About Novo Nordisk's Premium Stock Price. It's Still a Buy.
- Sales from Ozempic, Rybelsus, and Wegovy are increasing at unprecedented rates. Investors have continued to buy up stock in Novo Nordisk as its magic run continues.
- 02/11/2024
|
Novo Nordisk Just Gave Investors $16.5 Billion More Reasons to Get Excited
- Novo Nordisk just acquired Catalent, a subcontractor for the company's drug production. Per the deal, Novo Nordisk will take over three of Catalent's production plants.
- 02/10/2024
|
Weight loss drugs are still hard to find — but Novo Nordisk and Eli Lilly are trying to change that
- Novo Nordisk and Eli Lilly have given positive supply updates, aiming to reassure investors that they can continue to capitalize on the success of their drugs.
- 02/10/2024
|
Is It Really Just the Magnificent 7 Propping Up This Market?
- The choir has been preaching that these seven stocks are holding up an overall weak market.
- 02/09/2024
|
Catalent Q2 sales inch past estimates amid takeover by Novo Holdings
- Catalent reported second-quarter revenue slightly above Wall Street estimates on Friday, days after the contract drug manufacturer agreed to a $16.5-billion acquisition offer from Novo Nordisk's parent firm.
- 02/09/2024
|
Here's Why Merck, Eli Lilly, and Novo Nordisk Stocks Rose 11% Last Month
- Demand is surging for weight-loss treatments that are being rolled out by major pharmaceutical companies. Investors are still trying to assess the full market opportunity and competitive landscape.
- 02/08/2024
|
How Important Are Ozempic and Wegovy to Novo Nordisk's Business?
- Novo Nordisk's obesity sales more than doubled last quarter. Ozempic and Wegovy account for a significant part of total revenue.
- 02/08/2024
|
Novo Nordisk CEO on Catalent, Ozempic and Wegovy
- Novo Nordisk A/S CEO Lars Fruergaard Jorgensen discusses the company's acquisition of Catalent for for $16.5 billion and the production of its weight-loss drug Wegovy and diabetes treatment Ozempic. For more on this story, please see: https://www.bloomberg.com/news/articles/2024-02-05/novo-nordisk-spends-11-billion-on-meeting-obesity-drug-demand --------
- 02/07/2024
|
Eli Lilly, Novo Nordisk Could Be First Trillion-Dollar Drug Stocks
- The trillion-dollar market valuation club is currently dominated by the tech sector. Saudi Aramco is the sole exception.
- 02/06/2024
|
Healthy Returns: Novo Nordisk, Eli Lilly are tackling weight loss drug supply woes
- Novo Nordisk and Eli Lilly are working to increase supply of their popular weight loss drugs. Meanwhile, the implantable neurotechnology field is heating up.
- 02/06/2024
|
Novo Nordisk acquisition of Catalent production sensible, analysts say
- Novo Nordisk (NYSE:NVO)'s takeover of three production sites through the acquisition of Catalent Inc (NYSE:CTLT) is a sensible move, analysts say, and will help meet demand for its flagship weight loss drugs. Though Catalent already provides two filling lines for Novo's injectable Wegovy drug in Belgium and the US, transfer of ownership will see production capacity increase further, according to JP Morgan analysts, eventually also including the Ozempic treatment.
- 02/06/2024
|
Bio-pharma services are key to our strategy: Novo Holdings CEO
- Kasim Kutay, CEO of Novo Holdings, discusses Novo Holdings acquisition of U.S.-based medicines manufacturer Catalent.
- 02/06/2024
|
Novo Holdings invests in hospital chain Manipal in India
- Novo Holdings, the holding company of Novo Nordisk , said on Tuesday it was investing in Indian private hospital chain Manipal Hospitals, its largest investment in Asia to date.
- 02/06/2024
|
Why Novo Nordisk Stock Crushed the Market on Monday
- Its controlling shareholder has agreed to acquire U.S. contract manufacturer Catalent. The all-cash transaction's enterprise value is $16.5 billion.
- 02/05/2024
|
Novo Nordisk (NVO) to Acquire 3 Catalent Sites for $11B
- Novo Nordisk (NVO) will acquire Catalent's three manufacturing sites from Novo Holdings to expand its manufacturing capacity.
- 02/05/2024
|
Novo Nordisk Makes the Latest Big Pharma Deal. Why More Are Coming.
- Big drug companies have substantial free cash flow from older, cash-cow drugs, manageable debt burdens, and investor pressure to find new growth opportunities.
- 02/05/2024
|
Novo Holdings Buyout Sends Catalent Stock Surging
- The shares of pharmaceutical concern Catalent Inc (NYSE:CTLT) are surging today, after news that Novo Holdings, the controlling shareholder of Novo Nordisk (NVO), is purchasing the company for $11.5 billion.
- 02/05/2024
|
Novo Nordisk Parent Buys Catalent in $16.5 Billion Cash Deal
- Shares of syringe maker Catalent (CTLT) soared 10% in early trading after it signed a deal to be sold to the controlling shareholder of Novo Nordisk (NVO) for $16.5 billion.
- 02/05/2024
|
Catalent (CTLT) Stock Pops 10% on Sale to Novo Nordisk
- Catalent (NYSE: CTLT ) stock is climbing higher on Monday after the company agreed to sell itself to Novo Nordisk (NYSE: NVO ) parent Novo Holdings for $16.5 billion. The transaction will have Novo Holdings paying $63.50 per share in cash for CTLT stock.
- 02/05/2024
|
Novo Nordisk parent to buy Catalent for $16.5 billion to expand Wegovy supply
- Catalent is the main supplier of fill-finish work, which involves filling and packaging syringes and injection pens, for Novo Nordisk's Wegovy.
- 02/05/2024
|
Catalent surges on $16.5 billion takeover by Novo Nordisk shareholder
- Shares in drug manufacturer Catalent Inc (NYSE:CTLT) soared over 11% in pre-market trading as news broke that Novo Nordisk (NYSE:NVO)'s controlling shareholder was to buy the firm for US$16.5 billion. Novo Holdings, which owns a majority stake in the weight loss drug maker, unveiled the takeover on Monday, which includes assumed debt and, at US$63.50 a share, represents a 16.5% premium on Catalent's Friday closing price.
- 02/05/2024
|
Catalent Stock Jumps on $16.5 Billion Sale to Controlling Shareholder of Ozempic Maker Novo Nordisk
- Novo Holdings will acquire Catalent for $63.50 a share in cash.
- 02/05/2024
|
Novo Nordisk's controlling shareholder to buy Catalent for $16.5 billion
- Novo Holdings, the controlling shareholder of Novo Nordisk NVO, -1.80%, said it's buying Catalent CTLT, +2.67% for $16.5 billion in cash, or $63.50 per Catalent share, a 16.5% premium to Friday's close. The deal is a 39% premium to Catalent's close before it announced a strategic review.
- 02/05/2024
|
It's shaping up to be a great quarter for Europe's biggest companies — no thanks to Europe.
- Fourth-quarter earnings season in Europe is still in its early days, but the largest companies on the Continent are mostly hitting their stride.
- 02/05/2024
|
Is Novo Nordisk a Hot Stock to Buy Now After its Spectacular Q4?
- Novo Nordisk is one of the pharmaceutical stocks of the moment. And it just delivered an estimate-busting earnings report.
- 02/05/2024
|
3 Reasons Growth Investors Will Love Novo Nordisk (NVO)
- Novo Nordisk (NVO) could produce exceptional returns because of its solid growth attributes.
- 02/02/2024
|
4 Large Drug Stocks Trying to Survive the Industry Challenges
- Drug and biotech companies are likely to see significant innovation. In the Large-Cap Pharmaceuticals industry, Eli Lilly (LLY), Novo Nordisk (NVO), AbbVie (ABBV) and Novartis (NVS) are worth retaining in one's portfolio.
- 02/02/2024
|
The Road to a Trillion: 3 Stocks Next in Line for the Mega Milestone
- “A billion here, a billion there, and pretty soon you're talking real money.” While a trillion-dollar price tag is likely more common in today's inflationary times, only a handful of companies have managed to attain that real-money status.
- 02/01/2024
|
Novo Nordisk still a buy for Citi as return on capital hits 88%
- Novo Nordisk (NYSE:NVO) remains a buy for US bank Citigroup even though it is only the second European company in history to pass the half-a-trillion mark after LVMH temporarily hit the landmark last year. The Danish pharma accompanied its annual report with a management call that reiterated scaling up production of its blockbuster diabetes drugs Wegovy and Ozempic remains its number one priority.
- 02/01/2024
|
Obesity product competition benefits companies and society: Novo Nordisk
- Novo Nordisk CEO Lars Fruergaard Jørgensen speaks to CNBC following blockbuster earnings from Europe's largest company, driven by soaring demand for its obesity and diabetes drugs Wegovy and Ozempic.
- 02/01/2024
|
Obesity drug supply-demand imbalance is working in Novo Nordisk's favor: Mizuho's Jared Holz
- Jared Holz, Mizuho Securities, joins 'Fast Money' to talk demand in the obesity drug space and who is benefiting from the supply-demand imbalance.
- 01/31/2024
|
Novo Nordisk CFO discusses 36% surge in sales driven by Wegovy and Ozempic
- Pharmaceutical giant Novo Nordisk (NVO) reported a 36% surge in sales thanks to high demand for weight loss drugs Wegovy and Ozempic. Novo Nordisk CFO Karsten Munk Knudsen joins Yahoo Finance Senior Health Reporter Anjalee Khemlani to discuss the company's results and what it has in store in the coming months.
- 01/31/2024
|
Novo Nordisk increasing supply of Wegovy as demand continues to grow
- Novo Nordisk says it Is gradually ramping up supply of its sought-after drug Wegovy. However, the company is still warning patients demand will still outpace supply overall.
- 01/31/2024
|
Private-Sector Payrolls Declined More Than Expected
- January Jobs Week continues this morning, even as we're only just closing out the month today. Private-sector payrolls reported by Automatic Data Processing ( ADP ) came in below estimates: 107K versus 150K expected, and beneath the previous month's downwardly revised 158K.
- 01/31/2024
|
Ozempic and Wegovy maker Novo Nordisk now worth $500B amid soaring popularity
- The drug maker vaulted ahead of luxury goods maker LVMH to claim the title of Europe's most valuable company.
- 01/31/2024
|
ADP Cools to 107K Private-Sector Jobs; BA, NVO Beat in Q4
- We've now spent a full six months sub-200K private-sector job gains per month.
- 01/31/2024
|
Novo Nordisk Stock Hits Record High as Wegovy Maker Sees Up To 26% Sales Growth This Year
- The American depositary receipts (ADRs) of Novo Nordisk (NVO), the market leader in weight-loss drugs, rose sharply in early trading Wednesday, hitting an all-time high, after the Danish company said it expects sales growth this year of between 18% and 26% in constant exchange terms.
- 01/31/2024
|
Novo Nordisk (NVO) Q4 Earnings Top, GLP-1 Drugs Boost Sales
- Novo Nordisk (NVO) reports better-than-expected fourth-quarter results, beating both earnings and revenues, driven by strong sales of Diabetes and Obesity care products.
- 01/31/2024
|
Novo Nordisk CEO on Q4 results, soaring demand for Wegovy and Ozempic
- Novo Nordisk president and CEO Lars Fruergaard Jørgensen joins 'Squawk Box' to discuss the company's quarterly earnings results, which reported better-than-expected 2023 earnings, surging demand for Wegovy and Ozempic, and more.
- 01/31/2024
|
Norway's giant wealth fund touts possibility of Novo Nordisk, Eli Lilly joining the trillion-dollar club
- Norway's giant wealth fund says Novo Nordisk and Eli Lilly could be on course to become the first health care companies to join the trillion-dollar club.
- 01/31/2024
|
Best Growth Stocks to Buy for January 31st
- TX, POWL and NVO made it to the Zacks Rank #1 (Strong Buy) growth stocks list on January 31, 2024.
- 01/31/2024
|
Weight-Loss Drug Boom Sends Novo Nordisk Profits Soaring. Why the Success Brings Challenges.
- It's on to a real winner with its Wegovy treatment. The company's market capitalization climbed past $500 billion early Wednesday.
- 01/31/2024
|
Catalent's Indiana plant is filling Wegovy pens to Novo Nordisk for U.S. - ceo
- Novo Nordisk's CEO Lars Fruergaard Jorgensen confirmed on Wednesday that Catalent's Indiana plant in the United States has started filling injection pens for its obesity drug Wegovy, helping to boost output of the popular weekly injection.
- 01/31/2024
|
Ozempic maker Novo Nordisk reports 62% surge in profit
- Novo Nordisk on Wednesday said its fourth-quarter profit surged by nearly two-thirds, driven by the popularity of its weight-loss drugs that have made it Europe's largest company.
- 01/31/2024
|
Novo Nordisk Beats Profit Forecasts As Weight-Loss Sales Soar
- Danish pharma giant Novo Nordisk on Wednesday reported better-than-expected earnings for 2023, propelled by a tsunami of demand for its blockbuster weight loss and diabetes drugs as new treatments emerge and compete for a slice of the growing market.
- 01/31/2024
|
Novo Nordisk will more than double U.S. lower doses of Wegovy, CEO says
- Novo Nordisk will more than double the amount of lower doses of its obesity drug Wegovy in the United States compared with recent months, CEO Lars Fruergaard Jorgensen said on Wednesday as the Danish drugmaker ramps up output of its popular therapy.
- 01/31/2024
|
Novo Nordisk beats earnings expectations as Wegovy, Ozempic demand soars
- Novo Nordisk, Europe's largest company by market capitalization, on Wednesday reported better-than-expected 2023 earnings.
- 01/31/2024
|
Novo Nordisk Q4 profits beat expectations, expects double-digit growth in 2024
- Novo Nordisk on Wednesday posted fourth-quarter operating profit above expectations as it forecast another year of double-digit record sales growth due to its wildly popular Wegovy weight-loss drug.
- 01/31/2024
|
Big Earnings Afternoon: Microsoft, Alphabet, Starbucks & More
- Microsoft, Google-parent Alphabet, Mondelez and Skyworks all topped earnings expectations.
- 01/30/2024
|
Wall Street Analysts See Novo Nordisk (NVO) as a Buy: Should You Invest?
- Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter?
- 01/30/2024
|
Is a Surprise Coming for Novo Nordisk (NVO) This Earnings Season?
- Novo Nordisk (NVO) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
- 01/30/2024
|
2 Rising Biotechs That Could Become the Next Novo Nordisk
- Novo Nordisk has been a great investment due to its drugs for diabetes and obesity. Madrigal Pharmaceuticals has big plans for treating a serious liver disease known as NASH.
- 01/29/2024
|
5 top healthcare stocks for earnings growth in 2024
- Sector components forecast to show the biggest earnings year-over-year earnings improvement include Humana Inc. NYSE: HUM, Elevance Health Inc. NYSE: ELV, Incyte Corp. NASDAQ: INCY, Insulet Corp. NASDAQ: PODD and Cigna Group NYSE: CI.
- 01/25/2024
|
5 Momentum Stocks to Buy Ahead of Earnings Results
- We have narrowed our search to five momentum stocks that are poised to beat on earnings results next week. These are: BEN, NVO, CPA, CRS, JHG.
- 01/23/2024
|
Novo Nordisk (NVO) Stock Dips While Market Gains: Key Facts
- Novo Nordisk (NVO) reachead $105.49 at the closing of the latest trading day, reflecting a -1.37% change compared to its last close.
- 01/22/2024
|
3 Phenomenal Stock-Split Stocks You Should Be Buying Now
- Stock splits are a bullish sign that management sees more room for growth. Although they technically mean nothing as to the operation of the company, the market still sees them as a positive development.
- 01/22/2024
|
Novo Nordisk: Outlook For Weight Loss Drugs In 2024
- Novo Nordisk's weight loss drug, Wegovy, earned $1.38 billion last quarter and is projected to share a large piece of the growing weight-loss drug market. Despite its market dominance, Novo faces challenges in affordability, competition (like Eli Lilly's Zepbound), and sustainable obesity treatments. Novo Nordisk's recent financial performance exceeds expectations, indicating strong market confidence and robust growth projections.
- 01/22/2024
|
Can TikTok Do for Peloton What It Did for Novo Nordisk and Ozempic?
- Peloton is partnering with TikTok in a move that will make its content easier to find. Social media can play a big role in raising awareness around a product, as it did with Ozempic.
- 01/21/2024
|
3 High-Flying Stocks That Could Soar Even More in 2024
- CRISPR Therapeutics stock has room to run higher with the biotech's first therapy on the market. Eli Lilly is now the world's biggest drugmaker and has multiple growth drivers.
- 01/20/2024
|
Best Growth Stocks to Buy for January 19th
- ARCO, NVO and ENS made it to the Zacks Rank #1 (Strong Buy) growth stocks list on January 19, 2024.
- 01/19/2024
|
Best Growth Stocks to Buy for January 16th
- NVO, AIZ and PAX made it to the Zacks Rank #1 (Strong Buy) growth stocks list on January 16, 2024.
- 01/16/2024
|
4 Pharma Stocks to Buy, According to an Analyst. Novo Nordisk Isn't One.
- Drug stocks GSK, Sanofi, Merck KGaA, and Novartis look set for a good year on strong cash flows and attractive valuations, says UBS.
- 01/16/2024
|
2 biotechs with promising weight-loss drugs coming
- Clinical weight-loss medications have been making headlines. GLP-1 drugs like Novo Nordisk A/S NYSE: NVO owned Ozempic and Wegovy and Eli Lilly and Co. NYSE: LLY owned Mounjaro and Zepbound continue to see demand outstrip supply.
- 01/16/2024
|
Here is Why Growth Investors Should Buy Novo Nordisk (NVO) Now
- Novo Nordisk (NVO) is well positioned to outperform the market, as it exhibits above-average growth in financials.
- 01/15/2024
|
Novo Nordisk (NVO) Is Up 2.45% in One Week: What You Should Know
- Does Novo Nordisk (NVO) have what it takes to be a top stock pick for momentum investors? Let's find out.
- 01/15/2024
|
Weight loss drug hype to show no signs of slowing this year - analysts
- Weight loss drugs are set to remain well in focus of investors this year, as the rollout of such treatment looks to even affect the food industry, Liberum analysts say. Following Novo Nordisk (NYSE:NVO)'s announcement last August that such drugs reduce risk of stroke and heart attack in overweight people, Liberum said hype was set to continue for the treatments through 2024.
- 01/15/2024
|
Have Novo Nordisk shares got further to go? This investment bank has its say
- Stifel has identified Novo Nordisk (NYSE:NVO), Merck KGaA, and Sandoz as top picks in the European pharmaceutical sector for the first quarter of 2024, according to its recent research note. Novo Nordisk is highlighted for its exceptional growth outlook, with analysts anticipating over 20% growth in 2024, distinct from its big pharma peers.
- 01/15/2024
|
Move Over, Novo Nordisk -- This Is the Pharmaceutical Company I am Most Bullish On in 2024
- Eli Lilly manufactures medication similar to Ozempic called Mounjaro. Zepbound, which has the same active ingredient as Mounjaro, was recently approved for treating obesity.
- 01/14/2024
|
After Surging 53% in 2023, This Pharmaceutical Stock Might Be About to Crash. Here's Why I'm Probably Wrong
- Novo Nordisk makes the popular weight treatments Ozempic, Wegovy, Saxenda, and Rybelsus. Success of each of these medications has fueled unprecedented growth for the Danish company.
- 01/13/2024
|
3 Unstoppable Stocks to Buy in 2024
- Eli Lilly is growing by leaps and Zepbounds. Novo Nordisk is just getting warmed up after delivering a 53% gain last year.
- 01/13/2024
|
Why Novo Nordisk Stock Soared 53% in 2023 (Hint: It Wasn't Just Ozempic)
- Ozempic was a big factor behind Novo Nordisk's success last year, but not the biggest growth driver. The drugmaker had a lot of good news that boosted its stock price in 2023.
- 01/13/2024
|
Novo Nordisk resumes shipments of Wegovy 1.7 mg dose in US
- Novo Nordisk said on Friday it resumed shipments of weight loss drug Wegovy in the 1.7 milligram dose in early January, following a short-term stock-out in the U.S. in mid-December last year.
- 01/12/2024
|
FDA Finds No Link Between Obesity Drugs and Suicidal Thoughts
- The GLP-1 segment is an important class of drugs for multiple cardiometabolic diseases and is gaining significant popularity.
- 01/12/2024
|
Novo Nordisk: Enjoying The Tailwinds Of A Growing Market
- Novo Nordisk is the market leader of the fast-growing obesity care industry, which is expected to grow above 20% CAGR until 2030. The company raised three times its guidance during 2023, driven by a 481% growth in Wegovy's revenues. The company is increasing its production facilities to meet the demand and has already committed over $11.8B until 2029.
- 01/12/2024
|
Bullish Continuation in '24? 3 Market Areas to Watch
- Will stocks continue into 2024? Stock Strategist Andrew Rocco shares his prediction and unveils 3 important market areas to monitor.
- 01/10/2024
|
What is Wegovy worth to your employer? Companies wrestle with obesity drugs' costs, long-term value.
- Amid mounting evidence of obesity drugs' longer-term health benefits, thorny questions persist about their value to employers.
- 01/10/2024
|
Novo Nordisk (NVO) Ascends While Market Falls: Some Facts to Note
- In the most recent trading session, Novo Nordisk (NVO) closed at $106.95, indicating a +0.52% shift from the previous trading day.
- 01/09/2024
|
Novo Nordisk A/S (NVO) Presents at J.P. Morgan 42nd Annual Healthcare Conference Transcript
- Novo Nordisk A/S (NVO) Presents at J.P. Morgan 42nd Annual Healthcare Conference Transcript
- 01/09/2024
|
Novo Nordisk's (NVO) Phase III Diabetes Study Meets Primary Goal
- Novo Nordisk (NVO) reports positive top-line data from one of its late-stage studies under the COMBINE program evaluating once-weekly IcoSema in type II diabetes patients.
- 01/09/2024
|
3 Simple Tricks That Every Investor Should Use (but Most Don't)
- There's no rule that mandates betting on only one company in a sector. It's valuable to learn about the top people involved in a business.
- 01/09/2024
|
Wall Street Raises The Bar For These Four Stocks In 2024
- Nvidia is one of four stocks with rising profit estimates for 2024. Others are MercadoLibre, Deckers Outdoor and Novo Nordisk.
- 01/08/2024
|
Novo Nordisk says weekly IcoSema superior to daily insulin glargine, aspart
- Denmark's Novo Nordisk said on Monday its COMBINE 3 phase 3a drug trial had shown that a weekly injection of IcoSema was superior in controlling blood sugar level in people with type 2 diabetes compared to daily injections of insulin glargine combined with the insulin aspart.
- 01/08/2024
|
Novo Nordisk (NVO) Up on $1.1B Research Deals With 2 Biotechs
- Novo Nordisk (NVO) gains 4% after signing $1.1 billion research collaboration agreements with two biotech companies to develop novel treatment approaches for cardiometabolic diseases.
- 01/05/2024
|
Equity CEFs/ETFs: Top Picks For 2024 - Part II
- In Part I of my Top Picks For 2024, I explained why we saw such extreme valuation losses in most equity CEFs in 2023 and what that could-mean for 2024. In my opinion, liquidity was the over-riding factor for why so few stocks, think Magnificent 7, received the lion's share of buy-interest while most everything else suffered, including equity CEFs. But just because the Federal Reserve will continue its Quantitative Tapering doesn't mean that other Fed programs won't increase liquidity in other places.
- 01/05/2024
|
Global Giants: 3 Multinational Corporations to Outperform in 2024
- Global stocks are an excellent way to get exposure to emerging growth markets like India. Another advantage is their diversification across geographic regions, which promotes revenue stability.
- 01/04/2024
|
Why Novo Nordisk Stock Crushed the Market Today
- The pharmaceutical company has two new research partners. It signed separate but similar deals with Omega Therapeutics and Cellarity.
- 01/04/2024
|
Pharma Stock Surges on New Drug Partnerships
- Stocks are fighting tooth and nail to stay in positive territory today, as the sluggish start to 2024 continues.
- 01/04/2024
|
Novo Nordisk Stock Hit a Record on Thursday. Here's Why.
- Shares of Novo Nordisk (NVO), the market leader in weight-loss drugs, jumped more than 4% Thursday after the company said it inked research agreements with two American biotech firms.
- 01/04/2024
|
Is the January Effect reliable indicator for yearly performance?
- The S&P 500 and other major indexes are getting off to a slow start to kick off the new year. Some of 2023's leading stocks including Tesla Inc. NASDAQ: TSLA, Norwegian Cruise Line Holdings Ltd.
- 01/04/2024
|
Ozempic parent Novo Nordisk enters collaboration agreements with Omega and Cellarity on new treatments for obesity management
- Novo Nordisk NVO, +1.48% NOVO.B, +1.88% said Thursday it has entered research collaboration agreements with Omega Therapeutics Inc. OMGA, -8.08% and Cellarity on new treatments for obesity management. The Danish developer of weight-loss drugs Ozempic and Wegovy said the Omega collaboration will leverage its proprietary platform technology to develop an epigenomic controller that aims to enhance metabolic activity.
- 01/04/2024
|
Wegovy maker Novo Nordisk signs research partnerships with U.S. biotech firms
- Blockbuster weight-loss drug maker Novo Nordisk announced on Thursday research collaborations with two U.S. biotech firms, part of its efforts to stay ahead in big pharma's race to develop more treatments for cardiometabolic diseases.
- 01/04/2024
|
Novo Nordisk (NVO) Advances While Market Declines: Some Information for Investors
- In the closing of the recent trading day, Novo Nordisk (NVO) stood at $103.62, denoting a +1.48% change from the preceding trading day.
- 01/03/2024
|
Novo Nordisk faces number of overlooked trends including competition for Wegovy, warns investment bank
- Novo Nordisk (NYSE:NVO) was the European stock market success of last year, on the back of its anti-obsecity drug Wegovy/Ozempic, but analysts at Jefferies wonder if the valuation may be nearing the top as rivals including Pfizer and AstraZeneca work on rival weight loss drugs. 2024 is expected to see at least 20 possible clinical updates in obesity from 10 or more companies, which the investment bank said highlights the potential for significant competition facing Novo and Eli Lilly in the future Jefferies maintains an 'underperform' rating on the Danish drugmaker, saying it is the "least preferred" big cap stock in the sector, though they do not see a single event to catalyse a significant de-rating in the shares.
- 01/03/2024
|
Profiting From Obesity Drugs HRTS, Novo Nordisk And Eli Lilly
- Spending on anti-obesity medication is increasing, with some individuals spending more on medication than on food. Novo Nordisk's semaglutide drug, sold as Wegovy, is in high demand and the company is struggling to meet the soaring demand. Expenditures on obesity drugs may eventually exceed spending on food, becoming an important indicator of a country's wealth and standard of living.
- 01/02/2024
|
7 Investments To Avoid In 2024
- 7 Investments To Avoid In 2024
- 01/01/2024
|
Your New Year's Resolution For 2024: Invest $10,000 In These 5 Stocks
- I review the stocks of five world-class companies that I am convinced will bring me closer to my ambitious goal of being able to fund my living expenses through dividends.
- 12/29/2023
|
Obesity drug enthusiasm can continue in 2024: Mizuho's Jared Holz
- Mizuho's Jared Holz joins 'Fast Money' to talk enthusiasm surrounding obesity drugs and if that can endure into 2024.
- 12/27/2023
|
Pharmaceutical stocks to watch in 2024
- As the new year beckons, the pharmaceutical industry is poised for more developments, building on advances made in 2023. The industry harbors several companies leading the way in groundbreaking innovations, drug discoveries, pending approvals, and market advancements, an element likely to affect their stock price positively.
- 12/25/2023
|
Will Novo Nordisk Be Worth More Than Meta Platforms by 2030?
- Demand for Novo Nordisk's weight-loss products has become so significant that the company is investing billions into building more capacity. Meta Platforms has been one of the best-performing stocks this year, but it could face challenges.
- 12/23/2023
|
Novo Nordisk, FDA warn of fake Ozempic
- The U.S. Food and Drug Administration has seized thousands of units of fake Ozempic, the agency said Thursday, warning that some counterfeit units of the Novo Nordisk NVO, -0.15% diabetes drug may still be available for purchase.
- 12/22/2023
|
7 Low-Volatility Stocks for Stable Growth in 2024
- At first glance, targeting low-volatility stocks to buy for stable growth might seem too cautious. Yet, in the investment world, keeping tabs on volatility is imperative and a key indicator of risk.
- 12/21/2023
|
Weighing Their Chances: 5 Leading Healthcare Companies Fight for Market Share in the $100 Billion Weight-Loss Industry
- The anti-obesity drug market could be a significant growth opportunity for healthcare companies. Eli Lilly and Novo Nordisk are the big names in the market today, but there could soon be others.
- 12/21/2023
|
Looking to Invest in the Next Big Craze Like Ozempic? This 1 Emerging Field Could Be It.
- Investing early in an emerging field can sometimes lead to outsize returns. Medicines that extend life spans are going to be big someday.
- 12/21/2023
|
Why Novo Nordisk Stock Was Up on a Down Day for the Market
- An article in "The New York Times" pointed out that Ozempic and Wegovy's active ingredient could have other healing properties. It could help with ovarian disorders, for example, or even help combat alcoholism.
- 12/20/2023
|
Five obesity-drug trends to watch in 2024: Who can compete with Eli Lilly and Novo Nordisk?
- The obesity drugs that powered huge investor gains in 2023 are poised to inspire more corporate dealmaking, scientific breakthroughs and better patient access in the year ahead, analysts say.
- 12/20/2023
|
4 Drug Stocks Rising More Than 40% in 2023 With Room to Grow
- Novo Nordisk (NVO), Journey Medical Corporation (DERM), Lyra Therapeutics (LYRA) and Fusion Pharmaceuticals (FUSN) have returned 40% or higher year to date and have room for more growth in 2024.
- 12/20/2023
|
Why Novo Nordisk Stock Is Moving Higher Today
- The overall stock market rise likely helped boost Novo Nordisk's shares. A top Indian online marketplace is also working to halt illegal sales of Novo's weight loss drug Wegovy.
- 12/18/2023
|
5 Big Drug Stocks That May Continue to Outperform in 2024
- Novo Nordisk (NVO), Eli Lilly (LLY), Vertex Pharmaceuticals (VRTX), Regeneron (REGN) and GSK (GSK) have been performing well this year. These stocks are poised to keep the momentum alive in 2024.
- 12/18/2023
|
These Are the 3 Hottest Biopharma Trends of 2024. Should You Invest?
- Understanding what's hot and what's not is key to investing in biopharma. Drugs like Ozempic are going to continue being very popular next year.
- 12/18/2023
|
5 Non-U.S. Stocks to Buy as Wall Street Fires on All Cylinders
- We have selected five high-flying non-U.S. companies that have strong potential for 2024. These are: NVO, NTES, TM, PDD, STLA.
- 12/18/2023
|
Novo Nordisk owner channels some of Wegovy windfall into respiratory diseases
- The Novo Nordisk (NYSE:NVO) Foundation, which has the controlling holding of Novo Nordisk, has announced an investment of around $265 million to establish a new initiative focused on enhancing vaccines for respiratory diseases. This move comes as the foundation's financial resources have significantly increased due to the success of Novo Nordisk's weight-loss drug, Wegovy.
- 12/18/2023
|
Fake Wegovy: Pharma Giant Novo Nordisk Reportedly Steps Up Efforts Tackling Illegal Weight Loss Drugs Sold Online
- One of India's leading online marketplaces is working with pharma giant Novo Nordisk to tackle illegal sales of popular weight loss drug Wegovy, Reuters reported Monday, as its soaring popularity and strictly limited supply fosters a growing market for potentially dangerous fakes.
- 12/18/2023
|
Exclusive: IndiaMART is working with Novo Nordisk to halt illegal Wegovy sales -source
- Indian online marketplace IndiaMART has been removing unauthorized listings of Novo Nordisk's blockbuster weight-loss drug Wegovy after holding talks with the Danish drugmaker in early October, a source familiar with the matter told Reuters.
- 12/17/2023
|
Ozempic and Wegovy lead Novo Nordisk to Yahoo Finance's Company of the Year
- Novo Nordisk (NVO) and more specifically its weight-loss drugs Ozempic and Wagovy have been the topic of many conversations across Wall Street. The company's financial performance, impact and buzz has lead to Yahoo Finance naming Novo Nordisk its 2023 Company of the Year.
- 12/17/2023
|
The New Magnificent 7: 7 Stocks Rising to Prominence
- The magnificent seven stocks have had a fantastic 2023. Those firms dominate Silicon Valley and are amongst seven of the largest eight firms globally, as measured by market capitalization.
- 12/15/2023
|
Arecor's novel drug formulations could help cut burden on hospitals
- Arecor Therapeutics PLC (AIM:AREC)'s chief executive Sarah Howell said the company is at an advanced stage of recruiting patients for phase one trials of rapid ultra-concentrated insulin and should be ready to announce the results at the end of the first quarter of 2024. The new and ultra-concentrated formulation developed by Arecor has been designed to accelerate the absorption of insulin, a hormone made by the pancreas, after injection.
- 12/15/2023
|
Ozempic Isn't the Best Weight-Loss Treatment Anymore. Here's Why That Shouldn't Matter to Novo Nordisk Investors.
- In studies, Eli Lilly's Mounjaro has demonstrated that it is more effective in helping people lose weight than Ozempic. Street analysts project the weight-loss market to be massive.
- 12/14/2023
|
3 Biotech Stocks With Promising Pipelines and Big Growth Potential in 2024
- With such a high demand for items that can improve our longevity and health, biotechnology is at the forefront of today's innovation. Biotech products allow us to better understand the human body and how we can improve functioning within the body.
- 12/13/2023
|
LLY Down as Patients Regain Weight After Stopping Zepbound
- Full results from a late-stage study show that patients who stopped taking Eli Lilly's (LLY) weight-loss drug for over a year slowly started to regain their lost weight.
- 12/12/2023
|
3 Best Profitable Stocks to Invest in Using Net Income Ratio
- Perdoceo Education (PRDO), Novo Nordisk (NVO) and Merchants Bancorp (MBIN) have been selected as the top picks with a high net income ratio.
- 12/12/2023
|
Novo Nordisk: Latest Insights Confirm Exceptionally Bullish Opportunity
- Novo Nordisk reported strong Q3 results, beating analyst consensus on both top line and earnings. The SELECT CVOT study showed that Wegovy/Ozempic treatment may reduce the risk of death from cardiovascular disease by 18%. Novo Nordisk's investments in supply capacity expansion position the company for supercharged growth through 2030.
- 12/12/2023
|
Novo Nordisk: Everything investors need to know
- Yahoo Finance selected pharmaceutical firm Novo Nordisk (NVO) as it's 2023 Company of the Year. Developer of obesity medications Wegovy and Ozempic, Novo Nordisk stock has gained over 40% year-to-date.
- 12/11/2023
|
5 Reasons to be Bullish into 2024
- 2023: Predicting is Futile, Interpreting is Priceless
- 12/11/2023
|
Novo Nordisk: Yahoo Finance's Company of the Year, 2023
- Novo Nordisk (NVO) and more specifically its blockbuster weight-loss drugs Ozempic and Wagovy have been the topic of many conversations across Wall Street and well beyond this year, due to the company's financial performance driven by its success in helping people tackle both diabetes and being overweight. It is that impact and buzz that Yahoo Finance has chosen to name Novo Nordisk its 2023 Company of the Year.
- 12/11/2023
|
Why Novo Nordisk's corporate structure stands out
- Yahoo Finance selected Novo Nordisk (NVO) as its Company of the Year for 2023, and there are plenty of reasons why. One interesting reason some investors may not know about, however, is its unique corporate structure, which includes the fact that 77% of the company's voting power is owned by the non-profit Novo Nordisk Foundation, which owns all of the company's Class A shares.
- 12/11/2023
|
6 Health Care Dividend Stocks To By Hand Over Fist
- This biotech giant remains a top stock for investors to buy and pays a solid 3.13% dividend.
- 12/11/2023
|
Novo, Lilly rivals explore booming weight-loss drug market entry
- Novo Nordisk and Eli Lilly have pulled ahead in the race for a slice of the weight-loss drugs market, expected to be worth $100 billion by the end of the decade, and rivals are looking to catch up through acquisitions and trials.
- 12/08/2023
|
Could Eli Lilly Beat Novo Nordisk in the Billion-Dollar Weight Loss Market?
- Novo Nordisk was first to market with its blockbuster weight loss treatment Wegovy. Doctors have prescribed Eli Lilly's diabetes treatment for weight loss.
- 12/08/2023
|
Is It Worth Investing in Novo Nordisk (NVO) Based on Wall Street's Bullish Views?
- The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings often affect a stock's price.
- 12/07/2023
|
Goldman Sachs money manager digs into three themes for long-term growth
- Most exchange-traded funds are passively managed — they are designed to mirror the performance of stock indexes and typically have low management fees. They can work out very well for investors, which has been the case for funds that track the S&P 500.
- 12/05/2023
|
AstraZeneca and Novo Nordisk among the top picks of this top US bank - here's why
- JP Morgan has identified its top picks in the European pharmaceuticals and biotechnology sector for 2024, spotlighting large, mid, and small-cap companies poised for significant growth. Among its top tips were Novo Nordisk, AstraZeneca PLC (LSE:AZN), and Merck KGaA in the large-cap space, Argenx and DiaMonTech in mid-caps, and MorphoSys AG in small caps.
- 12/05/2023
|
Novo Nordisk: From diabetes to weight loss to obesity preventions
- Having developed a blockbuster diabetes treatment that has gained huge traction in the weight loss market, Novo Nordisk (NYSE:NVO) is now expanding its focus to include the prevention of obesity, according to the Financial Times. CEO Lars Fruergaard Jørgensen is spearheading efforts to explore why certain individuals are more prone to weight gain, the paper said.
- 12/05/2023
|
No more exercising? President RFK Jr.?
- Denmark's Saxo Bank makes a tradition of making “outrageous predictions,” which every once in a while comes true. The bank counts as a win its 2022 prediction that the plan to end fossil fuels will get a rain check, and its 2019 call that Germany will enter a recession.
- 12/05/2023
|
Ozempic vs. Mounjaro:: Battle of the bulge
- The year 2023 was a breakout year for glucagon-like peptide (GLP-1) weight-loss drugs in the medical sector, led by the popularity of Ozempic. Celebrity usage and social media exposure have caused Novo Nordisk A/S NYSE: NVO Semaglutide drug Ozempic to go mainstream and viral as countless consumers try the medication that was originally approved for type 2 diabetes patients.
- 12/04/2023
|
Roche Strikes $3.1 Billion Deal for Obesity Drugmaker. It Hopes to Compete with Eli Lilly, Novo Nordisk.
- Roche has agreed to buy obesity-drug developer Carmot Therapeutics for up to $3.1 billion. The Swiss company is hoping to join Eli Lilly and Novo Nordisk at the forefront of the weight-loss drug market.
- 12/04/2023
|
Roche strikes $3.1 billion deal to buy obesity-drug maker Carmot Therapeutics billion in race to rival Novo Nordisk's Ozempic
- Roche has agreed to buy obesity-drug developer Carmot Therapeutics for up to $3.1 billion, as the world's top drugmakers rush to capitalize on the booming market for weight-loss drugs that has seen Novo Nordisk become Europe's most valuable company.
- 12/04/2023
|
3 No-Brainer Growth Stocks to Buy in December
- Eli Lilly's weight-loss drug Zepbound should be a game changer. Novo Nordisk's momentum, driven by Ozempic and Wegovy, will likely keep going.
- 12/03/2023
|
Everyone Is Talking About This Stock. Is It a Good Long-Term Option?
- Novo Nordisk's weight-loss products soared in popularity this year. The company remains a leader in this area thanks to its innovations.
- 12/02/2023
|
Is Eli Lilly a Better Stock to Buy and Hold Over the Next 10 Years Than Novo Nordisk?
- Lilly's Mounjaro and Zepbound appear to have an efficacy advantage over Novo Nordisk's Ozempic and Wegovy. Lilly also has a stronger product lineup and pipeline outside of the diabetes and obesity indications than Novo Nordisk.
- 12/02/2023
|
There's still a long runway for obesity drugs, says Cantor Fitzgerald's Louise Chen
- Louise Chen, Cantor Fitzgerald analyst, joins 'Squawk on the Street' to discuss what's already priced into the big GLP-1 manufacturing stocks, Chen's thoughts on these companies over the long-term, and much more.
- 12/01/2023
|
Will Novo Nordisk Be a Trillion-Dollar Stock by 2030?
- Novo Nordisk is a big name in diabetes and obesity care. Both Wegovy and Ozempic are fast-growing drugs with a ton of upside.
- 12/01/2023
|
Novo Nordisk sues two pharmacies for allegedly selling tainted Wegovy, Ozempic knockoffs
- The lawsuits come as Novo Nordisk grapples with shortages of Wegovy and Ozempic in the U.S. due to skyrocketing demand.
- 11/30/2023
|
Novo Nordisk Sues Two Florida Pharmacies For Allegedly Selling Impure Weight-Loss Drugs
- The Danish drugmaker claims one pharmacy is adding a banned substance to its drugs.
- 11/30/2023
|
Novo Nordisk finds compounded Wegovy up to 33% impure, sues Florida pharmacies
- Novo Nordisk on Thursday said it sued one compounding pharmacy and refiled a lawsuit against another after finding their products claiming to contain the active ingredient for its in-demand weight-loss drug Wegovy were impure, some by as much as 33%.
- 11/30/2023
|
How to earn $500 a month from this stock?
- Pfizer's (NASDAQ: PFE) stock continued its 11-month decline in November after its third-quarter sales missed expectations amid waning demand for Covid products.
- 11/29/2023
|
Watch the buy range for Li Auto, MongoDB, Novo Nordisk
- With the November rally in the SPDR S&P 500 ETF Trust NYSEARCA: SPY, a number of large-cap stocks are in buy range. Among those names are three large companies that are not S&P 500 components: Li Auto Inc. NASDAQ: LI, MongoDB NASDAQ: MDB and Novo Nordisk A/S NYSE: NVO.
- 11/29/2023
|
Ozempic Receives Some Very Bad News: Is It Time to Sell Novo Nordisk Stock?
- New real-world data show that Lilly's Mounjaro helped patients achieve significantly greater weight loss than Ozempic did. This demonstration of Mounjaro's efficacy could lead to a shift in prescribing patterns that hurt Novo Nordisk.
- 11/29/2023
|
3 Large Drug Stocks That Have Outperformed Industry YTD
- Eli Lilly (LLY), Novo Nordisk (NVO) and Novartis (NVS) have outperformed the industry this year.
- 11/28/2023
|
Study finds Mounjaro outperforms Ozempic in overweight & obese adults: Truveta's VP of Research
- Dr. Nick Stucky, VP of Research at Truveta, joins 'Fast Money' to talk the results of a study comparing weight-loss drugs Mounjaro and Ozempic.
- 11/27/2023
|
Mounjaro is more effective for weight loss than Ozempic: study reveals
- Mounjaro – a popular treatment for diabetes is more effective for losing weight than Ozempic, as per a large study of real-word data by Truveta Research.
- 11/27/2023
|
Ozempic is not the most effective weight-loss drug on the market: study
- Diabetes-turned-weight loss drug Mounjaro is more effective for shedding off extra pounds than its ultra-popular counterpart, Ozempic, according to a new study.
- 11/27/2023
|
5 Must-Buy Stocks at 52-Week High With More Upside for 2024
- We have narrowed our search to five large-cap stocks with more upside for 2024. These are: IT, PGR, CBOE, IHG, NVO.
- 11/27/2023
|
4 Must-Buy Profitable Stocks Using Net Income Ratio
- Lamb Weston (LW), e.l.f. Beauty (ELF), Novo Nordisk (NVO), and NVIDIA (NVDA) have been selected as the top picks with a high net income ratio.
- 11/27/2023
|
Novo Nordisk: Massive Reality Check Awaits Greedy Investors
- Novo Nordisk's stock continues to surge as greedy investors exploit surging momentum, as they fear missing out on further potential gains. The company's impressive Q3 earnings results suggest the upward momentum could continue. I also have not assessed sell signals that could stall its momentum yet. Novo Nordisk's plans to broaden its geographical coverage and expand its production capacity should support investors' confidence in sustainable demand/supply dynamics.
- 11/25/2023
|
Could Ozempic Harm These 3 Medical Device Stocks?
- Ozempic could make some medical devices less necessary than before. If that happens, it would lead to lower revenue for the device makers.
- 11/25/2023
|
Novo Nordisk: Healthy Gains Ahead, EPS Growth Seen, Technical Strength
- Novo Nordisk has surpassed Nestle as the largest developed-market stock outside of the US, indicating the success of the GLP-1 drug segment. The company had a strong Q3 with a 29% YoY increase in revenue and raised its full-year outlook. Analysts expect significant earnings growth for Novo Nordisk in 2023 and beyond, and the stock is priced for strong growth ahead.
- 11/25/2023
|
New Highs: Novo Nordisk, PGT Innovations Among Best Stocks To Buy Now
- Novo Nordisk and PGT Innovations continue to show relative strength and are among the best stocks to buy now.
- 11/24/2023
|
Novo Nordisk (NVO) to Expand Manufacturing Site in France
- Novo Nordisk (NVO) announces that it is initiating plans to expand its existing manufacturing facility in Chartres, France, for the current and future product portfolio within serious chronic diseases.
- 11/24/2023
|
Pharma Stock Hits Record High After Expansion Plans
- Pharmaceutical name Novo Nordisk A/S (NYSE:NVO) is up 1.6% at $104.93 at last glance, earlier hitting a fresh record peak of $105.30.
- 11/24/2023
|
Eli Lilly and Novo Nordisk will remain winners in the weight-loss category: Barclays' Emily Field
- Emily Field, Barclays, joins 'Squawk Box' to discuss the latest news in the weight-loss drug market, the news to watch out for next year, and how investors should play the weight-loss drug market.
- 11/24/2023
|
New Strong Buy Stocks for November 24th
- NVO, PAY, AIZ, MOD and LEU have been added to the Zacks Rank #1 (Strong Buy) List on November 24, 2023.
- 11/24/2023
|
7 Stocks Set to Capitalize on the Coming Year-End Rally
- The story of the stock market in 2023 has largely been about optimism around AI tinged by the continued threat of recession. Generative AI has propelled tech shares much higher.
- 11/24/2023
|
Novo Nordisk to invest $2 billion in France production boost
- Weight loss drug developer Novo Nordisk (NYSE:NVO) has announced US$2.3 billion will be spent on ramping up production in France. Set to boost capacity, quality control lab space, aseptic and finished production processes at the drug giant's Chartres site, southwest of Paris, Novo Nordisk said the move would preempt future demand.
- 11/24/2023
|
Ozempic maker plans manufacturing blitz as market for the drug is expected to top $100 billion in 2030
- Novo Nordisk makes Ozempic and Wegovy, two hit drugs that treat obesity. Supply is a major issue right now, with the firm warning a European regulator it may ration Ozempic.
- 11/23/2023
|
$3,000 Invested in These 3 Top Stocks Could Make You Rich in 10 Years
- The hype seems eerily familiar, but Novo Nordisk's weight-loss drug may well meet lofty sales expectations. Despite plenty of headaches, Boeing is showing strength in front of a massive wave of demand for new passenger jets.
- 11/23/2023
|
Novo Nordisk to launch obesity drug Wegovy in Japan in February
- Novo Nordisk said on Thursday it will launch its hugely popular Wegovy obesity drug in Japan on Feb. 22 next year.
- 11/23/2023
|
Novo Nordisk invests $2.3 mln in France to boost output
- Danish drug maker Novo Nordisk said on Thursday it would invest more than 16 billion crowns ($2.34 billion) in the expansion of production facilities in Chartres in France.
- 11/23/2023
|
Macron to unveil 2.1 bln eur Novo Nordisk pharma investment in France
- French President Emmanuel Macron will on Thursday inaugurate a 2.1 billion euro ($2.3 billion) investment by Danish pharmaceutical company Novo Nordisk in France, his office said, pitching it as a sign of newly restored French industrial competitiveness.
- 11/23/2023
|
3 Consumer Goods Stocks That Will Define the Next Decade
- What will the next decade bring and how will we be living in the 2030s? It's a question marketing professionals and traders spend a lot of time trying to figure out as they forecast which stocks will define and dominate the next decade for consumers.
- 11/21/2023
|
Medicare's exclusion of weight-loss drug coverage under fire
- Medicare's decades-old exclusion of weight-loss drug coverage is coming under scrutiny amid mounting evidence that Wegovy and similar medications have health benefits that extend well beyond shedding pounds.
- 11/20/2023
|
Weight loss drugs Wegovy and Zepbound to debut in pill form
- Popular weight loss drugs Wegovy and Zepbound will soon be available in pill form. Pharmaceutical giants Novo Nordisk (NYSE:NVO) and Eli Lilly and Co (NYSE:LLY) are actively promoting pill versions of their successful weight-loss drugs, expected to hit the market as early as next year, Bloomberg reported.
- 11/17/2023
|
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
- The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.
- 11/17/2023
|
3 Industry Titans Benefitting from Mega Trends
- What do stretchy pants, fat-loss drugs, and sports betting have in common? Each of these is powering some of the strongest mega-trends on Wall Street.
- 11/16/2023
|
Novo Nordisk Eyes Another Breakout As Weight-Loss Battle Continues
- Novo Nordisk stock is Thursday's IBD Stock Of The Day after a study showed weight-loss drug, Wegovy, cut down on heart attacks and strokes.
- 11/16/2023
|
Weight loss drugs and stocks: Breaking down the GLP1 market for investors
- Weight loss drugs are at the forefront of demand in the pharmaceutical sector as major drug manufacturers Novo Nordisk (NVO) and Lilly (LLY) undergoing clinical trials for new GLP-1 drugs. And, one analyst says the impact could affect apparel markets, not just food sales.
- 11/16/2023
|
Investors increase holdings of weight-loss drug makers' shares in Q3 -filings
- Some big investors showed increased appetite for weight-loss drug makers in the third quarter, piling in to shares of Eli Lilly and Novo Nordisk amid growing demand for their product, securities filings showed on Tuesday.
- 11/14/2023
|
Employer coverage of GLP-1 drugs for weight loss lags far behind diabetes coverage, survey finds
- For workers in employer-sponsored health plans, coverage of Wegovy and other GLP-1 medications for weight loss is lagging far behind coverage of that class of drugs for diabetes, a new survey shows.
- 11/14/2023
|
Wegovy's Sales Potential Could Go Far Beyond Just Weight-Loss Treatment
- Wegovy is approved to treat chronic weight management, but it has far more potential in the future. Another indication, for reducing the risk of cardiovascular disease, could be coming in 2024.
- 11/14/2023
|
3 Growth Stocks to Buy That Could Be Massive Long-Term Winners
- Nvidia is leading the artificial intelligence revolution, and that's not likely to change. The world will always need new drugs, and Icon can help bring them to market.
- 11/14/2023
|
Belgium bans use of Ozempic for weight loss until summer
- Belgium has decided to temporarily ban the use of Novo Nordisk's diabetes drug Ozempic as a weight loss treatment amid a shortage of the medicine, according to a royal decree published in the country's Official Gazette on Tuesday.
- 11/14/2023
|
Better Growth Stock: Pfizer vs. Novo Nordisk
- Pfizer is looking to buy and develop new revenue drivers. Novo Nordisk aims to penetrate a profitable market even more.
- 11/14/2023
|
Jim Cramer weighs the market impact of Eli Lilly and Novo Nordisk's weight loss drugs
- 'Mad Money' host Jim Cramer compares the weight loss drug offerings from Novo Nordisk and Eli Lilly and talks what investors need to know about both companies.
- 11/13/2023
|
Jim Cramer says insurance companies will pay for 'revolutionary' weight-loss drugs for their members
- CNBC's Jim Cramer on Monday emphasized his belief that companies making GLP-1 diabetes and obesity drugs will be valuable.
- 11/13/2023
|
How Novo Nordisk's ‘select' study results could shake up the obesity drug space
- Jared Holz, Mizuho, joins 'Fast Money' to talk Novo Nordisk's ‘select' study and what it means for the obesity drug space.
- 11/13/2023
|
Novo Nordisk ADRs Climb After Study Suggests Its Wegovy Showed Heart Benefits
- American depositary receipts (ADRs) of Novo Nordisk (NVO) edged higher in early trading on Monday after reporting a study showed its flagship diabetes and weight-loss drug, Wegovy, helped reduce risks of heart attack, stroke, or death from cardiovascular disease.
- 11/13/2023
|
Novo Nordisk Stock Skids — But These Weight-Loss Results Are 'Hard To Ignore'
- Novo Nordisk stock slumped Monday despite unveiling promising test results for weight-loss drugs and diabetes development.
- 11/13/2023
|
Novo Nordisk's (NVO) Wegovy Positive in Cardiovascular Study
- Novo Nordisk's (NVO) obesity drug Wegovy shows potential in cardiovascular study beyond the benefits of associated weight loss.
- 11/13/2023
|
Novo Nordisk's Wegovy could reduce heart risks by 20%
- According to a new trial study, Novo Nordisk's (NVO) weight loss drug Wegovy may have the added benefit of cutting down risks tied to cardiovascular complications by at least 20%. Yahoo Finance Live monitors how Novo Nordisk's stock is reacting to this news in pre-market trading and analyzes how food brands may be planning to respond to the rise in GLP-1 drugs.
- 11/13/2023
|
Wegovy predicted to become huge drug as weight loss benefits confirmed
- Novo Nordisk (NYSE:NVO) did not disappoint with the latest trial data update of its blockbuster diabetes drug Wegovy, according to analysts at US bank Citi. Full results from the SELECT trial released on Saturday confirmed that patients had shed weight but also that it cut the risk of a non-fatal heart attack by 28% and non-fatal strokes by 7% in patients considered overweight.
- 11/13/2023
|
Better Buy Now: Novo Nordisk vs. Eli Lilly
- Novo Nordisk's weight management blockbuster produced some surprising results for its ability to reduce patients' risk of a second heart attack. The Food and Drug Administration recently approved Eli Lilly's weight management drug Zepbound.
- 11/13/2023
|
Novo's Wegovy Trial Shows Heart Benefit in Obesity Patients
- Novo Nordisk A/S revealed details from a key study backing the use of Wegovy, its blockbuster weight-loss drug, to cut heart attacks and deaths in obesity patients with a history of cardiovascular disease. Eric Pfanner reports on Bloomberg Television.
- 11/13/2023
|
Novo Nordisk shares rise as Wegovy shows heart benefits beyond weight loss
- Novo Nordisk shares rose 3.3% on Monday as the market reacted to data the drugmaker presented over the weekend showing that the heart protective benefits of its popular obesity drug Wegovy are not solely due to weight loss.
- 11/13/2023
|
Novo Nordisk's Wegovy cuts risk of heart attack and stroke by 20% among people without diabetes, study finds
- Novo Nordisk's NVO, +1.16% popular weight-loss drug Wegovy significantly cut the risk of heart attack, stroke or death due to cardiovascular disease in people who do not have diabetes, according to new data from a large international clinical trial.
- 11/11/2023
|
Novo Nordisk says Wegovy heart benefits due to more than weight loss
- Novo Nordisk on Saturday said the heart protective benefits of its wildly popular Wegovy obesity treatment are due to more than weight loss alone, according to new data presented at a major medical meeting on Saturday.
- 11/11/2023
|
Novo Nordisk's weight loss drug Wegovy slashes risk of serious heart events
- The findings could expand use of Wegovy and help Novo maintain its lead over Eli Lilly, whose competing weight-loss drug Zepbound was just approved in the U.S.
- 11/11/2023
|
Who's afraid of Ozempic? From restaurants to package makers, companies work to calm investors' GLP-1 jitters.
- That's the message from many corporate executives who have lately been peppered with questions about how Wegovy, Ozempic and other drugs widely used for weight loss may impact their bottom line.
- 11/10/2023
|
Wegovy Maker Novo Nordisk Pumps $6 Billion To Boost Production As Obesity Drug Rival Zepbound Is Approved
- Novo has struggled to keep up with booming demand for its weight loss drug and said it could be years until it or its rivals are able to satisfy the growing market.
- 11/10/2023
|
Novo Nordisk, maker of Ozempic and Wegovy, to invest more than $6 billion to expand production
- Novo Nordisk NVO, -1.36% said Friday that it will invest more than $6 billion to expand manufacturing facilities in Kalundborg, Denmark, where the company produces GLP-1 drugs such as Wegovy as well as other products.
- 11/10/2023
|
Drugmaker Novo Nordisk seeks obesity, diabetes 'bolt-on' deals
- Novo Nordisk wants to buy more companies with drugs in early- to mid-stages of development through "bolt-on" deals of up to a few billion dollars, CEO Lars Fruergaard Jorgensen told Reuters on Friday.
- 11/10/2023
|
Novo Nordisk unveils $6bn investment plans
- Europe's largest pharma company, Novo Nordisk (NYSE:NVO), has unveiled plans for a significant investment of more than $6 billion to cater to the increasing demand for its Wegovy weight-loss treatment and other pharmaceutical products. The company will focus on expanding its Kalundborg facility in Denmark, enhancing capabilities throughout its value chain.
- 11/10/2023
|
Novo Nordisk to invest $6 bln in Denmark expansions
- Novo Nordisk said on Friday it will invest more than 42 billion Danish crowns ($6 billion) from 2023 onwards to expand its manufacturing facilities in Denmark for the current and future product portfolio within serious chronic diseases.
- 11/10/2023
|
Former FDA commissioner: Expect more competition in Eli Lilly and Novo Nordisk's weight-loss drugs
- Former FDA commissioner Dr. Scott Gottlieb joins 'Power Lunch' to discuss Eli Lilly's highly anticipated weight-loss drug Zepbound, the demand and supply equation in the weight-loss drug space, and more.
- 11/09/2023
|
Novo Nordisk to discontinue Levemir insulin in U.S. market
- Novo Nordisk said on Wednesday it would discontinue its long-acting insulin Levemir in the United States, citing manufacturing constraints, reduced patient access and available alternatives.
- 11/08/2023
|
Novo Nordisk to present new cardiometabolic disease data mid-November
- Danish drugmaker Novo Nordisk said on Tuesday it will present new cardiometabolic disease data, including results from its SELECT trial, at the annual American Heart Association Scientific Sessions from Nov. 11-13.
- 11/07/2023
|
Why Novo Nordisk Stock Trounced the Market Today
- Two analysts separately raised their price targets on the shares. This provides even more bullish momentum for the Wegovy and Ozempic maker's stock.
- 11/06/2023
|
Why Novo Nordisk Stock Flopped on Friday
- An analyst's price target bump was overshadowed by an insider's stock sale. Both were relatively small-scale events.
- 11/03/2023
|
Novo Nordisk to release clinical update on star drug Wegovy
- Novo Nordisk (NYSE:NVO) remains firmly in favour with analysts at Barclays ahead of the latest trial data for diabetes drug Wegovy that is due next week. It was the “stunning” numbers from the previous update of the SELECT trial in August that sent the value of the Danish pharma soaring and sparked a stampede from people to get hold of the drug.
- 11/03/2023
|
Ozempic Sales Soar 56% in Q3. But Is Eli Lilly a Better Stock to Buy Than Novo Nordisk?
- Novo Nordisk delivered sizzling Q3 growth, thanks mainly to soaring sales for Ozempic. However, Eli Lilly's Q3 results looked even better than Novo Nordisk's.
- 11/03/2023
|
Weight loss drug Wegovy sales fuel Novo Nordisk stock performance
- Novo Nordisk (NVO) stock rose after the pharmaceutical company reported strong third-quarter sales growth, fueled by its popular weight-loss drug, Wegovy. The obesity treatment generated $1.7 billion in quarterly revenue for Novo Nordisk.
- 11/02/2023
|
Why Novo Nordisk Stock Is Surging Higher Today
- Danish pharma titan Novo Nordisk released its latest financial report Thursday morning. For the first nine months of 2023, the company posted double-digit percentage sales growth over the prior-year period.
- 11/02/2023
|
Novo Nordisk, Lilly see insatiable demand for weight-loss drugs
- Novo Nordisk and Eli Lilly both expect juggernaut sales for their diabetes and weight-loss drugs to extend into coming years - limited only by their availability.
- 11/02/2023
|
Novo Nordisk, Eli Lilly stocks see boost on obesity drugs
- Novo Nordisk (NVO) shares rose as the drugmaker's third-quarter profits jumped 56% year-over-year, fueled by surging demand for its obesity drugs Ozempic and Wegovy. Eli Lilly (LLY) shares also saw gains after beating third-quarter profit estimates, but lowering its full-year guidance.
- 11/02/2023
|
Novo Nordisk: 80% of U.S. Wegovy patients with insurance paying less than $25/month
- The majority of U.S. patients with health insurance coverage taking Novo Nordisk's powerful weight-loss drug Wegovy are paying less than $25 per month, a senior executive said on Thursday.
- 11/02/2023
|
US Wegovy Supply to Expand ‘Gradually': Novo Nordisk CEO
- Novo Nordisk CEO Lars Fruergaard Jorgensen says starter doses of the company's weight loss medications will “be lowered somewhat” through the end of the year as the company plans to be “gradually expanding and bringing more and more product to the US.” He speaks on "Bloomberg The Open.
- 11/02/2023
|
Novo Nordisk (NVO) Q3 Earnings and Sales Beat, 2023 View Up
- Novo Nordisk (NVO) reports encouraging third-quarter results, beating both earnings and sales estimates, driven by strong sales of diabetes and obesity care products. Management raises 2023 guidance.
- 11/02/2023
|
Weight-loss drug Wegovy could get expanded FDA approval within six months, Novo Nordisk says
- Novo Nordisk said its blockbuster weight-loss drug Wegovy could receive expanded approval from the U.S. Food and Drug Administration within six months.
- 11/02/2023
|
Novo Nordisk adding in-house fill-finish capacity for Wegovy's European pen, Ozempic
- Novo Nordisk is ramping up its in-house manufacturing capacity to fill injection pens for its diabetes drug Ozempic and for the European version of its hugely popular weight-loss drug Wegovy, a senior executive told Reuters on Thursday.
- 11/02/2023
|
7 A-Rated Tech Stocks to Buy for November
- Last year wasn't the best year for tech stocks. Some of the biggest names on Wall Street stumbled through the year as companies that were flush with growth during the Covid-19 pandemic adjusted to leaner times.
- 11/02/2023
|
Novo Nordisk: obesity drugs priority over century-old focus on insulin
- Novo Nordisk said on Thursday treating obesity with its weight-loss drug Wegovy as a precursor to type 2 diabetes was a priority for the company, continuing the Danish drugmaker's shift away from its century-long focus on insulin.
- 11/02/2023
|
Ozempic Sales Up 58% As Drugmaker Novo Nordisk Nets Record Profits
- Revenue for the Danish company behind the booming GLP-1 injectable drugs is up 29% so far this year.
- 11/02/2023
|
Weight-loss drug maker reports 56% profit surge, as it continues to limit supplies
- Novo Nordisk said Thursday it's still struggling to meet demand for its wildly popular weight-loss medications as its third-quarter profit jumped.
- 11/02/2023
|
Novo Nordisk shares higher on bumper Wegovy boost
- Shares in Europe's largest drugs company rose 1.6% in early trade boosted by the performance of its breakthrough weight loss drug Wegovy. Novo Nordisk (NYSE:NVO) said sales of obesity medication increased by 167% to DKr30.4 billion, while revenue from diabetes medications rose by 45%.
- 11/02/2023
|
Novo Nordisk flags continued restrictions on Wegovy supplies
- Novo Nordisk on Thursday reported record sales and operating profits for the third quarter but flagged continued restrictions on supplies of its hugely popular Wegovy weight-loss drug.
- 11/02/2023
|
Novo Nordisk Earnings Are Soon. It's All About Weight-Loss Drugs.
- The earnings report comes amid what has been a surprisingly grim two weeks for the pharmaceutical stocks.
- 11/01/2023
|
Looking for a Growth Stock? 3 Reasons Why Novo Nordisk (NVO) is a Solid Choice
- Novo Nordisk (NVO) is well positioned to outperform the market, as it exhibits above-average growth in financials.
- 11/01/2023
|
Exclusive: Novo hires FUJIFILM unit to help make Wegovy weight-loss drug - source
- Novo Nordisk has hired FUJIFILM Diosynth Biotechnologies to fill Wegovy injection pens, a source familiar with the matter told Reuters, as the Danish drugmaker scrambles to boost output of its hugely popular weight-loss drug.
- 11/01/2023
|
Should You Buy Novo Nordisk (NVO) Ahead of Earnings?
- Novo Nordisk (NVO) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
- 11/01/2023
|
How Novo Nordisk makes its weight-loss drug Wegovy
- Novo Nordisk is spending billions of dollars to boost output and ease shortages of its hugely popular, highly effective weight-loss medicine Wegovy.
- 11/01/2023
|
Novo Nordisk Just Consolidated Its Grip on Yet Another Market. Is It a Buy?
- Novo Nordisk just acquired a promising pharmaceutical asset for kidney disease. The candidate could also address hypertension, so the potential market could be huge.
- 10/29/2023
|
3 Monster Buy-and-Hold Growth Stocks to Buy Right Now for $1K
- Over the past 100 years, the stock market has proved to be the best way to build wealth. Even through recessions, depressions, and world wars, growth stocks generate better returns than any other asset class.
- 10/27/2023
|
Demand for Ozempic and Wegovy Is Through the Roof. Here's Why it Can Go Even Higher.
- Novo Nordisk has reported strong revenue and profit growth over the past five years. The company recently upgraded its guidance for 2023.
- 10/25/2023
|
Novo Nordisk's Ozempic to take center stage when the pharma giant reports 3Q earnings next week
- Novo Nordisk (NYSE:NVO) is scheduled to report earnings on November 2 before the opening bell The Street consensus for Novo Nordisk (NYSE:NVO) is earnings of $0.71 per share on revenue of $7.91 billion, compared to $0.90 per share on revenue of $6.47 billion a year earlier. Ozempic has seen a huge surge in sales, leading the company to increase its annual sales growth guidance earlier this month.
- 10/24/2023
|
Novo Nordisk Milks The Obesity Cash Cow - How Long Will It Last?
- NVO's obesity/diabetes drug, Wegovy/Ozempic, is projected to outperform the best-selling drug of all time, Humira, with an estimated $38.5B in annual sales by 2030. This has led to the stock's inflated P/E premium near to the pharmaceutical leaders, due to the market's optimism about its profitable growth trend and potential applications for new indications. Then again, NVO's supply constraints and potential competition may limit its upside potential moving forward, made uncertain by the US government's crack-down on prescription costs.
- 10/24/2023
|
Novo Nordisk: Growing To Potentially Become The First Trillion-Dollar European Champion
- Novo Nordisk stock has tripled since 2020 and is up over 30% YTD; but there is still upside. Novo is poised to benefit from the surging demand for diabetes and obesity care, with an estimated annual TAM potential of $350-400 billion by 2030. My projections suggest that Novo Nordisk could double its revenues by 2027 and achieve $100 billion in revenues by 2030.
- 10/24/2023
|
Novo Nordisk (NVO) Advances While Market Declines: Some Information for Investors
- The latest trading day saw Novo Nordisk (NVO) settling at $97.12, representing a +0.86% change from its previous close.
- 10/23/2023
|
Ozempic Maker Novo Nordisk Has a Weight Problem
- What happens when one company accounts for more than half of a stock index?
- 10/23/2023
|
3 Healthcare Stocks to Invest in for a Big Shot of Gains
- With a few exceptions, healthcare stocks have had a rough go of it in 2023. The Standards and Practices (S&P) 500 Healthcare Index is down 5% year to date, versus a 13% increase in the benchmark S&P 500 index.
- 10/23/2023
|
Eli Lilly, Novo Nordisk to test weight loss drugs for children
- Pharmaceutical manufacturers Eli Lilly (LLY) and Novo Nordisk (NVO) are reportedly planning to test their weight loss drugs for children six and older. Yahoo Finance Health Reporter Anjalee Khemlani details the GLP-1 clinical trials set up by each company.
- 10/22/2023
|
The $100 billion dollar opportunity in obesity drugs, Goldman Sachs analyst explains
- A Goldman Sachs report predicts that the total addressable market for weight loss drugs could reach $100 billion dollars by 2030. Popular weight loss drugs like Novo Nordisk's Ozempic (NVO) have piqued consumers and investors' interest as the drug has called into question its effect on food sales for companies like Walmart (WMT).
- 10/21/2023
|
Pharma firms testing weight loss drugs for kids amid Ozempic craze
- Get ready for Ozem-kids! The pharmaceutical companies behind Ozempic, Mounjaro and Wegovy — which have exploded in popularity with adults looking to lose weight — are testing whether the drugs are safe for children.
- 10/20/2023
|
Drugmakers test weigh-loss shots for kids as young as 6
- Former FDA commissioner Dr. Scott Gottlieb joins 'Power Lunch' to discuss the latest weight loss headlines.
- 10/20/2023
|
Options Traders Oh-Oh-Overjoyed With This Ozempic Trade
- Subscribers to Chart of the Week received this commentary on Sunday, October 15.
- 10/20/2023
|
1 Market-Beating Stock to Buy Near Its 52-Week High
- Eli Lilly's obesity diabetes medicine Mounjaro continues to show excellent prospects. It should be the biggest growth driver behind the company's sales in the coming years.
- 10/19/2023
|
4 Ways to Grow $100,000 Into $1 Million for Retirement
- Realty Income's total returns deliver. Alphabet is still turning investors into millionaires.
- 10/19/2023
|
GE HealthCare teams up with Novo Nordisk to treat diabetes without drugs
- GE HealthCare Technologies Inc. GEHC, -2.35% on Thursday said it is teaming up with Novo Nordisk NVO, -0.58% to develop an ultrasound treatment for type 2 diabetes and obesity.
- 10/19/2023
|
Global market for anti-obesity drugs could reach $100B by 2030: Goldman Sachs
- A report from Goldman Sachs predicts that the total addressable market globally for weight loss drugs could reach $100 billion dollars in sales by 2030. The current market is estimated to be at $6 billion globally.
- 10/17/2023
|
MedTech Earnings in the Age of Ozempic May Not Be That Bad
- September-quarter earnings among medical-device makers may prove better than expected in the age of weight-loss drugs.
- 10/17/2023
|
Novo Nordisk (NVO) to Acquire Hypertension Drug for $1.3B
- Novo Nordisk (NVO) aims to strengthen its pipeline by adding ocedurenone for treating uncontrolled hypertension for $1.3 billion.
- 10/17/2023
|
Novo Nordisk (NVO) Stock Falls Amid Market Uptick: What Investors Need to Know
- Novo Nordisk (NVO) closed at $101.15 in the latest trading session, marking a -0.97% move from the prior day.
- 10/16/2023
|
Food and Beverage Stocks Look Appetizing After Ozempic Selloff
- It may be time to eat, drink and buy the dip in food and beverage stocks. Shares of Coca-Cola (NYSE: KO ), Pepsi (NASDAQ: PEP ) and several other sugary drink and snack companies have been pummeled lately due to concerns that the rising popularity of injectable weight loss drugs like Novo Nordisk's (NYSE: NVO ) Ozempic and Wegovy and Eli Lilly's (NYSE: LLY ) Mounjaro is leading to a reduced appetite for guilty culinary pleasures.
- 10/16/2023
|
Novo Nordisk buys blood pressure treatment to bolster diabtetes portfolio
- Novo Nordisk (NYSE:NVO) has agreed to buy ocedurenone, a blood pressure drug for with potential applications in cardiovascular and kidney disease, the Danish group said today. Buoyed by the success of its diabetic treatments Ozempic and Wegovy, which have also been shown to cut weight and reduce heart attack risk, Novo Nordisk has surged to become Europe's biggest company.
- 10/16/2023
|
Novo Nordisk (NVO) Raises Sales Outlook for 2023, Shares Gain
- Novo Nordisk (NVO) increases its annual sales and operating profit forecast for the second time in 2023, driven by Ozempic (semaglutide) and Wegovy.
- 10/16/2023
|
Novo Nordisk Buys Hypertension Drug Ocedurenone For $1.3 Billion—Expanding Ozempic Maker's Arsenal
- The Danish firm said the drug has “best-in-class potential” for treating uncontrolled hypertension.
- 10/16/2023
|
Novo Nordisk Buys Hypertension Drug in $1.3 Billion Deal
- Novo Nordisk (NVO) agreed to buy ocedurenone, a drug that treats uncontrolled hypertension and has the potential to be used in cases of cardiovascular and kidney disease, from KBP Biosciences for up to $1.3 billion.
- 10/16/2023
|
Novo Nordisk in $1.3 bln deal to buy hypertension drug
- Novo Nordisk has agreed to buy ocedurenone, a drug for uncontrolled hypertension with potential application in cardiovascular and kidney disease, from KBP Biosciences for up to $1.3 billion, the Danish drugmaker said on Monday.
- 10/16/2023
|
Novo Nordisk to buy hypertension treatment from for $1.3 billion from KBP Biosciences
- Novo Nordisk A/S NVO, +1.96% NOVO.B, +0.08% said Monday it will pay $1.3 billion to KBP Biosciences to buy ocedurenone for uncontrolled hypertension. Ocedurenone is a pill that also has potential application for cardiovascular and kidney disease.
- 10/16/2023
|
How weight loss drugs could impact stocks
- Weight loss drugs, such as Novo Nordisk's (NVO) Ozempic and Wegovy, continue to grow in popularity. With many brand and retailer CEOs signaling the hit to snack food sales, how will these drugs impact the packaged food industry?
- 10/14/2023
|
1 Big Risk Facing Ozempic, Wegovy, and Other GLP-1 Weight-Loss Drugs
- Ozempic and Wegovy have soared in popularity because of their ability to help people lose weight. Some recent reports, however, have described several potential side effects of concern.
- 10/14/2023
|
Novo Nordisk Boosts Its Guidance on Demand for Its Weight-Loss Drugs, Again
- Novo Nordisk (NVO) boosted its guidance for the second time in two months as demand soars for its diabetes treatments, Ozempic and Wegovy. American depositary receipts (ADRs) of Novo Nordisk rose close to 2% to an all-time high on Friday following the news.
- 10/13/2023
|
Novo Nordisk raises full-year sales guidance due to Ozempic
- Novo Nordisk (NVO) shares are up on the last trading day of the week as the company raised its full-year sales and operating profit citing U.S. sales from GLP-1 drugs Wegovy and Ozempic. Yahoo Finance's Julie Hyman and Josh Lipton discuss the news.
- 10/13/2023
|
Why Novo Nordisk Stock Raced Higher Today
- The Danish pharmaceutical developer updated its 2023 guidance. It raised its projected growth rates for both sales and operating profit.
- 10/13/2023
|
Novo Nordisk Raises Sales Outlook on Soaring Demand for Ozempic and Wegovy
- Novo Nordisk now expects 2023 sales growth of between 32% and 38%.
- 10/13/2023
|
What exactly are patients taking new weight-loss drugs eating and what are they avoiding? Bernstein asked them.
- Bernstein analysts set out to determine that, analyzing online data to better understand changes in eating habits — and to evaluate which food companies may be most affected. They published the results in a report Friday.
- 10/13/2023
|
Novo Nordisk hikes outlook on soaring demand for Wegovy, Ozempic
- Novo Nordisk's forecast only confirms the frenzy for Wegovy and Ozempic, which patients seek for their ability to help them lose significant weight over time.
- 10/13/2023
|
Novo Nordisk ups guidance, sees higher sales of Ozempic
- Novo Nordisk (NYSE:NVO)'s shares have jumped after it lifted annual guidance, predicting a boost from higher sales of its diabetes drug Ozempic in the US. Europe's most valuable company, after recently dethroning LVMH, said that for the third-quarter its sales jumped 38% year-on-year at constant currency, while Ebit rose 47%.
- 10/13/2023
|
Novo Nordisk boosts sales and profit outlook, buoyed by Ozempic and Wegovy
- Novo Nordisk NVO, +1.36% on Friday boosted its full-year 2023 profit and sales outlook, reflecting heightened expectations for Ozempic and Wegovy sales. The company now projects full-year sales growth of 32% to 38%, up from 27% to 33% previously, and operating profit growth of 40% to 46%, up from 31% to 37% previously.
- 10/13/2023
|
Novo Nordisk raises outlook for full-year sales, operating profit
- Novo Nordisk has raised the outlook for its full-year sales and operating profit, the Danish drugmaker said in a statement on Friday.
- 10/13/2023
|
1 Dividend Legend Potentially Set To Soar And 2 To Ignore
- 1 Dividend Legend Potentially Set To Soar And 2 To Ignore
- 10/13/2023
|
Will Higher Ozempic Use Mean Slimmed-Down Food Sales?
- But does Novo Nordisk's good fortune translate to lower sales for companies like Walmart Inc. NYSE: WMT, Coca-Cola Co. NYSE: KO and PepsiCo Inc. NASDAQ: PEP?
- 10/12/2023
|
Novo Nordisk warns online offers of fake Ozempic, Wegovy are on the rise
- Novo Nordisk on Thursday warned of a surge in counterfeit versions of its weight-loss drug Wegovy and diabetes drug Ozempic offered online as illegal traders seek to take advantage of their huge popularity, putting users' health at risk.
- 10/12/2023
|
7 Affordable Stocks to Invest in as America's Population Ages
- There's no doubt that America is aging. The numbers do not lie.
- 10/12/2023
|
Australia's CSL tanks as Novo Nordisk's kidney trial success stokes competition concerns
- Shares of biotechnology firm CSL fell to a four-year low on Thursday, after rival Novo Nordisk's Ozempic drug showed early signs of success in delaying the progression of kidney disease in diabetes patients.
- 10/12/2023
|
Novo Nordisk stock pops on Ozempic kidney trial success
- Shares of Novo Nordisk (NVO) rose on Wednesday after the drugmaker announced it was stopping a trial because early results show its popular diabetes drug Ozempic was effective in treating failure. The news sent kidney-dialysis stocks such as Fresenius Medical Care (FMS) and DaVita (DVA) plunging.
- 10/11/2023
|
The 3 Widest Competitive Moats on Wall Street
- Competitive moats symbolize a company's sustainable advantage, protecting it from competitors and external threats. Three standout examples illustrate this principle vividly.
- 10/11/2023
|
Ozempic Study Shakes Up Market for Kidney and Insulin Treatments
- American depositary receipts (ADRs) of Novo Nordisk (NOVO) jumped over 6% in early trading on Wednesday, while shares of kidney dialysis machine and insulin pump makers tumbled, after the drug maker halted a test of its Ozempic diabetes medicine because of its early success in treating kidney problems.
- 10/11/2023
|
Novo Nordisk stops Ozempic trial early after signs of early success
- CNBC's Angelica Peebles reports on news from Novo Nordisk.
- 10/11/2023
|
Novo Nordisk Halts Ozempic Study
- Novo Nordisk is halting a study which looked at the impact of its blockbuster Ozempic drug on kidney failure after it showed effectiveness surprisingly early. Ed Ludlow reports.
- 10/11/2023
|
Novo Nordisk (NVO) Up on Positive Kidney Outcomes Study Update
- Novo Nordisk (NVO) is set to stop its kidney outcomes study on Ozempic based on interim analysis results that met certain pre-specified efficacy criteria for early closure. The stock rises 5.2%.
- 10/11/2023
|
Novo Nordisk data knocks $5bn from the value of three leading dialysis companies
- Over $5bn in value was wiped from the three main operators in the dialysis market after a clinical trial update that offers hope for thousands of diabetes sufferers with kidney disease. Earlier, Novo Nordisk (NYSE:NVO) revealed that its Ozempic – a weekly jab which also doubles as a weight-loss aid – had proven successful in treating the new patient group mentioned above.
- 10/11/2023
|
Ozempic Is Moving a Bunch of Stocks Wednesday Morning
- Markets were poised to move higher again on Wednesday morning. Shares of Novo Nordisk climbed on good news from a study of its drug Ozempic on kidney patients.
- 10/11/2023
|
New Strong Sell Stocks for October 11th
- NVO, MT and PRPL have been added to the Zacks Rank #5 (Strong Sell) List on October 11, 2023.
- 10/11/2023
|
Is Novo Nordisk Stock a Buy Now?
- GLP-1 drugs are combating the addictive properties of sugars and junk foods. Novo Nordisk has tens of millions of potential patients it can treat.
- 10/11/2023
|
Novo Nordisk Halts Ozempic Kidney Trial. Why It's Bad for DaVita.
- Novo Nordisk's Ozempic already is poised to disrupt a range of industries via its weight-loss benefits. Now it threatens companies which treat kidney failure.
- 10/11/2023
|
Novo Nordisk shares rise, Silk Road Medical stock slumps and other movers
- Shares of Thor Industries Inc. THO rose 2% after the RV maker said its board authorized a 7% dividend increase to 48 cents a share.
- 10/11/2023
|
Novo Nordisk to stop Ozempic trial to treat renal impairment early
- Denmark-based drugmaker Novo Nordisk said on Tuesday it will stop a trial studying Ozempic, its popular diabetes and weight-loss drug, to treat renal impairment in diabetes patients, as its independent data monitoring board concluded the drug had met efficacy criteria in an interim analysis.
- 10/10/2023
|
How Ozempic and Wegovy turned Novo Nordisk into a $400 billion company
- How Ozempic and Wegovy turned Novo Nordisk into a $400 billion company
- 10/10/2023
|
Novo Nordisk (NVO) Stock Drops Despite Market Gains: Important Facts to Note
- In the closing of the recent trading day, Novo Nordisk (NVO) stood at $92.06, denoting a -0.07% change from the preceding trading day.
- 10/09/2023
|
How Ozempic Accidentally Made Novo Nordisk A $400B Company
- Pharmaceutical giant, Novo Nordisk, is now Europe's most valuable company, worth more than its home country, Denmark's total economy. That wasn't always the case, and only recently, through its popular diabetes and weight-loss drugs, Ozempic and Wegovy, is it witnessing unprecedented financial success.
- 10/09/2023
|
3 No-Brainer Growth Stocks to Buy in October
- Eli Lilly is crushing the market because of its impressive product lineup and strong prospects. Novo Nordisk is just getting warmed up with a massive opportunity for Ozempic and Wegovy.
- 10/07/2023
|
Better Growth Stock: Novo Nordisk vs. Pfizer
- Pfizer has been actively acquiring companies as it looks to bolster its future growth prospects. Novo Nordisk's top weight-loss drug has more than quadrupled sales and there's more growth ahead.
- 10/06/2023
|
2 Reasons Why Eli Lilly's Mounjaro Might Beat Novo Nordisk's Ozempic, and 2 Reasons Why It Might Not
- Ozempic and Mounjaro are key drugs for Novo Nordisk and Eli Lilly, respectively. Both treat most of the same conditions, and both are major drivers of earnings.
- 10/06/2023
|
Both Wall Street and food companies are overreacting to weight-loss drugs, say Herb Greenberg
- Hosted by Brian Sullivan, “Last Call” is a fast-paced, entertaining business show that explores the intersection of money, culture and policy.
- 10/05/2023
|
Wegovy class has higher GI side effect risk than older weight loss drug in study
- Medicines in the same class as Novo Nordisk's popular weight-loss therapy Wegovy may carry an increased risk of pancreatitis, intestinal blockage, and stomach paralysis compared to an older obesity drug, according to a study published on Thursday.
- 10/05/2023
|
Weight loss drugs may be linked to stomach paralysis, other rare but severe issues, study says
- The study comes as Novo Nordisk's Wegovy, Ozempic and similar treatments skyrocket in popularity in the U.S. for causing dramatic weight loss over time.
- 10/05/2023
|
Novo Nordisk's Wegovy and Ozempic US patents to be examined by appeal board
- One of Novo Nordisk's (NYSE:NVO) US patents for its blockbuster weight-loss drugs Ozempic and Wegovy will be reviewed by the US Patent Office after it was questioned by generic drugmaker Mylan Pharmaceuticals, which had two other petitions over the drugs rejected earlier in the week. Mylan wants to make generic versions of the drugs.
- 10/05/2023
|
Here's the Best Big Pharma Stock of the Decade so Far (and It's Not Even Close)
- There have been relatively few big winners among pharma stocks so far in the 2020s. One big pharma stock stands out as the clear leader by roughly tripling over the last nearly four years.
- 10/05/2023
|
Focus: Novo Nordisk's Wegovy bonanza looms large in Denmark
- The whirlwind success of weight-loss treatment Wegovy is providing a bonanza not just for its developer, Novo Nordisk , but also for its home country of Denmark.
- 10/05/2023
|
Novo Nordisk receives US regulatory go ahead for kidney treatment
- Europe's largest drugs company, Novo Nordisk (NYSE:NVO), told investors its once-monthly injection, Rivfloza, has received approval from the US Food and Drug Administration (FDA) for treating a rare genetic kidney condition known as primary hyperoxaluria. Rivfloza employs RNA interference technology (RNAi) to silence or neutralise genes that contribute to the disease.
- 10/03/2023
|
US Patent Office won't review two Novo Nordisk patents for Wegovy, Ozempic
- A U.S. Patent Office tribunal on Monday rejected challenges to two key patents owned by Novo Nordisk covering the active ingredient in its weight-loss and diabetes drugs Wegovy and Ozempic brought by a generic drugmaker that is hoping to sell generic versions of the blockbuster medications.
- 10/02/2023
|
US FDA approves Novo Nordisk's therapy for rare genetic condition
- Novo Nordisk said on Monday the U.S. Food and Drug Administration (FDA) had approved its therapy to treat a rare genetic condition that affects the kidneys.
- 10/02/2023
|
Stable Giants: 3 Bigwig Biotech Stocks for Consistent Returns
- Biotech stocks have had a rough post-pandemic. In a year where the S&P500 is up more than 10% year to date, the biotech sector is still negative to flat.
- 10/02/2023
|
3 Stocks to Focus on as Demand for Obesity Drugs Booms
- The market for obesity and weight management drugs is attracting a lot of interest lately in the United States. Patients are gradually understanding the benefits of obesity drugs like Novo Nordisk's NVO Wegovy.
- 09/29/2023
|
Novo Nordisk India head eyes 2026 Wegovy launch, warns against copycats
- Danish drugmaker Novo Nordisk aims to bring its blockbuster weight-loss drug Wegovy to India in 2026, after securing regulatory approvals and ensuring it has enough supply to meet demand, a top company official told Reuters.
- 09/29/2023
|
3 Biotech Stocks to Watch Ahead of Potential Obesity Drug Approvals
- The companies that already have obesity drugs can't keep up with the demand for their treatments, and the demand for the drugs is only likely to become more intense. That's because over 42% of the U.S. population was obese as of 2020, while the pervasive publicity around these drugs will make them more popular, and the social and political pressure for insurers to cover the treatments will become more intense.
- 09/28/2023
|
Is Novo Nordisk a Good Passive Income Stock?
- Novo Nordisk has the income flow to pay a dividend for the long term. It also has a pipeline full of candidates to keep the growth going.
- 09/28/2023
|
US prescriptions for Ozempic and other weight loss drugs surged to 9 million in 4Q 2022
- Ozempic, Wegovy and other diabetes/weight loss drugs were prescribed more than 9 million times in the US during the fourth quarter of 2022, according to a new report. A Trilliant Health analysis of insurance claims from about 300 million Americans found that prescriptions for the drugs quadrupled from early 2020 to the end of 2022.
- 09/27/2023
|
Novo Nordisk Wegovy surge to continue, says Stifel
- Novo Nordisk (NYSE:NVO)'s stellar growth is unlikely to slow this year, according to Stifel, which was updating its views after a call with the Danish pharma's management. “Our main takeaway is that we should not expect any inflexion in the strong growth momentum that it had year-to-date,” said the broker.
- 09/27/2023
|
2 Magnificent Dividend Stocks to Buy Right Now
- High-quality dividend stocks frequently produce market-beating returns over the long term. Eli Lilly and Novo Nordisk are two blue-chip dividend stocks with rock-solid payouts and strong growth prospects.
- 09/26/2023
|
Novo Nordisk (NVO), Valo Ink Deal to Develop Heart Disease Drugs
- Novo Nordisk (NVO) collaborates with Valo Health to discover and develop novel treatments for cardiometabolic diseases using Valo's proprietary drug development platform.
- 09/26/2023
|
Novo Nordisk and Valo Health to Use AI to Develop Treatments for Cardiometabolic Diseases
- Denmark's Novo Nordisk (NVO) struck a deal with U.S.-based health tech firm Valo Health to use artificial intelligence (AI) to discover and develop treatments for cardiometabolic diseases such as heart attack, stroke, and diabetes.
- 09/25/2023
|
Morgan Stanley sees biopharma sector as a 'safe haven'
- Morgan Stanley (NYSE:MS) expects the EU biopharma sector to offer a safe haven from weakening growth/higher real yields. “Whilst we continue to favour growth/innovation narratives in biopharma over the long-term, we expect investors to reward earnings upgrade stories - Novo Nordisk, Novartis, AstraZeneca - in the near-term,” it said.
- 09/25/2023
|
Novo Nordisk announces AI collaboration with Valo Health for cardiometabolic treatments
- Novo Nordisk (NYSE:NVO) has announced a collaboration with Valo Health to discover and develop novel treatments for cardiometabolic using Valo's artificial intelligence (AI)-powered Opal Computational Platform. Under the agreement, the two organizations will leverage Opal for access to real-world patient data, AI-enabled small molecule discovery and Biowire human tissue modelling platform designed to speed up the discovery and development process.
- 09/25/2023
|
Novo Nordisk partners with Valo Health on AI drug discovery
- Novo Nordisk NVO, +0.01% on Monday announced a partnership with Valo Health Inc., a technology company specializing in AI-powered drug discovery and development, to focus on new cardiometabolic drug programs. The Danish pharmaceutical giant, maker of Ozempic and Wegovy, has also licensed three preclinical cardiovascular drug discovery programs from Valo, the companies said in a release.
- 09/25/2023
|
The disruptive effect of weight loss drugs like Ozempic could have surprising impacts on the stock market. Here are potential winners and losers.
- The potential ripple effects of GLP-1 weight loss drugs like Ozempic and Wegovy are far-reaching. There could be reduced demand for junk food and increased demand for athletic brands.
- 09/24/2023
|
Where Will Novo Nordisk Stock Be in 5 Years?
- Revenue is up 29% this year as Wegovy and Ozempic have been in high demand. Sales could go even higher as the company sorts out manufacturing issues.
- 09/22/2023
|
Novo Nordisk: Catching The Falling Knife Now Could Really Hurt
- Novo Nordisk shares reached all-time highs in September but have since dropped nearly 10%. Buyers must question whether peak optimism has been priced in. With an "F" valuation grade, it isn't the time to be aggressive unless robust buying sentiments justify the market's conviction to push for higher levels. Novo Nordisk's growth could slow further through FY27, suggesting much of its medium-term upside could have been reflected.
- 09/22/2023
|
Why Novo Nordisk Stock Was Tumbling on Thursday
- An analyst reiterated his recommendation and price target. Unfortunately, that recommendation is the equivalent of a sell.
- 09/21/2023
|
Why Novo Nordisk Stock Edged Higher Today
- The company inked yet another supply deal with a European healthcare tech specialist. Also, an analyst reiterated his buy recommendation on the Wegovy maker.
- 09/20/2023
|
Novo Nordisk: What The Stock Split Means For Traders And Investors
- Danish diabetes care giant Novo Nordisk is splitting its shares, with the Danish-listed B shares splitting on September 13 and the NYSE-listed ADRs splitting on September 20. This split marks a milestone in Novo Nordisk's share price appreciation, as well as making the size of options contracts more manageable to smaller investors. Novo Nordisk is one foreign stock where I prefer to trade the US ADR over the foreign local share because the US ADRs have liquid options.
- 09/20/2023
|
Flee to Healthcare Stocks if Recession Rears its Head?
- If you're looking for a sector that's on sale, look to healthcare. The Health Care Select Sector SPDR Fund NYSEARCA: XLV is down 2.50% in the past month, lagging the S&P 500.
- 09/20/2023
|
Ypsomed signs autoinjector supply deal with Novo Nordisk
- Swiss medical technology company Ypsomed announced on Wednesday a long-term supply agreement with Novo Nordisk for autoinjectors, as the Danish drugmaker struggles to keep up with demand for its new Wegovy drug.
- 09/20/2023
|
Novo Nordisk to establish insulin production in South Africa
- Novo Nordisk (NYSE:NVO) wants to produce insulin in South Africa along with a partner to treat diabetics across the African continent, it said. In a statement, the Danish pharmaceutical giant said it will work with Aspen SA Operations and Aspen Pharmacare (JSE:APN) in South Africa to produce 16 million vials next year which could treat 1.1 million people annually.
- 09/19/2023
|
Novo Nordisk contracts South Africa's Aspen to produce insulin for African nations
- Novo Nordisk said on Tuesday is has contracted Aspen Pharmacare to produce human insulin on its behalf in South Africa for export to African countries through a low-cost government tender system.
- 09/19/2023
|
Novo Nordisk shares fall after media report on quality lapses at US plant
- Novo Nordisk, a pharmaceutical company, experienced a decline in its stock prices following a report by financial news agency MarketWire.
- 09/18/2023
|
Why Novo Nordisk Stock Dipped Today
- A media report highlighted the struggles the company has faced in manufacturing its highly popular drug. That drug, Wegovy, is flying off pharmacy shelves thanks to its weight-loss qualities.
- 09/18/2023
|
Novo Nordisk shares fall after media report about quality lapses at U.S. plant
- Novo Nordisk's shares fell on Monday after financial news agency MarketWire reported that U.S. drug regulators had recently issued a report detailing quality control lapses at the group's Clayton, North Carolina plant, citing sources.
- 09/18/2023
|
3 Stock-Split Stocks Billionaire Investors Can't Stop Buying
- Eight high-flying stocks have conducted forward-stock splits over the past two years, with another on the way later this week. Some of Wall Street's most prominent billionaire fund managers have gravitated to three stock-split stocks.
- 09/18/2023
|
Ozempic maker Novo Nordisk isn't just Europe's second-most valuable company. It is also singlehandedly boosting Denmark's economy.
- Ozempic-maker Novo Nordisk is Europe's second-largest company by market capitalization. It's also boosting Denmark's economy all on its own.
- 09/18/2023
|
Yet Again, Ozempic Could Soon Get Even Better for Novo Nordisk Stock
- Ozempic is Novo Nordisk's crown jewel, and it's wildly successful so far. Researchers just found that it could also be useful for treating type 1 diabetes.
- 09/16/2023
|
3 (Bad) Reasons to Avoid or Sell Novo Nordisk Stock
- It's easy to get scared by arguments in favor of selling a stock. Novo Nordisk stock is flying to new heights thanks to its sales of Ozempic.
- 09/15/2023
|
3 Top Healthcare Stocks Defying the Bear Market
- Medtronic delivers a solid dividend as well as strong returns. CRISPR Therapeutics could soon have its first approved therapy on the market.
- 09/15/2023
|
Novo Nordisk (NVO) Announces Stock Split to Enhance Liquidity
- Novo Nordisk (NVO) conducts a two-for-one stock split. While this is already in effect at the stock exchange in Denmark, the ADRs listed on the NYSE will be split in the same ratio by next week.
- 09/14/2023
|
Novo Nordisk owner invests $290 mln in energy transition fund
- The controlling shareholder in drugmaker Novo Nordisk on Thursday announced a major investment in a new energy transition fund as it expands its portfolio beyond health.
- 09/14/2023
|
This Stock Is Lifting an Entire Country's Economy -- Is It a Buy?
- Novo Nordisk has been a meaningful contributor to growth of the Danish economy lately. The company's financial results are excellent thanks to a portfolio of diabetes and obesity drugs.
- 09/14/2023
|
Should You Buy Ozempic Maker Novo Nordisk Before Its Stock Split?
- Novo Nordisk plans to conduct a 2-for-1 stock split on Sept. 20, increasing share count and reducing share price.
- 09/14/2023
|
Is This a Dead-Cat Bounce? 3 Must-Buy Stocks Just in Case.
- After rallying 17% higher in 2023, volatility now rules the S&P 500. Sharp swings higher and lower has the popular benchmark sitting below its August highs.
- 09/13/2023
|
Should You Buy NVO Stock Ahead of the Novo Nordisk Stock Split?
- One of today's top trending names is Novo Nordisk (NYSE: NVO ). The Danish pharmaceutical producer has seen its international profile grow this year due to the success of Ozempic.
- 09/13/2023
|
"Blockbuster Status": 3 Bios to Buy and Hold
- The biotech sector is notorious for its sky-high R&D costs, regulatory hurdles, and lengthy timelines to bring a drug to market. Stock Strategist Andrew Rocco unveils 3 biotech stocks that have broken through and are set up for long term growth.
- 09/13/2023
|
Novo Nordisk shares slip on two-for-one stock split
- Novo Nordisk (NYSE:NVO) shares moved lower after the Denmark-based healthcare company announced its board of directors has approved a two-for-one stock split of its B shares listed on the Nasdaq Copenhagen and its American Depository Receipts (ADRs) listed on the New York Stock Exchange. The company said its B shares listed on the Nasdaq Copenhagen in trading units of DKK 0.20 have been changed to DKK 0.10 as of September 13, 2023.
- 09/13/2023
|
Wall Street Lunch: August CPI Won't Phase The Fed
- August consumer price index aligns with forecasts, Core CPI rose +0.3%. American Airlines lowers Q3 guidance; S&P cuts rating on Advance Auto Parts.
- 09/13/2023
|
Why Is Novo Nordisk (NVO) Stock Up 95% Today?
- Novo Nordisk (NYSE: NVO ) stock is on the rise Wednesday after the pharmaceutical company announced a split of its shares. According to a press release from Novo Nordisk, shares of NVO stock are undergoing a two-for-one split this morning.
- 09/13/2023
|
US FDA uncertain about supply timeline of Novo Nordisk's weight loss drug
- U.S. Food and Drug Administration on Tuesday changed its estimate for the availability of lower doses of Novo Nordisk's weight-loss drug Wegovy to "to be decided" from its earlier expectation of September.
- 09/12/2023
|
Pound for Pound: 3 Buzzworthy Drug Stocks Worth Their Weight in Gold
- Weight-loss drugs are taking the U.S. by storm. JPMorgan Chase (NYSE: JPM ) is forecasting that the market for weight-loss medications could reach $100 billion in annual sales.
- 09/11/2023
|
Ozempic, Wegovy may curb drinking, smoking and other addictive behaviors – here's what we know
- Scientists hope that a new class of treatments for alcohol use disorder, smoking and other addictive behaviors is on the horizon.
- 09/10/2023
|
Big pharma's blockbuster obesity drug battle is just getting started, and it's headed for $100 billion
- As Novo Nordisk and Eli Lilly duke it out in the weight-loss drug market with Ozempic, Wegovy and Mounjaro, drug company competitors plan to join the fray.
- 09/09/2023
|
3 Top Healthcare Stocks to Buy for September
- UnitedHealth Group is a foundational piece of the healthcare system in America. Demand for Pfizer's Covid vaccine may have waned, but profits are going to good use.
- 09/09/2023
|
The economic cost of obesity is expected to soar to $4 trillion by 2035. Weight loss drugs like Ozempic could change that, Goldman Sachs says.
- The rise in obesity is having a massive impact on the global economy, according to Goldman Sachs. The bank estimates that obesity will drag down the world's GDP by $4 trillion in 2035.
- 09/08/2023
|
1 Stock Split Stock to Buy Hand Over Fist Right Now
- Novo Nordisk is seeing unprecedented growth as demand surges for its diabetes and weight-loss treatments. Following its Q2 earnings release, the company announced a 2-for-1 stock split, which is set to occur shortly.
- 09/08/2023
|
Mizuho's Jared Holz reacts to JPMorgan's huge obesity drug call
- Jared Holz, Mizuho, joins 'Fast Money' to talk JPMorgans $100 billion call on weight loss drugs.
- 09/07/2023
|
The 3 Best Stocks to Buy Now: September 2023
- With the United States economy demonstrating strong performance recently, Federal Reserve officials are considering to double their 2023 growth projections. Economic data has consistently exceeded analysts' and economists' expectations, prompting the unofficial estimate from the Atlanta Federal Reserve to suggest a 5.6% annualized expansion in Q3 2023.
- 09/07/2023
|
Why Novo Nordisk Stock Topped the Market on Thursday
- The JPMorgan Chase analyst team tracking the European pharmaceutical company boosted its price target. "Boosted" might be an understatement, as the figure was raised by 25%.
- 09/07/2023
|
Weight-Loss Drug Market Can Hit $100 Billion, J.P. Morgan Says.
- Eli Lilly and Denmark's Novo Nordisk are expected to roughly split the market for weight-loss drugs, both as diabetes and obesity treatments.
- 09/07/2023
|
Wegovy drugmaker Novo Nordisk to make $70bn a year from weight-loss alone, as analysts await full SELECT trial data
- As researchers work to test whether Novo Nordisk (NYSE:NVO)'s fat-busting drug Wegovy can also be used as a treatment for dementia and alcohol addiction, some analysts are pointing to a potential "paradigm shift" in the way obesity is treated. Last week the Danish drugmaker, which is listed in Copenhagen and New York, briefly became Europe's largest company as investors continued to pile in following the initial data of its 'SELECT' trial of a once-weekly injection of Wegovy.
- 09/07/2023
|
Is Novo Nordisk Stock a Buy Now?
- Novo Nordisk makes multiple weight loss and diabetes drugs, including Wegovy and Ozempic. Demand has been so strong the company has been using multiple contract manufacturers.
- 09/07/2023
|
1 Weight-Loss Stock That's Been a Hotter Buy Than Eli Lilly and Novo Nordisk This Year
- Shares of WW International have been soaring this year as a result of some promising drugs. Even companies that aren't involved in making the drugs have piggybacked on the hype.
- 09/07/2023
|
Novo Nordisk Is Already Working on Ozempic 2.0. Here's How to Profit
- Novo Nordisk is keen to replicate Ozempic's success. It just made two acquisitions that could lead to another big victory.
- 09/07/2023
|
3 Nasdaq Stocks to Sell in September Before They Crash & Burn
- Due to what could be an unsustainable rally for equities, you may be looking for Nasdaq stocks to sell now. We've had an incredible run this year, but there are some additional indiciations that our luck has come to an end.
- 09/07/2023
|
CHART OF THE DAY: Ozempic maker Novo Nordisk overtakes LVMH to become the biggest company in Europe
- Novo Nordisk is now the biggest company in Europe with a valuation of more than $425 billion. The biotech company has taken over luxury goods maker LVMH in market cap size.
- 09/06/2023
|
How Novo Nordisk, Wegovy And Ozempic Are Changing The Weight Loss Game For Patients And Investors
- Novo Nordisk, the maker of Ozempic, for diabetes, and Wegovy, for obesity, is seeing revenue going off the scale. In fact, Wegovy saw a 344% gain in sales in just the first six months of 2023 in the U.S. alone.
- 09/05/2023
|
Novo Nordisk (NVO) Launches Wegovy in UK Amid Supply Issues
- Novo Nordisk (NVO) announces the controlled and limited launch of Wegovy in the U.K. amid rising demand for weight loss treatment and supply constraints.
- 09/05/2023
|
Novo Nordisk Becomes Europe's Most Valuable Company as Wegovy Launches in UK
- American depositary receipts of Novo Nordisk (NVO) climbed 1.5% in early trading on Tuesday after launching its popular weight-loss drug, Wegovy, in the U.K.
- 09/05/2023
|
Novo Nordisk Is Now Europe's Biggest Company, Driven by Weight-Loss Drug. How Eli Lilly Could Benefit.
- The pharma company's Wegovy medication helps it overtake luxury goods maker LVMH, with a market value of around $420 billion.
- 09/05/2023
|
Wegovy supply from Novo Nordisk has arrived in UK, Simple Online Pharmacy says
- UK-based Simple Online Pharmacy has received stock of Novo Nordisk's weight-loss drug Wegovy, a company spokesperson said on Tuesday, one day after Novo launched the drug in Britain.
- 09/05/2023
|
Novo Nordisk rolls out its weight loss drug Wegovy in the U.K.
- Novo Nordisk A/S (NYSE: NVO) is in focus on Monday after it launched its weight loss drug in another European market – the United Kingdom. Novo Nordisk is facing supply constraints But the pharmaceutical behemoth did confirm that the weekly injection will initially be available via NHS only to a limited number of eligible patients.
- 09/04/2023
|
Pent-up private Wegovy demand prompts UK availability concerns
- People in Britain who can afford to pay out of their own pocket may get easier access to Novo Nordisk's weight-loss drug Wegovy than those seeking treatment in the country's state-run health service, some doctors and medical experts warned on Monday.
- 09/04/2023
|
‘Miracle' weight-loss drug Wegovy will not be issued through major insurers
- Several prominent UK-based insurers including Aviva, Axa, and WPA will not cover the costs of the newly launched weight-loss drug, Wegovy, under their private medical insurance policies. Since insurers typically cover acute conditions, which are characterised as diseases, illnesses, or injuries that are likely to respond quickly to treatment, the so-called “miracle” obesity drug developed by Novo Nordisk (NYSE:NVO) does not qualify.
- 09/04/2023
|
Novo Nordisk's Wegovy weight loss drug launches in the UK
- Novo Nordisk launched its Wegovy weight loss injection in the U.K. Monday, furthering the drug's rollout in Europe despite ongoing supply constraints.
- 09/04/2023
|
Factbox: Launches of Novo Nordisk's weight-loss drug Wegovy
- Novo Nordisk is pushing ahead with the launches of weight-loss drug Wegovy in Europe even as it struggles to keep up with demand. The Danish drugmaker is working to convince European governments and insurers to reimburse the drug, seeking to position it as more than a lifestyle drug.
- 09/04/2023
|
Weight-Loss Drug Wegovy Launches In U.K. As Shares Of Drugmaker Novo Nordisk Hit New Peak
- In August, Novo Nordisk's CEO said it could “take quite some years” for the company to meet soaring demand for the popular drug.
- 09/04/2023
|
Novo Nordisk launches weight-loss drug Wegovy in UK
- Novo Nordisk launched its weight-loss injection Wegovy in Britain on Monday, its second debut in Europe in just over a month as the drugmaker seeks to expand in the region even as it struggles to keep up with soaring demand.
- 09/04/2023
|
Novo Nordisk briefly becomes Europe's No1 as investors binge on weight-loss stocks
- Novo Nordisk (NYSE:NVO) became Europe's largest company for a short time today as investors continued to pile into the Danish drugmaker following the recent trial of fat-busting drug Wegovy. Shares in Novo have jumped 17% since the trial showed that not only can Wegovy trim the waistline but cuts the risk of heart attack or stroke by a fifth.
- 09/01/2023
|
How Much Pain Will Lower Medicare Prices Cause for Pharma Stocks?
- Major pharmaceutical companies including Johnson & Johnson NYSE: JNJ, Novartis AG NYSE: NVS, Bristol-Myers Squibb (NYSE: BMY), Merck & Co., Inc. NYSE: MRK, Eli Lilly & Co. NYSE: LLY and Amgen Inc. NASDAQ: AMGN were trading normally following news that their drugs would be subject to next year's Medicare price negotiations.
- 09/01/2023
|
Ozempic could be the next target of Medicare drug price negotiations – here's why
- Wall Street analysts expect Ozempic to be selected for price negotiations in 2025 due to the amount of money Medicare Part D already spends on the drug.
- 08/31/2023
|
Novo Nordisk: Strong Fundamentals Meet Technical Uptrends
- Novo Nordisk is making strides in the weight loss and diabetes care markets, with strong financial performance and a diverse product portfolio. The company faces competition from Eli Lilly's GLP-1 treatment, but the expected market growth leaves room for multiple winners. Novo Nordisk's stock price displays a solid bullish trend, with potential for continued gains, but investors should be aware of potential price corrections.
- 08/30/2023
|
Novo Nordisk CEO: Not exactly clear yet what Medicare price negotiations will do for financials
- Lars Fruergaard Jørgensen, Novo Nordisk CEO, joins 'Squawk on the Street' to discuss what's known about the White House's negotiations for specific drug prices, long-term worries about suppressed R&D activity, and much more.
- 08/30/2023
|
Wegovy Maker Novo Nordisk Buys Embark Biotech to Boost Edge in Weight Loss Treatments
- Wegovy maker Novo Nordisk (NVO) agreed to buy Embark Biotech for €15 million ($16 million) in cash upfront, in a move that could boost Novo Nordisk's portfolio of weight loss treatments. In addition, Embark shareholders could receive up to €456 million ($500 million), depending on whether certain commercial milestones are reached.
- 08/30/2023
|
What the medicare decision means for pharma stocks
- Jared Holz, Mizuho, joins 'Fast Money' to talk the Biden Administration unveiling the first 10 drugs subject to medicare price negotiations and how pharma stocks are responding.
- 08/29/2023
|
Cantor's Louise Chen breaks down new Medicare drug pricing negotiations
- Louise Chen, Cantor Fitzgerald, joins 'Power Lunch' to discuss Medicare drug priced ahead of Biden's news conference on the negotiations.
- 08/29/2023
|
10 Drugs Selected for Medicare Price Reduction
- We're getting Case-Shiller home price numbers ahead of the opening bell this morning, but there's not enough time to dig into it. Give us till this afternoon to speak about these.
- 08/29/2023
|
Insulins and blood thinners among first 10 drugs up for Medicare price negotiations
- The Biden administration has revealed the first 10 prescription drugs that will be subject to price negotiations between manufacturers and the U.S. health program Medicare with the aim of reducing out-of-pocket costs for a range of drugs including insulins and blood thinners for Americans aged 65 and older. “There is no reason why Americans should be forced to pay more than any developed nation for life-saving prescriptions just to pad Big Pharma's pockets,” U.S.
- 08/29/2023
|
Does the Red-Hot Weight-Loss Market Make This Pharmaceutical Stock a Buy?
- Novo Nordisk has seen huge success with Ozempic, which treats type 2 diabetes. Now, it has followed up with a similar drug, Wegovy, for addressing obesity.
- 08/29/2023
|
Why Wegovy's Sales Potential Could Be Massively Understated
- Wegovy may generate more than $4 billion in revenue this year for Novo Nordisk. A recent study showed the weight-loss drug can also help people bring down their risk of heart attack or stroke.
- 08/29/2023
|
Novo Nordisk (NVO) Posts Upbeat Data From Heart Failure Study
- Novo Nordisk (NVO) announces positive results from its label-expanding study of Wegovy to treat patients with heart failure and obesity.
- 08/25/2023
|
Novo Nordisk's Wegovy Helped Heart-Failure Patients. What's Next?
- Proof that new weight-loss drugs will transform healthcare was bolstered with the news that heart-failure patients were helped by Novo Nordisk's drug Wegovy.
- 08/25/2023
|
Novo Nordisk obesity drug Wegovy eases symptoms of heart failure, study finds
- The Novo Nordisk NVO, -2.47% obesity drug semaglutide, marketed as Wegovy, can significantly reduce symptoms related to heart failure, according to a study published Friday in the New England Journal of Medicine. On a questionnaire measuring the symptoms and physical limitations of heart failure with preserved ejection fraction, patients on Wegovy showed an average increase of 16.6 points at 52 weeks, compared with 8.7 points on placebo, according to the study.
- 08/25/2023
|
Novo Nordisk CEO Lars Fruergaard Jorgensen at Reuters Newsmaker event
- Novo Nordisk CEO Lars Fruergaard Jorgensen spoke at a Reuters Newsmaker event on Friday. Below are some quotes from his interview which focused on the company's hugely popular Wegovy weight-loss drug.
- 08/25/2023
|
Novo Nordisk to address social inequality in dialogue with healthcare systems -CEO
- Novo Nordisk CEO Lars Fruergaard Jorgensen said on Friday the company will work with European government healthcare systems to ensure less fortunate and the most obese people get access to its Wegovy weight-loss drug.
- 08/25/2023
|
This New Development Is Helping to Send Eli Lilly and Novo Nordisk Stocks Soaring
- A new study by Novo Nordisk points to GLP-1 drugs reducing cardiac risks. It's a relevant finding for Eli Lilly, too, which is already moving forward in clinical trials.
- 08/24/2023
|
3 Massive New Markets Could Await Ozempic, And They Might Make Novo Nordisk Investors Richer
- The active ingredient in Ozempic could be useful for quite a few conditions. Cardiovascular disease, certain chronic liver diseases, and addiction are just a few.
- 08/24/2023
|
Why Novo Nordisk Stock Was Racing Higher on Wednesday
- Not surprisingly, this had to do with its highly popular weight-loss drug. A second contract manufacturer for Wegovy has been identified.
- 08/23/2023
|
Could This 1 Problem Put a Dent in Novo Nordisk and Eli Lilly Stock?
- Novo Nordisk and Eli Lilly want to use their medicines to treat NASH, a liver disease. Their chances of success are more uncertain than shareholders might wish to see.
- 08/22/2023
|
These 3 Large-Cap Pharma Stocks Have Been Red-Hot
- Large-cap pharmaceuticals have enjoyed buying pressure over the last month, delivering outsized gains to investors. And these three stocks have helped lead the charge.
- 08/21/2023
|
How soaring demand for Ozempic and Wegovy is altering Denmark's economy
- The dazzling success of weight-loss drugs in the United States is leading to lower interest rates in Denmark, home of one of their biggest manufacturers, according to the Nordic country's biggest bank.
- 08/21/2023
|
5 Large Drug Stocks to Watch as New Drug Approvals & M&A Gain Pace
- Drug, biotech companies are likely to see significant innovation. In the Large-Cap Pharmaceuticals industry, Eli Lilly (LLY), J&J (JNJ), Novo Nordisk (NVO), Novartis (NVS) and AstraZeneca (AZN) are worth retaining in your portfolio.
- 08/21/2023
|
Ozempic Just Got Even Better for Novo Nordisk Stock
- Ozempic is practically flying off the shelves to treat diabetes and obesity. The drug could also be useful in reducing cardiac event risk, per a new study.
- 08/20/2023
|
3 Fantastic Stocks to Buy in a New Bull Market
- Eli Lilly has explosive growth potential. Novo Nordisk is worth its premium price tag.
- 08/20/2023
|
Americans are paying dramatically higher prices for weight-loss drugs like Ozempic, report finds
- Weight-loss drugs are substantially more expensive in the US than in other comparably large, high-income countries, according to a new analysis from the health policy organization KFF. The analysis compared list prices (ie.
- 08/18/2023
|
3 Buy-Rated Stocks Displaying Notable Price Strength
- Many stocks have displayed relative strength in the recent term, providing investors with sizable gains.
- 08/16/2023
|
Wegovy could prevent up to 1.5 million heart attacks, strokes over 10 years, study says
- The results complement the data Novo Nordisk released last week, which found Wegovy slashed the risk of serious heart problems and heart-related death by 20%.
- 08/16/2023
|
Prediction: These 2 Stocks Could Double by 2030
- Growing revenue, an improving bottom line, and exciting opportunities paint a bright future for Exact Sciences. Novo Nordisk is virtually unmatched in the diabetes drug market, with more potential medicines on the way.
- 08/16/2023
|
Novo Nordisk (NVO) Rides on Ozempic & Wegovy Amid Rivalry
- Novo Nordisk (NVO) continues to witness increasing demand for its diabetes and obesity care products like Ozempic, Wegovy and Rybelsus amid rising competition from other pharma bigwigs.
- 08/15/2023
|
2 Stocks That Raised EPS but Lowered Revenue Estimates
- Growth or value? Top or bottom line?
- 08/14/2023
|
Why Novo Nordisk Stock Soared 16% This Week
- Novo Nordisk rose on news of encouraging outcomes for its SELECT trial of weight loss drug semaglutide. The Danish pharmaceutical leader also raised its full-year sales and profit outlook after posting strong first-half 2023 results.
- 08/12/2023
|
3 Reasons Why Novo Nordisk (NVO) Is a Great Growth Stock
- Novo Nordisk (NVO) is well positioned to outperform the market, as it exhibits above-average growth in financials.
- 08/11/2023
|
Novo Nordisk raises full-year outlook as Wegovy sales skyrocketed in 2Q
- Novo Nordisk (NYSE:NVO) has raised its full-year outlook based on a strong first half of 2023 driven by continued high demand for its popular weight-loss drug Wegovy. The Denmark-headquartered global pharmaceutical company expects its sales for 2023 to be up 27% to 33% from the last year, from its prior guidance range of 24% to 30%.
- 08/10/2023
|
Novo Nordisk Boosts Guidance as Sales of Weight-Loss Drug Wegovy Soar
- Novo Nordisk raised its outlook as revenue from its popular weight-loss treatment, Wegovy, skyrocketed.
- 08/10/2023
|
Novo Nordisk reports earnings miss, sees profit and sales growth
- Yahoo Finance Health Care Reporter Anjalee Khemlani breaks down Novo Nordisk's Q2 earnings which included profit up 43% and sales up 30%.
- 08/10/2023
|
Novo Nordisk (NVO) Q2 Earnings and Sales Miss, 2023 View Up
- Novo Nordisk (NVO) reports weaker-than-expected second-quarter 2023 results, missing both earnings and sales estimates. Management, however, raises 2023 guidance.
- 08/10/2023
|
Novo Nordisk to acquire obesity drug maker Inversago Pharma for up to $1 billion
- Inversago's drugs use a different approach than most treatments in the obesity and diabetes space.
- 08/10/2023
|
Novo eyes other health benefits from weight-loss drug Wegovy after major trial
- Novo Nordisk hopes to show additional health benefits from taking its hugely popular drug Wegovy, apart from losing weight and cutting the risk of heart disease, its drug development executive told Reuters on Thursday.
- 08/10/2023
|
Novo Nordisk: weight-loss Wegovy drug's heart benefits will help discussions with payers
- Novo Nordisk expects new data showing the heart benefits of its weight-loss drug Wegovy will help its discussions with public health authorities and other payers about the benefits of paying for it, executives said on Thursday.
- 08/10/2023
|
Novo Nordisk's limits on Wegovy US supply seen into 2024, CEO says
- Novo Nordisk's limits on U.S. supplies of starter doses of its hugely popular Wegovy weight-loss drug will likely last into next year, CEO Lars Fruergaard Jorgensen told Reuters on Thursday.
- 08/10/2023
|
Novo Nordisk to acquire obesity drug developer Inversago
- Danish drug maker Novo Nordisk said on Thursday it would acquire Canadian company Inversago Pharma in a $1.07 billion deal including the development of an appetite regulator.
- 08/10/2023
|
Novo Nordisk, now Europe's second-largest company by market cap, lifts outlook after 46% profit rise
- Novo Nordisk, the Danish drugmaker that's now the second-largest company in Europe by market capitalization, on Thursday reported a 46% rise in profit and lifted its outlook for the year.
- 08/10/2023
|
Wegovy-maker Novo Nordisk sales soar 30% on strong demand for its weight-loss drug
- The Danish company's diabetes and obesity division performed particularly well, bolstered by interest in its blockbuster injections Wegovy and Ozempic.
- 08/10/2023
|
Novo Nordisk hikes FY outlook as demand for weight-loss drug Wegovy soars
- Danish drugmaker Novo Nordisk on Thursday hiked its full-year profit and sales forecast for a second time as its weight-loss and diabetes drugs flew off the shelves in the United States.
- 08/10/2023
|
Fmr. FDA Commissioner Dr. Scott Gottlieb on diabetes drugs: Overall it's being used appropriately
- Former FDA Commissioner Dr. Scott Gottlieb joins 'Squawk Box' to discuss the growing interest in new diabetes drugs, with some showing promise for weight loss and heart disease prevention, the promise & unknowns of such medications, and more.
- 08/09/2023
|
Novo Nordisk Soars To New High On Weight-Loss Drug Trial Results
- Weight-loss drugs are the pharmaceutical industry's equivalent of AI, in the sense of being a product with the capability to send shares soaring. Novo Nordisk A/S NYSE: NVO, maker of Wegovy, saw its stock gap up more than 16% on August 8, after the weight-loss medication demonstrated a noteworthy reduction in the risk of cardiovascular events for overweight adults.
- 08/09/2023
|
Weight loss injections 'can lower heart attack and stroke risk by a fifth'
- Weight loss injections can lower the risk of a heart attack or stroke in obese people with cardiovascular disease by a fifth, a new study has suggested.
- 08/08/2023
|
Novo Nordisk weight loss drug Wegovy cuts heart disease risk by 20%, trial shows
- Novo Nordisk said the results of a late-stage drug trial showed weight loss drug Wegovy also can cut the risk of heart disease in certain patients.
- 08/08/2023
|
Weight-Loss Drug Frenzy Drives Eli Lilly And Novo Nordisk Stock To Record Highs
- Shares of Eli Lilly and Novo Nordisk both soared to record highs on Tuesday, as sales increased of Eli Lilly's Mounjaro and as Novo Nordisk reports a promising clinical trial of its drug Wegovy.
- 08/08/2023
|
Markets Plunge at Midday After Bank Downgrades
- U.S. equities sank at midday on Tuesday, Aug. 8, 2023, following bank downgrades by Moody's and data showing credit card debt rose to a record.
- 08/08/2023
|
Novo Nordisk A/S: A Biotech Giant with High Outperformance Potential
- Novo Nordisk A/S ( NVO , Financial), a leading player in the biotechnology industry, has been making waves in the stock market. As of August 8, 2023, the company's stock price stands at $190.22, with a market capitalization of $425.97 billion.
- 08/08/2023
|
Novo Nordisk ADRs Surge After Wegovy Shown to Reduce Heart Attack, Stroke Risks
- ADRs of Novo Nordisk surged to an all-time high after a study found Novo Nordisk's Wegovy weight-loss drug also helped cut risk of major adverse cardiovascular events by 20%.
- 08/08/2023
|
Novo weight-loss drug Wegovy shows heart benefit in trial
- The trial showed that patients on Wegovy had a 20% lower incidence of heart attack, stroke or death from heart disease compared to those on a placebo, Novo said.
- 08/08/2023
|
Why Eli Lilly, Novo Nordisk, and Viking Therapeutics Are On Fire Today
- Novo Nordisk's popular weight loss drug significantly reduced the risk of heart attack or stroke in a late-stage trial. These data bode well for the obesity drug category at large.
- 08/08/2023
|
The Obesity Drug Revolution Just Got Real
- New data show Novo Nordisk's Wegovy reduces risk of heart attack and stroke, paving the way for greater insurance coverage.
- 08/08/2023
|
Novo Nordisk shares pop after key trial data shows Wegovy cuts risk of heart attack or stroke by 20%
- Jared Holz, Mizuho healthcare sector strategist, joins 'Squawk Box' to discuss the impact of Novo Nordisk's weight-loss drug Wegovy cuts risk of heart attack or stroke by 20%, the obesity drug market at large and what it means for pharmaceutical companies, and more.
- 08/08/2023
|
Novo Nordisk weight loss drug impresses in heart trial
- Novo Nordisk (NYSE:NVO) shares soared as the Danish pharma reported its new treatment Wegovy reduced heart problems well as weight in on ongoing trial. Obesity treatment semaglutide (marketed as Wegovy) met its primary endpoint by reducing cardiovascular events by 20% in adults with overweight or obesity compared with placebo in the trial called Select.
- 08/08/2023
|
Wegovy's success in reducing cardio risk is ‘an important win,' and a ‘best-case scenario,' say Wolfe analysts
- The success of Novo Nordisk's NVO, +3.04% NOVO.B, +13.49% Wegovy in reducing cardiovascular events in obese adults is an important win for the obesity category with positive implications for that company and rival Eli Lilly & Co. LLY, +1.02%, Wolfe Research said Tuesday. “The study aimed to show that losing weight (using Wegovy, in this case) would lower things like heart attacks, and the primary endpoint (a reduction in major adverse cardiovascular events, or MACE) was achieved.
- 08/08/2023
|
Novo Nordisk shares pop after key trial data shows Wegovy cuts risk of heart attack or stroke by 20%
- The results of the trial were seen as a major boost for the firm's hopes of moving beyond Wegovy's image as a "vanity drug."
- 08/08/2023
|
Novo Nordisk says Wegovy reduced risk of adverse cardiovascular events by 20% in adults with obesity in trial
- Novo Nordisk's U.S.-listed stock NVO, +3.04% NOVO.B, +10.32% rose 10% premarket Tuesday, after the company said its obesity treatment semaglutide, marketed as Wegovy, met its main goal in a trial evaluating its ability to reduce cardiovascular events and not just help with weight loss. The Danish company said a 2.4 mg dose of semaglutide reduced the risk of major adverse cardiovascular events by 20% in adults with overweight or obesity in the trial called Select compared with placebo.
- 08/08/2023
|
People are 'scratching and clawing' for negative narrative around obesity drugs: Mizuho's Jared Holz
- Jared Holz, Mizuho healthcare sector specialist, joins 'Fast Money' to talk Eli Lilly earnings, obesity drug demand and more.
- 08/07/2023
|
Novo Nordisk A/S: A Biotech Giant with High Outperformance Potential
- Novo Nordisk A/S ( NVO , Financial), a leading player in the biotechnology industry, is currently trading at $161.48 with a market capitalization of $361.61 billion. The company's stock price has seen a gain of 3.12% today and an overall increase of 2.77% over the past four weeks.
- 08/07/2023
|
3 ‘Strong Buy' Stocks You Should Be Loading Up On Now
- The stock market in 2023 is like night and day compared to last year. After rallying sharply from last September's low points, the Dow Jones Industrial Average, S&P 500 and Nasdaq 100 are each up over 20% so far this year.
- 08/07/2023
|
Novo Nordisk Stock Isn't a Bargain. Here's Why You Should Buy It Anyway.
- Novo Nordisk's valuation is fairly high thanks to its newest weight-loss medicines. Given that it has other medications on the way, its valuation could hold up.
- 08/04/2023
|
Ozempic Could Have a New Multibillion-Dollar Market Opportunity. Is Novo Nordisk Stock a No-Brainer Buy?
- A recent survey found that doctors are most excited about semaglutide in treating NASH. Treating the liver disease could be a massive market over the next few years.
- 08/02/2023
|
Buy These 3 Top-Ranked Stocks for Dividend Growth
- Companies that pay dividends are often well-established, as they generally are no longer experiencing supercharged growth and opt to share profits with shareholders.
- 08/01/2023
|
Is a Surprise Coming for Novo Nordisk (NVO) This Earnings Season?
- Novo Nordisk (NVO) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
- 08/01/2023
|
Why Novo Nordisk Stock Thrashed the Market on Monday
- The Ozempic developer detailed its recent share buybacks. It launched a repurchase program at the end of January.
- 07/31/2023
|
Novo Nordisk weight-loss drug Wegovy launched in Germany, first big EU market
- Novo Nordisk has launched blockbuster weight-loss drug Wegovy in Germany, its first big European market, hoping Germans will pay hundreds of euros out of pocket for a drug that public health insurance plans are so far barred from covering.
- 07/29/2023
|
3 Biotech Stocks to Buy Before Drug Trials End
- Clinical trials can be like a tightrope over a minefield for biotech investors. Only a fraction of drugs even succeed through clinical trials to receive FDA approval.
- 07/28/2023
|
My International Portfolio: Approaching Another Major Milestone And Looking Into Recent Additions
- I'm your main street neighbor investor in his mid-30s sharing his brokerage account investment journey pursuing a dividend growth strategy. Dividends received YTD totaling $4155 up 18% compared to the same period last year. I believe the current market is strained but I keep investing as often as I can to ensure time in the market as opposed to timing the market.
- 07/27/2023
|
Eli Lilly vs. Novo Nordisk: What's the Better Weight-Loss Stock to Buy?
- Eli Lilly has a couple of promising weight-loss treatments that could gain approval in the near future. Novo Nordisk's obesity care revenue doubled in the first quarter -- and stands to go still higher.
- 07/27/2023
|
3 Biotech Stocks You Better Be Buying on Each and Every Dip
- Biotechnology is one of the most exciting and innovative sectors in the market, offering investors the potential for high returns coupled with groundbreaking discoveries. However, due to regulatory hurdles, clinical failures and intense competition, biotech investing also comes with high risks.
- 07/27/2023
|
7 ‘Monster' Stocks to Buy Right Now
- Some of the best-performing stocks, including market monsters helped buoy a rebound in equities. These firms are among the largest corporations in their respective niches and exert significant influence.
- 07/26/2023
|
AI Stocks Lead These 5 Names Near Buy Points
- Artificial intelligence stocks including chipmaker Marvell Technology, Arista Networks and Synopsys, which has launched AI-based chip-design tools, lead this weekend's watch list of five stocks near buy points.
- 07/22/2023
|
2 Unstoppable Growth Stocks That Could Make You Richer in The Next Decade
- Novo Nordisk and MercadoLibre have both delivered excellent results over the past year. Both companies should massively benefit from important long-term trends ahead.
- 07/22/2023
|
As Ozempic/Wegovy frenzy continues, Morgan Stanley lifts forecasts for weight-loss drugs to $77 billion
- Morgan Stanley on Friday lifted its forecast for annual sales of weight-loss drugs to $77 billion, as patient demand for the medicines has outstripped supply and been fueled by a social-media frenzy.
- 07/21/2023
|
3 Healthcare Stocks to Buy as the Market Gets Defensive
- With so much concern about the Federal Reserve and its decision-making implications for forward market trends, investors may do well targeting healthcare stocks. Fundamentally, the underlying sector represents a critical need.
- 07/18/2023
|
Is Novo Nordisk a Top Dividend Stock?
- Novo Nordisk stock pays a below-average dividend yield at current levels. Even so, income investors may still want to consider this name for a few solid reasons.
- 07/17/2023
|
Why Novo Nordisk Stock Flew Higher on Friday
- An analyst initiated coverage of the hot pharmaceutical title with a buy recommendation. This followed new indications that demand for Wegovy is surging.
- 07/14/2023
|
Novo Nordisk says German 4-week Wegovy at highest dose to cost 302 euros
- Novo Nordisk said on Friday its popular weight-loss drug Wegovy will cost 301.91 euros ($338.35) for four weeks of treatment at the highest dose in Germany, as the Danish drugmaker prepares for a market launch in Europe's largest pharmaceutical market at the end of this month.
- 07/14/2023
|
The Blazing Weight-Loss Drug Battle: Can Anyone Unseat Undisputed Leaders Novo Nordisk And Lilly?
- An overweight world is hungry for obesity treatments, driving big forecasts for weight loss drugs. For now, two pharmaceutical stocks own the market.
- 07/13/2023
|
Novo Nordisk (NVO) Falls on EMA Safety Review of Obesity Drugs
- Novo Nordisk's (NVO) important diabetes care and obesity drugs are under review by the EMA's safety committee for the risk of suicidal behavior with its use. The stock falls 3%.
- 07/12/2023
|
3 Biotech Stocks That AI is Loving in July
- Artificial intelligence (AI) has become an invaluable tool for investors seeking opportunities in the stock market. Its ability to analyze large amounts of data and recognize patterns makes it an ally in identifying high-potential stocks.
- 07/12/2023
|
Why Novo Nordisk Stock Sank on Tuesday
- A media report detailed the lack of staying power of weight loss drugs. Novo Nordisk has gained fame and popularity as the developer of one of those, Wegovy.
- 07/11/2023
|
EU medicines regulator is reviewing weight-loss drugs Ozempic and Wegovy for risk of suicidal thoughts and self-harm
- The European Medicines Agency said Tuesday it's reviewing data on the risk of suicidal thoughts and self-harm stemming from the use of the new medicines called GLP-1 receptor agonists, that are used to treat Type 2 diabetes and obesity. The review comes after Iceland's medical regulator reported self-injury and suicidal thoughts in people using Ozempic, Saxenda and Wegovy.
- 07/11/2023
|
DNA Stock Alert: Ginkgo Bioworks Moves Forward With Novo Nordisk Partnership
- Ginkgo Bioworks (NYSE: DNA ) stock is on the move Tuesday after the company announced a continued partnership with Novo Nordisk (NYSE: NVO ). These two companies have been working together on the development of expression systems for pharmaceutical products.
- 07/11/2023
|
The Case For Novo Nordisk: Growth, Dividends, And A New Treatment Frontier
- Novo Nordisk, a global healthcare company, is expected to see significant growth due to its focus on Anti-Obesity Medication and novel GLP-1 therapies, particularly semaglutide-based medications Ozempic, Rybelsus, and Wegovy. Despite current supply constraints, the company's growth potential is high due to the increasing global prevalence of obesity and type 2 diabetes and the expected production increase from a new plant in Clayton, North Carolina. While the company's valuation is high, there is still opportunity for investors to onboard at a fair price.
- 07/10/2023
|
Ozempic faces review over concerns it may trigger suicidal thoughts
- Rapid-weight-loss shot Ozempic, which is manufactured by pharmaceutical company Novo Nordisk, is being probed by European drug-safety regulators after two users reported thoughts of suicide.
- 07/10/2023
|
EU Investigates Ozempic Maker After Reports Of Suicidal Thoughts
- The Danish pharma giant finds itself under scrutiny once again- this time, from European regulators.
- 07/10/2023
|
Ozempic and other weight loss drugs are 'upending the entire idea' of weight loss, reporter says
- Nathan Bomey, Axios Business Reporter and Co-author of the Axios Closer Newsletter, joins Yahoo Finance Live anchors Julie Hyman and Brad Smith to discuss the popularity of prescription weight loss drugs.
- 07/10/2023
|
European regulator to review weight-loss drugs following reports of suicidal thoughts
- Danish firm Novo Nordisk says "patient safety is a top priority" following reports.
- 07/10/2023
|
Wegovy maker Novo Nordisk sues Florida pharmacies over copycat drugs
- Novo Nordisk on Thursday accused three Florida pharmacies of illegally selling products claiming to contain semaglutide, the active ingredient in the Danish drugmaker's weight loss and diabetes drugs Wegovy, Ozempic and Rybelsus.
- 07/06/2023
|
Novo Nordisk spent $11 million on Ozempic promotion
- Novo Nordisk spent $11 million on food and travel for doctors to promote weight loss and type 2 diabetes drug Ozempic. Yahoo Finance Healthcare Reporter Anjalee Khemlani discusses Novo Nordisk's lobbying, as well as Moderna's deal with China.
- 07/06/2023
|
Ozempic Sales Are Soaring -- Here's Why They Could Go Even Higher
- It has been hugely popular for weight loss even though it's not approved for that use. The drug's potential could go far beyond just weight loss and diabetes, however.
- 07/06/2023
|
Novo Nordisk A/S (NVO) Is a Trending Stock: Facts to Know Before Betting on It
- Novo Nordisk (NVO) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
- 06/29/2023
|
Medicare coverage of weight-loss drugs? Don't count on it, analysts say.
- Investors should not bank on Medicare covering the powerful new weight-loss drugs from Eli Lilly & Co. LLY, -1.25%, Novo Nordisk NVO, +0.52% and other drugmakers any time soon, Beacon Policy Advisors said in a report Thursday. A decades-old law generally prohibits Medicare from covering prescription drugs for weight loss.
- 06/29/2023
|
Here's Why Novo Nordisk (NVO) is a Strong Growth Stock
- Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
- 06/27/2023
|
Factbox: Weight-loss drugs: the next gold rush
- Drug developers are chasing an obesity drug gold rush that may be worth up to $100 billion by rolling out treatments that can help lose as much as 24% of weight in less than a year.
- 06/27/2023
|
New developments in weight-loss drugs: Novo Nordisk, Eli Lilly & Pfizer advance studies
- Dr. Angela Fitch, Knownwell chief medical officer and president of Obesity Medicine Association, joins 'Squawk Box' to discuss the advances in weight-loss drugs, what it means for the obesity epidemic in the U.S., and more.
- 06/27/2023
|
Obesity weight loss market will remain a duopoly between Novo Nordisk and Eli Lilly: BofA'S Meacham
- Geoff Meacham, Bank of America Securities, joins 'Fast Money to discuss the state of the weight-loss drug market as Eli Lilly and Novo Nordisk compete for market share.
- 06/26/2023
|
Trial anticipation for weight loss drugs shows they will be popular, says Dr. Kavita Patel
- Dr. Kavita Patel, NBC News medical contributor, joins 'Power Lunch' to discuss the anticipation for weight loss drugs.
- 06/26/2023
|
Weight-loss drugs in development aim to replace injections with pills
- Wall Street's obsession with next-generation obesity and diabetes treatments intensified over the weekend as drugmakers presented new clinical-trial data on the drugs — including weight-loss pills in development that could become alternatives to popular injectables like Wegovy and Ozempic.
- 06/26/2023
|
Novo Nordisk (NVO) Posts Upbeat Once-Weekly Insulin Icodec Data
- Novo Nordisk (NVO) announces encouraging new data from its late-stage ONWARDS 1 and 3 studies on once-weekly basal insulin icodec against once-daily comparators at 52 and 26 weeks, respectively.
- 06/26/2023
|
Novo Nordisk says high-dose experimental obesity pill leads to 15% weight loss
- Novo Nordisk's pill is an oral version of semaglutide, the active ingredient in the Danish company's blockbuster weight loss injections Ozempic and Wegovy.
- 06/26/2023
|
Novo Nordisk to seek approval for oral version of top-selling weight loss treatment
- Novo Nordisk (NYSE:NVO) said on Sunday that it plans to seek US and European regulatory approval of a high-dose oral version of its wight loss drug, semaglutide. Known as Wegovy and Ozempic, the new formulation was shown to be effective in a late-stage trial.
- 06/26/2023
|
Novo Nordisk says obesity pill leads to 15% weight loss; availability "to be determined"
- Drugmaker Novo Nordisk on Sunday said a late-stage trial found that a high-dose oral version of its drug semaglutide helped overweight or obese adults lose 15% of their body weight, which is in line with recent results for other experimental obesity pills.
- 06/25/2023
|
Investing In European Dividend Stocks - Worth The Hassle?
- Europe is a relevant place for investment due to its role as one of the world's leading economic areas. Europe is home to many well-established multinational companies. Major European stock indices have a lower average valuation and a higher dividend yield than the S&P 500. However, the S&P 500 has significantly outperformed these indices in recent years. Some individual European stocks have provided a great total return over the past years. However, there are significant practical challenges linked to diverging currencies, regulations and other factors.
- 06/23/2023
|
There's a 'strong desire' in big pharma to continue to acquire, says JPMorgan analyst
- Juha Anjala, co-head of EMEA health-care investment banking at JPMorgan, discusses government support for investment in life sciences, as well as innovation in the sector.
- 06/23/2023
|
Novo Nordisk stock falls on Ozempic investigation into possible cancer link
- Yahoo Finance's Anjalee Khemlani reports on an investigation into a possible link between its Type 2 diabetes drug, Ozempic, and thyroid cancer.
- 06/22/2023
|
Novo Nordisk shares slip on EMA drug safety signal
- Novo Nordisk said on Thursday the European Union's drug watchdog had last month raised a thyroid cancer safety signal for several of its drugs including semaglutide, the active ingredient in its popular diabetes and obesity drugs, Ozempic and Wegovy.
- 06/22/2023
|
More News Is Coming on Lilly, Novo Nordisk's New Weight-Loss Drugs
- At a conference beginning Friday, Eli Lilly and Novo Nordisk will show off next-generation weight-loss drugs. Wall Street—and Hollywood—are already mad for their existing weight-loss products.
- 06/22/2023
|
Novo Nordisk sues clinics allegedly selling knockoff versions of Ozempic and Wegovy
- Danish drugmaker Novo Nordisk initiated federal court lawsuits against medical spas and wellness clinics in New York, Texas, Florida and Tennessee.
- 06/20/2023
|
Novo Nordisk cracks down on alleged Ozempic imitations
- Drug maker Novo Nordisk NVO, +0.28% on Tuesday sued five wellness spas and clinics in federal court, accusing them of unlawfully peddling what they said were modified copies of the popular drug Ozempic and other medications being used for weight loss, according to the Wall Street Journal. The drug maker accused those businesses of “false advertising, trademark infringement and unfair competition,” according to the Journal.
- 06/20/2023
|
Novo Nordisk says launch of weight loss drug Wegovy in new markets delayed due to US demand
- Novo Nordisk (NYSE:NVO) executives announced on Tuesday that the launch of its obesity drug Wegovy in most of Europe will be slower than planned and the medication will likely not be sold in developing nations for a “very long time,” due to surging demand in the US following its launch there in mid-2021. Wegovy has lifted Novo Nordisk to record sales as well as its current position as the third largest pharma company globally by market capitalization, according to Refinitiv data.
- 06/20/2023
|
Novo Nordisk sues spas, wellness clinics for selling counterfeit weight-loss drugs
- Drug maker Novo Nordisk on Tuesday said it had sued medical spas and wellness clinics in the United States for selling products claiming to contain semaglutide, the key ingredient in its popular weight loss and diabetes drugs.
- 06/20/2023
|
Novo Nordisk's Wegovy launch in new markets will be slower due to high demand
- Novo Nordisk's launch of obesity drug Wegovy in most of Europe will be slower than planned and the drug will likely not be sold in developing nations for a very long time, executives said on Tuesday, as demand booms in the United States.
- 06/20/2023
|
Novo Nordisk: Wegovy launch in new markets slower due to high demand
- Novo Nordisk is taking the launch of its obesity drug Wegovy "a little slower than planned" in new markets due to higher than expected demand in the three countries where it is currently sold, an executive said on Tuesday.
- 06/20/2023
|
Hit Wegovy weight-loss drug on track for $4 billion in U.S. sales despite supply constraints, analyst says
- The hit Wegovy weight-loss drug is on track for sales of over $4 billion this year in the U.S. alone, despite its manufacturer Novo Nordisk struggling to keep up with demand.
- 06/20/2023
|
This Biotech Is Developing The Next Ozempic. Should You Buy It?
- Structure Therapeutics is working on therapies for diabetes and obesity. Its efforts are still early-stage, but it has plenty of cash to keep going.
- 06/16/2023
|
Five things to know about berberine, the supplement being compared to the weight-loss drug Ozempic
- By now, most Americans have heard of Ozempic, Mounjaro and Wegovy, the Type 2 diabetes drugs that are also helping people lose weight — in some cases, significant amounts.
- 06/15/2023
|
2 Market-Beating Stocks With More Upside Potential
- Eli Lilly and Novo Nordisk are among the leaders in diabetes and obesity care. Both companies will continue to makes important strides in these two areas.
- 06/15/2023
|
Better Long-Term Buy: AbbVie or Novo Nordisk?
- Novo Nordisk is forecasting revenue and operating profit growth this year. AbbVie said it expects to return to revenue growth in 2025.
- 06/10/2023
|
3 Reasons Why Growth Investors Shouldn't Overlook Novo Nordisk (NVO)
- Novo Nordisk (NVO) could produce exceptional returns because of its solid growth attributes.
- 06/09/2023
|
Why Novo Nordisk Stock Bumped Higher Today
- A bullish pundit reiterated his unambiguous buy recommendation on the company. He believes the share price could rise by nearly 30%.
- 06/06/2023
|
Novartis Announces Positive Data on Breast Cancer Drug Kisqali
- Novartis' (NVS) Kisqali reduces the risk of recurrence by 25% among patients with early breast cancer.
- 06/05/2023
|
Novo Nordisk (NVO) Gears Up to Acquire BIOCORP for 154M Euros
- Novo Nordisk (NVO) enters into negotiations to acquire a majority stake in BIOCORP, followed by a tender offer to acquire all remaining shares in BIOCORP for a total equity value of 154 million Euros.
- 06/05/2023
|
Best Momentum Stocks to Buy for June 5th
- VIPS, KOF and NVO made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on June 5, 2023.
- 06/05/2023
|
Is Novo Nordisk (NVO) Stock Outpacing Its Medical Peers This Year?
- Here is how Novo Nordisk (NVO) and Roche Holding AG (RHHBY) have performed compared to their sector so far this year.
- 06/05/2023
|
New Strong Buy Stocks for June 5th
- NEM, KMT, VIPS, NVO and BAMXF have been added to the Zacks Rank #1 (Strong Buy) List on June 5, 2023.
- 06/05/2023
|
Novo Nordisk in talks to buy controlling stake in Biocorp
- Novo Nordisk NVO, -0.53% has entered into exclusive negotiations to acquire a controlling stake in French medical device maker Biocorp in a deal that values Biocorp at 154.4 million euros, or about $165 million, the companies said in a release. The companies have been collaborating since 2021 on an add-on device for the Novo Nordisk FlexTouch pen used by people with diabetes and are looking to expand its use to other therapy areas, the companies said.
- 06/05/2023
|
Novo Nordisk's Smash-Hit Drug Could Become Even More Profitable. Here's Why.
- Novo Nordisk's heyday with semaglutide is just getting started. There's some evidence to suggest it could be useful in treating addiction.
- 06/05/2023
|
Novo Nordisk: Dominating In Diabetes And Obesity
- Novo Nordisk has performed extremely well in the past few years as it continues to dominate in diabetes and obesity. The massive market opportunities alongside the ongoing market share gain should continue to drive meaningful growth. The company's latest earnings were very strong as diabetes and obesity sales substantially boosted the overall growth.
- 06/05/2023
|
Got $5,000? These 2 Stocks Could Be Bargain Buys for 2023 and Beyond.
- Novo Nordisk's expertise in diabetes care is about to produce another promising medicine. Tandem Diabetes Care is looking to take advantage of the vast insulin-pump opportunity.
- 05/31/2023
|
This Could Be Novo Nordisk's Next Big Weight-Loss Product
- The Danish drugmaker recently announced phase 3 trial results for an oral version of Wegovy. The pill version of its popular weight-loss treatment demonstrated similar results to the injection.
- 05/31/2023
|
Brokers Suggest Investing in Novo Nordisk (NVO): Read This Before Placing a Bet
- When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?
- 05/30/2023
|
Better Dividend Stock: Eli Lilly or Novo Nordisk?
- Eli Lilly and Novo Nordisk have been two of the hottest dividend-paying pharma stocks of late. While both companies sport well-supported dividends, one company comes with inherently less risk and stronger growth prospects.
- 05/30/2023
|
This Pharma's Sales Are So Hot It's Trying to Curb Demand
- Novo Nordisk is struggling to keep up with demand for Wegovy. It's experiencing manufacturing problems and delaying new-patient starts.
- 05/30/2023
|
Novo Nordisk (NVO) Growth Hormone Drug Gets Positive CHMP Opinion
- Novo Nordisk (NVO) gets CHMP recommendation approval for Sogroya for expanded use in children and adolescents with growth hormone deficiency.
- 05/26/2023
|
Here's Why Novo Nordisk (NVO) is a Strong Growth Stock
- Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
- 05/26/2023
|
The dark side of the weight-loss drug craze: Eating disorders, medication shortages, dangerous knock-offs
- A national obsession with a new class of weight-loss drugs is turning dangerous, doctors and researchers say, as many patients are inappropriately prescribed Wegovy, Ozempic and similar medications and supply shortages generate a market for unauthorized, potentially risky copycat versions of these drugs.
- 05/26/2023
|
Time to Buy Stock in These Pharmaceutical Giants for EPS Growth
- The rising earnings estimate revisions are a strong sign that there could be more upside for Novartis and Novo Nordisk stock this year. Furthermore, both companies are leaders in critical areas of healthcare and remain sound long-term investments for 2023 and beyond.
- 05/25/2023
|
3 Biotech Stocks With Blockbuster Potential
- When it comes to possibilities of outsized rewards, few sectors can beat out biotech stocks with blockbuster potential. Fundamentally, the underlying sector enjoys a massive footprint.
- 05/24/2023
|
Novo Nordisk (NVO) Collaborates for Gene-Editing Therapies
- Novo Nordisk (NVO) partners with Life Edit Therapeutics to discover and develop gene-editing therapies for rare and cardiometabolic diseases.
- 05/24/2023
|
Is Novo Nordisk (NVO) a Solid Growth Stock? 3 Reasons to Think "Yes"
- Novo Nordisk (NVO) possesses solid growth attributes, which could help it handily outperform the market.
- 05/24/2023
|
Pharma industry remains in 'early innings' of new weight loss drug boom, says Scott Gottlieb
- Former FDA Commissioner and Pfizer Board Member Dr. Scott Gottlieb joins 'The Exchange' to discuss the Surgeon General's social media warning, new weight loss drugs coming to market, and the potential for Ozempic to treat addictions.
- 05/23/2023
|
Novo Nordisk (NVO) Announces Positive Obesity Program Data
- Novo Nordisk's (NVO) late-stage study of once-daily oral semaglutide 25 mg and 50 mg in obesity shows superior weight loss at week 68 compared with placebo.
- 05/23/2023
|
Why Novo Nordisk Stock Is Falling Today
- Yesterday, Pfizer published strong mid-stage trial data for its diabetes and weight-loss candidate, danuglipron. This development may spell bad news for Novo Nordisk's flagship medication, semaglutide.
- 05/23/2023
|
Novo Nordisk: Flourishing Financials And Emerging Opportunities In Diabetes And Obesity
- Novo Nordisk showed substantial Q1 2023 growth, with a 27% rise in net sales and a 39% boost in net profit. Diabetes and obesity care sales notably increased. The firm's solid capital structure, boasting a market cap of $374.33 billion, shows stability and investor confidence.
- 05/23/2023
|
The Important — And Overlooked — Caveat Behind Pfizer's Rival To Novo Nordisk In Diabetes
- It's the heyday of GLP-1 drugs, an analyst said Tuesday after Pfizer stock surged on the results of its study in patients with diabetes. The post The Important — And Overlooked — Caveat Behind Pfizer's Rival To Novo Nordisk In Diabetes appeared first on Investor's Business Daily.
- 05/23/2023
|
3 Healthcare Trends to Ride for Longevity
- Because of their longevity, predictability, and stability, healthcare trends can persist for years. The companies covered today are fundamentally and technically robust stocks currently taking advantage of these trends.
- 05/22/2023
|
Novo Nordisk says trial of oral weight-loss drug shows significant result
- Novo Nordisk's trial of the oral version of its weight-loss drug semaglutide has shown statistically significant and superior weight loss when compared to a placebo, the drugmaker said on Monday.
- 05/22/2023
|
Obesity drug brings heart health benefit alongside weight loss- study
- Taking Novo Nordisk's new obesity drug may help reduce the risk of heart disease as well as boosting weight loss, according to new research from the United States.
- 05/19/2023
|
Is Novo Nordisk Stock a Screaming Buy Right Now?
- Novo Nordisk's rocket-fueled growth in type 2 diabetes and obesity treatment has made its stock a winning play for two straight years. With novel competitive threats starting to emerge, Novo's sky-high premium might not be warranted.
- 05/16/2023
|
Don't Ignore the Momentum in These 3 Stocks
- Momentum investing is centered around targeting stocks displaying outperformance. And when you add in the Zacks Rank, the strategy can become even more potent.
- 05/15/2023
|
Prescription-drug costs in spotlight as pharmacy benefit reform advances in Senate
- A bipartisan effort to rein in prescription drug prices advanced Thursday as a key U.S. Senate committee approved a bill aimed at reforming pharmacy benefit managers.
- 05/11/2023
|
Novo Nordisk (NVO) is an Incredible Growth Stock: 3 Reasons Why
- Novo Nordisk (NVO) possesses solid growth attributes, which could help it handily outperform the market.
- 05/08/2023
|
Why Novo Nordisk Stock Is Marching Higher Today
- Last week, Novo's shares dipped on the news that it can't keep up with demand for its weight-loss medication Wegovy. Investors initially reacted poorly to this revelation due to a potential near-term competitive threat.
- 05/08/2023
|
Buy These 4 Low-Beta Stocks to Endure Market Volatility
- It is imperative to build a portfolio of low-beta stocks to sail through a choppy market. Penumbra (PEN), Lamb Weston (LW), Transportadora (TGS) and Novo Nordisk (NVO) are poised to gain.
- 05/05/2023
|
Why Novo Nordisk Stock Is Slumping Today
- Danish pharma giant Novo Nordisk reported strong 2023 Q1 results today. Even so, the company announced plans to start rationing lower-strength starter doses of its popular weight-loss drug.
- 05/04/2023
|
Novo Nordisk, A Top 1% Stock, Dives As Sales Of Obesity Blockbuster Drug Miss
- Novo Nordisk stock slumped Thursday after its weight loss blockbuster, Wegovy, missed sales expectations despite rocketing demand. The post Novo Nordisk, A Top 1% Stock, Dives As Sales Of Obesity Blockbuster Drug Miss appeared first on Investor's Business Daily.
- 05/04/2023
|
Wegovy weight-loss drug supply to be temporarily curtailed by Novo Nordisk as it ramps up production
- Novo Nordisk on Thursday said demand was so strong for its weight-loss injectable medicine that it will have to reduce the supply temporarily.
- 05/04/2023
|
Novo Nordisk Stock Skids As Obesity Drug Wegovy Misses Expectations
- Novo Nordisk stock skidded Thursday after the company beat overall sales and profit expectations, but obesity treatment Wegovy came in light. The post Novo Nordisk Stock Skids As Obesity Drug Wegovy Misses Expectations appeared first on Investor's Business Daily.
- 05/04/2023
|
Novo Nordisk cuts some supply of Wegovy obesity drug as demand grows
- Karsten Munk Knudsen, chief financial officer at Novo Nordisk, says the company is halving the supply of starter doses of its Wegovy weight loss drug to ensure "continuity of care" for existing patients.
- 05/04/2023
|
Novo Nordisk cuts some U.S. supply of Wegovy obesity drug as demand soars
- Novo Nordisk said Thursday that it was cutting the supply of some doses of its popular obesity drug in the U.S. as it struggles to keep up with surging demand.
- 05/04/2023
|
Novo Nordisk: U.S. is priority for weight-loss drug over launching in new markets
- Novo Nordisk is prioritising U.S. supplies of its popular weight-loss drug Wegovy over launching in new markets, a senior executive told Reuters on Thursday as the Danish drugmaker struggles to keep up with skyrocketing demand there.
- 05/04/2023
|
2 Stocks That Could Triple Your Investment by 2030
- Novo Nordisk's stock will probably ride its semaglutide sales to the moon. SNDL's anticipated entry into the U.S. market will soon juice its growth.
- 05/03/2023
|
V&M Breakouts: Top Long-Term Growth And Dividend Stocks For May 2023
- The May 2022 total return portfolio for 1-year is up +17.09%, and the May 2021 2-year portfolio is up 21.33%, not adjusted for greater than 2%+ dividends. The first May 2020 portfolio had +66.98% 2-year returns.
- 05/01/2023
|
1 No-Brainer Pharma Stock to Buy With $1,000 Right Now
- Novo Nordisk is aiming to fully exploit the gold mine it developed with semaglutide. Wegovy, Rybelsus, and Ozempic are just the first few formulations to be approved.
- 04/29/2023
|
Weight loss drug market is just beginning to take off, says Mizuho's Jared Holz
- Jared Holz, Mizuho healthcare equity strategist, joins 'The Exchange' to discuss new weight loss drugs coming to market, forecasts for market expansion in weight loss drugs, and key players in the weight loss drug sector.
- 04/28/2023
|
ETO: This Attractively-Valued CEF Is A Good Choice For An Income Seeker
- ETO: This Attractively-Valued CEF Is A Good Choice For An Income Seeker.
- 04/26/2023
|
Is It Worth Investing in Novo Nordisk (NVO) Based on Wall Street's Bullish Views?
- The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings often affect a stock's price.
- 04/26/2023
|
Better Buy: Novo Nordisk vs. Eli Lilly
- Sales of Novo Nordisk's diabetes drug and weight-management drugs are soaring. Eli Lilly's popular new diabetes drug, Mounjaro, could soon earn approval to address chronic weight management.
- 04/25/2023
|
3 Top-Ranked Stocks Displaying Immense Relative Strength
- Stop me if you've heard this before, but stocks making new highs tend to make even higher highs, especially when analysts' positive earnings estimate revisions roll in.
- 04/24/2023
|
Novo Nordisk Sinks As Eli Lilly Plots Its Showdown In The Red-Hot Obesity Shot Race
- Novo Nordisk stock dipped Monday after Eli Lilly posted the details of its study comparing Mounjaro and Wegovy in obesity treatment. The post Novo Nordisk Sinks As Eli Lilly Plots Its Showdown In The Red-Hot Obesity Shot Race appeared first on Investor's Business Daily.
- 04/24/2023
|
Are Medical Stocks Lagging Novo Nordisk (NVO) This Year?
- Here is how Novo Nordisk (NVO) and Novartis (NVS) have performed compared to their sector so far this year.
- 04/20/2023
|
Investors Heavily Search Novo Nordisk A/S (NVO): Here is What You Need to Know
- Novo Nordisk (NVO) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
- 04/20/2023
|
Buy These 4 Low-Beta Stocks to Sail Through Market Volatility
- It is imperative to build a portfolio of low-beta stocks to sail through a choppy market. Transportadora de Gas (TGS), Lamb Weston (LW), Vipshop (VIPS) and Novo Nordisk (NVO) are well-poised to gain.
- 04/20/2023
|
Got $5,000? 2 Unstoppable Stocks to Buy and Hold Forever
- Novo Nordisk boasts a strong expertise in diabetes and other critical areas of medicine. Medtronic offers a rich and growing portfolio of products as well as a solid dividend.
- 04/20/2023
|
7 Top Growth Stocks to Buy for the Next Decade
- A the market returns it's time to look for the best growth stocks to buy. successful investing strategy partially requires an ability to predict the future.
- 04/18/2023
|
Here are 2 Top Drug Makers Leading the Way in Weight Loss Drugs
- The topic of weight loss drugs has been making recent headlines. The positive phase 1 clinical trial for Viking Therapeutics Inc. (NASDAQ: VKTX) GLP-1 treatment VK2735 caused its shares to rally more than 50%.
- 04/17/2023
|
Are You Looking for a Top Momentum Pick? Why Novo Nordisk (NVO) is a Great Choice
- Does Novo Nordisk (NVO) have what it takes to be a top stock pick for momentum investors? Let's find out.
- 04/14/2023
|
Novo Nordisk Has Some Room To Run
- Shares have risen 20% over a month. Guidance was just upgraded.
- 04/14/2023
|
Novo (NVO) & Aspect Biosystems Unite to Develop Tissue Therapy
- Pharma Goliath Novo Nordisk (NVO) inks collaboration agreement with Aspect Biosystems to develop and commercialize transformative cell therapy treatments for type I diabetes patients.
- 04/13/2023
|
KALA Up on Fast Track Designation to Lead Ocular Candidate
- KALA gets Fast Track Designation from the FDA for lead candidate KPI-012 to treat persistent corneal epithelial defects.
- 04/13/2023
|
Novo Nordisk Surges To Another Record As Obesity Drugs Drive Higher Outlook
- Novo Nordisk stock forged a new high Thursday after raising financial estimates, citing its diabetes and obesity treatments. The post Novo Nordisk Surges To Another Record As Obesity Drugs Drive Higher Outlook appeared first on Investor's Business Daily.
- 04/13/2023
|
Novo Nordisk Charges Higher and Could be Just Getting Started
- Shares of Novo Nordisk A/S (NYSE: NVO) are up over 3.6% on April 12. The immediate catalyst is the announcement of a $2.6 billion collaboration with Aspect Biosystems.
- 04/13/2023
|
Novo Nordisk: Maybe It's Time To Trim The Position A Little Bit
- Novo Nordisk is trading for one of the highest valuation multiples in the last 20 years, and we should be cautious. Nevertheless, the company reported great results for fiscal 2022 and is also expecting high growth rates for fiscal 2023.
- 04/13/2023
|
Why Wegovy and Ozempic Could Be Cash Cows for Novo Nordisk
- Wegovy and Ozempic sales have skyrocketed on their ability to help people shed pounds. Novo Nordisk is working hard to ramp up production to meet this strong demand.
- 04/12/2023
|
Is Novo Nordisk (NVO) a Buy as Wall Street Analysts Look Optimistic?
- When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?
- 04/10/2023
|
Is Novo Nordisk Stock a Buy Now?
- Novo Nordisk is raking in big bucks thanks to sales of semaglutide. Its shares are quite pricey thanks to widespread optimism about its trajectory.
- 04/10/2023
|
3 Things About Novo Nordisk That Smart Investors Know
- Novo Nordisk is selling semaglutide at an impressive scale. But dividend investors might not be pleased with its history of payouts.
- 04/10/2023
|
Could Novo Nordisk Stock Help You Become a Millionaire?
- Novo Nordisk's sales have risen by more than 40% in the past five years. Even more growth opportunities are ahead for the company as its business focuses on two high-need areas: diabetes and obesity care.
- 04/08/2023
|
3 No-Brainer Stocks to Buy in a New Bull Market
- Novo Nordisk has exceptional growth prospects with its diabetes and obesity drugs. Pfizer isn't getting the respect it deserves.
- 04/08/2023
|
5 Diverse Medical Stocks to Buy for 2023 and Beyond
- The top and bottom-line growth make these Zacks Medical stocks very attractive.
- 04/06/2023
|
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
- Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.
- 04/06/2023
|
Novo Nordisk Seeks to Solidify Its Lead in Diabetes Treatment and Crushing the Market
- Novo Nordisk controls almost one-third of the entire worldwide diabetes market. Patent protection on Ozempic and Rybelsus, which treat type 2 diabetes and can help with weight loss, lasts until 2032 in the United States.
- 04/06/2023
|
4 Low-Beta Stocks to Buy to Endure Market Volatility
- It is imperative to build a portfolio of low-beta stocks to sail through a choppy market. Haemonetics (HAE), The Kroger Co. (KR), JOYY (YY) and Novo Nordisk (NVO) are poised to gain.
- 04/04/2023
|
3 Stocks That Could Benefit From the Ozempic Craze
- Novo Nordisk's business has been red-hot, thanks to soaring obesity-related revenue. Eli Lilly has its own promising weight-loss treatment which could be a game changer.
- 03/30/2023
|
A Perfect Storm In Pharmacotherapy: The Opportunity To Invest In NASH
- NASH, or nonalcoholic steatohepatitis, is a liver inflammatory disease that can progress to fibrosis and cirrhosis. NASH is now the second leading cause of liver transplantation, and the US patient population is forecast to increase from 16 million in 2015 to 27 million in 2030.
- 03/29/2023
|
Drugs for obesity are a massive market, says Mizuho's Jared Holz
- Jared Holz, Mizuho, joins 'Fast Money' to discuss obesity drugs with CNBC's Tyler Mathisen and the Fast Money traders.
- 03/29/2023
|
People taking obesity drugs Ozempic and Wegovy gain weight once they stop medication
- Some people may actually gain back more weight than they initially lost after stopping obesity drugs Ozempic and Wegovy.
- 03/29/2023
|
Novo Nordisk (NVO) is a Great Momentum Stock: Should You Buy?
- Does Novo Nordisk (NVO) have what it takes to be a top stock pick for momentum investors? Let's find out.
- 03/28/2023
|
Novo Nordisk (NVO) Meets Semaglutide Higher Dosage Study Goal
- Novo Nordisk (NVO) announces positive top-line results from its phase III increased dosage study of semaglutide, 25 mg and 50 mg, for the treatment of patients with type II diabetes.
- 03/27/2023
|
The Ozempic Obesity Battle Is Heating Up With Novo Scoring A Fresh Win
- Novo Nordisk stock popped Friday after higher doses of its popular drug, semaglutide, led to greater weight loss in diabetes patients. The post The Ozempic Obesity Battle Is Heating Up With Novo Scoring A Fresh Win appeared first on Investor's Business Daily.
- 03/24/2023
|
Brokers Suggest Investing in Novo Nordisk (NVO): Read This Before Placing a Bet
- Based on the average brokerage recommendation (ABR), Novo Nordisk (NVO) should be added to one's portfolio. Wall Street analysts' overly optimistic recommendations cast doubt on the effectiveness of this highly sought-after metric.
- 03/23/2023
|
Here's Why You Should Add Novo (NVO) Stock to Your Portfolio
- Novo (NVO), a top-ranked stock at present, enjoys a strong foothold in the Diabetes Care market with increasing market shares driven by Rybelsus, Ozempic and Victoza's strong performance.
- 03/22/2023
|
Sanofi becomes latest to cut insulin prices, joins Novo Nordisk, Eli Lilly
- Yahoo Finance's Anjalee Khemlani joins the Live show to report that Sanofi has become the latest major drug company to slash insulin prices, capping the cost at $35.
- 03/17/2023
|
2 Top Healthcare Stocks to Buy for the Long Haul
- Bristol Myers Squibb is counting on new approvals to fill the hole left by older medicines. Novo Nordisk is second to none in diabetes care, and it is expanding beyond this area.
- 03/17/2023
|
Sanofi Cuts Insulin Prices Up To 78%—Following Eli Lilly And Novo Nordisk
- The French company will cap the monthly cost of insulin at $35, after Novo Nordisk and Eli Lilly also announced major price cuts earlier this month.
- 03/16/2023
|
Sanofi to slash U.S. insulin prices in 2024 after similar cuts by Eli Lilly and Novo Nordisk
- The French drugmaker is the last major insulin manufacturer to try to head off government efforts to cap monthly costs by announcing its own steep price cuts.
- 03/16/2023
|
Novo Nordisk (NVO) Follows Lilly, to Cut Insulin Prices by 75%
- Novo Nordisk (NVO) plans to lower prices of several pre-filled insulin pens and vials by up to 75% in the United States. However, the company plans not to start this until January 2024.
- 03/15/2023
|
Novo Nordisk to slash US prices of insulin pens and vials by up to 75% for people with diabetes
- Novo Nordisk (NYSE:NVO) A/S is set to cut the US list prices for several insulin products by up to 75% for people struggling with diabetes, following similiar moves by Eli Lilly earlier this month. The Danish healthcare company said that the products include both pre-filled pens and vials of basal (long-acting), bolus (short-acting) and pre-mix insulins, specifically Levemir, Novolin, NovoLog and NovoLog Mix 70/30.
- 03/14/2023
|
Novo Nordisk to slash U.S. insulin prices by up to 75%, following move by Eli Lilly
- Novo Nordisk is planning to slash the price of several insulin drugs by up to 75% in the U.S., following a similar move by Eli Lilly.
- 03/14/2023
|
Novo Nordisk to lower prices of some insulins, following similar move by Lilly
- Novo Nordisk DK:NOVO.B NVO said that it is lowering the prices of several insulin products by up to 75% starting in 2024. The company's U.S.-listed shares were up about 1.0% in premarket trading on Tuesday.
- 03/14/2023
|
5 Large Drug Stocks to Watch as Sector Picks Up in 2023
- Drug/biotech companies are likely to see significant advances in innovation in 2023. In the Large-Cap Pharmaceuticals industry, J&J (JNJ), Novo Nordisk (NVO), AstraZeneca (AZN), Novartis (NVS), and Sanofi (SNY) are worth retaining in your portfolio.
- 03/09/2023
|
WW Stock Soars As Telehealth Deal Opens Up Hot Obesity Drug Market
- Former WeightWatchers is entering clinical weight management. WW stock surged.
- 03/07/2023
|
AI Stock Headlines 5 Leaders Flashing Buy Signals As Market Rally Gains Steam
- Arista Networks, which keeps popping up on lists of top AI stocks, leads this weekend's watch list of 5 stocks near buy points. The post AI Stock Headlines 5 Leaders Flashing Buy Signals As Market Rally Gains Steam appeared first on Investor's Business Daily.
- 03/04/2023
|
4 Low-Beta Stocks to Buy to Combat the Volatile Market
- It is imperative to build a portfolio of low-beta stocks to sail through a choppy market. Employers Holdings (EIG), The Hershey (HSY), Lamb Weston (LW) and Novo Nordisk (NVO) are poised to gain.
- 03/02/2023
|
Novo Nordisk laying off 86 workers as part of lab shutdown in Seattle
- Danish multinational biopharma company Novo Nordisk is laying off 86 employees in Seattle, according to a new filing with the Washington state Employment Security Department.
- 03/01/2023
|
What Makes Novo Nordisk (NVO) a New Strong Buy Stock
- Novo Nordisk (NVO) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
- 02/20/2023
|
SNY vs. NVO: Which Stock Should Value Investors Buy Now?
- SNY vs. NVO: Which Stock Is the Better Value Option?
- 02/17/2023
|
Competition Coming For AbbVie's Blockbuster Humira
- It's among the prohibitively expensive biologic pharmaceuticals being replaced by cheaper “biosimilar” copycats. Relief is on the way for patients who need Humira, a product made by AbbVie.
- 02/16/2023
|
New Strong Buy Stocks for February 14th
- INSP, ALK, SSKN, NVO and TBPH have been added to the Zacks Rank #1 (Strong Buy) List on February 14, 2023.
- 02/14/2023
|
2 Market-Beating Growth Stocks That Are Just Getting Started
- Winners keep winning.
- 02/10/2023
|
How To Allocate $5,000 Among 5 Dividend Income And Dividend Growth Stocks And ETFs
- In this article, I will show you a portfolio that consists of 5 picks that provide you with Dividend Income and Dividend Growth. When allocating $5,000 between 5 stocks, I would not recommend allocating the amount equally due to the higher risks that such an approach brings.
- 02/09/2023
|
Novo Nordisk CEO on safety concerns associated with off-label use of diabetes drugs
- CNBC's Meg Tirrell joins 'Closing Bell' to report on rapid prescription growth for diabetes medicine, celebrities using Ozempic and Wegovy for weight loss and the safety related to broad use of medicines.
- 02/06/2023
|
Novo Nordisk (NVO) Q4 Earnings Beat Estimates, Revenues Miss
- Novo Nordisk (NVO) reports mixed results for Q4 as earnings beat estimates but sales miss on the same. Sales are aided by growth in Diabetes and Obesity Care on higher GLP-1 revenues.
- 02/01/2023
|
SNY or NVO: Which Is the Better Value Stock Right Now?
- SNY vs. NVO: Which Stock Is the Better Value Option?
- 02/01/2023
|
Novo Nordisk A/S (NVO) Q4 2022 Earnings Call Transcript
- Novo Nordisk A/S (NVO) Q4 2022 Earnings Conference Call February 1, 2023 7:00 AM ET Company Participants Lars Fruergaard Jørgensen - President and Chief Executive Officer Camilla Sylvest - Executive Vice President and Head of Commercial Strategy & Corporate Affairs Doug Langa - Executive Vice President and Head of North America Operations Martin Holst Lange - Executive Vice President, Head of Development Karsten Munk Knudsen - Executive Vice President and Chief Financial Officer Conference Call Participants Harry Sephton - Credit Suisse Peter Verdult - Citi Michael Nedelcovych - Cowen Sachin Jain - Bank of America Richard Parkes - BNP Paribas Richard Vosser - JPMorgan Michael Leuchten - UBS Keyur Parekh - Goldman Sachs Simon Baker - Redburn Mattias Häggblom - Handelsbanken Operator Good day, and thank you for standing by. Welcome to the Q4 2022 Novo Nordisk A/S Earnings Conference Call.
- 02/01/2023
|
Pharma Giants GSK, Novo Nordisk Beat Expectations; But Novartis Dives On A Mixed Report
- GSK stock and NVO stock rose Wednesday on fourth-quarter beats, but Novartis stock fell on lighter-than-expected sales despite strong profit. The post Pharma Giants GSK, Novo Nordisk Beat Expectations; But Novartis Dives On A Mixed Report appeared first on Investor's Business Daily.
- 02/01/2023
|
Novo Nordisk Sees Obesity Drug Fueling Record Profit
- Novo Nordisk President and Chief Executive Officer Lars Fruergaard Jorgensen discusses soaring demand for the company's obesity drug Wegovy with Francine Lacqua on "Bloomberg Surveillance Early Edition." Follow Bloomberg for business news & analysis, up-to-the-minute market data, features, profiles and more: http://www.bloomberg.
- 02/01/2023
|
Novo Nordisk lifts dividend, launches $4.09 billion share buyback after earnings beat forecasts
- Danish pharmaceutical company Novo Nordisk AS DK:NOVO.B NVO on Wednesday raised its dividend and launched a new 28 billion Danish kroner ($4.09 billion) share buyback after fourth-quarter earnings beat expectations amid strong demand for its diabetes care and obesity treatments.
- 02/01/2023
|
A Dividend Aristocrat That Could Crash And One That Could Potentially Triple
- Dividend aristocrats are some of the world's safest and most dependable companies. Exactly the kinds of companies you want in a recession. But not all dividend aristocrats are safe buys. Some are almost 50% overvalued, like this red-hot medical aristocrat.
- 01/31/2023
|
3 Global Stocks to Buy to Get Around America's Slowdown
- If you've been avoiding stocks during the past few months in order to prevent yourself from making any more mistakes after 2022's bloodbath and you're looking to dip your toe back into equities, finding good global stocks to buy might be the wisest course of action. As of Jan. 27, the iShares MSCI ACWI ex U.S. ETF (NASDAQ: ACWX ) was up 20% in 2023.
- 01/30/2023
|
U.S. Appeals Court Sides With Drugmakers on Discount Program
- The court ruled that drugmakers can limit their shipments of federally-discounted drugs to pharmacies, in a blow to hospitals and clinics.
- 01/30/2023
|
Is a Beat on the Cards for Novo Nordisk (NVO) in Q4 Earnings?
- Novo Nordisk's (NVO) top line is likely to have been driven by sales of its Diabetes and Obesity Care products in the fourth quarter of 2022.
- 01/26/2023
|
2 Market-Beating Stocks to Buy in 2023 and Hold for 10 Years
- These two healthcare giants defied the bear market last year.
- 01/26/2023
|
Looking for Stocks with Positive Earnings Momentum? Check Out These 2 Medical Names
- Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.
- 01/25/2023
|
3 Reasons Growth Investors Will Love Novo Nordisk (NVO)
- Novo Nordisk (NVO) is well positioned to outperform the market, as it exhibits above-average growth in financials.
- 01/20/2023
|
SNY vs. NVO: Which Stock Is the Better Value Option?
- SNY vs. NVO: Which Stock Is the Better Value Option?
- 01/16/2023
|
Bet on These 5 Low Leverage Stocks Amid Easing Inflation
- A prudent investor knows that if one wants to avoid huge losses in times of crisis, one needs to look for relatively safe bets. You may buy OXM, INGR, NVO, HP & FOXF.
- 01/16/2023
|
Novo Nordisk: Momentum Continues While Valuation Remains 'Not Too' Expensive
- Along with 2022 winner Eli Lilly, Novo Nordisk has been a market leader in a favored equity niche. Two key drugs continue to catch the allure of major Wall Street banks, and Novo is a highly-rated pick despite featuring a valuation premium.
- 01/15/2023
|
State of California Sues Insulin Makers for Unfair Practices
- The lawsuit aims to curb the skyrocketing cost of insulin charged by insulin manufacturers and pharmacy benefit managers companies. The State also seeks to recover some monetary compensation.
- 01/13/2023
|
How Novo Nordisk Just Expanded Its Diabetes Lead Over Pfizer, Eli Lilly
- The Food and Drug Administration expanded the label for Novo Nordisk's oral diabetes medicine, leading NVO stock to jump Friday. The post How Novo Nordisk Just Expanded Its Diabetes Lead Over Pfizer, Eli Lilly appeared first on Investor's Business Daily.
- 01/13/2023
|
Can Health Care Stocks Outperform Again In 2023?
- How a recession could impact health care stocks in 2023. As Covid continues, what it could mean for the health care sector.
- 01/11/2023
|
2 Top Biotech Stocks Defying the Bear Market
- Some stocks are hitting new highs.
- 01/10/2023
|
Ranking The Top 10 Pharmaceuticals By Pipeline
- The pipeline is the heart of a drug discovery company. As such, analyzing the health of a pipeline can lead to suggestions about future performance.
- 01/09/2023
|
Is Novo Nordisk (NVO) Stock Outpacing Its Medical Peers This Year?
- Here is how Novo Nordisk (NVO) and Acumen Pharmaceuticals, Inc. (ABOS) have performed compared to their sector so far this year.
- 01/06/2023
|
Novo Nordisk (NVO) Upgraded to Strong Buy: Here's Why
- Novo Nordisk (NVO) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
- 01/05/2023
|
New Strong Buy Stocks for January 5th
- AAL, DLNG, BNPQY, NVO and SAP have been added to the Zacks Rank #1 (Strong Buy) List on January 5 , 2023.
- 01/05/2023
|
Here is Why Growth Investors Should Buy Novo Nordisk (NVO) Now
- Novo Nordisk (NVO) could produce exceptional returns because of its solid growth attributes.
- 01/04/2023
|
What Makes Novo Nordisk (NVO) a Strong Momentum Stock: Buy Now?
- Does Novo Nordisk (NVO) have what it takes to be a top stock pick for momentum investors? Let's find out.
- 01/04/2023
|
How TikTok Could Help This Healthcare Stock Take Off
- Novo Nordisk underestimated demand in 2022, but it's vowing not to make the same mistake this year.
- 01/04/2023
|
100 Best Stocks Of 2022: Oil Stocks And Medicals Shine
- Medical and energy companies, including oil stocks, lead the list of the 100 best stocks in 2022. The post 100 Best Stocks Of 2022: Oil Stocks And Medicals Shine appeared first on Investor's Business Daily.
- 12/30/2022
|
2 Market-Beating Stocks to Buy in 2023 and Hold Forever
- For these companies' shareholders, it may be tempting to take profits right now. But both stocks can keep growing for a while.
- 12/24/2022
|
7 Hot Stocks to Book Profits In Before 2023
- Although a new year tends to bring feelings of optimism, when it comes to the current market dynamics, it's time to consider hot stocks to book profits in before 2023 arrives. At first, circumstances appeared favorable, with CNN reporting on Dec. 13 that inflation cooled more than expected.
- 12/19/2022
|
Simplify Your Investing Process Using This Top-Down Approach
- Letting the market guide us rather than trying to predict what will happen is the most prudent course of action.
- 12/14/2022
|
4 Large Drug Stocks to Watch in a Booming Industry
- Drug/biotech companies are likely to see significant advances in innovation in 2023. In the Large-Cap Pharmaceuticals industry, Johnson & Johnson (JNJ), Novo Nordisk (NVO), Merck (MRK) and AstraZeneca (AZN) are worth retaining in your portfolio.
- 12/14/2022
|
2 Stocks That Could Be Red-Hot Buys in 2023
- These stocks have already begun to rally over the past few months.
- 12/14/2022
|
Our 7 Top Biotech Stock Picks for 2023
- If there's a silver lining regarding the coronavirus pandemic, it's that it demonstrated the importance of the top biotech stock picks for 2023. While medical innovations may seem frustratingly slow, the Covid-19 crisis proved that when humanity comes together, it can foster incredible advancements at breakneck speed.
- 12/09/2022
|
Amgen Is The Underdog In Obesity Treatment — But It's Creeping Up On Novo Nordisk, Eli Lilly
- Amgen stock could get a fresh boost Thursday after the company unveiled promising results for its obesity treatment. The post Amgen Is The Underdog In Obesity Treatment — But It's Creeping Up On Novo Nordisk, Eli Lilly appeared first on Investor's Business Daily.
- 12/01/2022
|
3 Healthcare Stocks That Could Set You Up For Life
- All offer products that are invaluable to their respective audiences.
- 11/24/2022
|
BAYRY vs. NVO: Which Stock Is the Better Value Option?
- BAYRY vs. NVO: Which Stock Is the Better Value Option?
- 11/16/2022
|
Novo Nordisk A/S (NVO) Q3 2022 Investor Call Transcript
- Novo Nordisk A/S (NVO) Q3 2022 Investor Conference Call November 3, 2022 9:15 AM ET Company Participants Karsten Munk Knudsen – Chief Financial Officer Camilla Sylvest – Executive Vice President and Head-Commercial Strategy & Corporate Affairs Ludovic Helfgott – Executive Vice President and Head-Rare Disease Martin Holst Lange – Executive Vice President, head-Development Conference Call Participants Keyur Parekh – Goldman Sachs Naresh Chouhan – Intron Mark Purcell – Morgan Stanley Richard Vosser – JPMorgan Jo Walton – Credit Suisse Sachin Jain – Bank of America Simon Baker – Redburn Michael Leuchten – UBS Wimal Kapadia – Bernstein Emily Field – Barclays Richard Parkes – BNP Paribas Exane Keyur Parekh Good afternoon all, and thank you for joining us. My name is Keyur Parekh and I cover Novo for Goldman Sachs.
- 11/03/2022
|
3 Unstoppable Investments Everyone Needs in Their Portfolio
- Not every company can thrive in -- or even survive -- a wobbly economy.
- 11/03/2022
|
Novo Nordisk's (NVO) Q3 Earnings & Revenues Beat Estimates
- Novo Nordisk (NVO) reports better-than-expected Q3 results. Sales are aided by growth in Diabetes and Obesity Care on higher GLP-1 revenues.
- 11/02/2022
|
Novo Nordisk Is Throwing Down The Gauntlet In Weight Loss As Eli Lilly Ramps Up
- Novo Nordisk is planning to boost production for weight-loss shot Wegovy as Eli Lilly angles for approval. NVO stock surged Wednesday.
- 11/02/2022
|
Novo Nordisk: Some Changes, But No Changes In Thesis
- Novo Nordisk is a company that I really want to own - but not unless it's offered at an appealing price. Doesn't have to be bargain-like - just better. I've written about the company twice in the past, both times taking a neutral stance. The latest stance was the right one to take. The company has underperformed.
- 11/02/2022
|
Novo Nordisk sees faster profit growth on demand for diabetes drug Ozempic
- Danish drugmaker Novo Nordisk raised its full-year earnings outlook on strong sales of diabetes treatment Ozempic, also reporting a better-than-expected profit.
- 11/02/2022
|
Novo Nordisk lifts guidance as earnings beat expectations
- Danish pharmaceutical company Novo Nordisk AS NOVO.B, -2.21% NVO, -2.21% on Wednesday raised full-year guidance and reported a third-quarter net profit that beat expectations amid strong demand for its diabetes care and obesity treatments.
- 11/02/2022
|
BAYRY or NVO: Which Is the Better Value Stock Right Now?
- BAYRY vs. NVO: Which Stock Is the Better Value Option?
- 10/31/2022
|
Prediction: This Could Be This Company's Next Billion-Dollar Product
- It would be a major addition to an already rich portfolio.
- 10/18/2022
|
Novo Nordisk is ‘a company investors should take a look at,' analyst says
- Cowen Vice President Equity Research Michael Nedelcovych joins Yahoo Finance Live to discuss Elon Musk touting a prescription weight-loss drug, the company Novo Nordisk, and U.S. adults living with obesity.
- 10/13/2022
|
7 Stocks for Beginners to Buy Now
- The best stocks for beginners in today's stock market can be tough to find and beginners face a steep learning curve. Volatility is high, and bear market conditions ensure that new portfolios will be tested.
- 10/07/2022
|
This Big Pharma Stock Just Got an Upgrade. Is It Time to Buy?
- Shares of this well-established drugmaker could soar on the back of a new diabetes drug.
- 09/27/2022
|
SNY vs. NVO: Which Stock Should Value Investors Buy Now?
- SNY vs. NVO: Which Stock Is the Better Value Option?
- 09/20/2022
|
Novo Nordisk Jumps Into Sickle Cell Fray With $1.1 Billion Forma Therapeutics Buyout
- Novo Nordisk said Thursday it will spend $1.1 billion to acquire Forma in a deal that sent biotech stock Forma flying. The post Novo Nordisk Jumps Into Sickle Cell Fray With $1.1 Billion Forma Therapeutics Buyout appeared first on Investor's Business Daily.
- 09/01/2022
|
Why Novo Nordisk (NVO) Is Buying Forma Therapeutics (FMTX) For $1.1 Billion
- Novo Nordisk (NYSE: NVO) is buying Forma Therapeutics, Holdings Inc (Nasdaq: FMTX) for $1.1 billion. This is why.
- 09/01/2022
|
Novo Nordisk to acquire Forma Therapeutics in $1.1. billion deal
- Danish drugmaker Novo Nordisk will acquire Forma Therapeutics in a deal valued at $1.1 billion to expand its rare blood disorders portfolio, the companies said on Thursday.
- 09/01/2022
|
Forma Therapeutics to be acquired by Novo Nordisk in a cash deal valued at $1.1 billion
- Forma Therapeutics Holdings Inc. FMTX, +1.67% announced Thursday and agreement to be acquired by Denmark-based Novo Nordisk NVO, +0.06% NOVO.B, -0.59% in a deal with an equity value of $1.1 billion. Forma shares are halted for news until 8:30 a.m.
- 09/01/2022
|
Novo Nordisk, Eli Lilly Could Fatten Up on Weight-Loss Treatments
- Given that less than 3% of the 110 million obese Americans are being treated with drugs, new medications from Novo Nordisk AS ( NVO , Financial) and Eli Lilly and Co. ( LLY , Financial) could fatten the bottom line of both companies along with their share prices.
- 08/31/2022
|
3 Stocks to Buy Before the Housing Market Crashes
- The notion of a looming housing market crash appears to be picking up steam. There are multiple signs the ongoing correction could morph into something worse.
- 08/26/2022
|
Novo Nordisk: Assessing Hype Towards Obesity Care Following The Q2 Results Drop, Story Is Intact
- A true compounder, Novo Nordisk is positioning itself beyond basal insulin amid market and government pressures. Crucial to this strategy is its fledgling Obesity Care unit, buoyed by successes like Wegovy.
- 08/23/2022
|
Novo (NVO) Posts Positive Data From Diabetes Study on CagriSema
- Novo Nordisk (NVO) completes the phase II study evaluating CagriSema, a combination of semaglutide and cagrilintide for treating type II diabetes.
- 08/23/2022
|
Novo Nordisk: Looming Danger In An Excellent Business
- NVO had excellent results in the past and a promising position to profit even further. Its pipeline should support good revenue and earnings growth in the coming years.
- 08/15/2022
|
3 Stocks to Buy and Hold Forever
- These stocks are keepers.
- 08/13/2022
|
7 Long-Term Stocks to Buy Before the Bull Market Returns
- The current market conditions aren't conducive for short-term investing. It's notoriously difficult to pick winning stocks with a limited time horizon, and it becomes doubly true in this extremely volatile market!
- 08/07/2022
|
Novo Nordisk CEO on treating diabetes and obesity, and challenges facing the industry
- Novo Nordisk CEO Lars Jorgensen discusses the company's latest results, developing and supplying the world with medication and devices to treat diabetes, and logistical challenges facing the company and the industry.
- 08/04/2022
|
Obesity drug supply delay not unusual says Novo Nordisk CEO
- Novo Nordisk sought to soothe concerns about supplies of its new obesity drug Wegovy on Thursday, saying there was nothing unusual about a slight delay in its availability.
- 08/04/2022
|
Novo Nordisk A/S (NVO) CEO Lars Fruergaard Joergensen on Q2 2022 Results - Earnings Call Transcript
- Novo Nordisk A/S (NVO) Q2 2022 Earnings Conference Call August 3, 2022 1:30 PM ET Company Participants Lars Fruergaard Joergensen - Chief Executive Officer Camilla Sylvest - Executive Vice President & Head of Commercial Strategy & Corporate Affairs Doug Langa - Executive Vice President & Head of North America Operations Martin Holst Lange - Executive Vice President & Head of Development Karsten Munk Knudsen - Chief Financial Officer Conference Call Participants Peter Verdult - Citi Wimal Kapadia - Bernstein Matthew Weston - Credit Suisse Sachin Jain - Bank of America Simon Mather - BNP Paribas Exane Martin Parkhøi - SEB Michael Novod - Nordea Richard Vosser - JPMorgan Kerry Holford - Berenberg Mark Purcell - Morgan Stanley Operator Good evening. This is the conference operator.
- 08/03/2022
|
Novo Nordisk's Obesity Sales Nearly Doubled, But That Wasn't Enough For NVO Stock
- Danish drugmaker Novo Nordisk missed quarterly views Wednesday, but raised its full-year outlook. Still, NVO stock tumbled.
- 08/03/2022
|
Novo Nordisk raises 2022 outlook after strong first half
- Danish drugmaker Novo Nordisk on Wednesday lifted its sales and operating profit outlook for the year on the back of strong first-half earnings.
- 08/03/2022
|
Beat the Market Like Zacks: AMN Healthcare, Boeing, Clorox, Home Depot in Focus
- Our time-tested methodologies were at work to help investors navigate the market well last week. Here are some of our accomplishments from last week.
- 07/18/2022
|
Marinus to sell rare-disease voucher to Novo Nordisk for $110 million
- Shares of Marinus Pharmaceuticals Inc. MRNS, +4.13% gained 7.9% in premarket trading on Thursday after the company said it plans to sell its Rare Pediatric Disease Priority Review Voucher for $110 million to Novo Nordisk NVO, +1.19% . Marinus CFO Steven Pfanstiel told investors in a news release that the sale "extends our cash runway into the fourth quarter of 2023.
- 07/14/2022
|
Updating On Novo Nordisk: Still Overvalued
- I wrote about Novo Nordisk a few months back, and called the company overvalued and a "Hold". It's time to update that thesis in today's market, and following a 5% drop. The company is still expensive, but we should be aware of the fact that Novo Nordisk does deserve a fair bit of premium here - because of the company's quality.
- 07/13/2022
|
Novo Nordisk's (NVO) Haemophilia A Study Meets Safety Endpoint
- Novo Nordisk's (NVO) phase I & II FRONTIER1 dose-escalation study investigating Mim8 for treating people with haemophilia A meets its primary safety endpoint.
- 07/12/2022
|
Novo Nordisk: EPS Growth With Impressive Relative Strength
- The Health Care sector is seen as a safety trade over recent weeks as global equities sputter. Novo Nordisk has a pipeline of drugs that should support high earnings growth in the coming years.
- 07/12/2022
|
Best Momentum Stocks to Buy for July 5th
- NVO and TMUS made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on July 5, 2022.
- 07/05/2022
|
New Strong Buy Stocks for July 5th
- CHS, PTMN, RYI, NVO and TMUS have been added to the Zacks Rank #1 (Strong Buy) List on July 5, 2022.
- 07/05/2022
|
Looking for a Growth Stock? 3 Reasons Why Novo Nordisk (NVO) is a Solid Choice
- Novo Nordisk (NVO) could produce exceptional returns because of its solid growth attributes.
- 07/04/2022
|
2 Safe Stocks That Can Survive Any Downturn
- These stocks are worth buying whether or not a recession is coming.
- 07/02/2022
|
ESG Investing: 7 Profitable Stock Picks for the Socially Responsible
- ESG investing has not been immune to declines in the current bear market The post ESG Investing: 7 Profitable Stock Picks for the Socially Responsible appeared first on InvestorPlace. More From InvestorPlace $200 Oil Sooner Than You Think – Buy This Now The Best $1 Investment You Can Make Today Early Bitcoin Millionaire Reveals His Next Big Crypto Trade “On Air” It doesn't matter if you have $500 in savings or $5 million.
- 06/24/2022
|
4 Top Biotech Stocks To Watch Today
- As the industry continues to make new discoveries, could biotech stocks be in focus?
- 06/17/2022
|
3 Reasons Why Novo Nordisk (NVO) Is a Great Growth Stock
- Novo Nordisk (NVO) possesses solid growth attributes, which could help it handily outperform the market.
- 06/17/2022
|
These 2 High-Growth Stocks Could Power the Bull Market's Next Record Run
- Look for companies with premium products that are marketable in any environment.
- 06/10/2022
|
Novo Nordisk A/S (NVO) Presents at ADA 82nd Scientific Sessions (Transcript)
- Novo Nordisk A/S (NVO) ADA 82nd Scientific Sessions Conference June 5, 2022 8:30 PM ET Company Participants Karsten Knudsen - Chief Financial Officer Martin Holst Lange - EVP and Head of Development Mads Frederik Rasmussen - Senior Vice President and Head of Clinical Drug Development Conference Call Participants Michael Novod - Nordea Markets Richard Vosser - JPMorgan Chase & Co Mark Purcell - Morgan Stanley Michael Nedelcovych - Cowen and Company Jesper Ilsoe - Carnegie Karsten Knudsen Welcome to the Novo Nordisk R&D event in conjunction with the ADA 2022 here in New Orleans in hot summer June. It's great to see all here, and we have a very nice R&D presentation coming up.
- 06/06/2022
|
The Scandinavian Shopping List In A Time Of Bargains
- A list of companies covering some of the world's strongest economies in Scandinavia. Diversification can take place not only across sectors but also across geographies, with opportunities here across pharma, logistics, oil, heavy industry, telecom, 5G, insurance, vehicles, conglomerates, and so forth.
- 06/03/2022
|
The 7 Best Long-Term Stocks to Buy and Hold Until 2032
- Markets are shaky right now. But these seven best long-term stocks to buy and hold should work in just about any economic environment.
- 05/26/2022
|
4 Large Drug Stocks to Watch as the Industry Recovers
- Drug/biotech companies are likely to see significant advances in innovation in 2022. In the Large-Cap Pharmaceuticals industry, Eli Lilly (LLY), Novo Nordisk (NVO), Merck (MRK) and Glaxo (GSK) are worth retaining in your portfolio.
- 05/19/2022
|
How Novo Nordisk Will Protect Insulin Sales
- Advancing insulin technology promises a better patient experience.
- 05/12/2022
|
3 Unstoppable Stocks to Buy in May
- These big drugmakers should be long-term winners.
- 05/07/2022
|
3 Top Biotech Stocks To Watch In May 2022
- Which biotech stocks do you have on your May 2022 watchlist?
- 05/02/2022
|
Novo Nordisk's (NVO) Q1 Earnings and Sales Beat Estimates
- Novo Nordisk (NVO) reports better-than-expected results for Q1. Sales are aided by growth in Diabetes and Obesity Care on higher GLP-1 revenues.
- 05/02/2022
|
Novo Nordisk: Overvalued Pharma That Should Be Rotated Here
- I'll review Novo Nordisk after a chat with one of my fellow contributors on the subject. The company is a popular holding due to its very liquid NYSE-listing NVO. I'll go through what makes the company good - and what makes it face competition here.
- 04/29/2022
|
5 Big Pharma, Biotech Stocks Set to Beat Q1 Earnings Estimates
- Let us take a look at some pharma/biotech stocks, REGN, BIIB, NVO, VRTX and MRNA that are poised to beat on first-quarter earnings.
- 04/29/2022
|
Novo Nordisk lifts 2022 outlook after strong quarter, shares jump
- Shares in Novo Nordisk jumped on Friday after the firm lifted its sales and operating profit guidance for the year on the back of forecast-beating first-quarter earnings, driven by strong sales of its newer diabetes and obesity treatments.
- 04/29/2022
|
Novo Nordisk: Inflation Hedge With Upside Potential
- Novo Nordisk continues to hold its leading position in insulin and the anti-obesity drugs market space that are projected to grow steadily within the next several decades. It has all metrics to inflation-proof your portfolio as it has considerable pricing power and stable dividend payouts.
- 04/27/2022
|
Novo Nordisk: Firing On All Cylinders, Which Is Reflected By The Share Price
- Novo Nordisk reported strong growth in fiscal 2021 with revenue and earnings per share growing in the double digits. And due to anti-obesity medications and GLP-1 products, we can expect Novo Nordisk to continue its high growth rates.
- 04/20/2022
|
Novo Nordisk: Growing Obesity Epidemic Will Generate Strong Demand
- Sales of obesity therapies grew strongly first 3 quarters of 2021. Obesity and related diseases are increasing in both number of cases and geographic diversity.
- 04/18/2022
|
4 Reasons to Add Novo Nordisk (NVO) Stock to Your Portfolio
- Novo Nordisk's (NVO) portfolio of marketed drugs are driving year over year growth. The company has one of the broadest diabetes portfolios in the industry.
- 04/11/2022
|
Novo Nordisk (NVO) Gets FDA Nod for Ozempic's Label Expansion
- The FDA approves Novo Nordisk's (NVO) Ozempic 2.0 mg dose for the treatment of adults with type II diabetes. The medicine is now approved at 0.5 mg, 1.0 mg and 2.0 mg doses for the given indication.
- 03/29/2022
|
Why Novo Nordisk Shares Are Trading Higher Today
- The FDA has approved Novo Nordisk A/S's (NYSE: NVO) 2.0 mg dose of Ozempic (once-weekly semaglutide subcutaneous injection), a glucagon-like peptide-1 (GLP-1) analog for type 2 diabetes. Ozempic is now approved in the US at 0.5 mg,1.0 mg, and 2.0 mg doses to treat type 2.
- 03/29/2022
|
Novo Nordisk's Ozempic drug gets FDA OK for 2 mg dose to treat Type-2 Diabetes
- By Dominic Chopping
- 03/29/2022
|
2 Healthcare Stocks You Can Buy and Hold for the Next Decade
- These two companies offer products that are always in demand, regardless of economic conditions.
- 03/24/2022
|
Got $5,000? These 2 Dividend Stocks Are Bargain Buys
- These stocks also make for promising long-term growth investments.
- 03/16/2022
|
BAYRY vs. NVO: Which Stock Is the Better Value Option?
- BAYRY vs. NVO: Which Stock Is the Better Value Option?
- 03/08/2022
|
Renaissance Technologies Is Taking Profits on Tech Stocks
- Jim Simons (Trades, Portfolio)' Renaissance Technologies recently disclosed its 13F portfolio updates for the fourth quarter of 2022, which ended on Dec. 31.
- 02/22/2022
|
Vir: Expansion Of Covid-19 Antiviral Drug And Hepatitis B Pipeline Makes It An Attractive Bet
- Vir: Expansion Of Covid-19 Antiviral Drug And Hepatitis B Pipeline Makes It An Attractive Bet
- 02/12/2022
|
High drug prices due to ‘complex health care system' in the U.S., Novo Nordisk CEO says
- Novo Nordisk CEO Lars Fruergaard Jørgensen joins Yahoo Finance Live to discuss the future of obesity and diabetes treatments, innovation in these fields, supply issues, drug prices, and the complexity of the U.S. health care system.
- 02/08/2022
|
2 Unstoppable Stocks to Buy and Hold Forever
- Don't underestimate companies that have already stood the test of time.
- 02/05/2022
|
Novo Nordisk's (NVO) Q4 Earnings and Sales Beat Estimates
- Novo Nordisk's (NVO) earnings and revenues beat estimates in Q4. Sales are driven by growth in Diabetes and Obesity Care on higher GLP-1 revenues.
- 02/02/2022
|
Novo Nordisk A/S (NVO) CEO Lars Jorgensen on Q4 2021 Results - Earnings Call Transcript
- Novo Nordisk A/S (NVO) CEO Lars Jorgensen on Q4 2021 Results - Earnings Call Transcript
- 02/02/2022
|
Novo Nordisk Posts Upbeat Q4 Earnings, Expects Obesity Drug Shortages May Soon Be Resolved
- Novo Nordisk A/S NVO reported Q4 sales of DKK 38.3 billion, up 19% Y/Y on a reported basis and 16% on constant exchange rates (CER). Thousands of new traders are learning the ins and outs on how to find profitable trades every day with Benzinga Trading School.
- 02/02/2022
|
Novo Nordisk posts Q4 operating profit below estimates
- Danish drug developer Novo Nordisk posted on Wednesday fourth quarter operating profit that was below expectations, and said it expected to generate sales growth in local currencies of between 6% and 10% in 2022.
- 02/02/2022
|
Pharma Stocks to Report Q4 Earnings on Feb 2: ABBV, NVS & NVO
- Let us take a look at three large pharma companies - ABBV, NVS and NVO - due to release their quarterly results on Feb 2.
- 02/01/2022
|
Novo Nordisk: Continued Dominance In Diabetes Care
- NVO has increased their market share more rapidly than the overall market growth for diabetes treatment.
- 01/19/2022
|
FDA Concerns At Catalent Site Spurred Novo Nordisk's Wegovy Supply Woes: Report
- Last week, Catalent Inc (NYSE: CTLT) received an FDA write-up for its syringe filling facility in Belgium, "allegedly" the culprit behind supply shortage for Novo Nordisk A/S's (NYSE: NVO) obesity drug Wegovy, reported BioProcess International reported. An FDA inspection of the CDMO's filling site in Brussels yielded a Form 483, the publication said, calling it a "recent" inspection.
- 01/14/2022
|
Novo Nordisk shares slump on U.S. supply challenges for obesity drug
- Novo Nordisk shares fell 16% on Monday after the Danish drugmaker late on Friday announced that it will not be able to meet demand for its new weight-loss drug after supply issues in the United States.
- 12/20/2021
|
Final Trades: WRK, NVO, LULU & TGT
- The final trades of the week. With CNBC's Melissa Lee and the Fast Money traders, Guy Adami, Steve Grasso, Jeff Mills and Nadine Terman.
- 12/17/2021
|
Final Trades: NVO, TSE, WMT & bitcoin
- The traders offer their final trades of the week. With CNBC's Dominic Chu and the Fast Money traders, Tim Seymour, Steve Grasso, Brian Kelly and Nadine Terman.
- 12/03/2021
|
Novo Nordisk (NVO) Set to Acquire Dicerna for $3.3 Billion
- Novo Nordisk (NVO) inks agreement to acquire Dicerna for $3.3 billion. The company is looking to boost its RNAi research platform with this acquisition.
- 11/19/2021
|
Novo Nordisk Enhances Metabolic Disorder Pipeline With RNAi Drug Maker Dicerna
- Novo Nordisk paid $3.3 billion to acquire RNAi drug maker Dicerna Pharmaceuticals. Acquisition of Dicerna makes sense from a business standpoint as Novo's strength lies in the metabolic disorder space, especially with key drugs like Ozempic, Wegovy and Saxenda.
- 11/18/2021
|
Dicerna Pharmaceuticals acquired by Novo Nordisk; Shares rocket 80%
- Dicerna Pharmaceuticals (Nasdaq: DRNA) is a biopharma company that concentrates on developing RNAi therapeutics that announced that Novo Nordisk would acquire it for a total equity value of about $3.3 billion, shares in cash of $38.25 each. Both the Board of Directors of Novo Nordisk and Dicerna Pharmaceuticals unanimously approved this transaction.
- 11/18/2021
|
DRNA Stock: The $3B Novo Nordisk Deal That Has Dicerna Pharma Shares Skyrocketing Today
- Dicerna Pharmaceuticals (DRNA) stock is surging higher on Thursday following news of a massive $3.3 billion deal with Novo Nordisk. The post DRNA Stock: The $3B Novo Nordisk Deal That Has Dicerna Pharma Shares Skyrocketing Today appeared first on InvestorPlace.
- 11/18/2021
|
Novo Nordisk Swallows Dicerna In $3.3B Buyout: All You Need To Know
- Novo Nordisk A/S (NYSE: NVO) has agreed to acquire Dicerna Pharmaceuticals Inc (NASDAQ: DRNA) for $38.25 per share in cash, representing a total equity value of $3.3 billion and a premium of 80% to Dicerna's closing price on November 17, 2021. "The acquisition of Dicerna accelerates Novo Nordisk's research within RNAi and expands the usage of the RNAi technology," said Marcus Schindler, the CSO of Novo Nordisk.
- 11/18/2021
|
Why Novo Nordisk (NVO) Is Buying Dicerna Pharmaceuticals (DRNA) For $3.3 Billion
- Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA) announced it entered into a definitive agreement with Novo Nordisk A/S (NYSE: NVO) under which Novo Nordisk will acquire Dicerna. This is why.
- 11/18/2021
|
Novo Nordisk strikes $3.3 billion to buy research partner Dicerna Pharmaceuticals
- Novo Nordisk NVO, +0.37% NOVO.B, +0.69% said it's buying Dicerna Pharmaceuticals DRNA, -0.09% for $3.3 billion, or $38.25 per share in cash. Dicerna ended Wednesday at $21.28.
- 11/18/2021
|
3 Big Pharma Outperformers to Watch Out For in the Near Term
- Eli Lilly (LLY), Pfizer (PFE) and Novo Nordisk (NVO) are three large drugmakers that have outperformed the industry and are good stocks to hold for the next few months and beyond.
- 11/17/2021
|
Novo Nordisk (NVO) Gets Positive CHMP Opinion for Wegovy
- The CHMP gives a positive opinion on, and recommends approval to Novo Nordisk's (NVO) Wegovy for chronic weight management in adults with obesity.
- 11/12/2021
|
EMA Backs Approval Of Novo Nordisk's Ozempic 2mg Dose For Diabetes
- The European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending a label extension for Novo Nordisk A/S's (NYSE: NVO) Ozempic's new dose of 2.0 mg. Ozempic (semaglutide) is currently approved in the EU in 0.5 mg and 1.0 mg doses for type 2 diabetes in adults.
- 11/12/2021
|
4 Top Biotech Stocks To Watch This Week
- Check out these biotech stocks that could prove to be valuable additions to your portfolio.
- 11/08/2021
|
Novo Nordisk A/S (NVO) CEO Lars Fruergaard Jorgensen on Q3 2021 Results - Earnings Call Transcript
- Novo Nordisk A/S (NVO) CEO Lars Fruergaard Jorgensen on Q3 2021 Results - Earnings Call Transcript
- 11/03/2021
|
Novo Nordisk's (NVO) Q3 Earnings and Sales Beat Estimates
- Novo Nordisk (NVO) reports better-than-expected results for Q3. Sales are aided by growth in Diabetes and Obesity Care owing to higher GLP-1 revenues.
- 11/03/2021
|
Novo Nordisk Q3 earnings lifted by demand for new obesity drug
- Drug developer Novo Nordisk on Wednesday reported third-quarter earnings lifted by strong demand for its new obesity drug.
- 11/03/2021
|
If I Could Only Own 1 Healthcare Stock, This Is What It Would Be
- Investing gets simple if you have to put all of your eggs in one basket.
- 10/21/2021
|
Novo Nordisk A/S – Share repurchase programme
- Novo Nordisk A/S – Share repurchase programme
- 10/04/2021
|
3 Big Drug/Biotech Stocks to Boost Your Portfolio's Health
- Sanofi (SNY), Pfizer (PFE) and Novo Nordisk (NVO) are three large drugmakers that are worth betting on in the current scenario.
- 09/30/2021
|
Novo Nordisk A/S – Share repurchase programme
- Novo Nordisk A/S – Share repurchase programme
- 09/20/2021
|
The 10 Richest People on Wall Street and How to Invest in Them
- Knowing what stocks the richest people on Wall Street currently own could help you find potential winners for your portfolio. The post The 10 Richest People on Wall Street and How to Invest in Them appeared first on InvestorPlace.
- 09/10/2021
|
Analysts Differ Most About Potential for Novo's Weight-Loss Drug
- Novo Nordisk AS's ( NVO , Financial) weight-loss drug is biopharma's most controversial blockbuster, according to a report from Evaluate Pharma. The highest and lowest forecasts for the Danish company's weight-loss drug, Saxenda, in 2026 equal 237% of consensus, according to sell-side analysts.
- 09/07/2021
|
Novo Nordisk A/S – Share repurchase programme
- Novo Nordisk A/S – Share repurchase programme
- 09/06/2021
|
4 Blue Chip Bargains In The Biopharma Space
- 4 Blue Chip Bargains In The Biopharma Space
- 09/01/2021
|
Novo Nordisk: Dominance In The Diabetes Market
- The potential continuation in diabetes and obesity trends may provide positive long-term tailwinds for Novo. With health experts now urging Americans to get tested for diabetes at age 35 vs. 40, a potential increase in diagnoses could create a short-term catalyst.
- 09/01/2021
|
3 Big Drug/Biotech Outperformers Worth Keeping an Eye On (Revised)
- Eli Lilly (LLY), Pfizer (PFE) and Novo Nordisk (NVO) are three large drugmakers that have outperformed the industry and are good stocks to hold for the next few months and beyond.
- 08/25/2021
|
House Committee Questions Eli Lilly, Sanofi, Novo Nordisk On 'Unacceptably High' Insulin Prices
- House Energy & Commerce Committee leaders sent three letters to execs at Eli Lilly And Co (NYSE: LLY), Sanofi SA (NASDAQ: SNY), and Novo Nordisk A/S (NYSE: NVO), raising concerns that despite their supposed concern over the past two years with the price of insulin, the price still remains "unacceptably high." Committee chair Frank Pallone (D-NJ) and subcommittee chair Diana DeGette (D-CO) note in all three letters that the price of insulin in the U.S. is more than 10 times that of 33 other countries.
- 08/20/2021
|
3 Big Drug/Biotech Outperformers Worth Keeping an Eye On
- Eli Lilly (LLY), Pfizer (PFE) and Novo Nordisk (NVO) are three large drugmakers that have outperformed the industry and are good stocks to hold for the next few months and beyond.
- 08/18/2021
|
3 Low-Risk Stocks for Conservative Investors
- Protecting capital can be just as important as growing it.
- 08/17/2021
|
Novo Nordisk CEO on product pricing: Our numbers are 'declining year-on-year'
- Novo Nordisk CEO Lars Fruergaard Jørgensen joins Yahoo Finance's Julie Hyman to break down the company's strong second-quarter earnings, assess the pharmaceutical space amid the pandemic, and discuss the FDA approving Novo Nordisk's anti-obesity drug Wegovy. Watch the 2021 Berkshire Hathaway Annual Shareholders Meeting on YouTube: https://youtu.be/gx-OzwHpM9k
- 08/11/2021
|
Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons on 9 August 2021
- Bagsværd, Denmark, 10 August 202 1 — This company announcement discloses the data of the transaction(s) made in Novo Nordisk shares by the company's board members, executives and their associated persons in accordance with Article 19 of Regulation No. 596/2014 on market abuse.
- 08/10/2021
|
Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons on 5 August 2021
- Bagsværd, Denmark, 9 August 202 1 — This company announcement discloses the data of the transaction(s) made in Novo Nordisk shares by the company's board members, executives and their associated persons in accordance with Article 19 of Regulation No. 596/2014 on market abuse.
- 08/09/2021
|
Here Are the Winners of Cowen's Big Pharma R&D Showdown
- The Wall Street firm put big drugmakers' R&D programs through five different tests.
- 08/07/2021
|
Novo Nordisk A/S (NVO) CEO Lars Jorgensen on Q2 2021 Results - Earnings Call Transcript
- Novo Nordisk A/S (NVO) CEO Lars Jorgensen on Q2 2021 Results - Earnings Call Transcript
- 08/05/2021
|
Novo Nordisk's (NVO) Q2 Earnings and Sales Beat Estimates
- Novo Nordisk (NVO) delivers better-than-expected results for Q2. Sales are aided by growth in Diabetes and Obesity Care owing to elevated GLP-1 revenues.
- 08/05/2021
|
BofA Upgrades Novo Nordisk, Says Wegovy Obesity Drug Launch 'Far Exceeded' Expectations
- Novo Nordisk A/S (NYSE:NVO) shares traded higher by 3.2% on Thursday morning after the insulin and diabetes care leader landed a major Wall Street upgrade. The Analyst: Bank of America analyst Sachin Jain upgraded Novo Nordisk from Neutral to Buy and raised his price target from $100.27 to $117.04.
- 08/05/2021
|
Novo Nordisk Shares Are Trading Higher As GLP-1 Treatments Boost Q2 Topline, Bottom-line
- Novo Nordisk A/S (NYSE: NVO) Q2 sales increased 10% Y/Y (17% at CER) to DKK 33.04 billion. Sales in International Operations increased 13% (17% CER) at DKK18.2 billion, and sales in North America Operations increased by 7% (16% at CER) to DKK14.8 billion.
- 08/04/2021
|
Novo Nordisk A/S – Share repurchase programme
- Novo Nordisk A/S – Share repurchase programme
- 08/04/2021
|
Novo Nordisk A/S – Share repurchase programme
- Bagsværd, Denmark, 26 July 2021 – On 7 May 2021, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules"). This programme is part of the overall share repurchase programme of up to DKK 18 billion to be executed during a 12-month period beginning 3 February 2021.
- 07/26/2021
|
Why Is Novo Nordisk Buying a Rare-Disease Candidate?
- The company is mainly known for its diabetes drugs but has some background in rare-disease drugs.
- 07/24/2021
|
Novo Nordisk A/S – Share repurchase programme
- Bagsværd , Denmark, 1 9 July 2021 – On 7 May 2021, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules"). This programme is part of the overall share repurchase programme of up to DKK 18 billion to be executed during a 12-month period beginning 3 February 2021.
- 07/19/2021
|
Novo Nordisk To Buy Prothena's ATTR Amyloidosis Program For Up To $1.2B
- Novo Nordisk A/S (NYSE: NVO) will acquire Prothena Corporation plc's (NASDAQ: PRTA) and clinical stage antibody PRX004 and broader ATTR amyloidosis program. PRX004 is a Phase 2 ready immunotherapy designed to deplete the amyloid deposits associated with the disease pathology of ATTR amyloidosis.
- 07/12/2021
|
Prothena sells amyloidosis portfolio to Novo Nordisk for up to $1.2 billion
- Shares of Prothena Corp. Plc were up 1.3% in premarket trading on Monday after the company announced a deal to sell its ATTR amyloidosis portfolio to Novo Nordisk in a $100 million deal that is worth up to $1.2 billion, based on milestones. ATTR amyloidosis is a rare disease that can cause a buildup of amyloid deposits in the body.
- 07/12/2021
|
Novo Nordisk to buy Prothena's heart drug in deal worth up to $1.2 billion
- Danish drugmaker Novo Nordisk will acquire U.S. drug developer Prothena Corp's experimental heart therapy, PRX004, in a deal that could be worth up to $1.23 billion, the companies said on Monday.
- 07/12/2021
|
ABBV vs. NVO: Which Stock Is the Better Value Option?
- ABBV vs. NVO: Which Stock Is the Better Value Option?
- 07/05/2021
|
Novo Nordisk A/S – Share repurchase programme
- Novo Nordisk A/S – Share repurchase programme
- 07/05/2021
|
Now on Sale at Walmart: Insulin That's Cheaper Than Brands from Lilly, Sanofi, or Novo Nordisk
- The discount chain's private label sells at prices more than 50% lower than brand names made by Lilly, Sanofi, and Novo Nordisk.
- 06/29/2021
|
Walmart, Novo Nordisk Unveil Own Low-Cost Brand Insulin
- Walmart Inc (NYSE: WMT) is launching its first-ever private label insulin analog, available exclusively at its stores. The company worked directly with manufacturer Novo Nordisk A/S (NYSE: NVO) on ReliOn Novolog, allowing it to offer the product in both vials and FlexPens at a far lower price.
- 06/29/2021
|
Investigational 2.0 mg dose of Ozempic® (semaglutide) demonstrates superior reductions in blood sugar vs Ozempic® 1.0 mg in adults with type 2 diabetes in a phase 3 trial
- Bagsv æ rd , Denmark, 26 June 2021 – Novo Nordisk today presented data showing that an investigational 2.0 mg dose of Ozempic® (semaglutide) provided statistically significant and superior reductions in blood sugar (HbA1C) compared with Ozempic® 1.0 mg1. These data were the outcome of the SUSTAIN FORTE trial, a phase 3b, 40-week, efficacy and safety trial comparing once-weekly semaglutide 2.0 mg vs Ozempic® 1.0 mg as add-on to metformin with or without sulfonylureas in 961 adults with type 2 diabetes in need of additional blood sugar reduction. The results were presented at the 81st Annual Scientific Sessions of the American Diabetes Association (ADA)1, 2 and primary results are in press for publication in The Lancet Diabetes & Endocrinology.
- 06/26/2021
|
This Leading Healthcare Company's New Obesity Treatment Has Great Potential
- A new FDA-approved product with the potential to triple weight loss in obesity patients should be a huge win for the company.
- 06/23/2021
|
Novo Nordisk Makes Big Move Into Diagnostics With $563 Million Investment
- The investment arm of Novo Nordisk AS (NVO) just added to its long list of life science companies, thrusting the Danish pharma giant into the growing market for diagnostics. Novo paid $563 million to become the majority shareholder of U.K.-based BBI Group, a world leader in producing diagnostic reagents and supplies for other test makers.
- 06/17/2021
|
Novo Nordisk, Lumen Bioscience Collaborate For Oral Biologics For Cardiometabolic Diseases
- Privately-held Lumen Bioscience has entered into a research collaboration with Novo Nordisk A/S (NYSE: NVO) to evaluate the use of Lumen's spirulina-based drug development and manufacturing platform in Novo Nordisk's R&D activities within obesity and other metabolic disorders. The initial stages of the research collaboration will take place over approximately one year.
- 06/16/2021
|
Novo Nordisk (NVO) Semaglutide Gets FDA Nod for Obesity
- Novo Nordisk's (NVO) GLP-1 product, semaglutide gets FDA approval for weight loss in people living with obesity. It will be marketed by the brand name of Wegovy.
- 06/07/2021
|
Novo Nordisk A/S – Share repurchase programme
- Bagsværd, Denmark, 7 June 2021 – On 7 May 2021, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules"). This programme is part of the overall share repurchase programme of up to DKK 18 billion to be executed during a 12-month period beginning 3 February 2021.
- 06/07/2021
|
Novo Nordisk (NVO) Inks Deal to Develop Heart Failure Treatment
- Novo Nordisk (NVO) inks an exclusive license agreement with Heartseed Inc. to manufacture and commercialize the latter's HS-001, a cell therapy developed for the treatment of heart failure.
- 06/01/2021
|
Novo Nordisk A/S – Share repurchase programme
- Novo Nordisk A/S – Share repurchase programme
- 05/31/2021
|
Novo Nordisk Resubmits Semaglutide 2mg For Type 2 Diabetes In US
- Novo Nordisk A/S (NYSE: NVO) has resubmitted a label expansion application to FDA for Ozempic (semaglutide) to introduce a new dose of 2.0 mg. Semaglutide is a glucagon-like peptide-1 (GLP-1) analog.
- 05/28/2021
|
Novo Nordisk A/S – Share repurchase programme
- Novo Nordisk A/S – Share repurchase programme
- 05/25/2021
|
Why Novo Nordisk Is Still a Top Stock for 2021
- This stock could be a great addition to any long-term portfolio.
- 05/19/2021
|
Novo Nordisk, Eli Lilly Obesity Drugs Could Be Game Changers
- Novo Nordisk AS ( NVO , Financial) and Eli Lilly and Co. ( LLY , Financial) are testing unique weight-loss drugs aimed at tackling the growing problem of obesity and beefing up the top and bottom lines of both pharmaceutical giants.
- 05/13/2021
|
Novo Nordisk A/S – Share repurchase programme
- Bagsværd, Denmark, 7 May 202 1 — As part of the up to DKK 18 billion 2021 share repurchase programme, Novo Nordisk A/S has now initiated a new share repurchase programme for an amount of up to DKK 3.3 billion in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules”).
- 05/07/2021
|
Novo Nordisk A/S purchases B shares worth DKK 2,586 million from Novo Holdings A/S under the 2021 share repurchase programme
- Bagsværd, Denmark, 7 May 202 1 — Novo Nordisk A/S has today entered into an agreement to purchase 5,610,000 B shares of DKK 0.20 to a value of DKK 2,586 million from Novo Holdings A/S. This transaction is part of Novo Nordisk A/S' 2021 share repurchase programme of up to a total of DKK 18 billion to be executed during a 12-month period beginning 3 February 2021. The transaction price is DKK 461.04 per share and has been calculated as the three-day volume weighted average market price from 5 May 2021 to 7 May 2021 in the open window following the announcement of Novo Nordisk A/S' quarterly financial results.
- 05/07/2021
|
These Top 2 Healthcare Companies Are in a Race to Riches
- Which diabetes drug maker will win this photo finish for investors?
- 05/06/2021
|
Novo Nordisk A/S (NVO) CEO Lars Jorgensen on Q1 2021 Results - Earnings Call Transcript
- Novo Nordisk A/S (NVO) CEO Lars Jorgensen on Q1 2021 Results - Earnings Call Transcript
- 05/05/2021
|
Novo Nordisk's (NVO) Q1 Earnings and Sales Beat Estimates
- Novo Nordisk (NVO) beat estimates for both earnings and sales in the first quarter of 2021.
- 05/05/2021
|
Growth is coming back following Covid-19, Novo Nordisk CEO says
- Novo Nordisk CEO Lars Fruergaard Jørgensen discusses first-quarter earnings and the outlook for the North American region for the Danish pharmaceutical company.
- 05/05/2021
|
Novo Nordisk ups guidance after Q1 results beat expectations
- Denmark's Novo Nordisk, the world's biggest manufacturer of diabetes drugs, raised its financial forecast in local currencies on Wednesday after reporting first quarter sales and earnings above expectations.
- 05/05/2021
|
Profitability Measurements Only One Of Many Attractions For Novo Nordisk
- Novo Nordisk is the biggest producer of antidiabetic pharmaceuticals in the world. The company is set to report first quarter results on May 5 and analysts are expecting very modest growth.
- 04/29/2021
|
Novo Nordisk A/S – Share repurchase programme
- Bagsværd , Denmark, 26 April 2021 – On 3 February 2021, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules"). This programme is part of the overall share repurchase programme of up to DKK 17 billion to be executed during a 12-month period beginning 3 February 2021.
- 04/26/2021
|
Novo Nordisk (NVO) to Begin Study on Oral Semaglutide in Obesity
- Novo Nordisk (NVO) to start a phase IIIa study testing oral semaglutide 50 mg in people with obesity or those who are overweight with comorbidities. The study is expected to begin in second-half 2021.
- 04/22/2021
|
Novo Nordisk To Start Phase 3 Obesity Trial With Oral Semaglutide
- Novo Nordisk A/S (NYSE: NVO) is entering the Phase 3a study in obesity with oral semaglutide 50 mg. The decision follows the completion of the STEP phase 3a trial with once-weekly subcutaneously administered semaglutide 2.4 mg.
- 04/21/2021
|
Why Novo Nordisk (NVO) is a Great Dividend Stock Right Now
- Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Novo Nordisk (NVO) have what it takes?
- 03/30/2021
|
Hunting For Recession-Proof Bargains: 10 Picks As Prey
- In the following article, I present 10 recession-proof stocks that are undervalued right now. Including companies from the healthcare sector like Gilead Sciences, Amgen, Novo Nordisk, Walgreens Boots Alliance, CVS Health, Cardinal Health and Bayer.
- 03/29/2021
|
Novo Nordisk A/S – Share repurchase programme
- Bagsværd, Denmark, 29 March 2021 – On 3 February 2021, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules"). This programme is part of the overall share repurchase programme of up to DKK 17 billion to be executed during a 12-month period beginning 3 February 2021.
- 03/29/2021
|
Novo Nordisk receives Refusal to File letter for once-weekly semaglutide 2.0 mg for the treatment of type 2 diabetes
- Bagsværd, Denmark, 22 March 2021 – Novo Nordisk today announced that the US Food and Drug Administration (FDA) has issued a Refusal to File letter covering the label expansion application for once-weekly semaglutide 2.0 mg for the treatment of type 2 diabetes which was filed on 20 January 2021. A refusal to file letter is received when the FDA determines additional information is required to review a complete application.
- 03/22/2021
|
Novo Nordisk A/S – Share repurchase programme
- Bagsværd, Denmark, 22 March 2021 – On 3 February 2021, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules"). This programme is part of the overall share repurchase programme of up to DKK 17 billion to be executed during a 12-month period beginning 3 February 2021.
- 03/22/2021
|
Gilead (GILD) Expands NASH Collaboration With Novo Nordisk
- Gilead (GILD) expands collaboration with Novo Nordisk for developing NASH treatments.
- 03/19/2021
|
4 Stocks in Focus as Diabetes Sector Grows Amid Pandemic
- Here are a few diabetes-centric MedTech stocks, ABT, NVO, MDT, PODD and TNDM, which investors can focus on to reap profits in the new normal.
- 03/19/2021
|
Gilead, Novo Nordisk To Test Triple Combo Therapy In New NASH Study
- Gilead Sciences Inc (NASDAQ: GILD) and Novo Nordisk A/S (NYSE: NVO) have expanded their clinical collaboration in non-alcoholic steatohepatitis (NASH). The companies will conduct a Phase 2b study of Novo Nordisk's semaglutide and a fixed-dose combination of Gilead's cilofexor and firsocostat, alone and in combination in people with compensated cirrhosis due to NASH.
- 03/18/2021
|
Obesity Offers Tremendous Potential For Novo Nordisk
- Obesity Offers Tremendous Potential For Novo Nordisk
- 02/22/2021
|
Trading in Novo Nordisk shares by board members, executives and associated persons on 15 February 2021
- Bagsværd, Denmark, 17 February 2021 — This document discloses the data of the transaction(s) made in Novo Nordisk shares by the company's board members, executives and their associated persons in accordance with Article 19 of Regulation No. 596/2014 on market abuse.
- 02/17/2021
|
Health care: Novo Nordisk CEO discusses 7% sales growth in 2020 and overall industry
- Yahoo Finance's Brian Sozzi, Julie Hyman, and Myles Udland speak with Novo Nordisk CEO Lars Jørgensen about the company's healthcare treatments and outlook. #healthcare Subscribe to Yahoo Finance: https://yhoo.it/2fGu5Bb About Yahoo Finance: At Yahoo Finance, you get free stock quotes, up-to-date news, portfolio management resources, international market data, social interaction and mortgage rates that help you manage your financial life.
- 02/10/2021
|
Novo Nordisk A/S – Share repurchase programme
- Bagsværd, Denmark, 8 February 2021 – On 3 February 2021, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules"). This programme is part of the overall share repurchase programme of up to DKK 17 billion to be executed during a 12-month period beginning 3 February 2021.
- 02/08/2021
|
Trading in Novo Nordisk shares by board members, executives and associated persons on 3-4 February 2021
- Bagsværd, Denmark, 5 February 2021 — This company announcement discloses the data of the transaction(s) made in Novo Nordisk shares by the company's board members, executives and their associated persons in accordance with Article 19 of Regulation No. 596/2014 on market abuse.
- 02/05/2021
|
Novo Nordisk A/S (NVO) CEO Lars Jørgensen on Q4 2020 Results - Earnings Call Transcript
- Novo Nordisk A/S (NVO) CEO Lars Jørgensen on Q4 2020 Results - Earnings Call Transcript
- 02/03/2021
|
Novo Nordisk's (NVO) Q4 Earnings and Sales Beat Estimates
- Novo Nordisk (NVO) beats both earnings and sales estimates for the fourth quarter of 2020.
- 02/03/2021
|
Novo Nordisk: Q4 Earnings Insights
- Shares of Novo Nordisk (NYSE:NVO) were unchanged after the company reported Q4 results. Quarterly Results Earnings per share rose 14.29% year over year to $0.64, which were in line with the estimate of $0.64.
- 02/03/2021
|
7 Safe Stocks to Buy for Solid Returns in Tumultuous Times
- While stocks keep going up and up, more risks are mounting under the surface. As such, you should be looking at safe stocks to buy now.
- 01/28/2021
|
Novo Nordisk A/S – Share repurchase programme
- Novo Nordisk A/S – Share repurchase programme
- 01/25/2021
|
Sana Biotechnology Seeks $150 Million U.S. IPO
- Sana Biotechnology Seeks $150 Million U.S. IPO
- 01/22/2021
|
Novo Nordisk (NVO) Files for Ozempic's Label Expansion in US
- Novo Nordisk (NVO) submits a label expansion application to the FDA for the existing marketing authorization for Ozempic to include a new dose of 2.0 mg.
- 01/21/2021
|
In This Overheated Market, It's Not If But When. Here's How To Prepare
- In This Overheated Market, It's Not If But When. Here's How To Prepare
- 01/20/2021
|
Novo Nordisk: Poised To Profit As The Lockdowns Make The Obesity Crisis Worse
- Novo Nordisk is the global leader in obesity and diabetes treatments. There is evidence that the lockdowns increased the number of people suffering from obesity.
- 01/19/2021
|
Novo Nordisk: An Outstanding Company For The Long Term
- Novo Nordisk is a well-managed business with long-term growth opportunities. It is the world market leader in diabetes and obesity care.
- 01/19/2021
|
Novo Nordisk A/S – Share repurchase programme
- Bagsværd, Denmark, 18 January 2021 – On 3 November 2020, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules"). This programme is part of the overall share repurchase programme of up to DKK 17 billion to be executed during a 12-month period beginning 5 February 2020.
- 01/18/2021
|
Novo Nordisk A/S (NVO) CEO Lars Jørgensen Presents at 39th Annual JPMorgan Virtual Healthcare Conference (Transcript)
- Novo Nordisk A/S (NVO) CEO Lars Jørgensen Presents at 39th Annual JPMorgan Virtual Healthcare Conference (Transcript)
- 01/12/2021
|
Novo Nordisk A/S – Share repurchase programme
- Bagsværd, Denmark, 11 January 2021 – On 3 November 2020, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules"). This programme is part of the overall share repurchase programme of up to DKK 17 billion to be executed during a 12-month period beginning 5 February 2020.
- 01/11/2021
|
Novo Nordisk (NVO) Files for Ozempic's Label Expansion in EU
- Novo Nordisk (NVO) files for a label expansion of Ozempic in the EU to include a new dose of 2.0 mg.
- 12/30/2020
|
Novo Nordisk files for EU regulatory approval of once-weekly semaglutide 2.0 mg for the treatment of type 2 diabetes
- Bagsværd, Denmark, 29 December 2020 – Novo Nordisk today announced the submission of a label extension application to the European Medicines Agency (EMA) for the existing marketing authorisation for Ozempic®, a once-weekly glucagon-like peptide-1 (GLP-1) analogue, to introduce a new dose of 2.0 mg. Ozempic® is currently approved in the EU in 0.5 mg and 1.0 mg doses for the treatment of type 2 diabetes in adults.
- 12/29/2020
|
5 Health Care Stocks Outperforming the Benchmark
- According to the GuruFocus All-in-One Screener, a Premium feature, the following guru-owned health care stocks have outperformed the S&P 500 Index over the past 12 months through Dec. 22.
- 12/22/2020
|
Novo Nordisk A/S – Share repurchase programme
- Bagsværd, Denmark, 22 December 2020 – On 3 November 2020, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules"). This programme is part of the overall share repurchase programme of up to DKK 17 billion to be executed during a 12-month period beginning 5 February 2020.
- 12/22/2020
|
Novo Nordisk (NVO) Files for Semaglutide Label Expansion in EU
- Novo Nordisk (NVO) files application in Europe for the label expansion of subcutaneous Ozempic (semaglutide) 2.4 mg.
- 12/21/2020
|
Novo Nordisk files for EU regulatory approval of once-weekly semaglutide 2.4 mg for weight management
- Bagsværd, Denmark 18 December 2020 – Novo Nordisk today announced the submission of a Marketing Authorisation Application (MAA) to the European Medicines Agency (EMA) for subcutaneous semaglutide 2.4 mg, a once-weekly glucagon-like peptide-1 (GLP-1) analogue for weight management. The potential indication is for the treatment of adults with obesity (BMI ≥ 30 kg/m2) or overweight (BMI ≥ 27 kg/m2) with at least one weight-related comorbidity, as an adjunct to reduced-calorie diet and increased physical activity.
- 12/18/2020
|
Novo Nordisk to enter phase 3 development in Alzheimer's disease with oral semaglutide
- Bagsværd, Denmark, 16 December 2020 – Novo Nordisk today announced the decision to enter phase 3 development in Alzheimer's disease with 14 mg oral semaglutide, a once-daily oral formulation of the long-acting GLP-1 analogue semaglutide. The decision follows evaluation of GLP-1 data from preclinical models, real-world evidence studies, post-hoc analysis of data from large cardiovascular outcomes trials, as well as discussions with regulatory authorities.
- 12/16/2020
|
How You Can Profit From the Best-Managed Drugmaker on Earth
- One metric shows that decades of dominance treating diabetes has created unrivaled profitability.
- 12/08/2020
|
7 Cheap Stocks to Buy for 2021 That Deserve Recognition
- These 7 cheap stocks span industry and have a great chance to appreciate in price next year. Click here for the metrics and reasoning.
- 12/03/2020
|
EMISPHERE INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Emisphere Technologies, Inc. - EMIS
- NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Emisphere Technologies, Inc. (OTC: EMIS) to Novo Nordisk A/S (NYSE: NVO). Under the terms of the proposed transaction, shareholders of Emisphere will receive only $7.82 in cash for each share of Emisphere that they own. KSF is seeking to determine whether this consideration and the process that led to it are a
- 12/03/2020
|
Novo Nordisk A/S (NVO) CEO Lars Jørgensen on ESG Conference Call - Transcript
- Novo Nordisk A/S (NVO) CEO Lars Jørgensen on ESG Conference Call - Transcript
- 11/30/2020
|
Novo Nordisk And Lego Board Member Joins Data-Focused Wellness Company Bellabeat
- Wellness, as many know, is a tremendous industry with a global value north of $4.5 trillion. Whether it's diet plans, exercise regimens, or the latest in meditation practices, more people around the world want to feel better and improve their health.
- 11/23/2020
|
Novo Nordisk A/S – Share repurchase programme
- Bagsværd, Denmark, 23 November 2020 – On 3 November 2020, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules"). This programme is part of the overall share repurchase programme of up to DKK 17 billion to be executed during a 12-month period beginning 5 February 2020.
- 11/23/2020
|
Novo Nordisk A/S – Share repurchase programme
- Bagsværd, Denmark, 9 November 2020 – On 3 November 2020, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules"). This programme is part of the overall share repurchase programme of up to DKK 17 billion to be executed during a 12-month period beginning 5 February 2020.
- 11/09/2020
|
Novo Nordisk, Trading Near Highs, Announces $1.8 Billion Acquisition
- Novo Nordisk, trading near record highs, early Friday announced it would buy a maker of proprietary oral drug delivery technology, a longtime partner, for $1.8 billion, and NVO stock rose. The post Novo Nordisk, Trading Near Highs, Announces $1.8 Billion Acquisition appeared first on Investor's Business Daily.
- 11/06/2020
|
Trading in Novo Nordisk shares by board members, executives and associated persons on 4 and 5 November 2020
- Bagsværd , Denmark, 6 November 202 0 — This document discloses the data of the transaction(s) made in Novo Nordisk shares by the company's board members, executives and their associated persons in accordance with Article 19 of Regulation No. 596/2014 on market abuse.
- 11/06/2020
|
Novo Nordisk to Acquire Emisphere Technologies for $1.35 Billion
- ROSELAND, N.J., Nov. 06, 2020 (GLOBE NEWSWIRE) -- Emisphere Technologies, Inc. (“Emisphere” or the “Company”) today announced that it has entered into a definitive agreement with Novo Nordisk A/S (“Novo Nordisk”), whereby Novo Nordisk will acquire Emisphere, on a cash-free, debt-free basis, for $1.35 billion in cash. The consideration to be paid per share will depend on the amount of cash and debt at closing, but the Company currently estimates it to be approximately $7.82 per share based on approximately 170.9 million fully diluted shares outstanding. This price represents a premium of approximately 17% over the volume-weighted average Emisphere share price for the five trading days ending on November 5, 2020.
- 11/06/2020
|
Denmark's Novo Nordisk to buy Emisphere Technologies in $1.8 billion deal
- Danish diabetes drug maker Novo Nordisk will acquire U.S. Emisphere Technologies, which specialises in developing orally administered versions of drugs, in a deal totalling $1.8 billion, it said on Friday.
- 11/06/2020
|
Trading in Novo Nordisk shares by board members, executives and associated persons on 4 November 2020
- Bagsværd, Denmark, 4 November 2020 — This document discloses the data of the transaction(s) made in Novo Nordisk shares by the company's board members, executives and their associated persons in accordance with Article 19 of Regulation No. 596/2014 on market abuse.
- 11/05/2020
|
Novo Nordisk A/S – Share repurchase programme
- Novo Nordisk A/S – Share repurchase programme
- 11/03/2020
|
Novo Nordisk A/S purchases B shares worth DKK 2,913 million from Novo Holdings A/S under the 2020 share repurchase programme
- Novo Nordisk A/S purchases B shares worth DKK 2,913 million from Novo Holdings A/S under the 2020 share repurchase programme
- 11/03/2020
|
Novo Nordisk A/S (NVO) CEO Lars Fruergaard Jorgensen on Q3 2020 Results - Earnings Call Transcript
- Novo Nordisk A/S (NVO) CEO Lars Fruergaard Jorgensen on Q3 2020 Results - Earnings Call Transcript
- 10/30/2020
|
Novo Nordisk's sales jump 2.1% to £3.74 billion in the fiscal third quarter
- Novo Nordisk (ETR: NOVC) said on Friday that its net profit in the fiscal third quarter came in better than expected. The company highlighted that patients in Europe and the United States stockpiled roughly £241.77 million worth of medicines in the fiscal first quarter amidst the ongoing COVID-19 crisis that has so far infected more than 45 million people worldwide and caused over 1.18 million deaths.
- 10/30/2020
|
Nicholas Ward's Dividend Growth Portfolio: August 2020 Review
- My passive income increased 15.9% year over year. My portfolio posted gains of 8.6% during August.
- 09/07/2020
|
Novo Nordisk A/S – Share repurchase programme
- Novo Nordisk A/S – Share repurchase programmeBagsværd, Denmark, 17 August 2020 – On 6 August 2020, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules"). This programme is part of the overall share repurchase programme of up to DKK 17 billion to be executed during a 12-month period beginning 5 February 2020.Under the programme, initiated 6 August 2020, Novo Nordisk will repurchase B shares for an amount up to DKK 2.8 billion in the period from 6 August 2020 to 28 October 2020.Since the announcement of the programme, the following transactions have been made: Number of B sharesAverage purchase priceTransaction value, DKK 6 August 2020115,000402.5446,292,373 7 August 2020115,000406.5946,758,374 10 August 2020115,000406.9446,798,239 11 August 2020115,000415.8147,818,109 12 August 2020112,000418.7246,897,030 13 August 2020112,000421.1847,172,388 14 August 2020110,000416.7545,842,291 Accumulated under the programme794,000 327,578,802 The details for each transaction made under the share repurchase programme are published on novonordisk.com.Transactions related to Novo Nordisk’s incentive programmes have resulted in a net transfer from Novo Nordisk of 14,577 B shares in the period from 6 August 2020 to 14 August 2020. The shares in these transactions were not part of the Safe Harbour repurchase programme. With the transactions stated above, Novo Nordisk owns a total of 20,843,403 B shares of DKK 0.20, corresponding to 0.9% of the share capital, as treasury shares. The total amount of A and B shares in the company is 2,350,000,000 including treasury shares.Novo Nordisk expects to repurchase B shares for an amount up to DKK 17 billion during a 12-month period beginning 5 February 2020. As of 14 August 2020, Novo Nordisk has since 5 February 2020 repurchased a total of 20,853,179 B shares at an average share price of DKK 425.76 per B share equal to a transaction value of DKK 8,878,366,533.Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat diabetes and other serious chronic diseases such as obesity and rare blood and endocrine disorders. We do so by pioneering scientific breakthroughs, expanding access to our medicines and working to prevent and ultimately cure disease. Novo Nordisk employs about 43,100 people in 80 countries and markets its products in around 170 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com, Facebook, Twitter, LinkedIn, YouTube.Further informationMedia: Anne Margrethe Hauge+45 4442 3450amhg@novonordisk.com Ken Inchausti (US)+1 609 240 9429kiau@novonordisk.com Investors: Daniel Muusmann Bohsen+45 3075 2175dabo@novonordisk.com Valdemar Borum Svarrer+45 3079 0301jvls@novonordisk.com Ann Søndermølle Rendbæk+45 3075 2253arnd@novonordisk.com Mark Joseph Root+45 3079 4211mjhr@novonordisk.com Kristoffer Due Berg (US)+1 609 235 2989krdb@novonordisk.com Company announcement No 50 / 2020Attachment * CA200817_Safe_Harbour
- 08/17/2020
|
Novo Nordisk: Long-Term Growth By CV Risk Factor Reduction
- Novo Nordisk reported solid H1 results; EPS projections by analysts for 2020 and 2021 have risen. The company has laid out increasingly detailed data that semaglutide (Ozempic), AM833 and (especially) the combination of the two can drive obesity treatment.
- 08/17/2020
|
Novo Nordisk: A Solid And Expanding Pharmaceutical Titan
- Novo Nordisk saw its revenues decline slightly QOQ because of countries reducing their stockpiles of its pharmaceuticals. Profits were up substantially YOY.
- 08/17/2020
|
Novo Nordisk (NVO) Resumes Phase III Hemophilia Studies
- Novo Nordisk (NVO) resumes the phase III studies on concizumabin in hemophilia A and B patients regardless of inhibitor status.
- 08/14/2020
|
3 Top Diabetes Stocks to Buy in August
- DexCom, Tandem Diabetes, and Novo Nordisk have plenty of momentum and growth ahead, making them excellent buys this month.
- 08/13/2020
|
Novo Nordisk A/S -- Moody's announces completion of a periodic review of ratings of Novo Nordisk A/S
- Moody's Investors Service ("Moody's") has completed a periodic review of the ratings of Novo Nordisk A/S and other ratings that are associated with the same analytical unit. The review was conducted through a portfolio review in which Moody's reassessed the appropriateness of the ratings in the context of the relevant principal methodology(ies), recent developments, and a comparison of the financial and operating profile to similarly rated peers.
- 08/11/2020
|
5 Health Care Companies Outperforming the Market
- UnitedHealth on the list Continue reading...
- 08/07/2020
|
Pharma Stock Roundup: ABBV, MRK Q2 Earnings & Coronavirus Updates in Focus
- Sanofi (SNY)/Glaxo (GSK) and J&J (JNJ) sign deals with U.S. government for coronavirus vaccine candidate. Several drugmakers announce second-quarter results.
- 08/07/2020
|
Novo Nordisk's (NVO) Q2 Earnings Beat Estimates, Sales Miss
- Novo Nordisk's (NVO) earnings surpass estimates but revenues miss the same in the second quarter of 2020.
- 08/06/2020
|
Novo Nordisk tweaks outlook higher after pandemic sales hit
- Diabetes drug maker Novo Nordisk raised its full-year earnings outlook slightly on Thursday as it managed to offset stagnant sales with cost cuts during the coronavirus crisis. The Danish company, whose shares rose 1%, said second quarter sales were hit by fewer patients starting treatments as well as coronavirus-related destocking, after its first quarter was boosted by a surge in demand for medicines. "Despite COVID-19, we are satisfied by the performance in the first half of 2020 and by the progress made on our strategic aspirations," CEO Lars Fruergaard Jorgensen said in a statement.
- 08/06/2020
|
Novo Nordisk beats profit estimates, lifts outlook slightly
|
Novo Nordisk's operating profit increased by 9% in Danish kroner and by 8% at constant exchange rates (CER) in the first six months of 2020
- Financial report for the period 1 January 2020 to 30 June 2020 6 August 2020Novo Nordisk's operating profit increased by 9% in Danish kroner and by 8% at constant exchange rates (CER) in the first six months of 2020 * Sales increased by 8% in Danish kroner and by 7% at CER to DKK 63.9 billion. Sales in International Operations increased by 11% in Danish kroner (12% at CER) and sales in North America Operations increased by 4% in Danish kroner (1% at CER). Sales growth was positively impacted by COVID-19-related stocking, largely offset by fewer patients initiating treatment. * Sales within Diabetes and Obesity care increased by 8% to DKK 53.9 billion (7% at CER), driven by GLP-1 sales increasing by 30% in Danish kroner (28% at CER) reflecting the uptake of Ozempic® and the Rybelsus® launch, Obesity care grew by 8% in Danish kroner (9% at CER) and Biopharm sales increased by 8% (6% at CER). * Sales in the second quarter were unchanged in both Danish kroner and at CER compared to the second quarter of 2019. Sales were negatively impacted by fewer patients initiating treatment and COVID-19-related destocking. * During the second quarter, Novo Nordisk reported the successful completion of the phase 3 programme with semaglutide 2.4 mg, the phase 2 trial with AM833 and the phase 1 combination trial with AM833 and semaglutide 2.4 mg, all in Obesity care. Further, Novo Nordisk signed an agreement to acquire Corvidia Therapeutics including their lead candidate, ziltivekimab, currently being investigated in a phase 2b trial in cardiovascular disease. * For the 2020 outlook, sales growth is still expected to be 3-6% at CER, and operating profit growth is now expected to be 2-5% at CER.PROFIT AND LOSSH1 2020H1 2019Growth as reportedGrowth at CER* DKK million Net sales63,881 59,327 8%7% Operating profit30,140 27,691 9%8% Net profit22,522 20,040 12%N/A Diluted earnings per share (in DKK)9.58 8.39 14%N/A * CER: Constant exchange rates (average 2019)Lars Fruergaard Jørgensen, president and CEO: "Despite COVID-19, we are satisfied by the performance in the first half of 2020 and by the progress made on our strategic aspirations. We saw a strong uptake of our GLP-1 portfolio and we continue to increase our diabetes value market share. Within R&D, the obesity clinical trial results are very encouraging. As COVID-19 continues to severely impact societies around the world, our priorities continue to be to safeguard our employees, continue supply of our life-saving medicines and help societies around the world to fight the pandemic."On 6 August 2020 at 13.00 CEST, corresponding to 7.00 am EDT, a conference call will be held. Investors will be able to listen in via a link on novonordisk.com, which can be found under ‘Investors’.Contacts for further information Media: Mette Kruse Danielsen+45 3079 3883mkd@novonordisk.com Ken Inchausti (US)+1 609 240 9429 kiau@novonordisk.com Investors: Daniel Muusmann Bohsen+45 3075 2175dabo@novonordisk.com Valdemar Borum Svarrer+45 3079 0301jvls@novonordisk.com Ann Søndermølle Rendbæk+45 3075 2253arnd@novonordisk.com Mark Joseph Root+45 3079 4211mjhr@novonordisk.com Kristoffer Due Berg (US)+1 609 235 2989 krdb@novonordisk.com Company announcement No 49 / 2020Attachment * PR200806_Q2_UK
- 08/06/2020
|
Novo Nordisk A/S – Share repurchase programme
- Novo Nordisk A/S – Share repurchase programmeBagsværd, Denmark, 5 August 2020 – On 11 May 2020, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules"). This programme is part of the overall share repurchase programme of up to DKK 17 billion to be executed during a 12-month period beginning 5 February 2020.Under the programme, initiated 11 May 2020, Novo Nordisk has repurchased B shares for an amount up to DKK 2.6 billion in the period from 12 May 2020 to 4 August 2020. The programme is now concluded.Since the announcement as of 28 July 2020, the following transactions have been made: Number of B sharesAverage purchase priceTransaction value, DKK Accumulated, last announcement5,359,150 2,338,027,461 28 July 2020103,000428.1544,099,961 29 July 2020101,000427.2143,148,533 30 July 2020103,000424.4843,720,976 31 July 2020103,000420.8243,344,297 3 August 2020103,000414.2142,663,250 4 August 2020109,810409.7644,995,285 Accumulated under the programme5,981,960 2,599,999,763 The details for each transaction made under the share repurchase programme are published on novonordisk.com.With the transactions stated above, Novo Nordisk owns a total of 20,063,980 B shares of DKK 0.20, corresponding to 0.9% of the share capital, as treasury shares. The total amount of A and B shares in the company is 2,350,000,000 including treasury shares.Novo Nordisk expects to repurchase B shares for an amount up to DKK 17 billion during a 12-month period beginning 5 February 2020. As of 4 August 2020, Novo Nordisk has since 5 February 2020 repurchased a total of 20,059,179 B shares at an average share price of DKK 426.28 per B share equal to a transaction value of DKK 8,550,787,732.Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat diabetes and other serious chronic diseases such as obesity and rare blood and endocrine disorders. We do so by pioneering scientific breakthroughs, expanding access to our medicines and working to prevent and ultimately cure disease. Novo Nordisk employs about 43,100 people in 80 countries and markets its products in around 170 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com, Facebook, Twitter, LinkedIn, YouTube.Further informationMedia: Anne Margrethe Hauge+45 4442 3450amhg@novonordisk.com Ken Inchausti (US)+1 609 240 9429kiau@novonordisk.com Investors: Daniel Muusmann Bohsen+45 3075 2175dabo@novonordisk.com Valdemar Borum Svarrer+45 3079 0301jvls@novonordisk.com Ann Søndermølle Rendbæk+45 3075 2253arnd@novonordisk.com Mark Joseph Root+45 3079 4211mjhr@novonordisk.com Kristoffer Due Berg (US)+1 609 235 2989krdb@novonordisk.com Company announcement no. 48 / 2020Attachment * CA200805_Safe_Harbour
- 08/05/2020
|
10 Biggest Biotechnology Companies
- With Novo Nordisk at the top of the list, these are the 10 biggest biotechnology companies by 12-month trailing revenue.
- 07/30/2020
|
Novo, Roche Scored Highest Returns on Invested Capital
- During same 10-year period, Eisai and Abbott were worst performers in measure Continue reading...
- 07/28/2020
|
Summers Value Partners Q2 2020 Investor Letter
- Summers Value Partners is a boutique value manager that uses a focused, long-term approach to investing in areas of the market where most managers are unwilling or unable to participate.
- 07/21/2020
|
Did Hedge Funds Make The Right Call On Novo Nordisk A/S (NVO)?
- The latest 13F reporting period has come and gone, and Insider Monkey have plowed through 821 13F filings that hedge funds and well-known value investors are required to file by the SEC. The 13F filings show the funds' and investors' portfolio positions as of March 31st, a week after the market trough. Now, we are […]
- 07/17/2020
|
300 Years Fighting The Fed Proves It Pays To Hedge Portfolios
- 300 years ago, central bank money printing inflated asset prices until the Mississippi bubble burst and the first international stock market crash began.
- 07/17/2020
|
How This Pioneer ESG Fund Still Outperforms 80% of Its Peers
- The Trillium ESG Global Equity fund’s thoughtful approach to data and commitment to its principles have paid off, especially lately.
- 07/16/2020
|
A Pioneer ESG Fund Is Still Shooting Out the Lights
- The Trillium ESG Global Equity fund’s thoughtful approach to data and commitment to its principles have paid off, especially lately.
- 07/16/2020
|
Novo Nordisk's Shares Rise on New Approvals, Strong Portfolio
- Shares of Novo Nordisk (NVO) rally on solid product portfolio aided by new approvals.
- 07/13/2020
|
Novo Nordisk A/S – Share repurchase programme
- Bagsværd, Denmark, 13 July 2020 – On 11 May 2020, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European.
- 07/13/2020
|
Biomarin's Hemophilia A Drug Among 5 Up for FDA Approval Soon
- If approved, company’s Roctavian would become first gene therapy for inherited disease Continue reading...
- 07/09/2020
|
5 Greenblatt Magic Formula Biotech Stocks to Weather the Summer Coronavirus Storm
- Stocks to consider as biotech company Novavax gets $1.6 billion in federal aid for Covie-19 vaccine Continue reading...
- 07/07/2020
|
Abbott Deal, UnitedHealth Coverage Push Up Tandem Shares
- Stock of San Diego-based medical device company hits one-year high Continue reading...
- 07/06/2020
|
12 European Stocks for the Second Half of 2020
- Bet on health care, utilities, technology, and staples headed into what could be an uncertain second half, says J.P. Morgan.
- 06/30/2020
|
Novo Nordisk Completes Two Studies on Obesity Candidate
- Novo Nordisk (NVO) provides data from a monotherapy study and a combination study on AM833.
- 06/22/2020
|
Novo Nordisk: A Plan To Grow Into The 2030s
- NVO is now expanding its horizons again, from diabetes to also treat obesity, now to treat or prevent CV disease more broadly. As Type 2 diabetes, or T2D, does
- 06/21/2020
|
ENDRA Life Sciences' NASH Test Device, TAEUS, At Commercialization Inflection Point
- TAEUS device fills the need for a non-invasive test for NASH. The device is the only point of care (POC) field diagnostic available. ENDRA is moving forward wit
- 06/19/2020
|
Is Novo Nordisk (NVO) a Smart Long-term Buy?
- Saturna Capital Corporation is the investment management company of Sextant Mutual Funds. Sextant Mutual Funds recently released Q1 2020 Investor Letter, a copy of which you can download here. The Sextant Growth Fund posted a return of -15.13% for the quarter, outperforming its benchmark, the S&P; 500 Index which returned -19.60% in the same quarter. […]
- 06/19/2020
|
Before You Buy Novo Nordisk (NVO) Stock, Read This
- Amana Mutual Funds Trust recently released its Q1 2020 Investor Letter, a copy of which you can download here. The Amana Income Fund posted a return of -18.01% for the quarter, outperforming its benchmark, the S&P; 500 Index which returned -19.60% in the same quarter. You should check out Amana Mutual Fund's top 5 stock […]
- 06/17/2020
|
Here is What Hedge Funds Think About Novo Nordisk A/S (NVO)
- The financial regulations require hedge funds and wealthy investors that exceeded the $100 million equity holdings threshold to file a report that shows their positions at the end of every quarter. Even though it isn't the intention, these filings to a certain extent level the playing field for ordinary investors. The latest round of 13F […]
- 06/15/2020
|
Pharma Stock Roundup: Coronavirus Updates From ABBV, LLY, JNJ, FDA Approvals
- J&J; (JNJ), AbbVie (ABBV) and Lilly (LLY) make progress in coronavirus research efforts.
- 06/12/2020
|
The Daily Biotech Pulse: FDA Nod For Viela, 3 IPOs And Hematology Congress Presentations
- Here's a roundup of top developments in the biotech space over the last 24 hours.Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 11) * ADC Therapeutics SA (NYSE: ADCT) * Applied Molecular Transport Inc (NASDAQ: AMTI) (IPOed June 5) * Celldex Therapeutics, Inc. (NASDAQ: CLDX) * Novo Nordisk A/S (NYSE: NVO)(announced a deal to buy privately held Corvidia Therapeutics that is developing therapies for cardio-renal diseases for up to $2.1 billion) * Regeneron Pharmaceuticals Inc (NASDAQ: REGN)(announced commencement of first human trial of REGN-COV2, its investigational dual antibody cocktail for the prevention and treatment of COVID-19) * Sarepta Therapeutics Inc (NASDAQ: SRPT) * Zynex Inc. (NASDAQ: ZYXI) (announced addition to the S&P; SmallCap 600 Index)Down In The Dumps (Biotech Stocks Hitting 52-week Lows June 11) * Ayala Pharmaceuticals Inc (NASDAQ: AYLA) * CALLIDITAS THER/S ADR (NASDAQ: CALT)(IPOed June 5) * Evofem Biosciences Inc (NASDAQ: EVFM) * Hoth Therapeutics Inc (NASDAQ: HOTH) * Vaccinex Inc (NASDAQ: VCNX)Stocks In Focus Leap Therapeutics's Cancer Drug Gets Orphan Drug Designation Leap Therapeutics Inc (NASDAQ: LPTX) said the FDA U.S. Food and granted orphan drug designation for its DKN-01 for the treatment of gastric and gastroesophageal junction cancer. The company said DKN-01 is currently being evaluated in Phase 1/2 and Phase 2 clinical trials for gastroesophageal, gynecologic, hepatobiliary, and prostate cancers.The stock climbed 28.44% to $2.40 in after-hours trading.Virtual European Hematology Association Congress Presentations Agios Pharmaceuticals Inc (NASDAQ: AGIO) reported interim data from its ongoing Phase 2 study evaluating single agent mitapivat in non-transfusion-dependent α\- and β-thalassemia, which showed it induced hemoglobin increase of 1 g/dl or more in 12 of 13 evaluable patients, including 4 of 4 α-thalassemia patients during Weeks 4-12. The company said 7 of the 8 evaluable patients achieved sustained hemoglobin response during Weeks 12-24.The company noted that one Grade 3 adverse events of renal dysfunction was reported related to the treatment post cut-off date but was resolved upon treatment discontinuation.The stock was sliding 9.79% to $45.71 in pre-market trading.Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) and Crispr Therapeutics AG (NASDAQ: CRSP) presented at the EHA meeting new clinical data for CTX001, an investigational CRISPR/Cas9 gene-editing therapy, from the CLIMB-111 and CLIMB-121 Phase 1/2 trials in transfusion-dependent beta thalassemia, or TDT, and severe sickle cell disease, or SCD.Long-term follow-up data from a TDT patient showed at 15 months after CTX001 infusion, the patient was transfusion independent and had appreciable hemoglobin levels. The second patient was transfusion independent at five months.New data from one SCD patient showed nine months after CTX001 infusion, the patient was free of vaso-occlusive crises, was transfusion independent and had an increase in hemoglobin levels.Vertex shares were edging up 0.42% to $265 and Crispr was advancing 2.18% to $61 in pre-market trading.Editas Medicine Inc (NASDAQ: EDIT) announced results from a pre-clinical, proof-of-concept study of EDIT-301 in SCD, with both in-vitro and in-vivo studies revealing several desirable properties.The stock was rising 4.40% to $26.11 in pre-market trading.Viela Receives FDA Approval For Neurological Autoimmune Disorder Drug Viela Bio Inc (NASDAQ: VIE) said the FDA approved its Uplizna for the treatment of adult patients with neuromyelitis optica spectrum disorder, or NMOSD, who are anti-AQP4 antibody positive as a twice-a-year maintenance regimen following initial doses. Approximately 80% of all patients with NMOSD test positive for anti-AQP4 antibodies. The company is expects to launch the drug commercially in June.In pre-market trading, the stock was gaining 6.55% to $54.82.Quidel Gets $635,000 BARDA Funding For 4-Virus Point-Of-Care Test Quidel Corporation (NASDAQ: QDEL) said it has received funding from the Biomedical Advanced Research and Development Authority, or BARDA, to support the development of a point-of-care diagnostic assay that potentially tests for four respiratory viruses: SARS-CoV-2, Influenza A, Influenza B, and Respiratory Syncytial Virus. The respiratory virus panel would be developed to run on Quidel's Sofia 2 flagship instrument.The company said funding began May 29, 2020, and will run through April 2021, totaling approximately $635,000. The goal of the funding, according to the company, is to achieve an Emergency Use Authorization for the test within the funding period.FDA Approves Mylan-Biocon's Diabetes Drug Mylan NV (NASDAQ: MYL) along with its Indian partner Biocon said the FDA approved their Semglee - insulin glargine injection - in vial and pre-filled pen presentations, to control high blood sugar in adults with type 2 diabetes and adult and pediatric patients with type 1 diabetes. Semglee has an identical amino acid sequence to Sanofi SA's (NASDAQ: SNY) Lantus and is approved for the same indications.Mylan shares were adding 3.37% to $16.85 in pre-market trading.On The Radar Clinical Readouts/Presentations Principia Biopharma is due to present at the American Academy of Dermatology Virtual Meeting Experience, full data set presentation from the Phase 2 Part B pemphigus trial with its investigational drug rilzabrutinib.Oramed Pharmaceuticals, Inc. (NASDAQ: ORMP) will present at the American Diabetes Association 80th Scientific Sessions posters on oral insulin ORMD-0801's effects on glucose parameters in uncontrolled Type 2 diabetes, oral insulin-induced reduction in liver fat content in Type 2 diabetic patients with non-alcoholic steatohepatitis and evening oral insulin glycemic effects in uncontrolled Type 2 diabetes patientsIPO Vaxcyte, Inc., a company developing vaccines to prevent or treat the most common and deadly infectious diseases, priced its upsized initial public offering, or IPO, of 15.625 million shares of its common stock at $16 per share. The shares will begin trading on the Nasdaq under the ticker symbol PCVX.La Jolla, California-based Avidity Biosciences, Inc. priced its upsized IPO of 14.4 million shares at $18 per share compared to the estimated price range of $17-$18. The shares of the biopharma, which develops a new class of oligonucleotide-based therapies called Antibody Oligonucleotide Conjugates to treat a wide range of serious diseases, will be listed on the Nasdaq under the ticker symbol RNA.Cambridge, Massachusetts-based gene therapy company Generation Bio Co priced its IPO of 10.53 million shares at $19 per share compared to the estimated price range of $18-$19. The company's shares will begin trading on the Nasdaq under the ticker symbol GBIO.See more from Benzinga * The Daily Biotech Pulse: Sorrento Submits EUA Application For Rapid Coronavirus Test, Decision Day For Viela, Lantern Pharma IPO * The Daily Biotech Pulse: Keytruda Setback For Merck, Denali Pulls The Plug On Neurological Asset * The Daily Biotech Pulse: Soleno Flunks Late-Stage Study, Sanofi Strikes Breast Cancer Partnership, NanoViricides Shortlists Coronavirus Treatment Candidates(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
- 06/12/2020
|
Novo Nordisk to Acquire Corvidia Therapeutics for $725M Cash
- Novo Nordisk (NVO) enters into a deal to acquire Corvidia Therapeutics for an upfront payment of $725 million in cash.
- 06/12/2020
|
Novo Nordisk expands into cardiovascular disease with $725 million deal
- Novo Nordisk has agreed to buy AstraZeneca spin-off Corvidia Therapeutics for an initial $725 million as the world's largest diabetes drugmaker seeks to expand into cardiovascular disease treatments. The acquisition is in line with Novo's strategy to diversify its portfolio and gain a foothold in markets for drugs closely linked to its core therapeutic areas of diabetes and obesity. "Novo Nordisk has in recent years formulated a clearer strategy in cardiovascular diseases," Novo's chief science officer Mads Krogsgaard Thomsen said in an interview.
- 06/11/2020
|
The Daily Biotech Pulse: Sorrento Submits EUA Application For Rapid Coronavirus Test, Decision Day For Viela, Lantern Pharma IPO
|
Novo Nordisk Reports Weight Loss Of 14.9% In STEP 1 Trial, Says Met Both Primary Endpoints
|
The Daily Biotech Pulse: FDA Nod For Roche's Combo Therapy In Liver Cancer, Allena Rips Higher, Pfizer To Invest Up To $500M In Biotechs
- Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs June 1)
Adaptimmune Therapeutics PLC...
- 06/02/2020
|
The Zacks Analyst Blog Highlights: Novo Nordisk, International Business Machines, Honeywell International, Amgen and S&P Global
- The Zacks Analyst Blog Highlights: Novo Nordisk, International Business Machines, Honeywell International, Amgen and S&P; Global
- 06/01/2020
|
Stocks That Hit 52-Week Highs On Monday
|
Top Stock Reports for Novo Nordisk, IBM & Honeywell
- Top Stock Reports for Novo Nordisk, IBM & Honeywell
- 05/29/2020
|
Shares of several healthcare companies are trading higher amid market strength. Strength potentially related to coronavirus efforts including testing, vaccine development and treatment measures from several names in the sector.
|
White House announces plan for Medicare enrollees to get insulin for $35 a month
- Medicare recipients will be able to get prescription plans that limit copays for insulin, a potential savings of hundreds of dollars, the White House announced Tuesday in a pivot to pocketbook issues that could influence November’s election.
- 05/27/2020
|
'List of external participants expected at Rose Garden event starting momentarily where @POTUS will announce @MedicareGov patients will be provided with new choices of Part D plans for insulin at no more than $35 for a month's supply.' -Steve Herman Tweet
|
Yield Growth's NeonMind at Forefront of Researching Psychedelics for Weight Control
|
Stocks That Hit 52-Week Highs On Wednesday
|
Novo Nordisk Option Alert: Jan 15 $75 Calls Sweep (34) near the Ask: 327 @ $1.351 vs 11 OI; Ref=$63.9799
|
Gyon Technologies Capital Management, LP Buys Berkshire Hathaway Inc, Coca-Cola Co, Novo ...
|
Bar Harbor Trust Services Buys Novo Nordisk A/S, CVS Health Corp, Wells Fargo, Sells Microsoft ...
|
Novo Nordisk Shares Quiet Following Press Release Co.'s Semaglutide 2.4 mg Shows Superior, Sustained Weight Loss vs Placebo
|
Reynders McVeigh Capital Management, LLC Buys Becton, Dickinson and Co, CVS Health Corp, ...
|
Pharma Stock Roundup: Q1 Earnings of BMY, NVO, Coronavirus Update From PFE, RHHBY
- Novo Nordisk (NVO) and Bristol-Myers (BMY) announce Q1 results. Pfizer (PFE), Roche (RHHBY) and Lilly (LLY) provide update on their coronavirus-related research efforts.
- 05/08/2020
|
Novo Nordisk A/S (CPH:NOVO B) Just Beat Earnings: Here's What Analysts Think Will Happen Next
- A week ago, Novo Nordisk A/S (CPH:NOVO B) came out with a strong set of quarterly numbers that could potentially lead...
- 05/08/2020
|
Novo Nordisk's (NVO) Q1 Earnings and Sales Beat Estimates
- Novo Nordisk (NVO) beats on Q1 sales and earnings, and maintains outlook amid the coronavirus pandemic.
- 05/07/2020
|
Novo Nordisk A/S (NVO) Q1 2020 Earnings Call Transcript
- Image source: The Motley Fool. Novo Nordisk A/S (NYSE: NVO)Q1 2020 Earnings CallMay 6, 2020, 7:00 a.m. ETContents: Prepared Remarks Questions and Answers Call Participants Prepared Remarks: OperatorHello and welcome to the Q1 2020 Novo Nordisk AS Earnings Conference Call.
- 05/07/2020
|
European shares flat as mixed earnings, U.S.-China tensions weigh
- European shares opened little changed on Wednesday as a batch of mixed earnings reports and simmering U.S.-China tensions added to doubts about a swift economic recovery even as many countries eased lockdown measures. The pan-European STOXX 600 index was flat as losses in oil and gas sector, following a recent surge, offset gains in healthcare shares. The global mood also remained fragile as U.S. President Donald Trump again took aim at China, urging it to be transparent about the origins of the novel coronavirus outbreak.
- 05/06/2020
|
Novo Nordisk Sales Rose by 16% in Q1 2020
|
Pharmaceutical Manufacturing Market & COVID-19 Assessment 2020 - ResearchAndMarkets.com
- The "Pharmaceutical Manufacturing - Global Market Outlook (2018-2027)" report has been added to ResearchAndMarkets.com's offering.
- 05/01/2020
|
Global Insulin Delivery Device Market (2019 to 2024) - Trends, Forecast, and Competitive Analysis
- Dublin, May 01, 2020 -- The "Insulin Delivery Device Market Report: Trends, Forecast, and Competitive Analysis" report has been added to ResearchAndMarkets.com's.
- 05/01/2020
|
Edited Transcript of OTEX.TO earnings conference call or presentation 30-Apr-20 9:00pm GMT
- Q3 2020 Open Text Corp Earnings Call
- 05/01/2020
|
Just - Evotec Biologics to Collaborate with Ology Bioservices On Antibodies Against Coronavirus
- PARTNERSHIP IS PART OF A CONTRACT AWARDED TO OLOGY BIOSERVICES BY THE DEPARTMENT OF DEFENSE TO DEVELOP AND MANUFACTURE MONOCLONAL ANTIBODIES FOR TREATMENT AND PREVENTION OF INFECTION WITH SARS-COV-2 JUST ...
- 04/30/2020
|
GSB Wealth Management, LLC Buys Canadian National Railway Co, Clorox Co, Novo Nordisk A/S, ...
|
Resumen: Novo Nordisk pronunciar el discurso de apertura de la cumbre Veeva R&D Summit Europe de I+D en lnea
- Veeva Systems (NYSE:VEEV) acogerá la cumbre Veeva R&D Summit Europe 2020 del 19 al 20 de mayo, que se desarrollará en línea, donde más de 1.000 pr
- 04/29/2020
|
Novo Nordisk hlt Keynote-Vortrag an Online-Veranstaltung Veeva R&D Summit Europe
- Veeva Systems (NYSE: VEEV) veranstaltet vom 19. bis 20. Mai 2020 den Veeva R&D Summit Europe 2020 als Online-Veranstaltung, bei der mehr als 1000
- 04/29/2020
|
Novo Nordisk inaugurera le Sommet europen virtuel R&D de Veeva
- Veeva Systems (NYSE : VEEV) organisera le 2020 Veeva R&D Summit Europe les 19 et 20 mai comme une conférence en ligne, durant laquelle plus de 100
- 04/29/2020
|
Samenvatting: Novo Nordisk geeft een keynote op de Online Veeva R&D Summit Europe
- Veeva Systems (NYSE: VEEV) organiseert de Veeva R&D Summit Europe 2020 van 19-20 mei als een online evenement, waar meer dan 1000 life sciences-pr
- 04/29/2020
|
Riassunto: Novo Nordisk terr il discorso di apertura del Vertice europeo online sulle attivit di ricerca e sviluppo di Veeva
- Il 19 e il 20 maggio Veeva Systems (NYSE:VEEV) terrà il Vertice europeo del 2020 sulle attività di ricerca e sviluppo di Veeva quale evento online che
- 04/29/2020
|
The Zacks Analyst Blog Highlights: Visa, Novo Nordisk, American Tower, Caterpillar and 3M
- The Zacks Analyst Blog Highlights: Visa, Novo Nordisk, American Tower, Caterpillar and 3M
- 04/29/2020
|
The Zacks Analyst Blog Highlights: Visa, Novo Nordisk, American Tower, Caterpillar and 3M
- The Zacks Analyst Blog Highlights: Visa, Novo Nordisk, American Tower, Caterpillar and 3M
- 04/29/2020
|
American Real Estate Partners (AREP) And Independencia Sell 1100-1200 American Boulevard In Premier New Jersey Office Park For $95M
- American Real Estate Partners (AREP) and Independencia Asset Management announced today the sale of 1100-1200 American Boulevard in Hopewell Township, NJ to an undisclosed buyer for $95M. Originally built in 2000 as part of the Merrill Lynch corporate campus, the property was constructed to the highest
- 04/29/2020
|
The Daily Biotech Pulse: Inovio's MERS Vaccine Data, Fast Track Designation For Erytech, FDA Approves Higher Dose Of Merck's Keytruda
- Here's a roundup of top developments in the biotech space over the last 24 hours:Scaling The Peaks (Biotech stocks that hit 52-week highs April 28.) * AstraZeneca plc (NYSE: AZN) * Arcturus Therapeutics Ltd (NASDAQ: ARCT) * Bio-Rad Laboratories, Inc. Class A Common Stock (NYSE: BIO) * Black Diamond
- 04/29/2020
|
Novo Nordisk to Keynote the Online Veeva R&D Summit Europe
- Novo Nordisk to Keynote the Online Veeva R&D Summit Europe
- 04/29/2020
|
WPP First Quarter Trading Update
- WPP (NYSE: WPP) today reported its 2020 First Quarter Trading Update.
- 04/29/2020
|
The Daily Biotech Pulse: Inovio's MERS Vaccine Data, Fast Track Designation For Erytech, FDA Approves Higher Dose Of Merck's Keytruda
- Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech stocks that hit 52-week highs April 28.)
AstraZeneca plc (NYSE:...
- 04/29/2020
|
Tracking Q2 and Full-Year 2020 Earnings Estimates
- Tracking Q2 and Full-Year 2020 Earnings Estimates
- 04/28/2020
|
Tracking Q2 and Full-Year 2020 Earnings Estimates
- In addition to featuring updated analyst reports on 16 stocks, Today's Research Daily provides a real-time Q1 scorecard and the revisions trend for Q2 and beyond.
- 04/28/2020
|
Stocks That Hit 52-Week Highs On Tuesday
|
The Daily Biotech Pulse: Pfizer Earnings, Roche's Spinal Muscular Dystrophy Treatment, Moderna COVID-19 Vaccine Update
- Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs April 27)
AstraZeneca plc (NYSE: AZN...
- 04/28/2020
|
Best & Worst ADRs - Monday, April 27
- The top-ranked sectors are healthcare, technology, consumer goods, and utilities.
- 04/27/2020
|
Stocks That Hit 52-Week Highs On Monday
- During Monday's morning session, these companies made new 52-week highs.
Noteworthy Points:
The largest company by market cap to set a new 52-week high was Novo Nordisk...
- 04/27/2020
|
Novo Nordisk (CPH:NOVO B) Could Easily Take On More Debt
- Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...
- 04/26/2020
|
Were Hedge Funds Right About Amgen, Inc. (AMGN)?
- We hate to say this but, we told you so. On February 27th we published an article with the title Recession is Imminent: We Need A Travel Ban NOW and predicted a US recession when the S&P 500 Index was trading at the 3150 level. We also told you to short the market and buy […]
- 04/24/2020
|
The Daily Biotech Pulse: FDA Approves Sanofi's Meningococcal Vaccine, Pluristem Secures $54M In Funding For COVID-19 Treatment, Oric Pharma Prices IPO
- Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech stocks hitting 52-week highs April 23.)
Arcturus Therapeutics Ltd...
- 04/24/2020
|
Outlook on the Worldwide Polymer-Drug Conjugate Industry to 2025 - by Manufacturers, Regions, Technology & Application
- Dublin, April 24, 2020 -- The "Polymer-Drug Conjugate Market Insights 2020, Analysis and Forecast Global and Chinese Market to 2025, by Manufacturers, Regions, Technology,.
- 04/24/2020
|
Lilly raises 2020 earnings forecast on pandemic stockpiling
- Eli Lilly Q1 revenues beat forecasts as COVID-19 pandemic boosts sales by $250 million, with diabetes drug Trulicity a big beneficiary
- 04/24/2020
|
Stocks That Hit 52-Week Highs On Thursday
- During Thursday's morning trading, these companies set new 52-week highs.Noteworthy Points: * Johnson & Johnson (NYSE: JNJ) was the largest company by market cap to set a new 52-week high. * The smallest company when looking at market cap to set a new 52-week high was LightPath Technologies (NASDAQ
- 04/23/2020
|
Hedge Funds’ This Stock Pick Debunked Naysayers
- Coronavirus is probably the 1 concern in investors' minds right now. It should be. On February 27th we published an article with the title Recession is Imminent: We Need A Travel Ban NOW. We predicted that a US recession is imminent and US stocks will go down by at least 20% in the next 3-6 […]
- 04/22/2020
|
Global Polymer-Drug Conjugate Market (2020 to 2025) - Analysis and Forecast - ResearchAndMarkets.com
- The "Polymer-Drug Conjugate Market Insights 2020, Analysis and Forecast Global and Chinese Market to 2025, by Manufacturers, Regions, Technology, Application" report has been added to ResearchAndMarkets.com's offering.
- 04/22/2020
|
Virta Health Appoints Dr. Robert Ratner, Former Chief Scientific and Medical Officer of the American Diabetes Association, as Chief Medical Officer
- Dr. Robert Ratner, former Chief Scientific and Medical Officer of the American Diabetes Association, joins Virta Health as Chief Medical Officer
- 04/22/2020
|
Evotec Regains Global Rights to Beta Cell Replacement Therapy
- BETA CELL REPLACEMENT THERAPY IS CONSIDERED AN ATTRACTIVE THERAPY FOR INSULIN-DEPENDENT DIABETES EVOTEC'S IPSC-DERIVED ISLET-LIKE CLUSTERS ARE FUNCTIONALLY EQUIVALENT TO PRIMARY HUMAN ISLETS HAMBURG, GERMANY ...
- 04/22/2020
|
- Early indications of a coronavirus lobbying boom — Will there be a bust, too?
- 04/21/2020
|
Global Pharmaceutical Manufacturing Market is Expected to Grow at a CAGR of 7.0% During 2018-2027
- Some of the key players profiled in the Pharmaceutical Manufacturing Market include Takeda, Sanofi, Roche, Pfizer, Novo Nordisk, Novartis, Lupin, GlaxoSmithKline, Gilead Sciences, Eli Lily, Merck & Co., Cipla, Astra Zeneca, Amgen, Actavis and Abbott Laboratories.
- 04/21/2020
|
The Daily Biotech Pulse: Applied DNA Begins Validating COVID-19 Test, Cara's Positive Readout, Novan Explores Strategic Alternatives
- Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech stocks that hit 52-week highs April 20)
Abbott Laboratories (NYSE...
- 04/21/2020
|
An insulin maker will give free insulin to diabetes patients whose jobs were affected by the coronavirus pandemic
- The pharmaceutical company announced on Tuesday that it will offer insulin free of charge for 90 days to diabetes patients who lost health insurance coverage because they lost their jobs.
- 04/17/2020
|
5 Pharmaceutical Companies to Consider as Coronavirus Vaccine Race Heats Up
- Biotech and drug manufacturing companies with the strength to weather further coronavirus storms Continue reading...
- 04/16/2020
|
5 Pharmaceutical Companies to Consider as Coronavirus Vaccine Race Heats Up
- 5 Pharmaceutical Companies to Consider as Coronavirus Vaccine Race Heats Up, Stocks: GSK,SNY,ALXN,BIIB,JNJ,NVO,TECH, Warren Buffett, Pioneer Investments, David Carlson, release date:Apr 16, 2020
- 04/16/2020
|
Global Oral Biologics & Biosimilars Market Global Report (2020 to 2030) - Identify Growth Segments for Investment
- Dublin, April 16, 2020 -- The "Oral Biologics & Biosimilars Market Global Report 2020-30" report has been added to ResearchAndMarkets.com's offering. The.
- 04/16/2020
|
Evotec Enters Nanomedicine Through Strategic Partnership with Leon-Nanodrugs
- NANO- AND MICROPARTICLES HAVE BROAD APPLICABILITY BOTH ACROSS MODALITIES AND ALONG THE DISCOVERY AND DEVELOPMENT VALUE CHAIN BY REFORMULATING MOLECULES, LEON-NANODRUGS' PROPRIETARY TECHNOLOGY ENHANCES ...
- 04/16/2020
|
Shares of several healthcare companies are trading higher. Strength could potentially be related to the increased demand in medical products stemming from the coronavirus pandemic.
|
Bringing Manufacturing Back to the U.S. Is Easier Said Than Done
- What will it take to reverse a decades-long shift to global supply chains?
- 04/15/2020
|
2 Top Small-Cap Stocks to Buy Right Now
- These development-stage drug companies are well positioned for success, even amid the current market uncertainty.
- 04/15/2020
|
Lost insurance & need insulin? Makers offer it free or cheap
- On Tuesday, Novo Nordisk announced a new program offering free insulin for at least three months for those who have lost insurance.
- 04/14/2020
|
Novo Nordisk offers free 90-day insulin supply to people experiencing financial hardship due to COVID-19
- People with diabetes using Novo Nordisk Inc. insulin who have lost health insurance coverage because of a change in job status due to the COVID-19 pandemic may now be eligible for enrollment in our Diabetes Patient Assistance Program (PAP) and receive insulin free of charge for 90 days.
- 04/14/2020
|
Lost insurance & need insulin? Makers offer it free or cheap
- TRENTON, N.J. (AP) — Diabetes patients struggling to afford insulin, especially those losing health insurance because of the coronavirus pandemic, can get it at sharply reduced prices — even for free. All top three insulin makers are now offering programs...
- 04/14/2020
|
Lost insurance & need insulin? Makers offer it free or cheap
- Diabetes patients struggling to afford insulin, especially those losing health insurance because of the coronavirus pandemic, can get it at sharply reduced prices — even for free. On Tuesday, Novo Nordisk announced a new program offering free insulin for at least three months for those who have lost
- 04/14/2020
|
The Zacks Analyst Blog Highlights: Alibaba, Pfizer, S&P Global, Novo Nordisk and Duke Energy
- The Zacks Analyst Blog Highlights: Alibaba, Pfizer, S&P Global, Novo Nordisk and Duke Energy
- 04/14/2020
|
The Zacks Analyst Blog Highlights: Alibaba, Pfizer, S&P Global, Novo Nordisk and Duke Energy
- The Zacks Analyst Blog Highlights: Alibaba, Pfizer, S&P Global, Novo Nordisk and Duke Energy
- 04/14/2020
|
Novo Nordisk offers free 9…-day insulin supply to people experiencing financial hardship due ...
|
Top Analyst Reports for Alibaba, Pfizer & S&P Global
- Top Analyst Reports for Alibaba, Pfizer & S&P; Global
- 04/13/2020
|
Top Analyst Reports for Alibaba, Pfizer & S&P Global
- Today's Research Daily features new research reports on 16 major stocks, including Alibaba Group (BABA), Pfizer (PFE) and S&P Global (SPGI).
- 04/13/2020
|
Avidity Biosciences Appoints Carsten Boess to its Board of Directors
- Avidity Biosciences (Avidity), a privately-held biopharmaceutical company pioneering Antibody Oligonucleotide Conjugates (AOCs™), announced today the appointment of Carsten Boess to its board of directors. Mr. Boess, who has nearly thirty years of industry experience as a finance executive and board
- 04/13/2020
|
Sunbelt Securities Inc. Boosts Position in Novo Nordisk A/S (NYSE:NVO)
- Sunbelt Securities Inc. boosted its holdings in Novo Nordisk A/S (NYSE:NVO) by 20.6% during the 4th quarter, HoldingsChannel reports. The institutional investor owned 19,976 shares of the company’s stock after purchasing an additional 3,410 shares during the quarter. Sunbelt Securities Inc.’s holdings in Novo Nordisk A/S were worth $955,000 at the end of the most […]
- 04/13/2020
|
Akero Heads to Top of Class in NASH; Genfit Says Pandemic Won’t Delay Data
- Akero’s FGF21 analog yields 63 percent to 72 percent relative hepatic fat reduction in Phase 2a study; the company awaits biopsy data hoping to see a
- 04/10/2020
|
Biotech Roundup: GSK’s Ante, Shakeup at Sage, Telehealth’s Rise & More
- The COVID-19 pandemic has stopped enrollment in many clinical trials and postponed the start of others but there is still life in the life sciences
- 04/10/2020
|
Europe's coronavirus export bans raise concern over insulin supplies
- Several European countries have banned the export of insulin in recent weeks, a move industry officials said was based on a misguided fear that the COVID-19 pandemic would cause shortages of a drug vital to millions of diabetes patients. EU curbs on drug exports during the coronavirus emergency mostly cover medication used to treat COVID-19, including muscle relaxants, painkillers and hydroxychloroquine.
- 04/09/2020
|
Diabetes Devices (BGM, Insulin Delivery) Market Worth $41.6 Billion by 2027: Key Insights & Opportunities - ResearchAndMarkets.com
- The "Diabetes Devices Market Size, Share & Trends Analysis Report by Product (BGM Devices, Insulin Delivery Devices) by Distribution Channel, by End Use (Hospitals, Homecare), by Region, and Segment Forecasts, 2020-2027" report has been added to ResearchAndMarkets.com's offering.
- 04/09/2020
|
Novo Nordisk Receives Health Approval For Rybelsus As Treatment Option To Improve Glycemic Control In Adults With Type 2 Diabetes Mellitus
|
Global Diabetes Devices Industry Assessment 2020-2027 - Technological Advancements in Diabetes Devices, Rising Awareness About Diabetes Preventive Care
- The "Diabetes Devices Market Size, Share & Trends Analysis Report by Product (BGM Devices, Insulin Delivery Devices) by Distribution Channel, by End Use (Hospitals, Homecare), by Region, and Segment Forecasts, 2020-2027" report has been added to ResearchAndMarkets.com's offering.
- 04/08/2020
|
Diabetes Devices Market Size, Share & Trends Analysis Report By Product By Distribution Channel, By End Use, By Region And Segment Forecasts, 2020 - 2027
- New York, April 08, 2020 -- Reportlinker.com announces the release of the report "Diabetes Devices Market Size, Share & Trends Analysis Report By Product By Distribution.
- 04/08/2020
|
Global Hormone Replacement Therapy Market (2020 to 2027) - by Product, Route of Administration, Type of Disease, Region and Segment Forecasts
- Dublin, April 08, 2020 -- The "Hormone Replacement Therapy Market Size, Share & Trends Analysis Report by Product (Estrogen, Human Growth), by Route Of Administration.
- 04/08/2020
|
Novo Nordisk A/S (NYSE:NVO) Shares Sold by Franklin Resources Inc.
- Franklin Resources Inc. reduced its position in Novo Nordisk A/S (NYSE:NVO) by 9.0% in the 4th quarter, Holdings Channel reports. The firm owned 309,200 shares of the company’s stock after selling 30,585 shares during the quarter. Franklin Resources Inc.’s holdings in Novo Nordisk A/S were worth $17,896,000 at the end of the most recent reporting […]
- 04/08/2020
|
Drugmaker Eli Lilly Caps Insulin Costs at $35 as CCP Virus Crisis Deepens
- Drugmaker Eli Lilly & Co. announced on April 7 that it has rolled out a scheme to cap ...
- 04/08/2020
|
Eli Lilly Introduces Program to Lower Insulin Costs
- Drug giant Eli Lilly said Tuesday that it is capping the out-of-pocket cost of its insulin at $35 a month to help patients who may face financial struggles as a result of the coronavirus pandemic. The new program is available for people with commercial insurance or without insurance. Patients with government
- 04/07/2020
|
As coronavirus worsens, Eli Lilly lowers insulin cost
- Eli Lilly is offering a new $35 co-pay for insulin as millions of Americans struggle to pay their bills during the coronavirus outbreak.
- 04/07/2020
|
Hormone Replacement Therapy Market Size, Share & Trends Analysis Report By Product, By Route Of Administration, By Type Of Disease, By Region And Segment Forecasts, 2020 - 2027
- Hormone Replacement Therapy Market Size, Share & Trends Analysis Report By Product (Estrogen, Human Growth), By Route Of Administration (Oral, Parenteral), By Type Of Disease, By Region, And Segment Forecasts, 2020 - 2027 Read the full report: https://www.reportlinker.com/p05879593/?utm_source=PRN The
- 04/07/2020
|
Futures, Global Markets Soar For Second Day As Virus Fears Fade, Dollars Slides
- "Optimism on the direction of equity markets will be difficult to maintain until we see more clarity on the corporate earnings outlook and until the dispersion of analysts’ forecasts subsides."
- 04/07/2020
|
Eli Lilly lowers insulin costs as coronavirus crisis deepens
- Drugmaker Eli Lilly & Co said on Tuesday it has capped the out-of-pocket cost for insulin to $35 per month to help diabetes patients across the United States, many of whom are facing financial …
- 04/07/2020
|
Eli Lilly lowers insulin costs as coronavirus crisis deepens
- Drugmaker Eli Lilly & Co said on Tuesday it has capped the out-of-pocket cost for insulin to $35 per month to help diabetes patients across the United States, many of whom are facing financial difficulties due to the coronavirus outbreak. The new co-pay scheme covers most of Lilly's insulins, including
- 04/07/2020
|
Achilles Therapeutics appoints Carsten Boess to the Board of Directors
- Achilles Therapeutics appoints Carsten Boess to the Board of Directors Stevenage, UK 7 April, 2020 – Achilles Therapeutics (“Achilles”), a clinical-stage oncology company.
- 04/07/2020
|
Alnylam, Dicerna Join Forces to Take on Arrowhead
- Companies in race to find treatment for genetic disease that can cause lung and liver disease Continue reading...
- 04/06/2020
|
Alnylam, Dicerna Join Forces to Take on Arrowhead
- Alnylam, Dicerna Join Forces to Take on Arrowhead, Stocks: ALNY,DRNA,ARWR,NTLA,VRTX,NVO,ALXN,LLY,RHHBY, release date:Apr 06, 2020
- 04/06/2020
|
Novo Nordisk's Rybelsus Gets EU Nod for Type II Diabetes
- Novo Nordisk (NVO) gains the EU approval for Rybelsus to address adult patients with insufficiently-controlled type II diabetes for improving glycemic control as an adjunct to diet and exercise.
- 04/06/2020
|
Novo Nordisk's Rybelsus Gets EU Nod for Type II Diabetes
- Novo Nordisk (NVO) gains the EU approval for Rybelsus to address adult patients with insufficiently-controlled type II diabetes for improving glycemic control as an adjunct to diet and exercise.
- 04/06/2020
|
Evotec and Takeda Enter into Multi-Year Gene Therapy Research Alliance
- TAKEDA LEVERAGES EVOTEC'S NEW GENE THERAPY UNIT TO ACCELERATE RESEARCH PROGRAMMES ACROSS TAKEDA'S THERAPEUTIC AREAS MULTI-YEAR ALLIANCE FUELS EXPANSION OF EVOTEC GENE THERAPY ("EVOTEC GT") HAMBURG, ...
- 04/06/2020
|
Evotec Expands into Gene Therapy
- EVOTEC ESTABLISHES GENE THERAPY R&D SITE WITH MORE THAN 20 EXPERIENCED SCIENTISTS IN AUSTRIA BECOMING FULLY MODALITY AGNOSTIC WITH EXPANSION INTO THE FIELD OF GENE THERAPY CONFIRMS EVOTEC'S ROLE AS LEADING ...
- 04/06/2020
|
Highlights From Fundsmith Equity Fund ‘s 2020 Investor Letter
- On March 31, Fundsmith Equity Fund published an investor letter in which it has reported how the fund is faring in the coronavirus Covid-19 pandemic environment. The Fundsmith Equity Fund continues to operate and the fund has been able to provide liquidity where required. According to their management
- 04/06/2020
|
Alnylam, Dicerna Join Forces to Take on Arrowhead
|
Retirement: The Future-Proof Portfolio For Young Investors - Decimated
- Statistically, every long term investor needs to go through a couple of bear markets. Still, the speed and violence with which my portfolio has been decimated b
- 04/05/2020
|
Coronavirus (COVID-19) resources available from Novo Nordisk in the US
- We recognize that people with chronic diseases, including diabetes, obesity and hemophilia, are at increased risk during this pandemic and Novo Nordisk is taking measures to support the communities we serve throughout the COVID-19 pandemic.
- 04/02/2020
|
Evotec Expands its iPSC-Based Cell Therapy Platform EVOcells Through Licensing Agreement with panCELLa
- HAMBURG , Germany and TORONTO , April 2, 2020 /CNW/ - Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809) and the innovative biotechnology company panCELLa Inc. announced today that the companies have entered into a licensing and investment agreement. Under the terms of the
- 04/02/2020
|
Evotec Expands Its IPSC-Based Cell Therapy Platform Evocells Through Licensing Agreement with panCella
- HAMBURG, GERMANY, AND TORONTO, ON / ACCESSWIRE / April 2, 2020 / Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809) and the innovative biotechnology company panCELLa Inc. announced today that the companies have entered into a licensing and investment agreement. Under the terms
- 04/02/2020
|
Coronavirus (COVID-–9) resources available from Novo Nordisk in the US
|
Global Orphan Drug Clinical Trials, Patent & Guidelines Insight 2026
- "Global Orphan Drug Clinical Trials, Patent & Guidelines Insight 2026" Report Highlights:Read the full report: https://www.reportlinker.com/p05874153/?utm_source=PRN • Global Orphan Drug Market Opportunity: US$ 300 Billion • US Dominates Global Orphan Drug Market: 50% Market Share• US Orphan
- 04/01/2020
|
FDA OKs new hemophilia treatment
- The FDA approves LFB Biotechnologies' Sevenfact [coagulation factor VIIa (recombinant)-jncw] for the treatment and control of bleeding episodes in adults and adolescents at least 12 years old with hem
- 04/01/2020
|
Artificial Intelligence in Supply Chain Management Market to 2025 - Analysis, Drivers & Opportunities - ResearchAndMarkets.com
- The "Artificial Intelligence (AI) in Supply Chain Management (SCM) Market: AI in SCM by Technology, Solution, Management Function (Automation, Planning and Logistics, Inventory, Fleet, Freight, Risk), and Region 2020 - 2025" report has been added to ResearchAndMarkets.com's offering.
- 04/01/2020
|
NVS vs. NVO: Which Stock Should Value Investors Buy Now?
|
The Zacks Analyst Blog Highlights: Alphabet, Procter & Gamble, Philip Morris, Novo Nordisk and Tesla
- The Zacks Analyst Blog Highlights: Alphabet, Procter & Gamble, Philip Morris, Novo Nordisk and Tesla
- 03/31/2020
|
The Zacks Analyst Blog Highlights: Alphabet, Procter & Gamble, Philip Morris, Novo Nordisk and Tesla
- The Zacks Analyst Blog Highlights: Alphabet, Procter & Gamble, Philip Morris, Novo Nordisk and Tesla
- 03/31/2020
|
NNIT A/S: 6/2020 NNIT renews operations maintenance agreement with Novo Nordisk
- NNIT A/S (“NNIT”), a leading provider of IT services and consultancy announces that it has entered into a five-year-agreement with Novo Nordisk, renewing the existing operations maintenance agreement which was to expire at the end of 2020. The contract covers the infrastructure operations of the global
- 03/31/2020
|
Evotec And Ildong To Collaborate With Development Projects On Indigo Platform
- EVOTEC LEVERAGES INDIGO PLATFORM TO ACCELERATE DEVELOPMENT OF VARIOUS ILDONG PROGRAMMES INTO THE CLINIC FIRST REGULATORY FILING ENVISAGED FOR Q1 2021 INDIGO IS A KEY VALUE-DRIVING COMPONENT OF EVOTEC'S ...
- 03/31/2020
|
The Zacks Analyst Blog Highlights: Alphabet, Procter & Gamble, Philip Morris, Novo Nordisk and Tesla
|
Top Analyst Reports for Alphabet, Procter & Gamble & Philip Morris
- Top Analyst Reports for Alphabet, Procter & Gamble & Philip Morris
- 03/30/2020
|
Top Analyst Reports for Alphabet, Procter & Gamble & Philip Morris
- Today's Research Daily features new research reports on 16 major stocks, including Alphabet (GOOGL), Procter & Gamble (PG) and Philip Morris International (PM).
- 03/30/2020
|
Shares of several healthcare companies are trading higher as the market rebounds on extended measures to help curb the coronavirus. NOTE: The sector could also be trading higher due to increased demand for medical products amid the coronavirus outbreak.
|
The Sell-Off Reversal?
- Uncle Sam may wind up owning a chunk of our country's airlines in return for bailing them out. That probably means low ball prices will not return soon, making my globe-trotting research costlier.
- 03/29/2020
|
Novo Nordisk Shows Market Leadership With Jump To 92 RS Rating
|
The 12 Highest Quality Blue Chips You Can Buy Right Now
- I'm dedicated to bringing the most truthful and accurate economic/pandemic updates to my readers, to fill the vacuum of fear with facts. The COVID-19 pandemic i
- 03/26/2020
|
Novo Nordisk shares are trading higher, notable above other healthcare names, not currently seeing company-specific news. Markets have been volatile over past few sessions amid US stimulus legislation.
|
20 Healthcare Stocks Moving In Wednesday's Pre-Market Session
|
Global Orphan Drug Market Projected to witness a Growth of 150% by 2026 - ResearchAndMarkets.com
- The "Global Orphan Drug Clinical Trials, Patent & Guidelines Insight 2026" report has been added to ResearchAndMarkets.com's offering.
- 03/24/2020
|
Genfit: Near-Term Upside Of 650% As Read-Out Of The Year Approaches
- NASH is a common disease with an expected market size of 20 Bn. $ in 2030 and currently no approved drugs. A handful of companies including most of big pharma a
- 03/24/2020
|
Peptide Therapeutics Market To Reach USD 50.60 Billion By 2026 | Reports and Data
- New York, March 23, 2020 -- The global Peptide Therapeutics market was valued at USD 25.35 billion in 2018 and is expected to reach USD 50.60 billion by the year 2026, at a.
- 03/23/2020
|
Notice Convening the Annual General Meeting
- March 23, 2020 Announcement no..
- 03/23/2020
|
The Zacks Analyst Blog Highlights: Microsoft, salesforce.com, Novo Nordisk, American Express and Fiserv
- The Zacks Analyst Blog Highlights: Microsoft, salesforce.com, Novo Nordisk, American Express and Fiserv
- 03/23/2020
|
The Zacks Analyst Blog Highlights: Microsoft, salesforce.com, Novo Nordisk, American Express and Fiserv
- The Zacks Analyst Blog Highlights: Microsoft, salesforce.com, Novo Nordisk, American Express and Fiserv
- 03/23/2020
|
SocGen cuts view on AbbVie in premarket analyst action
- Itamar Medical (NASDAQ:ITMR) initiated with Buy rating and $21 (149% upside) price target at H.C. Wainwright.Novo Nordisk (NYSE:NVO) upgraded to Buy at UBS. Shares up 2% premarket.AbbVie (NYSE:ABBV) d
- 03/23/2020
|
Shares of several healthcare companies are trading higher the Fed announced actions to support the U.S. economy. The Fed will do open-ended treasury, mortgage-backed securities and will buy $375 billion in treasury this week.
|
Top Analyst Reports for Microsoft, salesforce.com & Novo Nordisk
- Top Analyst Reports for Microsoft, salesforce.com & Novo Nordisk
- 03/20/2020
|
Top Analyst Reports for Microsoft, salesforce.com & Novo Nordisk
- Today's Research Daily features new research reports on 16 major stocks, including Microsoft (MSFT), salesforce.com (CRM) and Novo Nordisk (NVO).
- 03/20/2020
|
5 Dividend Growth Stocks Hedge Fund Gurus Own
- Ford suspends dividend payments as coronavirus outbreak cripples plant operations Continue reading...
- 03/19/2020
|
5 Dividend Growth Stocks Hedge Fund Gurus Own
- 5 Dividend Growth Stocks Hedge Fund Gurus Own, Stocks: F,SWKS,MSM,GWW,LECO,NVO, Ken Heebner, Jerome Dodson, Jim Simons, release date:Mar 19, 2020
- 03/19/2020
|
Building A Recession-Proof Retirement Portfolio With 13 Stocks And Bonds
- The COVID-19 bear market has seen stocks fall about 30% in a month, the fastest bear market in history. Uncertainty around how long the pandemic will last and h
- 03/19/2020
|
5 Dividend Growth Stocks Hedge Fund Gurus Own
|
$300 Billion Orphan Drugs Market Opportunity Assessment, 2026 - Insights Into Clinical Trials (900+ Drugs), Patents and Guidelines
- The "Global Orphan Drug Clinical Trials, Patent & Guidelines Insight 2026" report has been added to ResearchAndMarkets.com's offering.
- 03/18/2020
|
Global Injectable Drug Delivery Market (2019 to 2027) - CAGR of 8.67% Expected During the Forecast Period - ResearchAndMarkets.com
- The "Global Injectable Drug Delivery Market 2019-2027" report has been added to ResearchAndMarkets.com's offering.
- 03/18/2020
|
Artificial Intelligence in the Supply Chain Management Market to 2025 by Technology, Solution, Management Function (Automation, Planning & Logistics, Inventory, Fleet, Freight, Risk) and Region
- The "Artificial Intelligence (AI) in Supply Chain Management (SCM) Market: AI in SCM by Technology, Solution, Management Function (Automation, Planning and Logistics, Inventory, Fleet, Freight, Risk), and Region 2020-2025" report has been added to ResearchAndMarkets.com's offering.
- 03/17/2020
|
Serious safety issue forces Novo Nordisk to hit pause on late-stage hemophilia trials
- Novo Nordisk has halted one midstage and two late-stage tests of its bleeding disease drug concizumab after seeing blood clots in some patients.
- 03/17/2020
|
Genmab: An Attractive Biotechnology Platform Pick In March 2020
- Darzalex is a major revenue driver for Genmab. The company may start earning significant revenues from other approved products as well as from pipeline products
- 03/16/2020
|
Global Orphan Drug Clinical Trials, Patent & Guidelines Insight, 2026
- Dublin, March 16, 2020 -- The "Global Orphan Drug Clinical Trials, Patent & Guidelines Insight 2026" report has been added to ResearchAndMarkets.com's offering..
- 03/16/2020
|
AI in the Global Supply Chain Management Market, 2020-2025 - Cloud-based AIaaS for SCM Will Reach $1.9B by 2025, Globally
- Dublin, March 16, 2020 -- The "Artificial Intelligence (AI) in Supply Chain Management (SCM) Market: AI in SCM by Technology, Solution, Management Function (Automation,.
- 03/16/2020
|
Diabetes Devices Market Size Worth $41.6 Billion by 2027 | CAGR: 7.8%: Grand View Research, Inc.
- The global diabetes devices market size is expected to reach USD 41.6 billion by 2027, registering a CAGR of 7.8% over the forecast period, according to a new report by Grand View Research, Inc. The market is driven by factors such as increasing incidence of diabetes, technological advancements, and
- 03/16/2020
|
Novo Nordisk Pauses The Clinical Trials Investigating Concizumab In Haemophilia A And B With Or Without Inhibitors As A Result Of Non-Fatal Thrombotic Events In Three Patients
|
Were Hedge Funds Right About Buying Novo Nordisk A/S (NVO)?
- Coronavirus is probably the 1 concern in investors' minds right now. It should be. On February 27th we published an article with the title Recession is Imminent: We Need A Travel Ban NOW. We predicted that a US recession is imminent and US stocks will go down by at least 20% in the next 3-6 […]
- 03/13/2020
|
Shares of several healthcare companies are trading higher as the market rebounds following Thursday's selloff. NOTE: Since the coronavirus outbreak the healthcare sector has been extremely volatile.
|
